


PCT/DK 2004/000688

DK04/688



# Kongeriget Danmark

Patent application No.: PA 2004 00333

Date of filing: 01 March 2004


Applicant:  
(Name and address) Novozymes A/S  
Krogshøjvej 36  
DK-2880 Bagsværd  
Denmark

Title: Protese variants

IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)



**Patent- og Varemærkestyrelsen**  
Økonomi- og Erhvervsministeriet

12 October 2004

Pia Høybye-Olsen

## PROTEASE VARIANTS

### Field of the Invention

5       The present invention relates to variants of a parent protease, in particular variants of amended properties, such as improved thermostability and/or amended temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of  
10       generating and preparing protease variants of amended properties. Preferred parent proteases are the *Nocardiopsis* proteases comprising SEQ ID NOs: 2, 4, 6, 8 and 10.

### Background of the Invention

      Proteases derived from strains of *Nocardiopsis* are disclosed in WO 88/03947, WO  
15       01/58276, and DK 1996 00013 ("Protease 10," SEQ ID NOs: 1-2); DK 2003 00912 ("Protease 08," SEQ ID NOs: 9-10); DK 2003 00913 ("Protease 11," SEQ ID NOs: 5-6); DK 2003 00914 ("Protease 18," SEQ ID NOs: 3-4); DK 2003 00915 ("Protease 35," SEQ ID NO: 7-8), DD 2004328, and in JP 02255081.

      It is an object of the present invention to provide novel and improved protease variants,  
20       in particular of amended properties, such as improved thermostability and/or a higher or lower optimum temperature.

### Summary of the Invention

      The present invention relates to a variant of a parent protease, comprising a  
25       substitution in at least one position of at least one region selected from the group of regions consisting of: 6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188; wherein

- (a) the variant has protease activity; and
- (b) each position corresponds to a position of SEQ ID NO: 2; and
- 30       (c) the variant has a percentage of identity to SEQ ID NO: 2 of at least 60%.

      The present invention also relates to isolated nucleic acid sequences encoding the protease variant and to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the protease variants.

### Brief Description of the Figures

35       Figure 1 is a multiple alignment of Protease 10, Protease 18, Protease 11, Protease 35 and Protease 08 (the mature peptide parts of SEQ ID NOs: 2, 4, 6, 8 and 10, respectively) and

of a protease variant of the invention, viz. Protease 22 (amino acids 1-188 of SEQ ID NO: 12); and

Figure 2 provides the coordinates of the novel 3D structure of Protease 10 (SEQ ID NO: 2) derived from *Nocardioopsis* sp. NRRL 18262.

5

### Detailed Description of the Invention

#### Three-dimensional Structure of Protease 10

The structure of Protease 10 was solved in accordance with the principles for X-ray crystallographic methods as given, for example, in X-Ray Structure Determination, Stout, G.K. and Jensen, L.H., John Wiley & Sons, Inc. NY, 1989. The structural coordinates for the crystal structure at 2.2 Å resolution using the isomorphous replacement method are given in Fig. 2 in standard PDB format (Protein Data Bank, Brookhaven National Laboratory, Brookhaven, CT). The PDB file of Fig. 2 relates to the mature peptide part of Protease 10 corresponding to residues 1-188 of SEQ ID NO: 2.

15

#### Molecular Dynamics (MD)

Molecular Dynamics (MD) simulations are indicative of the mobility of the amino acids in a protein structure (see McCammon, JA and Harvey, SC., (1987), "Dynamics of proteins and nucleic acids", Cambridge University Press). Such protein dynamics are often compared to the crystallographic B-factors (see Stout, GH and Jensen, LH, (1989), "X-ray structure determination", Wiley). By running the MD simulation at, e.g., different temperatures, the temperature related mobility of residues is simulated. Regions having the highest mobility or flexibility (here isotropic fluctuations) may be suggested for random mutagenesis. It is here understood that the high mobility found in certain areas of the protein, may be thermally improved by substituting these residues,

25

Using the programs CHARMM (Accelrys) and NAMD (University of Illinois at Urbana-Champaign) the Protease 10 structure described above was subjected to MD at 300 and 400K. Starting from the coordinates of Figure 2 hydrogen and missing heavy atoms were built using CHARMM procedures HBUILD and IC BUILD respectively. Then the structure was minimized using CHARMM Conjugate Gradients (CONJ) minimization procedure for a total of 200 steps. The protein was then put on a 70 X 70 X 70 Angstrom box and solvated with TIP3 water molecules. A total of 11124 water molecules were added and then minimized, keeping the protein coordinates fixed, using CHARMM Adopted Basis Newton Raphson (ABNR) minimization procedure for 20000 steps. The system was then heated to the desired temperature at a rate of 1K every 100 steps using the NAMD software. After an equilibration of 50 picoseconds, an NVE ensemble MD was run for 1 nanosecond, both steps done with the software NAMD. A cut-off of 12 Angstrom was used for the non-bonded interactions. Periodic

35

boundary conditions were used after the solvation step and for all the subsequent ones. The isotropic root mean square (RMS) fluctuations were calculated with the CHARMM procedure COOR DYNA.

The following suggested regions for mutagenesis result from MD simulations: From  
 5 residue 160 to 170, from residue 78 to 90, from residue 43 to 50, from residue 66 to 75, and from residue 22 to 28.

### Strategy for Preparing Variants

Regions of amino acid residues, as well as individual amino acid substitutions, were  
 10 suggested for mutagenesis based on the 3D-structure of Fig. 2 and the alignment of Fig. 1, mainly with a view to improving thermostability.

The following regions were suggested, cf. claim 1: 6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188.

At least one of the following positions of the above regions are preferably subjected to  
 15 mutagenesis, cf. claim 3: 6; 7; 8; 9; 10; 12; 13; 16; 17; 18; 22; 23; 24; 25; 26; 27; 28; 32; 33; 37; 38; 39; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 58; 62; 63; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 103; 105; 106; 111; 113; 114; 118; 120; 122; 124; 125; 127; 129; 130;  
 20 131; 134; 135; 136; 139; 140; 141; 144; 145; 146; 147; 148; 149; 150; 151; 155; 156; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 179; 180; 181; 184; 185; 186; 187; and/or 188.

Contemplated specific variants are listed in the claims, viz. variants of Protease 10, Protease 18, Protease 11, Protease 35 as well as Protease 08 in claims 4 and 15; variants of  
 25 Protease 10 in claim 16; variants of Protease 18 in claim 17; variants of Protease 11 in claim 18; variants of Protease 35 in claim 19; and variants of Protease 08 in claim 20. Subgroups of specific variants are listed in claims 21-23.

The various concepts underlying the invention are also reflected in the claims as follows: Stabilization by disulfide-bridges in claims 5 and 6; proline-stabilization in claims 7-8;  
 30 substitution of exposed neutral residues with negatively charged residues in claims 9-10; substitution of exposed neutral residues with positively charged residues in claims 11-12; substitution of small residues with bulkier residues inside the protein in claim 13; and regions proposed for mutagenesis following MD simulations in claim 14.

The term "at least one" means "one or more," viz., e.g. in the context of regions: One,  
 35 two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen; or, in the context of positions or substitutions: One, two, three, four, five, and so on, up to e.g. ninety.



In a particular embodiment, the number of regions proposed for and/or subjected to mutagenesis is at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or at least seventeen.

5 In another particular embodiment, the number of regions proposed for and/or subjected to mutagenesis is no more than one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or no more than seventeen.

#### **Polypeptides Having Protease Activity**

10 Polypeptides having protease activity, or proteases, are sometimes also designated peptidases, proteinases, peptide hydrolases, or proteolytic enzymes. Proteases may be of the exo-type that hydrolyse peptides starting at either end thereof, or of the endo-type that act internally in polypeptide chains (endopeptidases). Endopeptidases show activity on N- and C-terminally blocked peptide substrates that are relevant for the specificity of the protease in question.

15 The term "protease" is defined herein as an enzyme that hydrolyses peptide bonds. This definition of protease also applies to the protease-part of the terms "parent protease" and "protease variant," as used herein. The term "protease" includes any enzyme belonging to the EC 3.4 enzyme group (including each of the thirteen subclasses thereof). The EC number refers to Enzyme Nomenclature 1992 from NC-IUBMB, Academic Press, San Diego, 20 California, including supplements 1-5 published in Eur. J. Bio-chem. 1994, 223, 1-5; Eur. J. Biochem. 1995, 232, 1-6; Eur. J. Biochem. 1996, 237, 1-5; Eur. J. Biochem. 1997, 250, 1-6; and Eur. J. Biochem. 1999, 264, 610-650; respectively. The nomenclature is regularly supplemented and updated; see e.g. the World Wide Web (WWW) at <http://www.chem.qmw.ac.uk/iubmb/enzyme/index.html>.

25 Proteases are classified on the basis of their catalytic mechanism into the following groups: Serine proteases (S), Cysteine proteases (C), Aspartic proteases (A), Metallo proteases (M), and Unknown, or as yet unclassified, proteases (U), see Handbook of Proteolytic Enzymes, A.J.Barrett, N.D.Rawlings, J.F.Woessner (eds), Academic Press (1998), in particular the general introduction part.

30 In particular embodiments, the parent proteases and/or the protease variants of the invention and for use according to the invention are selected from the group consisting of:

- (a) Proteases belonging to the EC 3.4.-- enzyme group;
- (b) Serine proteases belonging to the S group of the above Handbook;
- (c1) Serine proteases of peptidase family S2A; and
- 35 (c2) Serine proteases of peptidase family S1E as described in Biochem.J. 290:205-218 (1993) and in MEROPS protease database, release 6.20, March 24, 2003, ([www.merops.ac.uk](http://www.merops.ac.uk)). The database is described in Rawlings, N.D., O'Brien, E. A. & Barrett,

10508.010-DK

A.J. (2002) MEROPS: the protease database. *Nucleic Acids Res.* 30, 343-346.

For determining whether a given protease is a Serine protease, and a family S2A protease, reference is made to the above Handbook and the principles indicated therein. Such determination can be carried out for all types of proteases, be it naturally occurring or wild-type proteases; or genetically engineered or synthetic proteases.

Protease activity can be measured using any assay, in which a substrate is employed, that includes peptide bonds relevant for the specificity of the protease in question. Assay-pH and assay-temperature are likewise to be adapted to the protease in question. Examples of assay-pH-values are pH 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. Examples of assay-temperatures are 30, 35, 37, 40, 45, 50, 55, 60, 65, 70, 80, 90, or 95°C. Examples of protease substrates are casein, such as Azurine-Crosslinked Casein (AZCL-casein). Examples of suitable protease assays are described in Example 1.

#### Parent Protease

The parent protease is a protease from which the protease variant is, or can be, derived. For the present purposes, any protease can be used as the parent protease, as long as the resulting protease variant is homologous to Protease 10, i.e. the protease derived from *Nocardiopsis* sp. NRRL 18262 and comprising amino acids 1-188 of SEQ ID NO: 2.

In a particular embodiment the parent protease is also homologous to Protease 10.

In the present context, homologous means having an identity of at least 60% to SEQ ID NO: 2, viz. amino acids 1-188 of the mature peptide part of Protease 10. Homology is determined as generally described below in the section entitled Amino Acid Homology.

The parent protease may be a wild-type or naturally occurring polypeptide, or an allelic variant thereof, or a fragment thereof that has protease activity, in particular a mature part thereof. It may also be a variant thereof and/or a genetically engineered or synthetic polypeptide.

In a particular embodiment the wild-type parent protease is i) a bacterial protease; ii) a protease of the phylum *Actinobacteria*; iii) of the class *Actinobacteria*; iv) of the order *Actinomycetales* v) of the family *Nocardiopsaceae*; vi) of the genus *Nocardiopsis*; and/or a protease derived from vii) *Nocardiopsis* species, such as *Nocardiopsis alba*, *Nocardiopsis antarctica*, *Nocardiopsis composta*, *Nocardiopsis dassonvillei*, *Nocardiopsis exhalans*, *Nocardiopsis halophila*, *Nocardiopsis halotolerans*, *Nocardiopsis kunsanensis*, *Nocardiopsis listeri*, *Nocardiopsis lucentensis*, *Nocardiopsis metallicus*, *Nocardiopsis prasina*, *Nocardiopsis* sp., *Nocardiopsis synnemataformans*, *Nocardiopsis trehalosi*, *Nocardiopsis tropica*, *Nocardiopsis umidischolae*, or *Nocardiopsis xinjiangensis*.

Examples of such strains are: *Nocardiopsis alba* DSM 15647 (wild-type producer of Protease 08), *Nocardiopsis dassonvillei* NRRL 18133 (wild-type producer of Protease M58-1

10508.010-DK

described in WO 88/03947), *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235 (wild-type producer of Protease 18), *Nocardiopsis prasina* DSM 15648 (wild-type producer of Protease 11), *Nocardiopsis prasina* DSM 15649 (wild-type producer of Protease 35), *Nocardiopsis* sp. NRRL 18262 (wild-type producer of Protease 10), *Nocardiopsis* sp. strain  
 5 FERM P-10508 (described in JP 02255081), or *Nocardiopsis dassonvillei* strain ZIMET 43647 (described in DD 2,004,328).

Strains of these species are accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures  
 10 (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL), e.g. *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235 is publicly available from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). The strain was also deposited at other depositary institutions as follows: ATCC 23219, IMRU 1250, NCTC 10489.

15 The following biological materials were deposited in connection with the filing of other patent applications under the terms of the Budapest Treaty with the Agricultural Research Culture Collection (NRRL), Peoria, US, or the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg, 1b, D-38124 Braunschweig, and given the following accession numbers:

20	Deposit	Accession Number	Date of Deposit
	<i>Nocardiopsis</i> sp.	NRRL 18262	November 10, 1987
	<i>Nocardiopsis dassonvillei</i>	NRRL 18133	November 13, 1986
	<i>Nocardiopsis alba</i>	DSM 15647	May 30, 2003
	<i>Nocardiopsis prasina</i>	DSM 15648	May 30, 2003
25	<i>Nocardiopsis prasina</i>	DSM 15649	May 30, 2003

These strains have been deposited under conditions that assure that access to the cultures will be available during the pendency of the other patent applications to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122. The deposits represent substantially pure cultures of the  
 30 deposited strains. The deposits are available as required by foreign patent laws in countries wherein counterparts of these applications, or their progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the invention in derogation of patent rights granted by governmental action.

Of the above strains, the three last-mentioned were isolated in 2001 from soil samples  
 35 from Denmark.

Furthermore, such polypeptides may be identified and obtained from other sources including microorganisms or DNA isolated from nature (e.g., soil, composts, water, etc.) using

10508.010-DK

suitable probes. Techniques for isolating microorganisms or DNA from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a genomic or cDNA library of another microorganism. Once a nucleic acid sequence encoding a polypeptide has been detected with the probe(s), the sequence may be isolated or cloned by  
5 utilizing techniques which are known to those of ordinary skill in the art (see, e.g., Sambrook *et al.*, 1989, *supra*).

The parent protease may be a mature part of any of the amino acid sequences referred to above. A mature part means a mature amino acid sequence and refers to that part of an amino acid sequence which remains after a potential signal peptide part and/or pro-peptide part has been cleaved off.  
10

The parent protease may also be a fragment of a specified amino acid sequence, viz. a polypeptide having one or more amino acids deleted from the amino and/or carboxyl terminus of this amino acid sequence. In one embodiment, a fragment contains at least 80, or at least 90, or at least 100, or at least 110, or at least 120, or at least 130, or at least 140, or at least  
15 150, or at least 160, or at least 170, or at least 180, or at least 185 amino acid residues.

The parent protease may also be an allelic variant, allelic referring to the existence of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode  
20 polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

In another embodiment, the parent protease may be a genetically engineered protease, e.g. a variant of the wild-type or natural parent proteases referred to above comprising a substitution, deletion, and/or insertion of one or more amino acids. In other  
25 words: The parent protease may itself be a protease variant, such as Protease 22. The amino acid sequence of such parent protease may differ from the amino acid sequence specified by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. The amino acid changes may be of a minor, or of a major, nature. Amino acid changes of a major nature are e.g. those  
30 resulting in a variant protease of the present invention with amended properties. In another particular embodiment, the amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to  
35 about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids

10508.010-DK

(arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, In, *The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

Still further examples of genetically engineered parent proteases are synthetic proteases, designed by man, and expectedly not occurring in nature. EP 897985 discloses a process of preparing a consensus protein. Shuffled proteases are other examples of synthetic or genetically engineered parent proteases, which can be prepared as is generally known in the art, eg by Site-directed Mutagenesis, by PCR (using a PCR fragment containing the desired mutation as one of the primers in the PCR reactions), or by Random Mutagenesis. Included in the concept of a synthetic protease is also any hybrid or chimeric protease, i.e. a protease which comprises a combination of partial amino acid sequences derived from at least two proteases. Gene shuffling is generally described in e.g. WO 95/22625 and WO 96/00343. Re-combination of protease genes can be made independently of the specific sequence of the parents by synthetic shuffling as described in Ness, J.E. et al, in *Nature Biotechnology*, Vol. 20 (12), pp. 1251-1255, 2002. Synthetic oligonucleotides degenerated in their DNA sequence to provide the possibility of all amino acids found in the set of parent proteases are designed and the genes assembled according to the reference. The shuffling can be carried out for the full length sequence or for only part of the sequence and then later combined with the rest of the gene to give a full length sequence. Two, three, four, five or all six of the the proteases designated Protease 10, 18, 11, 35, 08 and 22 (SEQ ID NOs: 2, 4, 6, 8, 10, and 12) are particular examples of such parent proteases which can be subjected to shuffling as described above, to provide additional proteases of the invention.

In further particular embodiments, the parent protease comprises, or consists of, respectively, the amino acid sequence specified, or an allelic variant thereof, or a fragment thereof that has protease activity.

In still further particular embodiments, the protease variant of the invention is not identical to:

(i) amino acids 1-188 of SEQ ID NO: 2, amino acids 1-188 of SEQ ID NO: 4, amino acids 1-188 of SEQ ID NO: 6, amino acids 1-188 of SEQ ID NO: 8, and amino acids 1-188 of SEQ ID NO: 10;

(ii) the protease derived from *Nocardiopsis dassonvillei* NRRL 18133;

10508.010-DK

- (iii) the protease derived from *Nocardiosis sp.* FERM P-10508;
- (iv) the protease derived from *Nocardiosis dassonvillei* strain ZIMET 43647; and/or
- (v) any prior art protease of a percentage of identity to SEQ ID NO: 2 of at least 60%.

## 5 Microorganism Taxonomy

Questions relating to taxonomy may be solved by consulting a taxonomy data base, such as the NCBI Taxonomy Browser which is available at the following internet site: <http://www.ncbi.nlm.nih.gov/Taxonomy/taxonomyhome.html/>, and/or by consulting Taxonomy handbooks. For the present purposes, the taxonomy is preferably according to the chapter:

10 The road map to the Manual by G.M. Garrity & J. G. Holt in Bergey's Manual of Systematic Bacteriology, 2001, second edition, volume 1, David R. Boone, Richard W. Castenholz.

## Amino Acid Homology

The present invention refers to proteases, viz. parent proteases, and/or protease variants, having a certain degree of identity to SEQ ID NO: 2, such parent and/or variant proteases being hereinafter designated "homologous proteases".

For purposes of the present invention the degree of identity between two amino acid sequences, as well as the degree of identity between two nucleotide sequences, is determined by the program "align" which is a Needleman-Wunsch alignment (i.e. a global alignment). The program is used for alignment of polypeptide, as well as nucleotide sequences. The default scoring matrix BLOSUM50 is used for polypeptide alignments, and the default identity matrix is used for nucleotide alignments. The penalty for the first residue of a gap is -12 for polypeptides and -16 for nucleotides. The penalties for further residues of a gap are -2 for polypeptides, and -4 for nucleotides.

"Align" is part of the FASTA package version v20u6 (see W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," Methods in Enzymology 183:63-98). FASTA protein alignments use the Smith-Waterman algorithm with no limitation on gap size (see "Smith-Waterman algorithm", T. F. Smith and M. S. Waterman (1981) J. Mol. Biol. 147:195-197).

Multiple alignments of protein sequences may be made using "ClustalW" (Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Research, 22:4673-4680). Multiple alignment of DNA sequences may be done using the protein alignment as a template, replacing the amino acids with the corresponding codon from the DNA sequence.

In particular embodiments, the homologous protease has an amino acid sequence

10508.010-DK

which has a degree of identity to SEQ ID NO: 2 of at least 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or of at least about 99%.

5 In alternative embodiments, the homologous protease has an amino acid sequence which has a degree of identity to SEQ ID NO: 2 of at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, or at least 59%.

10 In another particular embodiment, the parent protease, and/or the protease variant, comprises a mature amino acid sequence which differs by no more than seventyfive, seventyfour, seventythree, seventytwo, seventyone, seventy, sixty-nine, sixtyeight, sixtyseven, sixty-six, sixtyfive, sixtyfour, sixtythree, sixtytwo, sixtyone, sixty, fifty-nine, fiftyeight, fiftyseven, fifty-six, fiftyfive, fiftyfour, fiftythree, fiftytwo, fiftyone, fifty, forty-nine, fortyeight, fortyseven, forty-six, fortyfive, fortyfour, fortythree, fortytwo, fortyone, forty, thirty-nine, thirtyeight, thirtyseven, thirtysix, thirtyfive, thirtyfour, thirtythree, thirtytwo, thirtyone, thirty, twenty-nine, twentyeight, twentyseven, twentysix, twentyfive, twentyfour, twentythree, twentytwo, 15 twentyone, twenty, nineteen, eighteen, seventeen, sixteen, fifteen, fourteen, thirteen, twelve, eleven, ten, nine, eight, seven, six, five, four, three, by no more than two, or only by one amino acid(s) from the specified amino acid sequence, e.g. SEQ ID NO: 2.

20 In a still further particular embodiment, the parent protease, and/or the protease variant, comprises a mature amino acid sequence which differs by at least seventyfive, seventyfour, seventythree, seventytwo, seventyone, seventy, sixty-nine, sixtyeight, sixtyseven, sixty-six, sixtyfive, sixtyfour, sixtythree, sixtytwo, sixtyone, sixty, fifty-nine, fiftyeight, fiftyseven, fifty-six, fiftyfive, fiftyfour, fiftythree, fiftytwo, fiftyone, fifty, forty-nine, fortyeight, fortyseven, forty-six, fortyfive, fortyfour, fortythree, fortytwo, fortyone, forty, thirty-nine, thirtyeight, thirtyseven, thirtysix, thirtyfive, thirtyfour, thirtythree, thirtytwo, thirtyone, thirty, twenty-nine, 25 twentyeight, twentyseven, twentysix, twentyfive, twentyfour, twentythree, twentytwo, twentyone, twenty, nineteen, eighteen, seventeen, sixteen, fifteen, fourteen, thirteen, twelve, eleven, ten, nine, eight, seven, six, five, four, three, by at least two, or by one amino acid(s) from the specified amino acid sequence, e.g. SEQ ID NO: 2.

### 30 Nucleic Acid Hybridization

In the alternative, homologous parent proteases, as well as variant proteases, may be defined as being encoded by a nucleic acid sequence which hybridizes under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more 35 preferably high stringency conditions, and most preferably very high stringency conditions with nucleotides 900-1466 of SEQ ID NO: 1, or a subsequence or a complementary strand thereof (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, Molecular Cloning, A Laboratory Manual,

10508.010-DK

2d edition, Cold Spring Harbor, New York). A subsequence may be at least 100 nucleotides, or at least 200, 300, 400, or at least 500 nucleotides. Moreover, the subsequence may encode a polypeptide fragment that has the relevant enzyme activity.

5 For long probes of at least 100 nucleotides in length, very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures.

10 For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 2 x SSC, 0.2% SDS preferably at least at 45°C (very low stringency), more preferably at least at 50°C (low stringency), more preferably at least at 55°C (medium stringency), more preferably at least at 60°C (medium-high stringency), even more preferably at least at 65°C (high stringency), and most preferably at least at 70°C (very high stringency).

15 For short probes which are about 15 nucleotides to about 70 nucleotides in length, stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at 5°C to 10°C below the calculated  $T_m$  using the calculation according to Bolton and McCarthy (1962, Proceedings of the National Academy of Sciences USA 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

20 For short probes which are about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes, and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated  $T_m$ .

### Position numbering

25 In the present context, the basis for numbering positions is SEQ ID NO: 2, Protease 10, starting with A1 and ending with T188, see Fig. 1. A parent protease, as well as a variant protease, may comprise extensions as compared to SEQ ID NO: 2, i.e. in the N-terminal, and/or the C-terminal ends thereof. The amino acids of such extensions, if any, are to be numbered as is usual in the art, i.e. for a C-terminal extension: 189, 190, 191 and so forth, and for an N-terminal extension -1, -2, -3 and so forth.

### 35 Alterations, such as Substitutions, Deletions, Insertions

In the present context, the following are examples of various ways in which a protease variant can be designed or derived from a parent amino acid sequence: An amino acid can be



10508.010-DK

substituted with another amino acid; an amino acid can be deleted; an amino acid can be inserted; as well as any combination of any number of such alterations.

For the present purposes, the term substitution is intended to include any number of any type of such alterations. This is a reasonable definition, because, for example, a deletion can be regarded as a substitution of an amino acid, AA, in a given position, nn, with nothing, (). Such substitution can be designated: AAnn(). Likewise, an insertion of only one amino acid, BB, downstream an amino acid, AA, in a given position, nn, can be designated: ()nnaBB. And if two amino acids, BB and CC, are inserted downstream of amino acid AA in position nn, this substitution (combination of two substitutions) can be designated: ()nnaBB+()nnbCC, the thus created gaps between amino acids nn and nn+1 in the parent sequence being assigned lower case or subscript letters a, b, c etc. to the former position number, here nn. A similar numbering procedure is followed when aligning a new sequence to the multiple alignment of Fig. 1, in case of a gap being created by the alignment between amino acids nn and nn+1. Each position of the gap is assigned a number: nna, nnb etc.. A comma (,) between substituents, as e.g. in the substitution T129E,D,Y,Q means "either or", i.e. that T129 is substituted with E, or D, or Y, or Q. A plus-sign (+) between substitutions, e.g. 129D+135P means "and", i.e. that these two single substitutions are combined in one and the same protease variant.

In the present context, the term "a" substitution" means at least one substitution. At least one means one or more, e.g. one, or two, or three, or four, or five, or six, or seven, or eight, or nine, or ten, or twelve, or fourteen, or fifteen, or sixteen, or eighteen, or twenty, or twentytwo or twentyfour, or twentyfive, or twenty eight, or thirty, and so on, to include in principle, any number of substitutions. The variants of the invention, however, still have to be, e.g., at least 60% identical to SEQ ID NO: 2, this percentage being determined by the above-mentioned program. The substitutions can be applied to any position encompassed by any region mentioned in claim 1, and variants comprising combinations of any number and type of such substitutions are also included. The term substitution as used herein also include deletions, as well as extensions, or insertions, that may add to the length of the sequence corresponding to SEQ ID NO: 2.

Furthermore, the term "a substitution" embraces a substitution into any one of the other nineteen natural amino acids, or into other amino acids, such as non-natural amino acids. For example, a substitution of amino acid T in position 22 includes each of the following substitutions: 22A, 22C, 22D, 22E, 22F, 22G, 22H, 22I, 22K, 22L, 22M, 22N, 22P, 22Q, 22R, 22S, 22V, 22W, and 22Y. This is, by the way, equivalent to the designation 22X, wherein X designates any amino acid. These substitutions can also be designated T22A, T22C, T22X, etc. The same applies by analogy to each and every position mentioned herein, to specifically include herein any one of such substitutions.

10508.010-DK

### Identifying Corresponding Position Numbers

For each amino acid residue in each parent or variant protease, of the invention and/or for use according to the invention, it is possible to directly and unambiguously assign an amino acid residue in SEQ ID NO: 2 to which it corresponds. Corresponding residues are assigned the same number, by reference to the Protease 10 sequence.

As it appears from the numbering of Fig. 1, in conjunction with the numbering of the sequence listing, for each amino acid residue of each of the proteases Protease 10, Protease 18, Protease 11, Protease 35, and Protease 08, the corresponding amino acid residue in SEQ ID NO: 2 has the same number. This number is easily derivable from Fig. 1. At least in case of these five proteases, the number is the same as the number assigned to this amino acid residue in the sequence listing for the mature part of the respective protease.

For a given position in another protease - be it a parent or a variant protease - a corresponding position of SEQ ID NO: 2 can always be found, as follows:

The amino acid sequence of another parent protease, or, in turn, of a variant protease amino acid sequence, is designated SEQ-X. A position corresponding to position N of SEQ ID NO: 2 is found as follows: The parent or variant protease amino acid sequence SEQ-X is aligned with SEQ ID NO: 2 as specified above in the section entitled Amino Acid Homology. From the alignment, the position in sequence SEQ-X corresponding to position N of SEQ ID NO: 2 can be clearly and unambiguously derived, using the principles described below.

SEQ-X may be a mature part of the protease in question, or it may also include a signal peptide part, or it may be a fragment of the mature protease which has protease activity, e.g. a fragment of the same length as SEQ ID NO: 2, and/or it may be the fragment which extends from A1 to T188 when aligned with SEQ ID NO: 2 as described herein.

### Region and Position

In the present context, the term region means at least one position of a parent protease amino acid sequence, the term position designating an amino acid residue of such amino acid sequence. In one embodiment, region means one or more successive positions of the parent protease amino acid sequence, e.g. one, two, three, four, five, six, seven, eight, etc., up to any number of consecutive positions of the sequence. Accordingly, a region may consist of one position only, or it may consist of any number of consecutive positions, such as, e.g., position no. 62 and 63; or position no. 111, 112, 113 and 114. For the present purposes, these two regions are designated 62-63, and 111-114, respectively. The boundaries of these regions or ranges are included in the region.

A region encompasses specifically each and every position it embraces. For example, region 111-114 specifically encompasses each of the positions 111, 112, 113, and 114. The

10508.010-OK

same applies by analogy for the other regions mentioned herein.

### Thermostability

For the present purposes, the term thermostable as applied in the context of a certain polypeptide, refers to the melting temperature,  $T_m$ , of such polypeptide, as determined using Differential Scanning Calorimetry (DSC) in 10mM sodium phosphate, 50 mM sodium chloride, pH 7.0, using a constant scan rate of 1.5°C/min.

The following  $T_m$ 's were determined under the above conditions: 76.5°C (Protease 10), 83.0°C (Protease 18), 78.3°C (Protease 08), 76.6°C (Protease 35), 73.7°C (Protease 11), and 83.5°C (Protease 22).

For a thermostable polypeptide, the  $T_m$  is at least 83.1°C. In particular embodiments, the  $T_m$  is at least 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or at least 100°C.

In the alternative, the term thermostable refers to a melting temperature of at least 73.8, or at least 76.7°C, or at least 78.4°C, preferably at least 74, 75, 76, 77, 78, 79, 80, 81, 82, or at least 83°C, still as determined using DSC at a pH of 7.0.

For the determination of  $T_m$ , a sample of the polypeptide with a purity of at least 90% (or 91, 92, 93, 94, 95, 96, 97, or 98%) as determined by SDS-PAGE may be used. Still further, the enzyme sample may have a concentration of between 0.5 and 2.5 mg/ml protein (or between 0.6 and 2.4, or between 0.7 and 2.2, or between 0.8 and 2.0 mg/ml protein), as determined from absorbance at 280 nm and based on an extinction coefficient calculated from the amino acid sequence of the enzyme in question.

The DSC takes place at the desired pH (e.g. pH 5.5, 7.0, 3.0, or 2.5) and with a constant heating rate, e.g. of 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10°C/min.

In a particular embodiment, the protease variant of the invention is more thermostable than the parent protease. A preferred parent protease for this purpose is Protease 18.

### Temperature Activity Profile

In a particular embodiment, the protease variant of the invention exhibits an amended temperature activity profile as compared to, e.g., Protease 10 (or Protease 18, Protease 11, Protease 35, or Protease 08). For example, the protease variant of the invention may exhibit a relative activity at pH 9 and 80°C of at least 0.40, preferably at least 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, or at least 0.95, the term "relative" referring to the maximum activity measured for the protease in question. For Protease 22, the activity is relative to the activity at 80°C which is set to 1.000 (100%), and for Protease 10, the activity at 70°C is set to 1.000 (100%), see Example 2. As another example, the protease variant of the invention exhibits a relative activity at pH 9 and 90°C of at least 0.10, preferably at least 0.15, 0.20,

10508.010-DK

0.25, 0.30, or of at least 0.35. In a particular embodiment, the protease activity is measured using the Protazyme AK assay of Example 1.

#### Low-allergenic Variants

5 In a specific embodiment, the protease variants of the present invention are (also) low-allergenic variants, designed to invoke a reduced immunological response when exposed to animals, including man. The term immunological response is to be understood as any reaction by the immune system of an animal exposed to the protease variant. One type of immunological response is an allergic response leading to increased levels of IgE in the  
10 exposed animal. Low-allergenic variants may be prepared using techniques known in the art. For example the protease variant may be conjugated with polymer moieties shielding portions or epitopes of the protease variant involved in an immunological response. Conjugation with polymers may involve in vitro chemical coupling of polymer to the protease variant, e.g. as described in WO 96/17929, WO 98/30682, WO 98/35026, and/or WO 99/00489. Conjugation  
15 may in addition or alternatively thereto involve in vivo coupling of polymers to the protease variant. Such conjugation may be achieved by genetic engineering of the nucleotide sequence encoding the protease variant, inserting consensus sequences encoding additional glycosylation sites in the protease variant and expressing the protease variant in a host capable of glycosylating the protease variant, see e.g. WO 00/26354. Another way of  
20 providing low-allergenic variants is genetic engineering of the nucleotide sequence encoding the protease variant so as to cause the protease variants to self-oligomerize, effecting that protease variant monomers may shield the epitopes of other protease variant monomers and thereby lowering the antigenicity of the oligomers. Such products and their preparation is described e.g. in WO 96/16177. Epitopes involved in an immunological response may be  
25 identified by various methods such as the phage display method described in WO 00/26230 and WO 01/83559, or the random approach described in EP 561907. Once an epitope has been identified, its amino acid sequence may be altered to produce altered immunological properties of the protease variant by known gene manipulation techniques such as site directed mutagenesis (see e.g. WO 00/26230, WO 00/26354 and/or WO 00/22103) and/or  
30 conjugation of a polymer may be done in sufficient proximity to the epitope for the polymer to shield the epitope.

#### Nucleic Acid Sequences and Constructs

35 The present invention also relates to nucleic acid sequences comprising a nucleic acid sequence which encodes a protease variant of the invention.

The term "isolated nucleic acid sequence" refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, e.g., at least about 20% pure, preferably at

10508.010-DK

least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

The nucleic acid sequences of the invention can be prepared by introducing at least one mutation into the parent protease coding sequence or a subsequence thereof, wherein the mutant nucleic acid sequence encodes a variant protease. The introduction of a mutation into the nucleic acid sequence to exchange one nucleotide for another nucleotide may be accomplished by site-directed mutagenesis using any of the methods known in the art, e.g. by site-directed mutagenesis, by random mutagenesis, or by doped, spiked, or localized random mutagenesis.

Random mutagenesis is suitably performed either as localized or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid sequence shown in question, or within the whole gene. When the mutagenesis is performed by the use of an oligonucleotide, the oligonucleotide may be doped or spiked with the three non-parent nucleotides during the synthesis of the oligonucleotide at the positions which are to be changed. The doping or spiking may be performed so that codons for unwanted amino acids are avoided. The doped or spiked oligonucleotide can be incorporated into the DNA encoding the protease enzyme by any technique, using, e.g., PCR, LCR or any DNA polymerase and ligase as deemed appropriate.

Preferably, the doping is carried out using "constant random doping", in which the percentage of wild-type and mutation in each position is predefined. Furthermore, the doping may be directed toward a preference for the introduction of certain nucleotides, and thereby a preference for the introduction of one or more specific amino acid residues. The doping may be made, e.g., so as to allow for the introduction of 90% wild type and 10% mutations in each position. An additional consideration in the choice of a doping scheme is based on genetic as well as protein-structural constraints.

The random mutagenesis may be advantageously localized to a part of the parent protease in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme.

Alternative methods for providing variants of the invention include gene shuffling e.g.

10508.010-DK

as described in WO 95/22625 or in WO 96/00343, and the consensus derivation process as described in EP 897985 (see the section "Parent Protease" for more details).

The present invention does not relate to the following nucleic acid sequences:

(i) Nucleotides 900-1466 of SEQ ID NO: 1, nucleotides 499-1062 of SEQ ID NO: 3,  
5 nucleotides 496-1059 of SEQ ID NO: 5, nucleotides 496-1059 of SEQ ID NO: 7, and  
nucleotides 502-1065 of SEQ ID NO: 9;

(ii) the nucleic acid sequence encoding the mature peptide part of the protease derived  
from *Nocardiopsis dassonvillei* NRRL 18133, in the event that this protease has at least 60%  
identity to SEQ ID NO: 2;

10 (iii) the nucleic acid sequence encoding the mature peptide part of the protease derived  
from *Nocardiopsis* sp. FERM P-10508, in the event that this protease has at least 60% identity  
to SEQ ID NO: 2;

(iv ) the nucleic acid sequence encoding the mature peptide part of the protease  
derived from *Nocardiopsis dassonvillei* strain ZIMET 43647; and/or

15 (v) nucleic acid sequences encoding any prior art proteases of at least 60% identity to  
SEQ ID NO: 2.

#### Nucleic Acid Constructs

20 A nucleic acid construct comprises a nucleic acid sequence of the present invention  
operably linked to one or more control sequences which direct the expression of the coding  
sequence in a suitable host cell under conditions compatible with the control sequences.  
Expression will be understood to include any step involved in the production of the polypeptide  
including, but not limited to, transcription, post-transcriptional modification, translation, post-  
translational modification, and secretion.

25

#### Expression vector

A nucleic acid sequence encoding a protease variant of the invention can be  
expressed using an expression vector which typically includes control sequences encoding a  
promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a  
30 repressor gene or various activator genes.

The recombinant expression vector carrying the DNA sequence encoding a protease  
variant of the invention may be any vector which may conveniently be subjected to  
recombinant DNA procedures, and the choice of vector will often depend on the host cell into  
which it is to be introduced. The vector may be one which, when introduced into a host cell, is  
35 integrated into the host cell genome and replicated together with the chromosome(s) into  
which it has been integrated.

The protease variant may also be co-expressed together with at least one other

10508.010-DK

enzyme of animal feed interest, such as an alpha-amylase, a phytase, a galactanase, a xylanase, an endoglucanase, an endo-1,3(4)-beta-glucanase, an alpha-galactosidase, and/or a protease. The enzymes may be co-expressed from different vectors, from one vector, or using a mixture of both techniques. When using different vectors, the vectors may have different selectable markers, and different origins of replication. When using only one vector, the genes can be expressed from one or more promoters. If cloned under the regulation of one promoter (di- or multi-cistronic), the order in which the genes are cloned may affect the expression levels of the proteins. The protease variant may also be expressed as a fusion protein, i.e. that the gene encoding the protease variant has been fused in frame to the gene encoding another protein. This protein may be another enzyme or a functional domain from another enzyme.

#### Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a nucleic acid sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote cell, such as an animal, a mammalian, an insect, a plant, or a fungal cell. Preferred animal cells are non-human animal cells.

In a preferred embodiment, the host cell is a fungal cell, or a yeast cell, such as a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell. The fungal host cell may be a filamentous fungal cell, such as a cell of a species of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma*. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*, or a *Streptomyces* cell, such as *Streptomyces lividans* or *Streptomyces murinus*, or a *Nocardiopsis* cell, or cells of lactic acid bacteria; or gram negative bacteria such as *E. coli* and *Pseudomonas sp.* Lactic acid bacteria include, but are not limited to, species of the genera *Lactococcus*, *Lactobacillus*, *Leuconostoc*, *Streptococcus*, *Pediococcus*, and *Enterococcus*.

10508,010-DK

### Methods of Production

The present invention also relates to methods for producing a protease variant of the present invention comprising (a) cultivating a host cell under conditions conducive for  
5 production of the protease variant; and (b) recovering the protease variant.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory  
10 or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture  
15 Collection). If the protease is secreted into the nutrient medium, it can be recovered directly from the medium. If it is not secreted, it can be recovered from cell lysates.

The resulting protease may be recovered by methods known in the art. For example, it can be recovered from the nutrient medium by conventional procedures, including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The proteases of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden,  
20 editors, VCH Publishers, New York, 1989).

### Plants

The present invention also relates to a transgenic plant, plant part, or plant cell which has been transformed with a nucleic acid sequence encoding a polypeptide having protease  
30 activity of the present invention so as to express and produce the polypeptide in recoverable quantities. The polypeptide may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the recombinant polypeptide may be used as such for improving the quality of a food or feed, e.g., improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.

In a particular embodiment, the polypeptide is targeted to the endosperm storage vacuoles in seeds. This can be obtained by synthesizing it as a precursor with a suitable signal peptide, see Horvath et al in PNAS, Feb. 15, 2000, vol. 97, no. 4, p. 1914-1919.



10508.010-DK

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot) or engineered variants thereof. Examples of monocot plants are grasses, such as meadow grass (blue grass, *Poa*), forage grass such as *Festuca*, *Lolium*, temperate grass, such as *Agrostis*, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, and maize (corn).

5 Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, rape seed, and the closely related model organism *Arabidopsis thaliana*. Low-phytate plants as described e.g. in US patent no. 5,689,054 and US patent no. 6,111,168 are examples of engineered plants. Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers, as well as the individual tissues comprising these parts, e.g. epidermis, mesophyll, parenchyma, vascular tissues, meristems. Also specific plant cell compartments, such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes, and cytoplasm are considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part. Likewise, plant parts such as specific tissues and cells isolated to facilitate the  
10 utilisation of the invention are also considered plant parts, e.g. embryos, endosperms, aleurone and seed coats.

Also included within the scope of the present invention are the progeny of such plants, plant parts and plant cells.

The transgenic plant or plant cell expressing a polypeptide of the present invention  
20 may be constructed in accordance with methods known in the art. Briefly, the plant or plant cell is constructed by incorporating one or more expression constructs encoding a polypeptide of the present invention into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

Conveniently, the expression construct is a nucleic acid construct which comprises a  
25 nucleic acid sequence encoding a polypeptide of the present invention operably linked with appropriate regulatory sequences required for expression of the nucleic acid sequence in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the  
30 latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences are determined, for example, on the basis of when, where, and how the polypeptide is desired to be expressed. For instance, the expression of the gene encoding a polypeptide of the present invention may be constitutive or inducible, or  
35 may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are, for example, described by Tague et al., 1988, *Plant Physiology* 86: 506.

10508.010-DK

For constitutive expression, the following promoters may be used: The 35S-CaMV promoter (Franck et al., 1980, Cell 21: 285-294), the maize ubiquitin 1 (Christensen AH, Sharrock RA and Quail 1992. Maize polyubiquitin genes: structure, thermal perturbation of expression and transcript splicing, and promoter activity following transfer to protoplasts by electroporation), or the rice actin 1 promoter (Plant Mo. Biol. 18, 675-689. Zhang W, McElroy D. and Wu R 1991, Analysis of rice Act1 5' region activity in transgenic rice plants. Plant Cell 3, 1155-1165). Organ-specific promoters may be, for example, a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990, Ann. Rev. Genet. 24: 275-303), or from metabolic sink tissues such as meristems (Ito et al., 1994, Plant Mol. Biol. 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice (Wu et al., 1998, Plant and Cell Physiology 39: 885-889), a Vicia faba promoter from the legumin B4 and the unknown seed protein gene from Vicia faba (Conrad et al., 1998, Journal of Plant Physiology 152: 708-711), a promoter from a seed oil body protein (Chen et al., 1998, Plant and Cell Physiology 39: 935-941), the storage protein napA promoter from Brassica napus, or any other seed specific promoter known in the art, e.g., as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the rbcS promoter from rice or tomato (Kozuka et al., 1993, Plant Physiology 102: 991-1000, the chlorella virus adenine methyltransferase gene promoter (Mittra and Higgins, 1994, Plant Molecular Biology 26: 85-93), or the aldP gene promoter from rice (Kagaya et al., 1995, Molecular and General Genetics 248: 668-674), or a wound inducible promoter such as the potato pin2 promoter (Xu et al., 1993, Plant Molecular Biology 22: 573-588). Likewise, the promoter may be inducible by abiotic treatments such as temperature, drought or alterations in salinity or inducible by exogenously applied substances that activate the promoter, e.g. ethanol, oestrogens, plant hormones like ethylene, abscisic acid, gibberellic acid, and/or heavy metals.

A promoter enhancer element may also be used to achieve higher expression of the enzyme in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding a polypeptide of the present invention. For instance, Xu et al., 1993, supra disclose the use of the first intron of the rice actin 1 gene to enhance expression.

Still further, the codon usage may be optimized for the plant species in question to improve expression (see Horvath et al referred to above).

The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.

The nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including Agrobacterium-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation,

10508.010-DK

and electroporation (Gasser et al., 1990, Science 244: 1293; Potrykus, 1990, Bio/Technology 8: 535; Shimamoto et al., 1989, Nature 338: 274).

Presently, *Agrobacterium tumefaciens*-mediated gene transfer is the method of choice for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, Plant Molecular Biology 19: 15-38), and it can also be used for transforming monocots, although other transformation methods are generally preferred for these plants. Presently, the method of choice for generating transgenic monocots, supplementing the *Agrobacterium* approach, is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, Plant Journal 2: 275-281; Shimamoto, 1994, Current Opinion Biotechnology 5: 158-162; Vasil et al., 1992, Bio/Technology 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh et al., 1993, Plant Molecular Biology 21: 415-428.

Following transformation, the transformants having incorporated therein the expression construct are selected and regenerated into whole plants according to methods well-known in the art.

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a transgenic plant or a plant cell comprising a nucleic acid sequence encoding a protease variant of the present invention under conditions conducive for production of the protease variant; and (b) recovering the protease variant.

#### Animals as Expression Hosts

The present invention also relates to a transgenic, non-human animal and products or elements thereof, examples of which are body fluids such as milk and blood, organs, flesh, and animal cells. Techniques for expressing proteins, e.g. in mammalian cells, are known in the art, see e.g. the handbook Protein Expression: A Practical Approach, Higgins and Hames (eds), Oxford University Press (1999), and the three other handbooks in this series relating to Gene Transcription, RNA processing, and Post-translational Processing. Generally speaking, to prepare a transgenic animal, selected cells of a selected animal are transformed with a nucleic acid sequence encoding a protease variant of the present invention so as to express and produce the protease variant. The protease variant may be recovered from the animal, e.g. from the milk of female animals, or it may be expressed to the benefit of the animal itself, e.g. to assist the animal's digestion. Examples of animals are mentioned below in the section headed Animal Feed and Animal Feed Additives.

To produce a transgenic animal with a view to recovering the protease variant from the milk of the animal, a gene encoding the protease variant may be inserted into the fertilized eggs of an animal in question, e.g. by use of a transgene expression vector which comprises a

10508.010-DK

suitable milk protein promoter, and the gene encoding the protease variant. The transgene expression vector is microinjected into fertilized eggs, and preferably permanently integrated into the chromosome. Once the egg begins to grow and divide, the potential embryo is implanted into a surrogate mother, and animals carrying the transgene are identified. The  
5 resulting animal can then be multiplied by conventional breeding. The protease variant may be purified from the animal's milk, see e.g. Meade, H.M. et al (1999): Expression of recombinant proteins in the milk of transgenic animals, Gene expression systems: Using nature for the art of expression. J. M. Fernandez and J. P. Hoeffler (eds.), Academic Press.

In the alternative, in order to produce a transgenic non-human animal that carries in  
10 the genome of its somatic and/or germ cells a nucleic acid sequence including a heterologous transgene construct including a transgene encoding the protease variant, the transgene may be operably linked to a first regulatory sequence for salivary gland specific expression of the protease variant, as disclosed in WO 2000064247.

#### 15 **Animal Feed and Animal Feed Additives**

For the present purposes, the term animal includes all animals, including human beings. In a particular embodiment, the protease variants and compositions of the invention can be used as a feed additive for non-human animals. Examples of animals are non-ruminants, and ruminants, such as sheep, goats, horses, and cattle, e.g. beef cattle, cows,  
20 and young calves. In a particular embodiment, the animal is a non-ruminant animal. Non-ruminant animals include mono-gastric animals, e.g. pigs or swine (including, but not limited to, piglets, growing pigs, and sows); poultry such as turkeys, ducks and chicken (including but not limited to broiler chicks, layers); young calves; and fish (including but not limited to salmon, trout, tilapia, catfish and carps; and crustaceans (including but not limited to shrimps and  
25 prawns).

The term feed or feed composition means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal. The feed can be fed to the animal before, after, or simultaneously with the diet. The latter is preferred.

The composition of the invention, when intended for addition to animal feed, may be  
30 designated an animal feed additive. Such additive always comprises the protease variant in question, preferably in the form of stabilized liquid or dry compositions. The additive may comprise other components or ingredients of animal feed. The so-called pre-mixes for animal feed are particular examples of such animal feed additives. Pre-mixes may contain the enzyme(s) in question, and in addition at least one vitamin and/or at least one mineral.

35 Accordingly, in a particular embodiment, in addition to the component polypeptides, the composition of the invention may comprise or contain at least one fat-soluble vitamin, and/or at least one water-soluble vitamin, and/or at least one trace mineral. Also at least one macro

10508.010-DK

mineral may be included.

Examples of fat-soluble vitamins are vitamin A, vitamin D3, vitamin E, and vitamin K, e.g. vitamin K3.

5 Examples of water-soluble vitamins are vitamin B12, biotin and choline, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid and panthothenate, e.g. Ca-D-panthothenate.

Examples of trace minerals are manganese, zinc, iron, copper, iodine, selenium, and cobalt.

Examples of macro minerals are calcium, phosphorus and sodium.

10 Further, optional, feed-additive ingredients are colouring agents, aroma compounds, stabilizers, additional enzymes, and antimicrobial peptides.

Additional enzyme components of the composition of the invention include at least one polypeptide having alpha-amylase activity, and/or at least one polypeptide having xylanase activity; and/or at least one polypeptide having endoglucanase activity; and/or at least one polypeptide having endo-1,3(4)-beta-glucanase activity; and/or at least one polypeptide having phytase activity; and/or at least one polypeptide having galactanase activity; and/or at least one polypeptide having alpha-galactosidase activity.

Alpha-amylase activity can be measured as is known in the art, e.g. using a starch-based substrate.

20 Xylanase activity can be measured using any assay, in which a substrate is employed, that includes 1,4-beta-D-xylosidic endo-linkages in xylans. Different types of substrates are available for the determination of xylanase activity e.g. Xylazyme cross-linked arabinoxylan tablets (from MegaZyme), or insoluble powder dispersions and solutions of azo-dyed arabinoxylan.

25 Endoglucanase activity can be determined using any endoglucanase assay known in the art. For example, various cellulose- or beta-glucan-containing substrates can be applied. An endoglucanase assay may use AZCL-Barley beta-Glucan, or preferably (1) AZCL-HE-Cellulose, or (2) Azo-CM-cellulose as a substrate. In both cases, the degradation of the substrate is followed spectrophotometrically at OD<sub>595</sub> (see the Megazyme method for AZCL-polysaccharides for the assay of endo-hydrolases at <http://www.megazyme.com/book-lets/AZCLPOL.pdf>).

30 Endo-1,3(4)-beta-glucanase activity can be determined using any endo-1,3(4)-beta-glucanase assay known in the art. A preferred substrate for endo-1,3(4)-beta-glucanase activity measurements is a cross-linked azo-coloured beta-glucan Barley substrate, wherein the measurements are based on spectrophotometric determination principles.

35 Phytase activity can be measured using any suitable assay, e.g. the FYT assay described in Example 4 of WO 98/28408.

Galactanase can be assayed e.g. with AZCL galactan from Megazyme, and alpha-

galactosidase can be assayed e.g. with pNP-alpha-galactoside.

For assaying these enzyme activities the assay-pH and the assay-temperature are to be adapted to the enzyme in question (preferably a pH close to the optimum pH, and a temperature close to the optimum temperature). A preferred assay pH is in the range of 2-10, preferably 3-9, more preferably pH 3 or 4 or 5 or 6 or 7 or 8, for example pH 3 or pH 7. A preferred assay temperature is in the range of 20-90°C, preferably 30-90°C, more preferably 40-80°C, even more preferably 40-70°C, preferably 40 or 45 or 50°C. The enzyme activity is defined by reference to appropriate blinds, e.g. a buffer blind.

Examples of antimicrobial peptides (AMP's) are CAP18, Leucocin A, Tritrpticin, Pro-tegrin-1, Thanatin, Defensin, Lactoferrin, Lactoferricin, and Ovispirin such as Novispirin (Robert Lehrer, 2000), Plectasins, and Statins, including the compounds and polypeptides disclosed in WO 03/044049 and WO 03/048148, as well as variants or fragments of the above that retain antimicrobial activity.

Examples of antifungal polypeptides (AFP's) are the *Aspergillus giganteus*, and *As-pergillus niger* peptides, as well as variants and fragments thereof which retain antifungal activity, as disclosed in WO 94/01459 and WO 02/090384.

Usually fat and water soluble vitamins, as well as trace minerals form part of a so-called premix intended for addition to the feed; whereas macro minerals are usually separately added to the feed. A premix enriched with a protease of the invention, is an example of an animal feed additive of the invention.

In a particular embodiment, the animal feed additive of the invention is intended for being included (or prescribed as having to be included) in animal diets or feed at levels of 0.01 to 10.0%; more particularly 0.05 to 5.0%; or 0.2 to 1.0% (% meaning g additive per 100 g feed). This is so in particular for premixes.

The nutritional requirements of these components (exemplified with poultry and piglets/pigs) are listed in Table A of WO 01/58275. Nutritional requirement means that these components should be provided in the diet in the concentrations indicated.

In the alternative, the animal feed additive of the invention comprises at least one of the individual components specified in Table A of WO 01/58275. At least one means either of, one or more of, one, or two, or three, or four and so forth up to all thirteen, or up to all fifteen individual components. More specifically, this at least one individual component is included in the additive of the invention in such an amount as to provide an in-feed concentration within the range indicated in column four, or column five, or column six of Table A.

The present invention also relates to animal feed compositions. Animal feed compositions or diets have a relatively high content of protein. Poultry and pig diets can be characterised as indicated in Table B of WO 01/58275, columns 2-3. Fish diets can be characterised as indicated in column 4 of this Table B. Furthermore such fish diets usually

10508.010-DK

have a crude fat content of 200-310 g/kg. WO 01/58275 corresponds to US 09/779334 which is hereby incorporated by reference.

An animal feed composition according to the invention has a crude protein content of 50-800 g/kg, and furthermore comprises at least one protease variant as claimed herein.

Furthermore, or in the alternative (to the crude protein content indicated above), the animal feed composition of the invention has a content of metabolisable energy of 10-30 MJ/kg; and/or a content of calcium of 0.1-200 g/kg; and/or a content of available phosphorus of 0.1-200 g/kg; and/or a content of methionine of 0.1-100 g/kg; and/or a content of methionine plus cysteine of 0.1-150 g/kg; and/or a content of lysine of 0.5-50 g/kg.

In particular embodiments, the content of metabolisable energy, crude protein, calcium, phosphorus, methionine, methionine plus cysteine, and/or lysine is within any one of ranges 2, 3, 4 or 5 in Table B of WO 01/58275 (R. 2-5).

Crude protein is calculated as nitrogen (N) multiplied by a factor 6.25, i.e. Crude protein (g/kg) = N (g/kg) x 6.25. The nitrogen content is determined by the Kjeldahl method (A.O.A.C., 1984, Official Methods of Analysis 14th ed., Association of Official Analytical Chemists, Washington DC).

Metabolisable energy can be calculated on the basis of the NRC publication Nutrient requirements in swine, ninth revised edition 1988, subcommittee on swine nutrition, committee on animal nutrition, board of agriculture, national research council. National Academy Press, Washington, D.C., pp. 2-6, and the European Table of Energy Values for Poultry Feed-stuffs, Spelderholt centre for poultry research and extension, 7361 DA Beekbergen, The Netherlands. Grafisch bedrijf Ponsen & Iooijen bv, Wageningen. ISBN 90-71463-12-5.

The dietary content of calcium, available phosphorus and amino acids in complete animal diets is calculated on the basis of feed tables such as Veevoedertabel 1997, gegevens over chemische samenstelling, verteerbaarheid en voederwaarde van voedermiddelen, Central Veevoederbureau, Runderweg 6, 8219 pk Lelystad. ISBN 90-72839-13-7.

In a particular embodiment, the animal feed composition of the invention contains at least one vegetable protein or protein source as defined above.

In still further particular embodiments, the animal feed composition of the invention contains 0-80% maize; and/or 0-80% sorghum; and/or 0-70% wheat; and/or 0-70% Barley; and/or 0-30% oats; and/or 0-40% soybean meal; and/or 0-10% fish meal; and/or 0-20% whey. Animal diets can e.g. be manufactured as mash feed (non pelleted) or pelleted feed. Typically, the milled feed-stuffs are mixed and sufficient amounts of essential vitamins and minerals are added according to the specifications for the species in question. Enzymes can be added as solid or liquid enzyme formulations. For example, a solid enzyme formulation is typically added before or during the mixing step; and a liquid enzyme preparation is typically added after the pelleting step. The enzyme may also be incorporated in a feed additive or premix.

10508.010-DK

The final enzyme concentration in the diet is within the range of 0.01-200 mg enzyme protein per kg diet, for example in the range of 0.5-25 mg enzyme protein per kg animal diet.

5 The protease variant should of course be applied in an effective amount, i.e. in an amount adequate for improving solubillisation and/or improving nutritional value of feed. It is at present contemplated that the enzyme is administered in one or more of the following amounts (dosage ranges): 0.01-200; 0.01-100; 0.5-100; 1-50; 5-100; 10-100; 0.05-50; or 0.10-10 – all these ranges being in mg protease enzyme protein per kg feed (ppm).

10 For determining mg enzyme protein per kg feed, the protease is purified from the feed composition, and the specific activity of the purified protease is determined using a relevant assay (see under protease activity, substrates, and assays). The protease activity of the feed composition as such is also determined using the same assay, and on the basis of these two determinations, the dosage in mg enzyme protein per kg feed is calculated.

15 The same principles apply for determining mg enzyme protein in feed additives. Of course, if a sample is available of the protease used for preparing the feed additive or the feed, the specific activity is determined from this sample (no need to purify the protease from the feed composition or the additive).

#### Detergent Compositions

20 The protease variant of the invention may be added to and thus become a component of a detergent composition.

The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.

25 In a specific aspect, the invention provides a detergent additive comprising the protease variant of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as another protease, such as alkaline proteases from *Bacillus*, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.

30 In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

35 Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from *Humicola* (synonym *Thermomyces*), e.g. from *H. lanuginosa* (*T. lanuginosus*) as described in



10508.010-DK

EP 258068 and EP 305216 or from *H. insolens* as described in WO 96/13580, a *Pseudomonas* lipase, e.g. from *P. alcaligenes* or *P. pseudoalcaligenes* (EP 218272), *P. cepacia* (EP 331376), *P. stutzeri* (GB 1,372,034), *P. fluorescens*, *Pseudomonas* sp. strain SD 705 (WO 95/06720 and WO 96/27002), *P. wisconsinensis* (WO 96/12012), a *Bacillus* lipase, e.g. from *B. subtilis* (Dartois et al. (1993), Biochemica et Biophysica Acta, 1131, 253-360), *B. stearothermophilus* (JP 64/744992) or *B. pumilus* (WO 91/16422). Other examples are lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407225, EP 260105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202. Preferred commercially available lipase enzymes include Lipolase<sup>TM</sup> and Lipolase Ultra<sup>TM</sup> (Novozymes A/S).

Suitable amylases (alpha- and/or beta-) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, alpha-amylases obtained from *Bacillus*, e.g. a special strain of *B. licheniformis*, described in more detail in GB 1,296,839. Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 95/26397, WO 96/23873, WO 97/43424, WO 00/60060, and WO 01/66712, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444. Commercially available amylases are Natalase<sup>TM</sup>, Supramyl<sup>TM</sup>, Stainzyme<sup>TM</sup>, Duramyl<sup>TM</sup>, Termamyl<sup>TM</sup>, Fungamyl<sup>TM</sup> and BAN<sup>TM</sup> (Novozymes A/S), Rapidase<sup>TM</sup> and Purastar<sup>TM</sup> (from Genencor International Inc.).

Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g. the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259. Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495257, EP 531372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and WO 99/01544. Commercially available cellulases include Celluzyme<sup>TM</sup>, and Carezyme<sup>TM</sup> (Novozymes A/S), Clazinase<sup>TM</sup>, and Puradax HATM (Genencor International Inc.), and KAC-500(B)TM (Kao Corporation).

Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g. from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include Guardzyme<sup>TM</sup> (Novozymes).

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separate additive or a combined additive, can be formulated e.g. as a granulate, a liquid, a slurry, etc. Preferred  
5 detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean  
10 molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming, coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme  
15 preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238216.

The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically  
20 containing up to 70 % water and 0-30 % organic solvent, or non-aqueous.

The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight.

When included therein the detergent will usually contain from about 1% to about 40%  
25 of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.

When included therein the detergent will usually contain from about 0.2% to about 40%  
30 of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyl dimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine ("glucamides").

The detergent may contain 0-65 % of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid,  
35 ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are

10508.010-DK

carboxymethylcellulose, poly(vinylpyrrolidone), poly (ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

5 The detergent may contain a bleaching system which may comprise a H<sub>2</sub>O<sub>2</sub> source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylenediamine or nonanoyloxybenzenesulfonate. Alternatively, the bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.

10 The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.

15 The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

20 It is at present contemplated that in the detergent compositions any enzyme, in particular the enzyme of the invention, may be added in an amount corresponding to 0.01-100 mg of enzyme protein per liter of wash liquor, preferably 0.05-5 mg of enzyme protein per liter of wash liquor, in particular 0.1-1 mg of enzyme protein per liter of wash liquor.

The enzyme of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202.

#### Method for Generating Protease Variants

25 The invention also relates to a method for generating a protease variant of an improved property, the method comprising the following steps:

- (a) selecting a parent protease of at least 60% identity to SEQ ID NO: 2;
- (b) establishing a 3D structure of the parent protease by homology modelling using the Fig. 2 structure as a model; and/or aligning the parent protease according to the alignment of Fig. 1;
- 30 (c) proposing at least one amino acid substitution, e.g. by:
  - (i) subjecting the 3D structure of (b) to MD simulations at increased temperatures, and identifying regions in the amino acid sequence of the parent protease of high mobility (isotropic fluctuations);
  - 35 (ii) introducing disulfid bridges by way of cysteine substitutions (C-C);
  - (iii) introducing proline substitutions (P);
  - (iv) replacing exposed neutral amino acid residues with negatively charged

10508.010-DK

amino acid residues (E,D);

(v) replacing exposed neutral amino acid residues with positively charged amino acid residues (R,K);

(vi) replacing small amino acid residues inside the protein with bulkier amino acid residues (W);

(vii) comparing by homology alignment and/or homology modelling according to step (c)(i) at least two related parent proteases and transferring amino acid residue differences inbetween these protease backbones, preferably from a backbone having the improved property to a backbone not having this improved property;

(d) preparing a DNA sequence encoding the parent protease but for inclusion of a DNA codon of the at least one amino acid substitution proposed in steps (c)(ii)-(c)(vii), or subjecting the parent DNA sequence to random mutagenesis, targetting at least one of the regions identified in step (c)(i);

(e) expressing the DNA sequence obtained in step (d) in a host cell, and

(h) selecting a host cell expressing a protease variant with an improved property.

The invention furthermore relates to a method for producing a protease variant obtainable or obtained by the method of generating protease variants described above, comprising (a) cultivating the host cell to produce a supernatant comprising the variant; and (b) recovering the variant.

#### Alternative Embodiment

In an alternative embodiment, the term "alteration" is used instead of "substitution" as the general term for amendments in the protease molecule. This alternative embodiment includes each of the claims formulated as exemplified below for claim 1, and also specifically includes everything what is stated herein, e.g. definitions (other than the definition of substitution), i.e. the various aspects, particular embodiments etc.

A variant of a parent protease, comprising an alteration in at least one position of at least one region selected from the group of regions consisting of:

6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188; wherein

(a) the alteration(s) are independently

(i) an insertion of an amino acid immediately downstream of the position,

(ii) a deletion of the amino acid which occupies the position, and/or

(iii) a substitution of the amino acid which occupies the position;

(b) the variant has protease activity; and

(c) each position corresponds to a position of SEQ ID NO: 2; and

10508.010-DK

(d) the variant has a percentage of identity to SEQ ID NO: 2 of at least 60%.

The term "polypeptide variant", "protein variant", "enzyme variant", "protease variant" or simply "variant" refers to a polypeptide of the invention comprising one or more alteration(s), such as substitution(s), insertion(s), deletion(s), and/or truncation(s) of one or more specific amino acid residue(s) in one or more specific position(s) in the polypeptide.

The term "parent polypeptide", "parent protein", "parent enzyme", "standard enzyme", "parent protease" or simply "parent" refers to the polypeptide on which the variant was based. This term also refers to the polypeptide with which a variant is compared and aligned.

The term "randomized library", "variant library", or simply "library" refers to a library of variant polypeptides. Diversity in the variant library can be generated via mutagenesis of the genes encoding the variants at the DNA triplet level, such that individual codons are variegated e.g. by using primers of partially randomized sequence in a PCR reaction. Several techniques have been described, by which one can create a diverse combinatorial library by variegating several nucleotide positions in a gene and recombining them, for instance where these positions are too far apart to be covered by a single (spiked or doped) oligonucleotide primer. These techniques include the use of in vivo recombination of the individually diversified gene segments as described in WO 97/07205 on page 3, lines 8 to 29 (Novozymes A/S). They also include the use of DNA shuffling techniques to create a library of full length genes, wherein several gene segments are combined, and wherein each segment may be diversified e.g. by spiked mutagenesis (Stemmer, Nature 370, pp. 389-391, 1994 and US 5,811,238; US 5,605,793; and US 5,830,721). One can use a gene encoding a protein "backbone" (wildtype parent polypeptide) as a template polynucleotide, and combine this with one or more single or double-stranded oligonucleotides as described in WO 98/41623 and in WO 98/41622 (Novozymes A/S). The single-stranded oligonucleotides could be partially randomized during synthesis. The double-stranded oligonucleotides could be PCR products incorporating diversity in a specific region. In both cases, one can dilute the diversity with corresponding segments encoding the sequence of the backbone protein in order to limit the average number of changes that are introduced.

Methods have also been established for designing the ratios of nucleotide mixtures (A; C; T; G) to be inserted in specific codon positions during oligo- or polynucleotide synthesis, so as to introduce a bias in order to approximate a desired frequency distribution towards a set of one or more desired amino acids that will be encoded by the particular codons. It may be of interest to produce a variant library, that comprises permutations of a number of known amino acid modifications in different locations in the primary sequence of the polypeptide. These could be introduced post-translationally or by chemical modification sites, or they could be introduced through mutations in the encoding genes. The modifications by themselves may previously have been proven beneficial for one reason or another (e.g. decreasing antigenicity,

10508.010-DK

or improving specific activity, performance, stability, or other characteristics). In such instances, it may be desirable first to create a library of diverse combinations of known sequences. For example, if twelve individual mutations are known, one could combine (at least) twelve segments of the parent protein encoding gene, wherein each segment is present in two forms: one with, and one without the desired mutation. By varying the relative amounts of those segments, one could design a library (of size 2<sup>12</sup>) for which the average number of mutations per gene can be predicted. This can be a useful way of combining mutations, that by themselves give some, but not sufficient effect, without resorting to very large libraries, as is often the case when using 'spiked mutagenesis'. Another way to combine these 'known mutations' could be by using family shuffling of oligomeric DNA encoding the known mutations with fragments of the full length wild type sequence.

In describing the various variants produced or contemplated according to the invention, a number of nomenclatures and conventions are used which are described in detail below. A frame of reference is first defined by aligning the variant polypeptide with a parent enzyme. A preferred parent enzyme is Protease 10 (SEQ ID NO: 2). Thereby a number of alterations will be defined in relation to the amino acid sequence of SEQ ID NO: 2.

A substitution in a variant is indicated as:

Original amino acid - position - substituted amino acid;

The three or one letter codes are used, including the codes Xaa and X to indicate any amino acid residue. Accordingly, the notation "T82S" or "Thr82Ser" means, that the variant comprises a substitution of threonine with serine in the variant amino acid position corresponding to the amino acid in position 82 in the parent enzyme, when the two are aligned as indicated above.

Where the original amino acid residue may be any amino acid residue, a short hand notation may at times be used indicating only the position, and the substituted amino acid, for example:

Position - substituted amino acid; or "82S",

Such a notation is particular relevant in connection with modification(s) in a series of homologous polypeptides.

Similarly when the identity of the substituting amino acid residue(s) is immaterial:

Original amino acid - position; or "T82"

When both the original amino acid(s) and substituted amino acid(s) may be any amino acid, then only the position is indicated, e.g.: "82".

When the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s), then the amino acids are listed separated by commas:

Original amino acids - position no. - substituted amino acids; or "T10E,D,Y".

A number of examples of this nomenclature are listed below:

10508.010-DK

The substitution of threonine for histidine in position 91 is designated as: "His91Thr" or "H91T"; or the substitution of any amino acid residue acid for histidine in position 91 is designated as: "His91Xaa" or "H91X" or "His91" or "H91".

For a modification where the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s), the substitution of glutamic acid, aspartic acid, or tyrosine for threonine in position 10:

"Thr10Glu,Asp,Tyr" or "T10E,D,Y"; which indicates the specific variants: "T10E", "T10D", and "T10Y".

A deletion of glycine in position 26 will be indicated by: "Gly26\*" or "G26\*"

Correspondingly, the deletion of more than one amino acid residue, such as the deletion of glycine and glutamine in positions 26 and 27 will be designated "Gly26\*+Gln27\*" or "G26\*+Q27\*"

The insertion of an additional amino acid residue such as e.g. a lysine after G26 is indicated by: "Gly26GlyLys" or "G26GK"; or, when more than one amino acid residue is inserted, such as e.g. a Lys, and Ala after G26 this will be indicated as: "Gly26GlyLysAla" or "G26GKA".

In such cases the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s). In the above example the sequences would thus be:

20	Parent:	Variant:		
	26	26	26a	26b
	G	G	K	A

In cases where an amino acid residue identical to the existing amino acid residue is inserted, it is clear that degeneracy in the nomenclature arises. If for example a glycine is inserted after the glycine in the above example this would be indicated by "G26GG".

Given that an alanine were present in position 25, the same actual change could just as well be indicated as "A25AG":

	Parent:	Variant:				
	Numbering I:	25	26	25	26	26a
30	Sequence:	A	G	A	G	G
	Numbering II:			25	25a	26

Such instances will be apparent to the skilled person, and the indication "G26GG" and corresponding indications for this type of insertions is thus meant to comprise such equivalent degenerate indications.

By analogy, if amino acid sequence segments are repeated in the parent polypeptide and/or in the variant, it will be apparent to the skilled person that equivalent degenerate indications are comprised, also when other alterations than insertions are listed such as

deletions and/or substitutions. For instance, the deletion of two consecutive amino acids "AG" in the sequence "AGAG" from position 194-197, may be written as "A194\*+G1956\*" or "A196\*+G197\*":

	Parent:				Variant:		
5	Numbering I:	194	195	196	197	194	195
	Sequence:	A	G	A	G	A	G
	Numbering II:					196	197

Variants comprising multiple modifications are separated by pluses, e.g.:

"Arg170Tyr+Gly195Glu" or "R170Y+G195E", representing modifications in positions 170 and 195 substituting tyrosine and glutamic acid for arginine and glycine, respectively. Thus,

"Tyr167Gly,Ala,Ser,Thr+Arg170Gly,Ala,Ser,Thr" designates the following variants:

"Tyr167Gly+Arg170Gly", "Tyr167Gly+Arg170Ala", "Tyr167Gly+Arg170Ser",  
 "Tyr167Gly+Arg170Thr", "Tyr167Ala+Arg170Gly", "Tyr167Ala+Arg170Ala",  
 "Tyr167Ala+Arg170Ser", "Tyr167Ala+Arg170Thr", "Tyr167Ser+Arg170Gly",  
 15 "Tyr167Ser+Arg170Ala", "Tyr167Ser+Arg170Ser", "Tyr167Ser+Arg170Thr",  
 "Tyr167Thr+Arg170Gly", "Tyr167Thr+Arg170Ala", "Tyr167Thr+Arg170Ser", and  
 "Tyr167Thr+Arg170Thr".

This nomenclature is particular relevant relating to modifications aimed at substituting, inserting or deleting amino acid residues having specific common properties, such  
 20 modifications are referred to as conservative amino acid modification(s).

The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

## 25 Examples

### Example 1: Protease assays

#### pNA assay

pNA substrate : Suc-AAPF-pNA (Bachem L-1400).

Temperature : Room temperature (25°C)

30 Assay buffers :100mM succinic acid, 100mM HEPES, 100mM CHES, 100mM CABS, 1mM CaCl<sub>2</sub>, 150mM KCl, 0.01% Triton X-100 adjusted to pH-values 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, and 12.0 with HCl or NaOH.

20µl protease (diluted in 0.01% Triton X-100) is mixed with 100µl assay buffer. The assay is started by adding 100µl pNA substrate (50mg dissolved in 1.0ml DMSO and further  
 35 diluted 45x with 0.01% Triton X-100). The increase in OD<sub>405</sub> is monitored as a measure of the protease activity.



25	0.010	0.024
37	0.028	0.068
50	0.069	0.199
60	0.138	0.510
70	0.474	1.000
80	1.000	0.394
90	0.375	-

From these results it appears that Protease 22 has a higher temperature optimum at pH 9 than the 10R protease, viz. around 80°C as compared to around 70°C.

Differential Scanning Calorimetry (DSC) was used to determine temperature stability at pH 7.0 of Protease 22 and Protease 10. The purified proteases were dialysed over night at 4°C against 10 mM sodium phosphate, 50 mM sodium chloride, pH 7.0 and run on a VP-DSC instrument (Micro Cal) with a constant scan rate of 1.5°C/min from 20 to 100°C. Data-handling was performed using the MicroCal Origin software.

The resulting denaturation or melting temperatures, T<sub>m</sub>'s, were: For Protease 22: 83.5°C; for Protease 10: 76.5°C.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. In the case of conflict, the present disclosure including definitions will control.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

### Claims

1. A variant of a parent protease, comprising a substitution in at least one position of at least one region selected from the group of regions consisting of:  
6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188; wherein
  - (a) the variant has protease activity; and
  - (b) each position corresponds to a position of SEQ ID NO: 2; and
  - (c) the variant has a percentage of identity to SEQ ID NO: 2 of at least 60%.
2. The variant of claim 1 which comprises a substitution in at least one of the following positions: 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 22; 23; 24; 25; 26; 27; 28; 32; 33; 34; 35; 36; 37; 38; 39; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57; 58; 62; 63; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 103; 104; 105; 106; 111; 112; 113; 114; 118; 119; 120; 121; 122; 123; 124; 125; 126; 127; 128; 129; 130; 131; 134; 135; 136; 139; 140; 141; 144; 145; 146; 147; 148; 149; 150; 151; 155; 156; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 179; 180; 181; 184; 185; 186; 187; and/or 188.
3. The variant of claim 2 which comprises a substitution in at least one of the following positions: 6; 7; 8; 9; 10; 12; 13; 16; 17; 18; 22; 23; 24; 25; 26; 27; 28; 32; 33; 37; 38; 39; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 58; 62; 63; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 103; 105; 106; 111; 113; 114; 118; 120; 122; 124; 125; 127; 129; 130; 131; 134; 135; 136; 139; 140; 141; 144; 145; 146; 147; 148; 149; 150; 151; 155; 156; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 179; 180; 181; 184; 185; 186; 187; and/or 188.
4. The variant of claim 3, which comprises at least one of the following substitutions: 6C; 7P; 8C; 9C; 10E,D; 12E,D; 13E,D,P; 16C; 17C; 18C; 22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; 23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; 25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; 26A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y; 28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; 32C; 33C; 37C; 39R,K; 42E,D; 43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; 44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y; 45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; 46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 49A,C,D,E,F,G,H,I,K,L,M,N,P,S,V,W,Y; 50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 52C;

55C; 56R,K; 58E,D; 62C; 63C; 66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; 70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 5 73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; 74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 76C; 78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y;  
 79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y; 80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W;  
 81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y;  
 83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 10 85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; 86C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y; 88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y; 90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 92P,R,K;  
 93P; 94C,P; 95E,D; 96E,D,P; 97R,K; 98P; 99R,K; 103C; 105C,P; 106C; 111R,K; 113E,D;  
 118R,K; 120E,D; 122K; 124R,K; 125P; 127R,K; 129E,D; 130E,D; 134C; 135P; 136P; 139C;  
 15 140E,D; 141C; 144C; 145C; 146C; 147W; 148C; 149C; 150E,D; 151P,E,D; 155C; 156C;  
 160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y;  
 162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,T,V,W,Y;  
 166A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,W,Y; 167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 20 168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; 172C; 173C; 174P; 175P; 176P; 180R,K;  
 181R,K; 184P; 187P; and/or 188R,K.

5. The variant of any one of claims 1-4 which comprises at least one of the following pairs  
 25 of substitutions: 6C+103C; 8C+105C; 76C+85C; 94C+149C; 55C+63C; 16C+145C;  
 33C+144C; 62C+173C; 106C+141C; 9C+17C; 18C+156C; 32C+144C; 37C+52C; 67C+71C;  
 134C+170C; 139C+163C; 146C+148C; and/or 155C+172C.

6. The variant of claim 5, which comprises at least one of the following pairs of  
 30 substitutions: 6C+103C; 8C+105C; 76C+85C; 94C+149C; 55C+63C; 16C+145C; 33C+144C;  
 62C+173C; and/or 106C+141C.

7. The variant of any one of claims 1-4 which comprises at least one of the following  
 substitutions: 81P; 82P; 151P; 176P; 24P; 25P; 92P; 93P; 94P; 96P; 98P; 105P; 136P; 184P;  
 35 187P; 174P; 7P; 13P; 23P; 27P; 125P; 135P; and/or 175P.

8. The variant of claim 7, which comprises at least one of the following substitutions: 81P;

10508.010-DK

82P; 151P; 176P; 24P; 25P; 92P; 93P; 94P; 96P; 98P; 105P; 136P; 184P; and/or 187P.

9. The variant of any one of claims 1-4 which comprises at least one of the following substitutions: 95E,D; 42E,D; 84E,D; 96E,D; 47E,D; 46E,D; 150E,D; 70E,D; 13E,D; 140E,D;  
 5 10E,D; 151E,D; 129E,D; 130E,D; 166E,D; 161E,D; 120E,D; 82E,D; 58E,D; 12E,D; 81E,D; 69E,D; 113E,D; 89E,D; and/or 160E,D.

10. The variant of claim 9 which comprises at least one of the following substitutions: 95E,D; 42E,D; 84E,D; 96E,D; 47E,D; 46E,D; 150E,D; 70E,D; 13E,D; and/or 140E,D.

- 10 11. The variant of any one of claims 1-4 which comprises at least one of the following substitutions: 124R,K; 72R,K; 97R,K; 127R,K; 56R,K; 122R,K; 181R,K; 180R,K; 25R,K; 92R,K; 39R,K; 99R,K; 111R,K; 24R,K; 118R,K; 162R,K; and/or 188R,K.

- 15 12. The variant of claim 11 which comprises at least one of the following substitutions: 124R,K; 72R,K; 97R,K; 127R,K; 56R,K; 122R,K; 181R,K; 180R,K; 25R,K; and/or 92R,K.

13. The variant of any one of claims 1-4 which comprises at least one of the following substitutions: 147W; 43W.

- 20 14. The variant of any one of claims 1-4 which comprises a substitution in at least one position of at least one region selected from the group of regions consisting of:  
 (i) 160-170, 78-90, 43-50, 66-75, and 22-28;  
 (ii) 160-170, 78-90, 43-50, and 66-75;  
 25 (iii) 160-170, 78-90, and 43-50;  
 (iv) 160-170, and 78-90; and/or  
 (v) 160-170.

15. The variant of any one of claims 1-4 which comprises at least one of the following  
 30 substitutions: 6C; 8C; 13E,D; 16C; 24P; 25K,P,R; 33C; 42E,D; 46D,E; 47D,E; 55C; 56R,K; 62C; 63C; 70D,E; 72K,R; 76C; 81P; 82P; 84D,E; 85C; 92P,R,K; 93P; 94C,P; 95E,D; 96E,D,P; 97R,K; 98P; 103C; 105C,P; 106C; 122R,K; 124R,K; 127R,K; 136P; 140E,D; 141C; 144C; 145C; 149C; 150E,D; 151P; 173C; 176P; 180R,K; 181R,K; 184P; and/or 187P.

- 35 16. The variant of any one of claims 1-3, which comprises at least one of the following substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C; T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;

- A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);  
 A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S);  
 G26A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; R38T; V39R,K;  
 5 Q42E,D,G,P; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 T44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T44S);  
 I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R49A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R49T,Q);  
 10 G50A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; Q54N,R; S55C; V56I,R,K;  
 P58E,D; A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 G67A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 15 L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;  
 S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 20 G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);  
 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; A89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A89T,S); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; H91T,S; N92P,R,K,S;  
 25 Q93P; A94C,P; P95A,E,D; I96A,E,D,P; G97R,K; S98P; S99A,Q,R,K; V100I; S103C; S105C,P;  
 T106C; C111R,K; T113E,D; I114V; G118N,R,K; S120T,E,D; S122R,K; P124R,K; E125P,Q;  
 T127R,K; T129E,D,Y,Q; N130E,D,S; M131L; T134C; T135P,N; V136P; E139C; P140E,D;  
 G141C; G144C; G145C; S146C; Y147F,W; I148C; S149C; G150E,D; T151P,E,D,S; G155C;  
 V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 30 S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R165S);  
 T166A,C,D,F,E,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T166V,F);  
 G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 35 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 F171Y; Y172C; Q173C; E174P; V175P; T176N,P; V179I,L; N180R,K,S; S181R,K; V184L,P;  
 R185T; L186I; R187P; and/or T188R,K; preferably at least one of the following:

T10Y, A25S, R38T, Q42P, T44S, R49K, Q54R, V56I, A62S, T82S, S99A, G118N, S120T, S122R, E125Q, T129Y, N130S, M131L, R165S, T166A, F171Y, T176N, V179L, N180S, V184L, and/or R185T.

- 5 17. The variant of any one of claims 1-3, which comprises at least one of the following substitutions: G6C; L7P; A8C; Y9C; Y10E,D,T; G12E,D; G13E,D,P; S16C; V17C; G18C; T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; S24A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S24A); A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S);
- 10 G26A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y; P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; T38R; V39R,K; G42E,D,P,Q; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; T44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T44S); I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;
- 15 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T49A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T49R,Q); G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T51V; F52C; Q53E; N54Q,R; S55C; V56I,R,K; P58E,D; A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y; G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;
- 20 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C; S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;
- 25 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; S82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S82T); G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; Q86A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y (preferably Q86A); S87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S87T);
- 30 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; T89A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T89A,S); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T91H,S; S92P,R,K,N; Q93P; A94C,P; P95A,E,D; A96E,D,I,P; G97R,K; S98P; A99R,K,S; V100I; S103C; S105C,P; T106C; C111R,K; T113E,D; I114V; N118G,R,K; T120E,D,S; R122K,S; P124R,K; Q125E,P; T127R,K; Y129E,D,T; S130E,D,N; L131M; T134C; N135P,T; V136P; E139C; P140E,D;
- 35 G141C; G144C; G145C; S146C; F147W,Y; I148C; S149C; G150E,D; S151P,E,D,T; G155C; V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;

10508.010-DK

N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 S165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S165R);  
 V166A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y (preferably V166F,T);  
 G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 5 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 Y171F; Y172C; Q173C; E174P; V175P; T176P,N; I179L;V N180R,K,S; S181R,K; V184L,P;  
 R185T; I186L; R187P; and/or T188R,K; preferably  
 S24A, A25S, G42P, T44S, T49K, T51V, Q53E, N54R, V56I, A62S, Q86A, S87T, T89A, T91H,  
 S92N, A96I, N135T, F147Y, S151T, V166A, T176N, I179L, N180S, V184L, R185T, and/or  
 10 I186L.

18. The variant of any one of claims 1-3, which comprises at least one of the following  
 substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C;  
 T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 15 A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);  
 A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S);  
 G26A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; R38T; V39R,K;  
 Q42E,D,G,P; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 20 S44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S44T);  
 I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Q49A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y (preferably Q49R,T);  
 G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; Q54N,R; S55C; I56R,K;  
 25 P58E,D; A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 30 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;  
 S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 35 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);  
 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; A89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y

- (preferably A89T,S); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; H91T,S; N92P,R,K,S;  
 Q93P; A94C,P; P95A,E,D; I96A,E,D,P; G97R,K; S98P; S99A,Q,R,K; V100I; S103C; S105C,P;  
 T106C; C111R,K; T113E,D; I114V; G118N,R,K; S120E,D,T; S122R,K; P124R,K; E125P,Q;  
 T127R,K; T129E,D,Q,Y; N130E,D,S; M131L; T134C; T135N,P; V136P; E139C; P140E,D;  
 5 G141C; G144C; G145C; S146C; Y147F,W; I148C; S149C; G150E,D; N151P,E,D,T; G155C;  
 V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R165S);  
 10 T166A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T166F,V);  
 G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 F171Y; Y172C; Q173C; E174P; V175P; T176N,P; V179I,L; N180R,K,S; S181R,K; V184L,P;  
 R185T; L186I; R187P; and/or T188R,K; preferably  
 15 T10Y, A25S, R38T, Q42P, Q49K, Q54R, A62S, T82S, S99A, G118N, S120T, S122R, E125Q,  
 T129Y, N130S, M131L, N151T, R165S, T166A, F171Y, T176N, V179L, N180S, V184L, and/or  
 R185T.
19. The variant of any one of claims 1-3, which comprises at least one of the following  
 20 substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C;  
 T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);  
 A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S);  
 G26A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 25 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; R38T; V39R,K;  
 Q42E,D,G,P; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 T44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T44S);  
 I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 30 R49A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R49Q,T);  
 G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; Q54N,R; S55C; I56R,K;  
 P58E,D; A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 35 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;



- S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 G83A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 5 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);  
 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; A89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A89S,T); G90A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; H91T,S; N92P,R,K,S;  
 Q93P; A94C,P; P95A,E,D; I96A,E,D,P; G97R,K; S98P; S99A,Q,R,K; V100I; S103C; S105C,P;  
 10 T106C; C111R,K; T113E,D; I114V; G118N,R,K; S120E,D,T; S122R,K; P124R,K; E125P,Q;  
 T127R,K; T129E,D,Q,Y; N130E,D,S; M131L; T134C; T135N,P; V136P; E139C; P140E,D;  
 G141C; G144C; G145C; S146C; Y147F,W; I148C; S149C; G150E,D; N151P,E,D,S,T;  
 G155C; V156C; G160A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 15 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R165S);  
 T166A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T166V);  
 G167A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 20 F171Y; Y172C; Q173C; E174P; V175P; T176N,P; V179I,L; N180R,K,S; S181R,K; V184L,P;  
 R185T; L186I; R187P; and/or T188R,K; preferably  
 T10Y, A25S, R38T, G42P, T44S, R49K, Q54R, A62S, T82S, S99A, G118N, S120T, S122R,  
 E125Q, T129Y, N130S, M131L, N151T, R165S, T166A, F171Y, T176N, V179L, N180S,  
 V184L, and/or R185T.
- 25  
 20. The variant of any one of claims 1-3, which comprises at least one of the following  
 substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C;  
 T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);  
 30 S25A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S25A);  
 G26A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; T38R; V39R,K;  
 P42E,D,G,Q; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 S44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S44T);  
 35 I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Q49A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y (preferably Q49R,T);

G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; R54N,Q; S55C; V56I,R,K;  
 P58E,D; S62A,C; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 5 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 L73A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;  
 S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 10 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,R,Q,S,T,V,W,Y  
 (preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);  
 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; S89A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y  
 15 (preferably S89A,T); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; S91H,T; S92P,R,K,N;  
 Q93P; A94C,P; A95E,D,P; I96A,E,D,P; G97R,K; S98P; Q99A,R,K,S; I100V; S103C; S105C,P;  
 T106C; C111R,K; T113E,D; V114I; G118N,R,K; T120E,D,S; S122R,K; P124R,K; Q125E,P;  
 T127R,K; Q129E,D,Y,T; N130E,D,S; L131M; T134C; N135P,T; V136P; E139C; P140E,D;  
 G141C; G144C; G145C; S146C; F147W,Y; I148C; S149C; G150E,D; S151P,E,D,T; G155C;  
 20 V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 S165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S165R);  
 F166A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably F166,T,V);  
 25 G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 Y171F; Y172C; Q173C; E174P; V175P; T176N,P; L179I,V; S180R,K,N; S181R,K; L184P,V;  
 T185R; L186I; R187P; and/or T188R,K; preferably  
 T10Y, Q49K, V56I, T82S, S89A, S91H, S92N, A95P, Q99A, I100V, V114I, G118N, S122R,  
 30 Q129Y, N130S, N135T, F147Y, S151T, and/or F166A.

21. The variant of any one of claims 1-16 and 18-20 which comprises at least one of the  
 following substitutions: T10Y, A24S, V51T, E53Q, T82S, A86Q, T87S, I96A, G118N, S122R,  
 N130S, L186I.

35

22. The variant of any one of claims 1-16 and 18-19 which comprises at least one of the  
 following substitutions: R38T; Q42G,P; R49T,Q; Q54N,R; A89S,T; H91S,T; N92S; S99A,Q;

10508.010-DK

A120T; E125Q; T129Y,Q; M131L; T135N; Y147F; N151S; R165S; T166V,F; F171Y; V179I,L; preferably at least one of the following substitutions: R38T; N92S; A120T; E125Q; M131L; T135N; Y147F; N151S; R165S; and/or F171Y.

5 23. The variant of any one of claims 1-19 which comprises at least one of the following substitutions: A25S, T44S, A62S, P95A, V100I, I114V, T176N, N180S, V184L, R185T.

24. The variant of any one of claims 1-23 which is not identical to any one of the following amino acid sequences: SEQ ID NO: 2, amino acids 1-188 of SEQ ID NO: 4, amino acids 1-188 of SEQ ID NO: 6, amino acids 1-188 of SEQ ID NO: 8, and amino acids 1-188 of SEQ ID NO: 10.

15 25. The variant of any one of claims 1-24 which is not identical to the protease derived from *Nocardiopsis dassonvillei* NRRL 18133, provided the latter has at least 60% identity to SEQ ID NO: 2.

26. The variant of any one of claims 1-25 which is not identical to the protease derived from *Nocardiopsis* sp. FERM P-10508, and/or *Nocardiopsis dassonvillei* strain ZIMET 43647 provided the respective protease has at least 60% identity to SEQ ID NO: 2.

20 27. The variant of any one of claims 1-26 which is not identical to any protease that may belong to the prior art and which has at least 60% identity to SEQ ID NO: 2.

25 28. The variant of any one of claims 1-27 which has amended properties, such as an improved thermostability and/or a higher or lower optimum temperature.

29. The variant of claim 28 which has a  $T_m$  of at least 83.1°C as measured by DSC in 10mM sodium phosphate, 50 mM sodium chloride, pH 7.0.

30 30. The variant of any one of claims 1-29 which derives from a strain of the genus *Nocardiopsis*.

35 31. The variant of claim 30 which derives from a strain of *Nocardiopsis alba*, *Nocardiopsis antarctica*, *Nocardiopsis prasina*, *Nocardiopsis composta*, *Nocardiopsis dassonvillei*, *Nocardiopsis exhalans*, *Nocardiopsis halophila*, *Nocardiopsis halotolerans*, *Nocardiopsis kunsanensis*, *Nocardiopsis listeri*, *Nocardiopsis lucentensis*, *Nocardiopsis metallicus*, *Nocardiopsis* sp., *Nocardiopsis synnematiformans*, *Nocardiopsis trehalosi*, *Nocardiopsis*

10508.010-DK

*tropica*, *Nocardioopsis umidischolae*, or *Nocardioopsis xinjiangensis*.

32. The variant of claim 31 which derives from *Nocardioopsis alba* DSM 15647, *Nocardioopsis dassonvillei* NRRL 18133, *Nocardioopsis dassonvillei* subsp. *dassonvillei* DSM 43235, *Nocardioopsis prasina* DSM 15648, *Nocardioopsis prasina* DSM 15649, *Nocardioopsis sp.* NRRL 18262, *Nocardioopsis dassonvillei* strain ZIMET 43647, or *Nocardioopsis sp.* FERM P-10508.

33. A method for generating a protease variant of an improved property, the method comprising the following steps:

- (a) selecting a parent protease of at least 60% identity to SEQ ID NO: 2;
- (b) establishing a 3D structure of the parent protease by homology modelling using the Fig. 2 structure as a model; and/or aligning the parent protease according to the alignment of Fig. 1;
- (c) proposing at least one amino acid substitution, e.g. by:
  - (i) subjecting the 3D structure of (b) to MD simulations at increased temperatures, and identifying regions in the amino acid sequence of the parent protease of high mobility (isotropic fluctuations);
  - (ii) introducing disulfid bridges by way of cysteine substitutions (C-C);
  - (iii) introducing proline substitutions (P);
  - (iv) replacing exposed neutral amino acid residues with negatively charged amino acid residues (E,D);
  - (v) replacing exposed neutral amino acid residues with positively charged amino acid residues (R,K);
  - (vi) replacing small amino acid residues inside the protein with bulkier amino acid residues (W);
  - (vii) comparing by homology alignment and/or homology modelling according to step (c)(i) at least two related parent proteases and transferring amino acid residue differences inbetween these protease backbones, preferably from a backbone having the improved property to a backbone not having this improved property;
- (d) preparing a DNA sequence encoding the parent protease but for inclusion of a DNA codon of the at least one amino acid substitution proposed in steps (c)(ii)-(c)(vii), or subjecting the parent DNA sequence to random mutagenesis, targetting at least one of the regions identified in step (c)(i);
- (e) expressing the DNA sequence obtained in step (d) in a host cell, and
- (h) selecting a host cell expressing a protease variant with an improved property.

10508.010-DK

34. A method of preparing a protease variant, the method comprising the steps of  
(a) cultivating the host cell of claim 33(h) to produce a supernatant comprising the variant; and  
(b) recovering the variant.
- 5 35. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the protease variant of any of claims 1-32, or the protease variant obtainable according to claim 34.
- 10 36. The nucleic acid sequence of claim 35 which is not identical to any one of the following nucleic acid sequences: Nucleotides 900-1466 of SEQ ID NO: 1, nucleotides 499-1062 of SEQ ID NO: 3, nucleotides 496-1059 of SEQ ID NO: 5, nucleotides 496-1059 of SEQ ID NO: 7, and nucleotides 502-1065 of SEQ ID NO: 9.
- 15 37. The nucleic acid sequence of claim 35 which is not identical to the nucleic acid sequence encoding the mature peptide part of the protease derived from *Nocardiopsis dassonvillei* NRRL 18133, provided this protease has at least 60% identity to SEQ ID NO: 2.
- 20 38. The nucleic acid sequence of claim 35 which is not identical to the nucleic acid sequence encoding the mature peptide part of the proteases derived from *Nocardiopsis* sp. FERM P-10508, and/or *Nocardiopsis dassonvillei* strain ZIMET 43647, provided the respective protease has at least 60% identity to SEQ ID NO: 2.
- 25 39. A nucleic acid construct comprising the nucleic acid sequence of any one of claims 35-38 operably linked to one or more control sequences that direct the production of the protease variant in a suitable expression host.
40. A recombinant expression vector comprising the nucleic acid construct of claim 39.
- 30 41. A recombinant host cell comprising the nucleic acid construct of claim 39 and/or the expression vector of claim 40.
42. A method for producing the protease variant of any one of claims 1-32, or the variant obtainable according to claim 34, the method comprising:  
(a) cultivating the host cell of claim 41 to produce a supernatant comprising the variant; and  
(b) recovering the variant.
- 35

10508.010-DK

43. A transgenic plant, or plant part, capable of expressing a protease variant of any one of claims 1-32, and/or a protease variant obtainable according to claim 34.
- 5 44. A transgenic, non-human animal, or products, or elements thereof, being capable of expressing a protease variant of any one of claims 1-32, and/or a protease variant obtainable according to claim 34.
- 10 45. A composition comprising at least one protease variant of any one of claims 1-32, and/or a protease variant obtainable according to claim 34, and
- (a) at least one fat soluble vitamin;
- (b) at least one water soluble vitamin; and/or
- (c) at least one trace mineral.
- 15 46. The composition of claim 45 further comprising at least one enzyme selected from the following group of enzymes: alpha-amylases, galactanases, alpha-galactosidases, xylanases, endoglucanases, endo-1,3(4)-beta-glucanases, and phytases.
47. The composition of any one of claims 45-46 which is an animal feed additive.
- 20 48. An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-47.
- 25 49. A method for improving the nutritional value of an animal feed, wherein the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-48 is added to the feed.
- 30 50. A method for the treatment of vegetable proteins, comprising the step of adding the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-48 to at least one vegetable protein or protein source.
- 35 51. Use of the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-48 (i) in animal feed; (ii) in the preparation of animal feed; (iii) for improving the nutritional value of animal feed; and/or (iv) for the treatment of vegetable proteins.

52. Use of the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34 in detergents.

**Abstract**

The invention relates to variants of a parent protease homologous to *Nocardopsis* proteases, in particular variants of improved thermostability and/or with an amended temperature activity profile, e.g. a temperature optimum of 80°C instead of 70°C. The  
5 invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.



	1	50
Protease 10	ADIIGGLAYTMGGRCVGF	AAATNAAGQPGFVTAGHCGRVGTQVTIGNGRG
Protease 18	ADIIGGLAYYMGGRCVGF	AAATNSAGQPGFVTAGHCGTVGTGVTIGNGTG
Protease 11	ADIIGGLAYTMGGRCVGF	AAATNAAGQPGFVTAGHCGRVGTQVSI
Protease 35	ADIIGGLAYTMGGRCVGF	AAATNAAGQPGFVTAGHCGRVGTQVTIGNGRG
Protease 08	ADIIGGLAYTMGGRCVGF	AAATNASGQPGFVTAGHCGTVGTPVSI
Protease 22	ADIIGGLAYYMGGRCVGF	AAATNASGQPGFVTAGHCGTVGTPVSI
		NGKG
	51	100
Protease 10	VFEQSVFPGNDAAFVRGTSNFTLTNLV	SRYNTGGYATVAGHNQAPIGSSV
Protease 18	TFQNSVFPGNDAAFVRGTSNFTLTNLV	SRYNSGGYQSVTGTSQAPAGSAV
Protease 11	VFEQSIFPGNDAAFVRGTSNFTLTNLV	SRYNTGGYATVAGHNQAPIGSSV
Protease 35	VFEQSIFPGNDAAFVRGTSNFTLTNLV	SRYNTGGYATVAGHNQAPIGSSV
Protease 08	VFERSVFPGNDAFVRGTSNFTLTNLV	SRYNTGGYATVSGSSQAAIGSQI
Protease 22	VFERSIFPGNDAFVRGTSNFTLTNLV	SRYNSGGYATVAGHNQAPIGSAV
	101	150
Protease 10	CRSGSTTGWHCGTIQARGQSVSY	PEGTVTNMTRTTVCAEPGDSGGSYISG
Protease 18	CRSGSTTGWHCGTIQARNQTVRY	PQGTVYSLTRTNVCAEPGDSGGSFISG
Protease 11	CRSGSTTGWHCGTIQARGQSVSY	PEGTVTNMTRTTVCAEPGDSGGSYISG
Protease 35	CRSGSTTGWHCGTIQARGQSVSY	PEGTVTNMTRTTVCAEPGDSGGSYISG
Protease 08	CRSGSTTGWHCGTVQARGQTVSY	PQGTVQNLTRTNVCAEPGDSGGSFISG
Protease 22	CRSGSTTGWHCGTIQARNQTVRY	PQGTVYSLTRTTVCAEPGDSGGSYISG
	151	188
Protease 10	TQAQGVTSGGSGNCRTGGTTFYQ	EVTMPVNSWGVRLRT
Protease 18	SQAQGVTSGGSGNCVGGTTYQ	EVTMPINSWGVRIRT
Protease 11	NQAQGVTSGGSGNCRTGGTTFYQ	EVTMPVNSWGVRLRT
Protease 35	NQAQGVTSGGSGNCRTGGTTFYQ	EVTMPVNSWGVRLRT
Protease 08	SQAQGVTSGGSGNCVGGTTYQ	EVPNMLSSWGLTLRT
Protease 22	TQAQGVTSGGSGNCVAGTTYQ	EVPNMLSSWGLTLRT

Fig. 1

O 1 MRS. 2004

Modtaget

1/25

ATOM	1	N	ALA	1	-18.517	32.531	28.661	1.00	8.90
ATOM	2	CB	ALA	1	-18.802	30.741	30.290	1.00	12.24
ATOM	3	CA	ALA	1	-19.308	31.313	28.965	1.00	10.86
ATOM	4	C	ALA	1	-20.783	31.666	29.080	1.00	12.18
ATOM	5	O	ALA	1	-21.113	32.695	29.712	1.00	12.73
ATOM	6	N	ASP	2	-21.722	30.930	28.510	1.00	12.01
ATOM	7	CA	ASP	2	-23.176	31.225	28.612	1.00	12.07
ATOM	8	C	ASP	2	-23.667	30.604	29.929	1.00	10.24
ATOM	9	O	ASP	2	-23.359	29.410	30.109	1.00	11.30
ATOM	10	CB	ASP	2	-23.995	30.629	27.422	1.00	12.43
ATOM	11	CG	ASP	2	-23.545	31.314	26.129	1.00	16.23
ATOM	12	OD1	ASP	2	-23.300	30.668	25.134	1.00	21.68
ATOM	13	OD2	ASP	2	-23.346	32.527	26.168	1.00	17.64
ATOM	14	N	ILE	3	-24.387	31.321	30.757	1.00	9.80
ATOM	15	CA	ILE	3	-24.850	30.687	32.027	1.00	8.80
ATOM	16	C	ILE	3	-26.252	30.135	31.768	1.00	7.97
ATOM	17	O	ILE	3	-27.160	30.953	31.648	1.00	8.91
ATOM	18	CB	ILE	3	-24.789	31.723	33.207	1.00	7.85
ATOM	19	CG1	ILE	3	-23.378	32.342	33.312	1.00	5.63
ATOM	20	CG2	ILE	3	-25.284	31.096	34.549	1.00	4.75
ATOM	21	CD1	ILE	3	-22.221	31.320	33.579	1.00	5.82
ATOM	22	N	ILE	4	-26.319	28.814	31.563	1.00	7.21
ATOM	23	CD1	ILE	4	-26.578	27.854	27.424	1.00	8.61
ATOM	24	CG1	ILE	4	-27.102	28.463	28.794	1.00	8.70
ATOM	25	CB	ILE	4	-27.272	27.363	29.888	1.00	7.20
ATOM	26	CG2	ILE	4	-28.446	26.419	29.544	1.00	6.35
ATOM	27	CA	ILE	4	-27.569	28.083	31.259	1.00	7.04
ATOM	28	C	ILE	4	-27.799	27.046	32.350	1.00	7.12
ATOM	29	O	ILE	4	-26.841	26.414	32.764	1.00	5.80
ATOM	30	N	GLY	5	-29.017	26.894	32.834	1.00	8.40
ATOM	31	CA	GLY	5	-29.415	25.958	33.863	1.00	5.51
ATOM	32	C	GLY	5	-29.031	24.550	33.483	1.00	6.74
ATOM	33	O	GLY	5	-29.222	24.181	32.306	1.00	8.02
ATOM	34	N	GLY	6	-28.492	23.787	34.436	1.00	5.32
ATOM	35	CA	GLY	6	-28.113	22.385	34.125	1.00	6.51
ATOM	36	C	GLY	6	-26.697	22.143	33.678	1.00	7.67
ATOM	37	O	GLY	6	-26.264	20.957	33.687	1.00	8.08
ATOM	38	N	LEU	7	-25.941	23.127	33.235	1.00	7.02
ATOM	39	CD2	LEU	7	-25.075	23.250	29.859	1.00	15.01
ATOM	40	CD1	LEU	7	-24.009	25.544	29.892	1.00	12.10
ATOM	41	CG	LEU	7	-24.823	24.494	30.662	1.00	11.57
ATOM	42	CB	LEU	7	-24.100	24.149	31.987	1.00	7.81
ATOM	43	CA	LEU	7	-24.543	22.889	32.774	1.00	7.23
ATOM	44	C	LEU	7	-23.543	22.624	33.891	1.00	8.17
ATOM	45	O	LEU	7	-23.779	23.055	35.054	1.00	8.83
ATOM	46	N	ALA	8	-22.450	21.931	33.560	1.00	7.85
ATOM	47	CB	ALA	8	-20.568	20.517	33.998	1.00	7.20
ATOM	48	CA	ALA	8	-21.436	21.658	34.583	1.00	6.67
ATOM	49	C	ALA	8	-20.554	22.867	34.856	1.00	8.14
ATOM	50	O	ALA	8	-20.241	23.793	34.058	1.00	7.62
ATOM	51	N	TYR	9	-20.078	22.906	36.110	1.00	6.90
ATOM	52	CA	TYR	9	-19.074	23.854	36.602	1.00	7.03
ATOM	53	C	TYR	9	-18.138	22.960	37.480	1.00	8.21
ATOM	54	O	TYR	9	-18.560	21.945	38.048	1.00	7.51

Fig. 2

2/25

ATOM	55	CB	TYR	9	-19.474	25.108	37.320	1.00	7.45
ATOM	56	CG	TYR	9	-20.138	24.925	38.664	1.00	9.14
ATOM	57	CD1	TYR	9	-19.401	24.898	39.853	1.00	8.86
ATOM	58	CD2	TYR	9	-21.559	24.818	38.673	1.00	8.66
ATOM	59	CE1	TYR	9	-20.044	24.756	41.062	1.00	7.11
ATOM	60	CE2	TYR	9	-22.214	24.696	39.930	1.00	8.78
ATOM	61	CZ	TYR	9	-21.438	24.673	41.072	1.00	7.41
ATOM	62	OH	TYR	9	-22.115	24.537	42.248	1.00	8.28
ATOM	63	N	THR	10	-16.867	23.367	37.552	1.00	8.23
ATOM	64	CG2	THR	10	-15.380	21.144	36.171	1.00	21.51
ATOM	65	OG1	THR	10	-14.022	22.954	36.816	1.00	17.27
ATOM	66	CB	THR	10	-14.816	21.869	37.398	1.00	15.54
ATOM	67	CA	THR	10	-15.881	22.592	38.334	1.00	12.22
ATOM	68	C	THR	10	-15.190	23.495	39.381	1.00	12.59
ATOM	69	O	THR	10	-15.040	24.724	39.295	1.00	11.83
ATOM	70	N	MET	11	-14.719	22.854	40.422	1.00	13.86
ATOM	71	CE	MET	11	-18.117	21.521	42.992	0.70	10.20
ATOM	72	SD	MET	11	-16.364	21.817	43.260	0.70	13.92
ATOM	73	CG	MET	11	-16.351	23.607	42.742	0.70	8.87
ATOM	74	CB	MET	11	-14.945	24.074	42.557	0.70	13.60
ATOM	79	CA	MET	11	-14.003	23.423	41.576	1.00	14.74
ATOM	80	C	MET	11	-13.204	22.219	42.141	1.00	16.84
ATOM	81	O	MET	11	-13.132	22.126	43.360	1.00	18.29
ATOM	82	N	GLY	12	-12.650	21.380	41.252	1.00	17.41
ATOM	83	CA	GLY	12	-11.931	20.160	41.721	1.00	20.30
ATOM	84	C	GLY	12	-12.961	19.034	41.377	1.00	22.00
ATOM	85	O	GLY	12	-12.730	18.252	40.444	1.00	25.04
ATOM	86	N	GLY	13	-14.079	19.064	42.126	1.00	17.68
ATOM	87	CA	GLY	13	-15.219	18.171	41.900	1.00	15.21
ATOM	88	C	GLY	13	-16.127	18.873	40.846	1.00	15.26
ATOM	89	O	GLY	13	-15.681	19.862	40.228	1.00	14.61
ATOM	90	N	ARG	14	-17.370	18.410	40.657	1.00	12.77
ATOM	91	NH2	ARG	14	-20.479	14.276	37.036	1.00	17.15
ATOM	92	NH1	ARG	14	-21.587	16.075	36.340	1.00	13.21
ATOM	93	CZ	ARG	14	-20.415	15.529	36.584	1.00	16.51
ATOM	94	NE	ARG	14	-19.265	16.236	36.423	1.00	15.10
ATOM	95	CD	ARG	14	-19.240	17.643	36.031	1.00	15.25
ATOM	96	CG	ARG	14	-19.255	18.517	37.291	1.00	14.76
ATOM	97	CB	ARG	14	-18.333	18.056	38.435	1.00	11.53
ATOM	98	CA	ARG	14	-18.269	19.018	39.659	1.00	11.00
ATOM	99	C	ARG	14	-19.665	19.162	40.278	1.00	9.52
ATOM	100	O	ARG	14	-20.027	18.274	41.091	1.00	8.13
ATOM	101	N	CYS	15	-20.368	20.221	39.853	1.00	8.85
ATOM	102	CA	CYS	15	-21.782	20.417	40.285	1.00	6.14
ATOM	103	C	CYS	15	-22.455	21.027	39.084	1.00	6.53
ATOM	104	O	CYS	15	-21.754	21.176	38.036	1.00	8.10
ATOM	105	CB	CYS	15	-21.897	21.271	41.568	1.00	7.27
ATOM	106	SG	CYS	15	-21.795	20.241	43.088	1.00	8.70
ATOM	107	N	SER	16	-23.746	21.368	39.154	1.00	5.13
ATOM	108	CA	SER	16	-24.402	21.936	37.975	1.00	4.73
ATOM	109	C	SER	16	-24.969	23.294	38.269	1.00	6.73
ATOM	110	O	SER	16	-25.331	23.536	39.470	1.00	7.15
ATOM	111	CB	SER	16	-25.540	20.930	37.602	1.00	5.02
ATOM	112	OG	SER	16	-25.031	19.670	37.228	1.00	7.01

Fig. 2

3/25

ATOM	113	N	VAL	17	-25.177	24.129	37.276	1.00	5.71
ATOM	114	CA	VAL	17	-25.780	25.469	37.450	1.00	6.30
ATOM	115	C	VAL	17	-27.274	25.365	37.742	1.00	6.27
ATOM	116	O	VAL	17	-27.904	24.514	37.084	1.00	6.87
ATOM	117	CB	VAL	17	-25.589	26.211	36.113	1.00	4.80
ATOM	118	CG1	VAL	17	-26.252	27.572	36.079	1.00	2.00
ATOM	119	CG2	VAL	17	-24.108	26.435	35.892	1.00	5.56
ATOM	120	N	GLY	18	-27.836	26.136	38.622	1.00	5.84
ATOM	121	CA	GLY	18	-29.277	26.067	38.899	1.00	4.89
ATOM	122	C	GLY	18	-29.898	27.072	37.958	1.00	7.79
ATOM	123	O	GLY	18	-30.578	26.683	36.960	1.00	8.56
ATOM	124	N	PHE	19	-29.783	28.366	38.175	1.00	6.84
ATOM	125	CA	PHE	19	-30.368	29.391	37.291	1.00	8.35
ATOM	126	C	PHE	19	-29.457	30.625	37.254	1.00	8.67
ATOM	127	O	PHE	19	-28.889	30.984	38.285	1.00	7.20
ATOM	128	CB	PHE	19	-31.761	29.873	37.827	1.00	6.74
ATOM	129	CG	PHE	19	-32.786	28.779	38.033	1.00	8.40
ATOM	130	CD1	PHE	19	-33.490	28.300	36.918	1.00	9.81
ATOM	131	CD2	PHE	19	-32.921	28.194	39.301	1.00	8.27
ATOM	132	CE1	PHE	19	-34.414	27.241	37.060	1.00	7.45
ATOM	133	CE2	PHE	19	-33.804	27.129	39.460	1.00	7.36
ATOM	134	CZ	PHE	19	-34.541	26.662	38.347	1.00	8.66
ATOM	135	N	ALA	20	-29.375	31.284	36.114	1.00	8.32
ATOM	136	CB	ALA	20	-28.552	32.954	34.501	1.00	7.08
ATOM	137	CA	ALA	20	-28.577	32.514	35.976	1.00	6.99
ATOM	138	C	ALA	20	-29.347	33.558	36.793	1.00	8.39
ATOM	139	O	ALA	20	-30.614	33.548	36.744	1.00	6.62
ATOM	140	N	ALA	21	-28.653	34.461	37.453	1.00	6.45
ATOM	141	CB	ALA	21	-29.774	34.943	39.600	1.00	6.04
ATOM	142	CA	ALA	21	-29.305	35.514	38.244	1.00	9.09
ATOM	143	C	ALA	21	-28.267	36.598	38.599	1.00	10.25
ATOM	144	O	ALA	21	-27.048	36.412	38.434	1.00	10.39
ATOM	145	N	THR	22	-28.734	37.704	39.154	1.00	10.87
ATOM	146	CA	THR	22	-27.795	38.747	39.633	1.00	9.81
ATOM	147	C	THR	22	-28.044	38.773	41.139	1.00	12.70
ATOM	148	O	THR	22	-29.153	38.378	41.607	1.00	13.28
ATOM	149	CB	THR	22	-28.009	40.191	39.000	1.00	12.32
ATOM	150	OG1	THR	22	-29.443	40.520	39.201	1.00	17.96
ATOM	151	CG2	THR	22	-27.730	40.314	37.512	1.00	10.22
ATOM	152	N	ASN	23	-27.067	39.261	41.919	1.00	12.56
ATOM	153	ND2	ASN	23	-23.651	39.789	44.187	1.00	14.15
ATOM	154	OD1	ASN	23	-25.034	41.090	43.182	1.00	11.99
ATOM	155	CG	ASN	23	-24.917	40.044	43.825	1.00	13.60
ATOM	156	CB	ASN	23	-26.025	39.065	44.153	1.00	12.41
ATOM	157	CA	ASN	23	-27.308	39.367	43.381	1.00	14.31
ATOM	158	C	ASN	23	-27.947	40.754	43.600	1.00	15.71
ATOM	159	O	ASN	23	-28.252	41.558	42.664	1.00	13.68
ATOM	160	N	ALA	24	-28.043	41.088	44.883	1.00	16.68
ATOM	161	CB	ALA	24	-28.899	42.370	46.862	1.00	19.20
ATOM	162	CA	ALA	24	-28.626	42.344	45.371	1.00	20.06
ATOM	163	C	ALA	24	-27.831	43.543	44.936	1.00	22.43
ATOM	164	O	ALA	24	-28.408	44.658	44.795	1.00	24.93
ATOM	165	N	ALA	25	-26.556	43.412	44.648	1.00	23.59
ATOM	166	CA	ALA	25	-25.727	44.513	44.128	1.00	20.79

Fig. 2

4/25

ATOM	167	C	ALA	25	-25.765	44.542	42.613	1.00	21.34
ATOM	168	O	ALA	25	-25.018	45.388	42.040	1.00	24.26
ATOM	169	CB	ALA	25	-24.278	44.379	44.584	1.00	24.28
ATOM	170	N	GLY	26	-26.508	43.687	41.910	1.00	16.97
ATOM	171	CA	GLY	26	-26.453	43.763	40.456	1.00	15.31
ATOM	172	C	GLY	26	-25.320	43.024	39.803	1.00	13.98
ATOM	173	O	GLY	26	-25.158	43.168	38.560	1.00	15.90
ATOM	174	N	GLN	27	-24.594	42.196	40.523	1.00	13.26
ATOM	175	NE2	GLN	27	-19.688	42.607	42.319	1.00	23.84
ATOM	176	OE1	GLN	27	-21.306	41.674	43.669	1.00	19.08
ATOM	177	CD	GLN	27	-20.952	42.234	42.626	1.00	20.42
ATOM	178	CG	GLN	27	-21.934	42.487	41.519	1.00	16.87
ATOM	179	CB	GLN	27	-22.364	41.130	40.909	1.00	13.66
ATOM	180	CA	GLN	27	-23.488	41.430	39.904	1.00	11.98
ATOM	181	C	GLN	27	-24.023	40.113	39.345	1.00	11.67
ATOM	182	O	GLN	27	-24.829	39.428	39.949	1.00	11.63
ATOM	183	N	PRO	28	-23.539	39.714	38.197	1.00	10.36
ATOM	184	CG	PRO	28	-22.111	39.444	36.367	1.00	11.95
ATOM	185	CD	PRO	28	-22.544	40.519	37.403	1.00	10.61
ATOM	186	CB	PRO	28	-23.429	38.692	36.116	1.00	11.06
ATOM	187	CA	PRO	28	-23.977	38.497	37.537	1.00	9.08
ATOM	188	C	PRO	28	-23.418	37.248	38.194	1.00	9.80
ATOM	189	O	PRO	28	-22.278	37.282	38.749	1.00	9.50
ATOM	190	N	GLY	29	-24.245	36.179	38.101	1.00	6.29
ATOM	191	CA	GLY	29	-23.721	34.885	38.671	1.00	4.48
ATOM	192	C	GLY	29	-24.827	33.875	38.440	1.00	6.36
ATOM	193	O	GLY	29	-25.604	34.036	37.454	1.00	7.58
ATOM	194	N	PHE	30	-24.889	32.917	39.339	1.00	7.28
ATOM	195	CA	PHE	30	-25.971	31.891	39.292	1.00	7.77
ATOM	196	C	PHE	30	-26.232	31.306	40.703	1.00	6.83
ATOM	197	O	PHE	30	-25.281	31.334	41.532	1.00	8.49
ATOM	198	CB	PHE	30	-25.653	30.741	38.312	1.00	3.78
ATOM	199	CG	PHE	30	-24.384	29.955	38.483	1.00	5.51
ATOM	200	CD1	PHE	30	-24.299	28.836	39.311	1.00	5.54
ATOM	201	CD2	PHE	30	-23.251	30.336	37.752	1.00	8.26
ATOM	202	CE1	PHE	30	-23.126	28.108	39.451	1.00	8.21
ATOM	203	CE2	PHE	30	-21.996	29.661	37.898	1.00	6.20
ATOM	204	CZ	PHE	30	-21.971	28.509	38.739	1.00	7.61
ATOM	205	N	VAL	31	-27.413	30.739	40.862	1.00	4.85
ATOM	206	CA	VAL	31	-27.751	30.017	42.118	1.00	6.26
ATOM	207	C	VAL	31	-27.445	28.530	41.828	1.00	6.68
ATOM	208	O	VAL	31	-27.515	28.036	40.680	1.00	4.79
ATOM	209	CB	VAL	31	-29.141	30.296	42.666	1.00	7.03
ATOM	210	CG1	VAL	31	-29.230	31.765	43.136	1.00	11.46
ATOM	211	CG2	VAL	31	-30.190	29.902	41.646	1.00	8.54
ATOM	212	N	THR	32	-27.150	27.786	42.910	1.00	5.51
ATOM	213	CA	THR	32	-26.762	26.373	42.892	1.00	7.30
ATOM	214	C	THR	32	-26.833	25.866	44.356	1.00	8.85
ATOM	215	O	THR	32	-27.382	26.568	45.240	1.00	6.58
ATOM	216	CB	THR	32	-25.318	26.271	42.249	1.00	6.85
ATOM	217	OG1	THR	32	-24.927	24.904	42.030	1.00	6.22
ATOM	218	CG2	THR	32	-24.141	26.895	43.109	1.00	4.90
ATOM	219	N	ALA	33	-26.318	24.676	44.619	1.00	8.92
ATOM	220	CA	ALA	33	-26.313	24.007	45.928	1.00	9.53

Fig. 2

5/25

ATOM	221	C	ALA	33	-25.158	24.465	46.827	1.00	9.16
ATOM	222	O	ALA	33	-24.007	24.503	46.369	1.00	8.53
ATOM	223	CB	ALA	33	-26.294	22.473	45.773	1.00	7.77
ATOM	224	N	GLY	34	-25.408	24.724	48.076	1.00	7.16
ATOM	225	CA	GLY	34	-24.348	25.143	49.024	1.00	8.05
ATOM	226	C	GLY	34	-23.390	24.043	49.347	1.00	7.39
ATOM	227	O	GLY	34	-22.194	24.315	49.698	1.00	8.30
ATOM	228	N	HIS	35	-23.788	22.780	49.271	1.00	7.52
ATOM	229	CA	HIS	35	-22.821	21.714	49.636	1.00	6.58
ATOM	230	C	HIS	35	-21.744	21.601	48.560	1.00	8.95
ATOM	231	O	HIS	35	-20.702	20.945	48.747	1.00	8.96
ATOM	232	CB	HIS	35	-23.497	20.364	49.883	1.00	8.85
ATOM	233	CG	HIS	35	-23.991	19.599	48.686	1.00	6.87
ATOM	234	ND1	HIS	35	-25.305	19.481	48.321	1.00	8.56
ATOM	235	CD2	HIS	35	-23.326	18.872	47.769	1.00	5.55
ATOM	236	CE1	HIS	35	-25.414	18.744	47.228	1.00	7.54
ATOM	237	NE2	HIS	35	-24.217	18.313	46.906	1.00	8.64
ATOM	238	N	CYS	36	-21.930	22.183	47.376	1.00	8.15
ATOM	239	CA	CYS	36	-20.940	22.145	46.312	1.00	8.05
ATOM	240	C	CYS	36	-19.746	23.062	46.679	1.00	11.13
ATOM	241	O	CYS	36	-18.715	22.841	45.999	1.00	10.34
ATOM	242	CB	CYS	36	-21.518	22.598	44.977	1.00	5.97
ATOM	243	SG	CYS	36	-22.774	21.389	44.403	1.00	9.16
ATOM	244	N	GLY	37	-19.855	24.012	47.601	1.00	9.60
ATOM	245	CA	GLY	37	-18.632	24.821	47.862	1.00	8.52
ATOM	246	C	GLY	37	-18.853	25.793	48.998	1.00	11.72
ATOM	247	O	GLY	37	-19.923	26.350	49.153	1.00	12.57
ATOM	248	N	ARG	38	-17.807	26.044	49.767	1.00	9.44
ATOM	249	NH2	ARG	38	-13.066	27.478	54.730	0.00	41.69
ATOM	250	NH1	ARG	38	-14.258	25.862	55.765	0.00	42.03
ATOM	251	CZ	ARG	38	-13.968	26.494	54.619	0.00	41.38
ATOM	252	NE	ARG	38	-14.559	26.142	53.467	0.00	39.87
ATOM	253	CD	ARG	38	-15.763	25.165	53.320	0.00	37.50
ATOM	254	CG	ARG	38	-17.064	25.666	52.814	1.00	23.13
ATOM	255	CB	ARG	38	-16.602	26.727	51.799	1.00	14.90
ATOM	256	CA	ARG	38	-17.812	27.040	50.845	1.00	12.65
ATOM	257	C	ARG	38	-17.566	28.415	50.239	1.00	11.84
ATOM	258	O	ARG	38	-16.987	28.562	49.137	1.00	10.80
ATOM	259	N	VAL	39	-17.953	29.488	50.953	1.00	12.22
ATOM	260	CA	VAL	39	-17.723	30.881	50.483	1.00	11.55
ATOM	261	C	VAL	39	-16.224	31.002	50.149	1.00	11.46
ATOM	262	O	VAL	39	-15.406	30.540	50.944	1.00	12.65
ATOM	263	CB	VAL	39	-18.195	31.902	51.513	1.00	14.37
ATOM	264	CG1	VAL	39	-17.541	33.262	51.282	1.00	18.26
ATOM	265	CG2	VAL	39	-19.720	32.035	51.617	1.00	19.01
ATOM	266	N	GLY	40	-15.853	31.595	49.017	1.00	10.59
ATOM	267	CA	GLY	40	-14.467	31.715	48.658	1.00	9.21
ATOM	268	C	GLY	40	-13.962	30.690	47.689	1.00	11.61
ATOM	269	O	GLY	40	-12.904	30.954	47.066	1.00	13.99
ATOM	270	N	THR	41	-14.603	29.592	47.441	1.00	10.26
ATOM	271	CG2	THR	41	-14.886	26.180	45.550	1.00	8.90
ATOM	272	OG1	THR	41	-15.058	26.792	47.930	1.00	14.49
ATOM	273	CB	THR	41	-15.123	27.285	46.571	1.00	12.41
ATOM	274	CA	THR	41	-14.199	28.566	46.525	1.00	9.98

Fig. 2

6/25

ATOM	275	C	THR	41	-14.360	29.148	45.121	1.00	11.13
ATOM	276	O	THR	41	-15.404	29.657	44.713	1.00	10.17
ATOM	277	N	GLN	42	-13.297	28.983	44.365	1.00	12.36
ATOM	278	NE2	GLN	42	-11.317	32.840	43.178	0.70	32.68
ATOM	279	OE1	GLN	42	-9.407	31.714	42.552	0.70	35.48
ATOM	280	CD	GLN	42	-10.512	31.791	43.080	0.70	30.29
ATOM	281	CG	GLN	42	-11.132	30.558	43.680	0.70	24.69
ATOM	282	CB	GLN	42	-11.801	29.729	42.592	0.70	18.80
ATOM	288	CA	GLN	42	-13.263	29.456	42.977	1.00	11.77
ATOM	289	C	GLN	42	-13.852	28.392	42.063	1.00	13.86
ATOM	290	O	GLN	42	-13.615	27.187	42.330	1.00	12.07
ATOM	291	N	VAL	43	-14.544	28.817	41.002	1.00	13.96
ATOM	292	CG2	VAL	43	-17.397	28.751	39.309	1.00	15.91
ATOM	293	CG1	VAL	43	-17.192	27.656	41.542	1.00	10.29
ATOM	294	CB	VAL	43	-16.657	27.731	40.117	1.00	14.08
ATOM	295	CA	VAL	43	-15.132	27.886	40.018	1.00	11.05
ATOM	296	C	VAL	43	-14.717	28.297	38.584	1.00	10.70
ATOM	297	O	VAL	43	-14.393	29.467	38.214	1.00	8.75
ATOM	298	N	THR	44	-14.726	27.266	37.757	1.00	8.19
ATOM	299	CG2	THR	44	-13.085	26.655	34.277	1.00	16.80
ATOM	300	OG1	THR	44	-12.054	27.080	36.423	1.00	14.72
ATOM	301	CB	THR	44	-13.232	26.536	35.773	1.00	7.96
ATOM	302	CA	THR	44	-14.459	27.387	36.328	1.00	8.95
ATOM	303	C	THR	44	-15.708	26.877	35.588	1.00	10.78
ATOM	304	O	THR	44	-16.155	25.743	35.947	1.00	9.00
ATOM	305	N	ILE	45	-16.219	27.660	34.626	1.00	10.77
ATOM	306	CA	ILE	45	-17.352	27.175	33.850	1.00	11.78
ATOM	307	C	ILE	45	-16.950	27.476	32.396	1.00	10.56
ATOM	308	O	ILE	45	-16.976	28.673	32.030	1.00	10.62
ATOM	309	CB	ILE	45	-18.743	27.767	34.312	1.00	8.73
ATOM	310	CG1	ILE	45	-19.767	27.359	33.217	1.00	14.25
ATOM	311	CG2	ILE	45	-18.635	29.300	34.483	1.00	14.91
ATOM	312	CD1	ILE	45	-21.239	27.351	33.717	1.00	17.74
ATOM	313	N	GLY	46	-16.588	26.493	31.623	1.00	11.49
ATOM	314	CA	GLY	46	-16.162	26.796	30.214	1.00	13.72
ATOM	315	C	GLY	46	-15.009	27.812	30.282	1.00	12.34
ATOM	316	O	GLY	46	-14.011	27.661	31.002	1.00	14.15
ATOM	317	N	ASN	47	-15.134	28.895	29.512	1.00	13.14
ATOM	318	ND2	ASN	47	-15.075	31.342	26.221	1.00	26.89
ATOM	319	OD1	ASN	47	-16.257	31.266	28.086	1.00	18.12
ATOM	320	CG	ASN	47	-15.180	31.045	27.520	1.00	19.67
ATOM	321	CB	ASN	47	-13.914	30.476	28.081	1.00	17.20
ATOM	322	CA	ASN	47	-14.106	29.967	29.522	1.00	14.86
ATOM	323	C	ASN	47	-14.409	31.129	30.484	1.00	14.20
ATOM	324	O	ASN	47	-13.929	32.264	30.367	1.00	16.69
ATOM	325	N	GLY	48	-15.234	30.900	31.476	1.00	11.79
ATOM	326	CA	GLY	48	-15.629	31.860	32.487	1.00	10.60
ATOM	327	C	GLY	48	-15.114	31.350	33.840	1.00	8.68
ATOM	328	O	GLY	48	-14.741	30.180	34.021	1.00	8.85
ATOM	329	N	ARG	49	-15.067	32.286	34.782	1.00	8.71
ATOM	330	NH2	ARG	49	-10.753	29.684	38.714	0.00	43.61
ATOM	331	NH1	ARG	49	-9.430	30.717	37.086	0.00	39.51
ATOM	332	CZ	ARG	49	-10.647	30.223	37.466	0.00	42.12
ATOM	333	NE	ARG	49	-11.803	30.174	36.714	0.00	38.98

Fig. 2

7/25

ATOM	334	CD	ARG	49	-11.625	30.774	35.625	1.00	24.44
ATOM	335	CG	ARG	49	-12.079	32.161	35.395	1.00	20.17
ATOM	336	CB	ARG	49	-13.190	32.537	36.355	1.00	13.15
ATOM	337	CA	ARG	49	-14.600	31.985	36.143	1.00	8.87
ATOM	338	C	ARG	49	-15.485	32.746	37.136	1.00	9.56
ATOM	339	O	ARG	49	-16.026	33.814	36.747	1.00	10.73
ATOM	340	N	GLY	50	-15.644	32.236	38.337	1.00	10.04
ATOM	341	CA	GLY	50	-16.416	32.933	39.372	1.00	6.68
ATOM	342	C	GLY	50	-15.985	32.438	40.758	1.00	7.46
ATOM	343	O	GLY	50	-15.035	31.654	40.838	1.00	8.57
ATOM	344	N	VAL	51	-16.755	32.885	41.756	1.00	9.13
ATOM	345	CG2	VAL	51	-15.047	33.181	45.219	1.00	9.31
ATOM	346	CG1	VAL	51	-16.041	34.936	43.760	1.00	9.54
ATOM	347	CB	VAL	51	-15.469	33.510	43.768	1.00	10.40
ATOM	348	CA	VAL	51	-16.439	32.474	43.145	1.00	8.97
ATOM	349	C	VAL	51	-17.739	32.363	43.951	1.00	8.46
ATOM	350	O	VAL	51	-18.657	33.166	43.726	1.00	8.01
ATOM	351	N	PHE	52	-17.778	31.394	44.846	1.00	7.71
ATOM	352	CD2	PHE	52	-20.510	28.198	46.287	1.00	7.34
ATOM	353	CE2	PHE	52	-20.952	27.038	45.614	1.00	12.48
ATOM	354	CZ	PHE	52	-20.103	26.415	44.672	1.00	11.92
ATOM	355	CE1	PHE	52	-18.857	26.983	44.355	1.00	8.56
ATOM	356	CD1	PHE	52	-18.454	28.151	45.012	1.00	7.30
ATOM	357	CG	PHE	52	-19.269	28.765	45.964	1.00	10.46
ATOM	358	CB	PHE	52	-18.820	30.015	46.703	1.00	9.22
ATOM	359	CA	PHE	52	-18.916	31.237	45.766	1.00	9.28
ATOM	360	C	PHE	52	-18.928	32.498	46.637	1.00	10.11
ATOM	361	O	PHE	52	-17.979	32.752	47.403	1.00	10.33
ATOM	362	N	GLU	53	-20.038	33.239	46.481	1.00	8.81
ATOM	363	OE2	GLU	53	-22.012	37.756	45.426	1.00	27.06
ATOM	364	OE1	GLU	53	-21.229	39.265	46.722	1.00	33.78
ATOM	365	CD	GLU	53	-21.338	38.087	46.413	1.00	28.53
ATOM	366	CG	GLU	53	-20.701	36.961	47.162	1.00	15.08
ATOM	367	CB	GLU	53	-20.818	35.612	46.441	1.00	10.91
ATOM	368	CA	GLU	53	-20.172	34.475	47.239	1.00	10.55
ATOM	369	C	GLU	53	-21.035	34.208	48.485	1.00	13.01
ATOM	370	O	GLU	53	-20.664	34.743	49.558	1.00	11.89
ATOM	371	N	GLN	54	-22.095	33.444	48.352	1.00	9.12
ATOM	372	NE2	GLN	54	-26.256	36.329	49.251	1.00	43.84
ATOM	373	OE1	GLN	54	-25.933	35.594	51.419	1.00	46.53
ATOM	374	CZ	GLN	54	-25.586	35.741	50.241	1.00	40.72
ATOM	375	CG	GLN	54	-24.256	35.205	49.756	1.00	29.81
ATOM	376	CB	GLN	54	-24.346	33.707	49.555	1.00	17.82
ATOM	377	CA	GLN	54	-22.955	33.105	49.508	1.00	10.81
ATOM	378	C	GLN	54	-23.164	31.600	49.527	1.00	12.82
ATOM	379	O	GLN	54	-23.418	31.101	48.410	1.00	13.75
ATOM	380	N	SER	55	-23.074	30.926	50.665	1.00	10.56
ATOM	381	OG	SER	55	-22.169	27.372	50.204	1.00	14.02
ATOM	382	CB	SER	55	-21.995	28.781	50.228	1.00	9.88
ATOM	383	CA	SER	55	-23.280	29.470	50.637	1.00	11.20
ATOM	384	C	SER	55	-23.730	28.998	52.014	1.00	12.70
ATOM	385	O	SER	55	-23.084	29.298	53.011	1.00	11.84
ATOM	386	N	VAL	56	-24.824	28.274	52.086	1.00	11.38
ATOM	387	CA	VAL	56	-25.345	27.735	53.342	1.00	9.56

Fig. 2



8/25

ATOM	388	C	VAL	56	-25.516	26.223	53.218	1.00	11.47
ATOM	389	O	VAL	56	-26.250	25.756	52.302	1.00	10.80
ATOM	390	CB	VAL	56	-26.691	28.365	53.715	1.00	12.57
ATOM	391	CG1	VAL	56	-27.250	27.561	54.895	1.00	13.65
ATOM	392	CG2	VAL	56	-26.542	29.809	54.111	1.00	14.61
ATOM	393	N	PHE	57	-24.903	25.475	54.116	1.00	9.44
ATOM	394	CA	PHE	57	-25.035	24.030	54.173	1.00	10.86
ATOM	395	C	PHE	57	-24.351	23.597	55.503	1.00	12.68
ATOM	396	O	PHE	57	-23.200	24.057	55.632	1.00	14.31
ATOM	397	CB	PHE	57	-24.383	23.289	52.962	1.00	9.20
ATOM	398	CG	PHE	57	-24.530	21.797	53.071	1.00	7.41
ATOM	399	CD1	PHE	57	-23.489	20.999	53.547	1.00	10.87
ATOM	400	CD2	PHE	57	-25.748	21.211	52.762	1.00	10.76
ATOM	401	CE1	PHE	57	-23.654	19.621	53.690	1.00	16.75
ATOM	402	CE2	PHE	57	-25.948	19.851	52.869	1.00	9.80
ATOM	403	CZ	PHE	57	-24.897	19.033	53.326	1.00	17.07
ATOM	404	N	PRO	58	-24.888	22.759	56.355	1.00	11.76
ATOM	405	CA	PRO	58	-26.182	22.082	56.294	1.00	11.15
ATOM	406	C	PRO	58	-27.302	22.967	56.755	1.00	9.63
ATOM	407	O	PRO	58	-27.072	24.207	56.657	1.00	10.82
ATOM	408	CB	PRO	58	-25.955	20.768	57.043	1.00	11.03
ATOM	409	CG	PRO	58	-24.947	21.178	58.078	1.00	12.71
ATOM	410	CD	PRO	58	-24.125	22.322	57.531	1.00	12.73
ATOM	411	N	GLY	59	-28.466	22.432	57.103	1.00	10.97
ATOM	412	CA	GLY	59	-29.594	23.338	57.495	1.00	11.26
ATOM	413	C	GLY	59	-30.330	23.680	56.200	1.00	10.98
ATOM	414	O	GLY	59	-31.477	23.240	56.091	1.00	11.30
ATOM	415	N	ASN	60	-29.767	24.482	55.291	1.00	10.66
ATOM	416	CA	ASN	60	-30.400	24.729	53.962	1.00	8.17
ATOM	417	C	ASN	60	-29.377	24.099	52.981	1.00	9.56
ATOM	418	O	ASN	60	-28.346	23.532	53.474	1.00	8.76
ATOM	419	CB	ASN	60	-30.598	26.175	53.595	1.00	9.50
ATOM	420	CG	ASN	60	-31.369	26.934	54.664	1.00	12.19
ATOM	421	OD1	ASN	60	-30.872	27.984	55.082	1.00	16.81
ATOM	422	ND2	ASN	60	-32.478	26.340	55.060	1.00	15.11
ATOM	423	N	ASP	61	-29.582	24.193	51.661	1.00	7.15
ATOM	424	CA	ASP	61	-28.544	23.661	50.701	1.00	7.83
ATOM	425	C	ASP	61	-28.598	24.692	49.547	1.00	8.69
ATOM	426	O	ASP	61	-29.213	24.393	48.519	1.00	7.71
ATOM	427	CB	ASP	61	-28.818	22.216	50.313	1.00	4.48
ATOM	428	CG	ASP	61	-27.637	21.575	49.640	1.00	6.18
ATOM	429	OD1	ASP	61	-27.591	20.419	49.245	1.00	6.86
ATOM	430	OD2	ASP	61	-26.622	22.316	49.431	1.00	8.20
ATOM	431	N	ALA	62	-28.041	25.868	49.751	1.00	7.72
ATOM	432	CB	ALA	62	-29.258	27.857	49.385	1.00	8.64
ATOM	433	CA	ALA	62	-28.134	26.967	48.775	1.00	8.98
ATOM	434	C	ALA	62	-26.880	27.802	48.618	1.00	9.19
ATOM	435	O	ALA	62	-26.114	27.939	49.618	1.00	10.25
ATOM	436	N	ALA	63	-26.667	28.360	47.434	1.00	7.69
ATOM	437	CA	ALA	63	-25.476	29.189	47.173	1.00	7.50
ATOM	438	C	ALA	63	-25.668	30.110	45.987	1.00	7.33
ATOM	439	O	ALA	63	-26.526	29.843	45.116	1.00	6.36
ATOM	440	CB	ALA	63	-24.247	28.263	46.886	1.00	4.57
ATOM	441	N	PHE	64	-24.889	31.172	45.985	1.00	8.23

Fig. 2

9/25

ATOM	442	CD2	PHE	64	-24.221	35.364	43.942	1.00	6.73
ATOM	443	CE2	PHE	64	-24.051	36.237	42.841	1.00	7.23
ATOM	444	CZ	PHE	64	-25.063	36.205	41.842	1.00	6.08
ATOM	445	CE1	PHE	64	-26.166	35.352	41.959	1.00	10.30
ATOM	446	CD1	PHE	64	-26.263	34.453	43.038	1.00	10.04
ATOM	447	CG	PHE	64	-25.287	34.477	44.027	1.00	6.69
ATOM	448	CB	PHE	64	-25.415	33.537	45.240	1.00	6.42
ATOM	449	CA	PHE	64	-24.840	32.152	44.922	1.00	7.87
ATOM	450	C	PHE	64	-23.351	32.196	44.518	1.00	10.06
ATOM	451	O	PHE	64	-22.454	32.478	45.362	1.00	10.39
ATOM	452	N	VAL	65	-23.080	31.952	43.234	1.00	8.61
ATOM	453	CA	VAL	65	-21.722	32.028	42.662	1.00	8.62
ATOM	454	C	VAL	65	-21.686	33.327	41.831	1.00	8.89
ATOM	455	O	VAL	65	-22.514	33.548	40.948	1.00	7.44
ATOM	456	CB	VAL	65	-21.338	30.840	41.722	1.00	11.34
ATOM	457	CG1	VAL	65	-20.018	31.055	40.967	1.00	10.37
ATOM	458	CG2	VAL	65	-21.333	29.530	42.493	1.00	9.94
ATOM	459	N	ARG	66	-20.744	34.213	42.094	1.00	6.55
ATOM	460	NH2	ARG	66	-16.111	39.098	43.470	1.00	18.29
ATOM	461	NH1	ARG	66	-17.309	39.979	41.747	1.00	18.67
ATOM	462	CZ	ARG	66	-17.271	39.260	42.832	1.00	18.74
ATOM	463	NE	ARG	66	-18.308	38.673	43.409	1.00	22.97
ATOM	464	CD	ARG	66	-19.672	38.751	42.950	1.00	23.13
ATOM	465	CG	ARG	66	-19.916	37.827	41.797	1.00	18.33
ATOM	466	CB	ARG	66	-19.949	36.464	42.422	1.00	12.11
ATOM	467	CA	ARG	66	-20.545	35.475	41.416	1.00	8.00
ATOM	468	C	ARG	66	-19.501	35.310	40.305	1.00	7.85
ATOM	469	O	ARG	66	-18.447	34.738	40.557	1.00	8.51
ATOM	470	N	GLY	67	-19.828	35.857	39.132	1.00	8.23
ATOM	471	CA	GLY	67	-18.921	35.779	37.962	1.00	3.28
ATOM	472	C	GLY	67	-17.838	36.834	38.114	1.00	7.11
ATOM	473	O	GLY	67	-18.123	38.019	38.332	1.00	9.23
ATOM	474	N	THR	68	-16.585	36.418	37.933	1.00	6.19
ATOM	475	CA	THR	68	-15.407	37.292	37.994	1.00	6.13
ATOM	476	C	THR	68	-14.784	37.468	36.611	1.00	10.55
ATOM	477	O	THR	68	-13.939	38.358	36.375	1.00	9.20
ATOM	478	CB	THR	68	-14.366	36.832	39.071	1.00	13.02
ATOM	479	OG1	THR	68	-13.865	35.569	38.579	1.00	9.29
ATOM	480	CG2	THR	68	-14.870	36.773	40.522	1.00	11.87
ATOM	481	N	SER	69	-15.205	36.672	35.618	1.00	12.02
ATOM	482	CA	SER	69	-14.736	36.796	34.233	1.00	11.62
ATOM	483	C	SER	69	-15.660	36.069	33.264	1.00	12.37
ATOM	484	O	SER	69	-15.911	34.865	33.480	1.00	11.23
ATOM	485	CB	SER	69	-13.337	36.184	34.027	1.00	12.32
ATOM	486	OG	SER	69	-12.823	36.389	32.763	1.00	15.07
ATOM	487	N	ASN	70	-16.100	36.767	32.236	1.00	12.58
ATOM	488	ND2	ASN	70	-16.685	36.201	28.330	1.00	20.03
ATOM	489	OD1	ASN	70	-15.425	34.370	28.194	1.00	19.07
ATOM	490	CG	ASN	70	-15.954	35.243	28.878	1.00	14.54
ATOM	491	CB	ASN	70	-15.848	35.335	30.379	1.00	8.27
ATOM	492	CA	ASN	70	-16.894	36.195	31.131	1.00	11.17
ATOM	493	C	ASN	70	-18.166	35.424	31.400	1.00	10.53
ATOM	494	O	ASN	70	-18.343	34.319	30.817	1.00	14.17
ATOM	495	N	PHE	71	-19.048	35.946	32.209	1.00	8.98

Fig. 2

10/25

ATOM	496	CD2	PHE	71	-21.139	34.054	36.002	1.00	5.72
ATOM	497	CE2	PHE	71	-20.735	33.063	36.900	1.00	7.44
ATOM	498	C2	PHE	71	-19.483	32.395	36.669	1.00	10.35
ATOM	499	CE1	PHE	71	-18.713	32.681	35.550	1.00	10.41
ATOM	500	CD1	PHE	71	-19.159	33.681	34.652	1.00	9.67
ATOM	501	CG	PHE	71	-20.350	34.372	34.873	1.00	5.76
ATOM	502	CB	PHE	71	-20.839	35.417	33.897	1.00	7.11
ATOM	503	CA	PHE	71	-20.346	35.257	32.435	1.00	10.26
ATOM	504	C	PHE	71	-21.337	35.958	31.503	1.00	11.61
ATOM	505	O	PHE	71	-21.429	37.207	31.537	1.00	14.68
ATOM	506	N	THR	72	-22.071	35.275	30.691	1.00	11.03
ATOM	507	CA	THR	72	-23.133	35.902	29.860	1.00	9.26
ATOM	508	C	THR	72	-24.405	35.261	30.425	1.00	9.51
ATOM	509	O	THR	72	-24.562	34.027	30.269	1.00	11.35
ATOM	510	CB	THR	72	-23.036	35.596	28.328	1.00	15.41
ATOM	511	OG1	THR	72	-21.768	36.189	27.928	1.00	15.46
ATOM	512	CG2	THR	72	-24.177	36.178	27.494	1.00	14.54
ATOM	513	N	LEU	73	-25.282	36.028	31.020	1.00	11.12
ATOM	514	CA	LEU	73	-26.502	35.479	31.608	1.00	9.31
ATOM	515	C	LEU	73	-27.504	35.184	30.484	1.00	9.04
ATOM	516	O	LEU	73	-27.563	35.896	29.460	1.00	8.44
ATOM	517	CB	LEU	73	-27.046	36.412	32.687	1.00	8.84
ATOM	518	CG	LEU	73	-26.215	36.869	33.883	1.00	13.85
ATOM	519	CD1	LEU	73	-27.074	37.521	34.968	1.00	12.85
ATOM	520	CD2	LEU	73	-25.471	35.702	34.530	1.00	9.85
ATOM	521	N	THR	74	-28.295	34.161	30.737	1.00	7.42
ATOM	522	CG2	THR	74	-27.696	32.554	28.200	1.00	3.40
ATOM	523	OG1	THR	74	-29.174	31.283	29.642	1.00	9.42
ATOM	524	CB	THR	74	-29.063	32.532	28.922	1.00	7.73
ATOM	525	CA	THR	74	-29.389	33.735	29.859	1.00	7.40
ATOM	526	C	THR	74	-30.600	33.347	30.732	1.00	10.05
ATOM	527	O	THR	74	-30.473	33.184	31.959	1.00	7.44
ATOM	528	N	ASN	75	-31.775	33.201	30.069	1.00	8.53
ATOM	529	ND2	ASN	75	-36.021	33.747	28.974	1.00	14.07
ATOM	530	OD1	ASN	75	-33.929	33.279	28.252	1.00	14.16
ATOM	531	CG	ASN	75	-34.723	33.526	29.157	1.00	15.69
ATOM	532	CB	ASN	75	-34.178	33.518	30.570	1.00	11.17
ATOM	533	CA	ASN	75	-32.924	32.729	30.849	1.00	9.39
ATOM	534	C	ASN	75	-33.156	31.252	30.465	1.00	10.95
ATOM	535	O	ASN	75	-34.322	30.835	30.620	1.00	13.03
ATOM	536	N	LEU	76	-32.177	30.516	29.993	1.00	7.99
ATOM	537	CD2	LEU	76	-32.993	29.592	26.412	1.00	11.04
ATOM	538	CD1	LEU	76	-30.530	29.917	26.112	1.00	13.41
ATOM	539	CG	LEU	76	-31.687	29.987	27.082	1.00	11.12
ATOM	540	CB	LEU	76	-31.416	29.013	28.250	1.00	10.63
ATOM	541	CA	LEU	76	-32.315	29.158	29.530	1.00	8.79
ATOM	542	C	LEU	76	-31.876	28.059	30.512	1.00	8.97
ATOM	543	O	LEU	76	-31.038	28.290	31.385	1.00	6.01
ATOM	544	N	VAL	77	-32.529	26.936	30.323	1.00	8.54
ATOM	545	CA	VAL	77	-32.285	25.689	31.062	1.00	8.05
ATOM	546	C	VAL	77	-32.125	24.578	29.973	1.00	9.00
ATOM	547	O	VAL	77	-33.126	24.380	29.178	1.00	6.78
ATOM	548	CB	VAL	77	-33.397	25.290	32.052	1.00	8.09
ATOM	549	CG1	VAL	77	-33.049	23.911	32.715	1.00	5.84

Fig. 2

11/25

ATOM	550	CG2	VAL	77	-33.575	26.350	33.142	1.00	10.07
ATOM	551	N	SER	78	-31.017	23.871	29.974	1.00	8.67
ATOM	552	OG	SER	78	-29.161	21.344	27.899	1.00	9.85
ATOM	553	CB	SER	78	-29.355	22.409	28.857	1.00	12.29
ATOM	554	CA	SER	78	-30.831	22.814	28.929	1.00	8.23
ATOM	555	C	SER	78	-31.710	21.583	29.189	1.00	9.82
ATOM	556	O	SER	78	-31.759	21.055	30.305	1.00	7.69
ATOM	557	N	ARG	79	-32.337	21.082	28.116	1.00	9.80
ATOM	558	NH2	ARG	79	-37.443	22.028	24.212	1.00	31.34
ATOM	559	NH1	ARG	79	-38.500	22.780	26.184	1.00	27.56
ATOM	560	CZ	ARG	79	-37.601	21.991	25.554	1.00	28.07
ATOM	561	NE	ARG	79	-36.785	21.131	26.161	1.00	21.89
ATOM	562	CD	ARG	79	-36.718	20.936	27.589	1.00	18.78
ATOM	563	CG	ARG	79	-35.265	21.118	27.992	1.00	9.14
ATOM	564	CB	ARG	79	-34.499	19.957	27.396	1.00	7.07
ATOM	565	CA	ARG	79	-33.163	19.879	28.166	1.00	10.01
ATOM	566	C	ARG	79	-32.272	18.740	27.659	1.00	11.09
ATOM	567	O	ARG	79	-32.799	17.622	27.476	1.00	11.76
ATOM	568	N	TYR	80	-30.980	18.901	27.456	1.00	10.89
ATOM	569	OH	TYR	80	-25.669	19.608	31.411	1.00	13.70
ATOM	570	CD2	TYR	80	-28.969	18.626	30.175	1.00	8.55
ATOM	571	CE2	TYR	80	-28.018	19.277	30.962	1.00	9.07
ATOM	572	CZ	TYR	80	-26.667	19.006	30.683	1.00	13.15
ATOM	573	CE1	TYR	80	-26.290	18.103	29.673	1.00	13.12
ATOM	574	CD1	TYR	80	-27.305	17.481	28.921	1.00	12.00
ATOM	575	CG	TYR	80	-28.646	17.742	29.153	1.00	10.87
ATOM	576	CB	TYR	80	-29.686	17.010	28.331	1.00	11.71
ATOM	577	CA	TYR	80	-30.100	17.809	27.036	1.00	13.19
ATOM	578	C	TYR	80	-30.669	16.889	25.939	1.00	15.57
ATOM	579	O	TYR	80	-31.074	17.414	24.848	1.00	16.53
ATOM	580	N	ASN	81	-30.732	15.583	26.157	1.00	15.67
ATOM	581	ND2	ASN	81	-30.251	12.075	23.672	0.50	23.42
ATOM	582	OD1	ASN	81	-31.653	10.851	24.930	0.50	22.68
ATOM	583	CG	ASN	81	-31.012	11.924	24.769	0.50	24.69
ATOM	584	CB	ASN	81	-30.915	13.117	25.699	0.50	20.33
ATOM	589	CA	ASN	81	-31.169	14.536	25.163	1.00	17.67
ATOM	590	C	ASN	81	-32.611	14.689	24.807	1.00	18.70
ATOM	591	O	ASN	81	-33.067	14.207	23.731	1.00	20.41
ATOM	592	N	THR	82	-33.405	15.385	25.621	1.00	15.25
ATOM	593	CG2	THR	82	-36.933	16.845	26.136	1.00	15.50
ATOM	594	OG1	THR	82	-35.944	14.838	27.235	1.00	15.80
ATOM	595	CB	THR	82	-35.663	16.070	26.495	1.00	13.76
ATOM	596	CA	THR	82	-34.787	15.661	25.275	1.00	16.61
ATOM	597	C	THR	82	-34.775	16.712	24.128	1.00	19.57
ATOM	598	O	THR	82	-35.725	16.765	23.314	1.00	20.18
ATOM	599	N	GLY	83	-33.765	17.555	23.973	1.00	17.44
ATOM	600	CA	GLY	83	-33.611	18.551	22.941	1.00	16.21
ATOM	601	C	GLY	83	-34.082	19.964	23.286	1.00	12.64
ATOM	602	O	GLY	83	-35.127	20.225	23.908	1.00	12.83
ATOM	603	N	GLY	84	-33.281	20.926	22.859	1.00	11.84
ATOM	604	CA	GLY	84	-33.604	22.331	23.082	1.00	11.09
ATOM	605	C	GLY	84	-33.492	22.741	24.541	1.00	9.78
ATOM	606	O	GLY	84	-32.796	22.177	25.384	1.00	10.83
ATOM	607	N	TYR	85	-34.104	23.875	24.825	1.00	10.88

Fig. 2

12/25

ATOM	608	OH	TYR	85	-28.004	24.555	24.203	1.00	18.98
ATOM	609	CD2	TYR	85	-31.561	25.395	24.068	1.00	12.07
ATOM	610	CE2	TYR	85	-30.266	25.023	23.693	1.00	13.73
ATOM	611	CZ	TYR	85	-29.263	24.890	24.644	1.00	15.05
ATOM	612	CE1	TYR	85	-29.519	25.081	26.012	1.00	12.94
ATOM	613	CD1	TYR	85	-30.826	25.421	26.395	1.00	12.96
ATOM	614	CG	TYR	85	-31.850	25.570	25.445	1.00	11.64
ATOM	615	CB	TYR	85	-33.264	25.866	25.882	1.00	10.50
ATOM	616	CA	TYR	85	-34.079	24.539	26.116	1.00	10.86
ATOM	617	C	TYR	85	-35.418	25.002	26.674	1.00	13.82
ATOM	618	O	TYR	85	-36.268	25.491	25.854	1.00	14.41
ATOM	619	N	ALA	86	-35.569	24.891	27.969	1.00	9.86
ATOM	620	CB	ALA	86	-37.046	24.630	29.971	1.00	9.75
ATOM	621	CA	ALA	86	-36.735	25.425	28.695	1.00	11.67
ATOM	622	C	ALA	86	-36.361	26.918	28.958	1.00	11.87
ATOM	623	O	ALA	86	-35.188	27.341	28.972	1.00	9.92
ATOM	624	N	THR	87	-37.345	27.829	29.131	1.00	10.43
ATOM	625	CG2	THR	87	-36.841	29.875	26.861	1.00	17.11
ATOM	626	OG1	THR	87	-38.959	29.934	28.083	1.00	17.19
ATOM	627	CB	THR	87	-37.539	30.174	28.200	1.00	17.24
ATOM	628	CA	THR	87	-37.057	29.241	29.379	1.00	10.64
ATOM	629	C	THR	87	-37.640	29.593	30.724	1.00	11.34
ATOM	630	O	THR	87	-38.696	29.055	31.041	1.00	13.09
ATOM	631	N	VAL	88	-37.001	30.448	31.521	1.00	10.66
ATOM	632	CA	VAL	88	-37.441	30.863	32.856	1.00	9.45
ATOM	633	C	VAL	88	-38.255	32.155	32.696	1.00	11.88
ATOM	634	O	VAL	88	-37.698	33.094	32.136	1.00	10.63
ATOM	635	CB	VAL	88	-36.246	31.053	33.821	1.00	7.00
ATOM	636	CG1	VAL	88	-36.652	31.636	35.192	1.00	5.32
ATOM	637	CG2	VAL	88	-35.478	29.746	33.985	1.00	9.05
ATOM	638	N	ALA	89	-39.467	32.233	33.201	1.00	10.89
ATOM	639	CB	ALA	89	-41.539	33.201	32.260	1.00	9.11
ATOM	640	CA	ALA	89	-40.325	33.440	33.132	1.00	11.01
ATOM	641	C	ALA	89	-40.690	33.918	34.548	1.00	11.13
ATOM	642	O	ALA	89	-41.242	35.028	34.655	1.00	13.90
ATOM	643	N	GLY	90	-40.351	33.181	35.617	1.00	9.54
ATOM	644	CA	GLY	90	-40.632	33.592	36.976	1.00	8.75
ATOM	645	C	GLY	90	-40.322	32.409	37.921	1.00	10.19
ATOM	646	O	GLY	90	-39.660	31.477	37.500	1.00	9.62
ATOM	647	N	HIS	91	-40.857	32.540	39.135	1.00	11.81
ATOM	648	CD2	HIS	91	-40.073	33.404	43.018	1.00	18.32
ATOM	649	NE2	HIS	91	-40.052	34.763	43.177	1.00	17.97
ATOM	650	CE1	HIS	91	-39.622	35.366	42.127	1.00	17.17
ATOM	651	ND1	HIS	91	-39.350	34.411	41.259	1.00	16.07
ATOM	652	CG	HIS	91	-39.605	33.184	41.765	1.00	16.04
ATOM	653	CB	HIS	91	-39.411	31.883	41.060	1.00	11.82
ATOM	654	CA	HIS	91	-40.637	31.530	40.180	1.00	10.58
ATOM	655	C	HIS	91	-41.854	31.229	41.025	1.00	12.38
ATOM	656	O	HIS	91	-41.723	31.032	42.248	1.00	13.11
ATOM	657	N	ASN	92	-43.013	31.126	40.369	1.00	12.46
ATOM	658	ND2	ASN	92	-46.608	32.760	41.360	1.00	44.37
ATOM	659	OD1	ASN	92	-45.564	33.225	39.385	1.00	40.52
ATOM	660	CG	ASN	92	-45.903	32.418	40.259	1.00	35.33
ATOM	661	CB	ASN	92	-45.524	30.938	40.252	1.00	23.82

Fig. 2

13/25

ATOM	662	CA	ASN	92	-44.261	30.746	41.119	1.00	13.35
ATOM	663	C	ASN	92	-44.164	29.268	41.493	1.00	12.66
ATOM	664	O	ASN	92	-43.930	28.437	40.582	1.00	11.76
ATOM	665	N	GLN	93	-44.364	28.935	42.749	1.00	11.08
ATOM	666	NE2	GLN	93	-42.340	27.432	47.693	1.00	21.50
ATOM	667	OE1	GLN	93	-44.559	27.501	47.458	1.00	31.26
ATOM	668	CD	GLN	93	-43.422	27.632	46.972	1.00	27.63
ATOM	669	CG	GLN	93	-43.291	28.002	45.511	1.00	20.72
ATOM	670	CB	GLN	93	-44.409	27.379	44.700	1.00	15.24
ATOM	671	CA	GLN	93	-44.262	27.516	43.171	1.00	12.74
ATOM	672	C	GLN	93	-45.394	26.705	42.566	1.00	13.82
ATOM	673	O	GLN	93	-46.572	27.162	42.672	1.00	15.94
ATOM	674	N	ALA	94	-45.166	25.549	42.048	1.00	11.74
ATOM	675	CA	ALA	94	-46.178	24.676	41.481	1.00	11.41
ATOM	676	C	ALA	94	-46.815	23.934	42.649	1.00	14.20
ATOM	677	O	ALA	94	-46.120	23.587	43.637	1.00	14.08
ATOM	678	CB	ALA	94	-45.495	23.704	40.529	1.00	6.58
ATOM	679	N	PRO	95	-48.112	23.645	42.551	1.00	14.96
ATOM	680	CG	PRO	95	-50.259	23.275	41.661	1.00	15.96
ATOM	681	CD	PRO	95	-48.954	24.020	41.412	1.00	15.38
ATOM	682	CB	PRO	95	-50.261	22.810	43.087	1.00	13.99
ATOM	683	CA	PRO	95	-48.815	22.843	43.571	1.00	13.77
ATOM	684	C	PRO	95	-48.308	21.414	43.670	1.00	12.85
ATOM	685	O	PRO	95	-47.789	20.722	42.764	1.00	13.21
ATOM	686	N	ILE	96	-48.439	20.860	44.892	1.00	9.64
ATOM	687	CD1	ILE	96	-46.305	19.698	47.937	1.00	20.39
ATOM	688	CG1	ILE	96	-47.785	19.940	47.690	1.00	17.20
ATOM	689	CB	ILE	96	-48.425	19.023	46.634	1.00	13.72
ATOM	690	CG2	ILE	96	-48.131	17.530	46.952	1.00	17.91
ATOM	691	CA	ILE	96	-48.058	19.444	45.141	1.00	11.51
ATOM	692	C	ILE	96	-48.841	18.627	44.138	1.00	13.14
ATOM	693	O	ILE	96	-50.052	18.979	43.880	1.00	15.21
ATOM	694	N	GLY	97	-48.332	17.575	43.528	1.00	10.18
ATOM	695	CA	GLY	97	-49.020	16.783	42.537	1.00	9.00
ATOM	696	C	GLY	97	-48.645	17.200	41.126	1.00	11.33
ATOM	697	O	GLY	97	-48.867	16.374	40.221	1.00	12.32
ATOM	698	N	SER	98	-48.108	18.393	40.935	1.00	10.97
ATOM	699	OG	SER	98	-48.122	21.262	40.073	0.70	15.96
ATOM	700	CB	SER	98	-47.149	20.355	39.724	0.70	13.01
ATOM	703	CA	SER	98	-47.643	18.918	39.637	1.00	11.70
ATOM	704	C	SER	98	-46.376	18.198	39.140	1.00	11.01
ATOM	705	O	SER	98	-45.567	17.708	39.906	1.00	12.53
ATOM	706	N	SER	99	-46.203	18.149	37.825	1.00	8.54
ATOM	707	OG	SER	99	-45.372	18.423	34.957	1.00	12.93
ATOM	708	CB	SER	99	-45.157	17.258	35.747	1.00	7.78
ATOM	709	CA	SER	99	-45.010	17.562	37.226	1.00	8.54
ATOM	710	C	SER	99	-43.921	18.659	37.391	1.00	7.90
ATOM	711	O	SER	99	-44.195	19.884	37.534	1.00	10.31
ATOM	712	N	VAL	100	-42.675	18.231	37.384	1.00	9.21
ATOM	713	CA	VAL	100	-41.468	19.082	37.505	1.00	5.59
ATOM	714	C	VAL	100	-40.375	18.343	36.773	1.00	5.35
ATOM	715	O	VAL	100	-40.380	17.108	36.785	1.00	9.03
ATOM	716	CB	VAL	100	-41.112	19.395	38.979	1.00	5.88
ATOM	717	CG1	VAL	100	-40.630	18.114	39.670	1.00	8.61

Fig. 2

14/25

ATOM	718	CG2	VAL	100	-40.142	20.579	39.127	1.00	5.24
ATOM	719	N	CYS	101	-39.423	19.055	36.168	1.00	5.24
ATOM	720	CA	CYS	101	-38.304	18.494	35.437	1.00	4.35
ATOM	721	C	CYS	101	-36.989	18.996	36.086	1.00	5.37
ATOM	722	O	CYS	101	-36.984	20.152	36.529	1.00	8.17
ATOM	723	CB	CYS	101	-38.312	18.824	33.935	1.00	5.99
ATOM	724	SG	CYS	101	-39.723	18.001	33.063	1.00	8.35
ATOM	725	N	ARG	102	-35.982	18.175	36.084	1.00	6.08
ATOM	726	CA	ARG	102	-34.649	18.527	36.587	1.00	7.57
ATOM	727	C	ARG	102	-33.605	18.534	35.462	1.00	8.71
ATOM	728	O	ARG	102	-33.604	17.647	34.598	1.00	8.00
ATOM	729	CB	ARG	102	-34.261	17.489	37.655	1.00	4.69
ATOM	730	CG	ARG	102	-32.859	17.784	38.286	1.00	3.27
ATOM	731	CD	ARG	102	-32.303	16.653	39.077	1.00	6.25
ATOM	732	NE	ARG	102	-32.250	15.402	38.343	1.00	7.04
ATOM	733	CZ	ARG	102	-31.471	15.083	37.294	1.00	9.62
ATOM	734	NH1	ARG	102	-31.692	13.864	36.773	1.00	9.55
ATOM	735	NH2	ARG	102	-30.608	15.953	36.805	1.00	5.91
ATOM	736	N	SER	103	-32.662	19.454	35.404	1.00	7.27
ATOM	737	CA	SER	103	-31.567	19.475	34.435	1.00	4.96
ATOM	738	C	SER	103	-30.259	19.365	35.228	1.00	6.42
ATOM	739	O	SER	103	-30.059	20.177	36.162	1.00	6.49
ATOM	740	CB	SER	103	-31.571	20.781	33.624	1.00	5.59
ATOM	741	OG	SER	103	-30.581	20.673	32.575	1.00	7.71
ATOM	742	N	GLY	104	-29.359	18.411	34.965	1.00	7.52
ATOM	743	CA	GLY	104	-28.071	18.282	35.661	1.00	5.92
ATOM	744	C	GLY	104	-27.031	17.745	34.686	1.00	6.41
ATOM	745	O	GLY	104	-27.354	17.083	33.665	1.00	7.09
ATOM	746	N	SER	105	-25.757	18.002	34.912	1.00	7.88
ATOM	747	OG	SER	105	-22.953	18.433	35.504	1.00	11.75
ATOM	748	CB	SER	105	-23.430	18.504	34.179	1.00	7.00
ATOM	749	CA	SER	105	-24.638	17.559	34.049	1.00	10.37
ATOM	750	C	SER	105	-24.255	16.085	34.102	1.00	10.06
ATOM	751	O	SER	105	-23.505	15.679	33.176	1.00	10.75
ATOM	752	N	THR	106	-24.719	15.248	35.018	1.00	9.74
ATOM	753	CA	THR	106	-24.403	13.811	35.029	1.00	9.92
ATOM	754	C	THR	106	-25.458	13.046	34.238	1.00	8.56
ATOM	755	O	THR	106	-25.079	12.174	33.464	1.00	10.42
ATOM	756	CB	THR	106	-24.322	13.103	36.435	1.00	10.71
ATOM	757	OG1	THR	106	-23.436	13.978	37.167	1.00	10.45
ATOM	758	CG2	THR	106	-23.782	11.671	36.508	1.00	6.76
ATOM	759	N	THR	107	-26.723	13.319	34.467	1.00	7.87
ATOM	760	CA	THR	107	-27.804	12.599	33.831	1.00	5.96
ATOM	761	C	THR	107	-28.634	13.349	32.838	1.00	7.88
ATOM	762	O	THR	107	-29.531	12.664	32.266	1.00	8.47
ATOM	763	CB	THR	107	-28.695	11.935	34.969	1.00	8.85
ATOM	764	OG1	THR	107	-29.241	13.086	35.695	1.00	7.24
ATOM	765	CG2	THR	107	-27.869	11.012	35.858	1.00	8.14
ATOM	766	N	GLY	108	-28.523	14.609	32.643	1.00	7.16
ATOM	767	CA	GLY	108	-29.341	15.323	31.611	1.00	8.94
ATOM	768	C	GLY	108	-30.668	15.756	32.223	1.00	10.50
ATOM	769	O	GLY	108	-30.722	16.175	33.436	1.00	8.98
ATOM	770	N	TRP	109	-31.691	15.642	31.408	1.00	6.52
ATOM	771	CD2	TRP	109	-35.413	18.684	30.968	1.00	5.39

Fig. 2

15/25

ATOM	772	CE3	TRP	109	-34.790	19.728	31.656	1.00	5.67
ATOM	773	CZ3	TRP	109	-35.588	20.864	31.900	1.00	10.11
ATOM	774	CH2	TRP	109	-36.931	20.950	31.533	1.00	7.46
ATOM	775	CZ2	TRP	109	-37.555	19.912	30.864	1.00	5.36
ATOM	776	CE2	TRP	109	-36.762	18.789	30.603	1.00	8.40
ATOM	777	NE1	TRP	109	-37.097	17.619	29.964	1.00	11.33
ATOM	778	CD1	TRP	109	-35.996	16.771	29.909	1.00	8.89
ATOM	779	CG	TRP	109	-34.928	17.409	30.506	1.00	7.87
ATOM	780	CB	TRP	109	-33.558	16.856	30.594	1.00	4.08
ATOM	781	CA	TRP	109	-33.070	16.106	31.803	1.00	6.13
ATOM	782	C	TRP	109	-34.031	15.013	32.176	1.00	7.55
ATOM	783	O	TRP	109	-34.244	14.017	31.372	1.00	8.28
ATOM	784	N	HIS	110	-34.566	15.040	33.380	1.00	6.29
ATOM	785	CD2	HIS	110	-32.409	12.573	33.819	1.00	8.99
ATOM	786	NE2	HIS	110	-31.845	11.558	33.121	1.00	10.03
ATOM	787	CE1	HIS	110	-32.751	10.595	32.981	1.00	12.94
ATOM	788	ND1	HIS	110	-33.856	11.027	33.562	1.00	12.68
ATOM	789	CG	HIS	110	-33.678	12.246	34.128	1.00	9.92
ATOM	790	CB	HIS	110	-34.761	13.004	34.840	1.00	8.94
ATOM	791	CA	HIS	110	-35.487	13.971	33.861	1.00	7.82
ATOM	792	C	HIS	110	-36.648	14.637	34.584	1.00	7.74
ATOM	793	O	HIS	110	-36.444	15.708	35.190	1.00	8.03
ATOM	794	N	CYS	111	-37.832	13.990	34.506	1.00	7.77
ATOM	795	CA	CYS	111	-39.052	14.589	35.065	1.00	7.64
ATOM	796	C	CYS	111	-39.864	13.660	35.952	1.00	9.31
ATOM	797	O	CYS	111	-39.559	12.451	35.928	1.00	11.03
ATOM	798	CB	CYS	111	-39.988	15.100	33.925	1.00	9.61
ATOM	799	SG	CYS	111	-39.150	16.153	32.711	1.00	9.12
ATOM	800	N	GLY	112	-40.828	14.245	36.638	1.00	8.81
ATOM	801	CA	GLY	112	-41.625	13.408	37.597	1.00	8.51
ATOM	802	C	GLY	112	-42.521	14.315	38.399	1.00	10.25
ATOM	803	O	GLY	112	-42.794	15.437	37.941	1.00	12.04
ATOM	804	N	THR	113	-42.979	13.969	39.595	1.00	10.08
ATOM	805	CA	THR	113	-43.870	14.809	40.372	1.00	8.62
ATOM	806	C	THR	113	-43.359	15.387	41.685	1.00	9.71
ATOM	807	O	THR	113	-42.441	14.786	42.268	1.00	10.48
ATOM	808	CB	THR	113	-45.240	13.996	40.648	1.00	17.08
ATOM	809	OG1	THR	113	-44.930	12.755	41.340	1.00	19.10
ATOM	810	CG2	THR	113	-46.004	13.705	39.362	1.00	15.24
ATOM	811	N	ILE	114	-43.963	16.488	42.073	1.00	8.35
ATOM	812	CA	ILE	114	-43.662	17.108	43.365	1.00	9.73
ATOM	813	C	ILE	114	-44.554	16.338	44.383	1.00	13.59
ATOM	814	O	ILE	114	-45.816	16.336	44.198	1.00	12.54
ATOM	815	CB	ILE	114	-44.008	18.621	43.384	1.00	10.58
ATOM	816	CG1	ILE	114	-43.089	19.319	42.341	1.00	12.00
ATOM	817	CG2	ILE	114	-43.864	19.215	44.814	1.00	12.84
ATOM	818	CD1	ILE	114	-43.555	20.750	42.065	1.00	10.62
ATOM	819	N	GLN	115	-43.977	15.668	45.379	1.00	12.39
ATOM	820	NE2	GLN	115	-43.951	10.378	45.759	1.00	33.00
ATOM	821	OE1	GLN	115	-42.098	11.415	46.407	1.00	34.76
ATOM	822	CD	GLN	115	-43.243	11.496	45.943	1.00	30.30
ATOM	823	CG	GLN	115	-43.993	12.758	45.524	1.00	18.83
ATOM	824	CB	GLN	115	-44.077	13.606	46.811	1.00	11.43
ATOM	825	CA	GLN	115	-44.732	14.936	46.396	1.00	11.59

Fig. 2



16/25

ATOM	826	C	GLN	115	-44.956	15.640	47.693	1.00	11.61
ATOM	827	O	GLN	115	-46.105	15.494	48.196	1.00	14.96
ATOM	828	N	ALA	116	-44.037	16.355	48.292	1.00	12.17
ATOM	829	CA	ALA	116	-44.291	16.976	49.618	1.00	10.65
ATOM	830	C	ALA	116	-43.263	18.055	49.863	1.00	9.88
ATOM	831	O	ALA	116	-42.162	17.978	49.326	1.00	13.41
ATOM	832	CB	ALA	116	-44.101	15.894	50.689	1.00	10.10
ATOM	833	N	ARG	117	-43.586	19.020	50.636	1.00	9.81
ATOM	834	NH2	ARG	117	-43.870	23.560	45.115	1.00	13.10
ATOM	835	NH1	ARG	117	-45.496	23.020	46.568	1.00	17.40
ATOM	836	C2	ARG	117	-44.191	23.340	46.386	1.00	16.37
ATOM	837	NE	ARG	117	-43.268	23.465	47.330	1.00	14.91
ATOM	838	CD	ARG	117	-43.450	23.251	48.783	1.00	13.89
ATOM	839	CG	ARG	117	-43.323	21.801	49.092	1.00	10.78
ATOM	840	CB	ARG	117	-43.392	21.470	50.596	1.00	10.30
ATOM	841	CA	ARG	117	-42.725	20.137	50.983	1.00	10.62
ATOM	842	C	ARG	117	-42.465	20.023	52.496	1.00	12.42
ATOM	843	O	ARG	117	-43.122	19.229	53.201	1.00	14.36
ATOM	844	N	GLY	118	-41.566	20.803	52.999	1.00	10.94
ATOM	845	CA	GLY	118	-41.246	20.891	54.430	1.00	14.46
ATOM	846	C	GLY	118	-40.590	19.675	55.005	1.00	13.77
ATOM	847	O	GLY	118	-40.761	19.531	56.229	1.00	14.95
ATOM	848	N	GLN	119	-39.874	18.886	54.215	1.00	11.83
ATOM	849	NE2	GLN	119	-42.518	16.522	54.159	1.00	27.14
ATOM	850	OE1	GLN	119	-41.331	14.597	53.939	1.00	29.04
ATOM	851	CD	GLN	119	-41.505	15.779	53.683	1.00	26.05
ATOM	852	CG	GLN	119	-40.511	16.511	52.791	1.00	23.83
ATOM	853	CB	GLN	119	-39.161	16.633	53.499	1.00	15.28
ATOM	854	CA	GLN	119	-39.228	17.649	54.654	1.00	12.25
ATOM	855	C	GLN	119	-37.819	17.866	55.191	1.00	13.13
ATOM	856	O	GLN	119	-37.023	18.655	54.674	1.00	11.96
ATOM	857	N	SER	120	-37.520	17.136	56.272	1.00	12.77
ATOM	858	OG	SER	120	-36.874	16.674	59.024	0.50	13.43
ATOM	859	CB	SER	120	-36.074	17.591	58.330	0.50	15.06
ATOM	862	CA	SER	120	-36.147	17.234	56.873	1.00	11.79
ATOM	863	C	SER	120	-35.513	15.938	56.438	1.00	14.19
ATOM	864	O	SER	120	-36.167	14.855	56.352	1.00	14.17
ATOM	865	N	VAL	121	-34.228	16.035	56.037	1.00	14.53
ATOM	866	CG2	VAL	121	-34.392	15.445	53.235	1.00	20.02
ATOM	867	CG1	VAL	121	-32.537	13.814	53.494	1.00	22.53
ATOM	868	CB	VAL	121	-33.176	15.085	54.041	1.00	19.23
ATOM	869	CA	VAL	121	-33.466	14.920	55.565	1.00	14.60
ATOM	870	C	VAL	121	-32.106	14.892	56.248	1.00	17.85
ATOM	871	O	VAL	121	-31.399	15.890	56.335	1.00	16.78
ATOM	872	N	SER	122	-31.749	13.694	56.677	1.00	18.77
ATOM	873	OG	SER	122	-31.320	13.436	59.447	1.00	35.50
ATOM	874	CB	SER	122	-30.306	12.902	58.611	1.00	26.24
ATOM	875	CA	SER	122	-30.397	13.594	57.262	1.00	20.95
ATOM	876	C	SER	122	-29.504	12.911	56.238	1.00	20.78
ATOM	877	O	SER	122	-29.704	11.746	55.840	1.00	25.20
ATOM	878	N	TYR	123	-28.548	13.651	55.794	1.00	19.04
ATOM	879	CA	TYR	123	-27.479	13.164	54.927	1.00	21.72
ATOM	880	C	TYR	123	-26.478	12.615	55.995	1.00	25.29
ATOM	881	O	TYR	123	-26.521	13.015	57.187	1.00	26.53

Fig. 2

17/25

ATOM	882	CB	TYR	123	-26.981	14.342	54.135	1.00	18.93
ATOM	883	CG	TYR	123	-27.915	14.920	53.100	1.00	18.61
ATOM	884	CD1	TYR	123	-27.849	16.273	52.784	1.00	15.70
ATOM	885	CD2	TYR	123	-28.840	14.144	52.381	1.00	21.00
ATOM	886	CE1	TYR	123	-28.658	16.844	51.808	1.00	15.37
ATOM	887	CE2	TYR	123	-29.712	14.700	51.423	1.00	18.34
ATOM	888	CZ	TYR	123	-29.581	16.067	51.133	1.00	16.62
ATOM	889	OH	TYR	123	-30.390	16.593	50.172	1.00	15.25
ATOM	890	N	PRO	124	-25.578	11.721	55.647	1.00	28.48
ATOM	891	CG	PRO	124	-24.105	10.334	54.354	1.00	32.40
ATOM	892	CD	PRO	124	-25.391	11.155	54.297	1.00	30.53
ATOM	893	CB	PRO	124	-23.748	10.168	55.828	1.00	32.32
ATOM	894	CA	PRO	124	-24.583	11.183	56.598	1.00	31.44
ATOM	895	C	PRO	124	-23.732	12.285	57.226	1.00	32.68
ATOM	896	O	PRO	124	-23.355	12.124	58.408	1.00	33.64
ATOM	897	N	GLU	125	-23.417	13.329	56.485	1.00	32.09
ATOM	898	CA	GLU	125	-22.646	14.515	56.843	1.00	32.45
ATOM	899	C	GLU	125	-23.410	15.484	57.766	1.00	33.22
ATOM	900	O	GLU	125	-22.932	15.954	58.861	1.00	33.87
ATOM	901	CB	GLU	125	-22.144	15.220	55.588	1.00	28.10
ATOM	902	CG	GLU	125	-22.899	15.278	54.299	1.00	34.56
ATOM	903	CD	GLU	125	-23.341	14.605	53.384	0.00	53.35
ATOM	904	OE1	GLU	125	-23.517	15.100	52.231	0.00	59.96
ATOM	905	OE2	GLU	125	-23.156	13.352	53.591	0.00	58.46
ATOM	906	N	GLY	126	-24.666	15.793	57.397	1.00	31.75
ATOM	907	CA	GLY	126	-25.549	16.682	58.182	1.00	28.25
ATOM	908	C	GLY	126	-27.017	16.695	57.720	1.00	25.07
ATOM	909	O	GLY	126	-27.393	16.107	56.682	1.00	25.93
ATOM	910	N	THR	127	-27.811	17.417	58.486	1.00	19.30
ATOM	911	CG2	THR	127	-31.485	17.638	59.616	1.00	15.49
ATOM	912	OG1	THR	127	-29.548	16.190	60.199	1.00	22.50
ATOM	913	CB	THR	127	-29.964	17.487	59.664	1.00	14.93
ATOM	914	CA	THR	127	-29.242	17.558	58.256	1.00	13.91
ATOM	915	C	THR	127	-29.689	18.791	57.491	1.00	11.25
ATOM	916	O	THR	127	-29.203	19.885	57.803	1.00	10.59
ATOM	917	N	VAL	128	-30.649	18.626	56.584	1.00	11.18
ATOM	918	CA	VAL	128	-31.201	19.747	55.791	1.00	9.77
ATOM	919	C	VAL	128	-32.688	19.787	56.164	1.00	8.45
ATOM	920	O	VAL	128	-33.182	18.697	56.393	1.00	11.45
ATOM	921	CB	VAL	128	-30.956	19.633	54.298	1.00	7.25
ATOM	922	CG1	VAL	128	-29.466	19.790	54.013	1.00	11.55
ATOM	923	CG2	VAL	128	-31.377	18.285	53.735	1.00	9.36
ATOM	924	N	THR	129	-33.266	20.960	56.248	1.00	9.49
ATOM	925	CG2	THR	129	-34.182	21.202	59.125	1.00	18.71
ATOM	926	OG1	THR	129	-34.282	23.173	57.758	1.00	14.40
ATOM	927	CB	THR	129	-34.884	21.913	57.959	1.00	8.96
ATOM	928	CA	THR	129	-34.680	21.088	56.613	1.00	9.66
ATOM	929	C	THR	129	-35.407	21.804	55.487	1.00	10.11
ATOM	930	O	THR	129	-34.796	22.467	54.615	1.00	10.92
ATOM	931	N	ASN	130	-36.709	21.619	55.563	1.00	10.84
ATOM	932	ND2	ASN	130	-38.570	25.717	53.765	1.00	35.10
ATOM	933	OD1	ASN	130	-39.854	23.969	54.369	1.00	28.19
ATOM	934	CG	ASN	130	-38.739	24.527	54.362	1.00	30.11
ATOM	935	CB	ASN	130	-37.496	23.827	54.952	1.00	17.09

Fig. 2

18/25

ATOM	936	CA	ASN	130	-37.620	22.299	54.616	1.00	12.34
ATOM	937	C	ASN	130	-37.388	21.988	53.136	1.00	11.59
ATOM	938	O	ASN	130	-37.557	22.883	52.268	1.00	11.46
ATOM	939	N	MET	131	-37.056	20.742	52.880	1.00	9.76
ATOM	940	CB	MET	131	-33.020	20.248	50.187	1.00	16.57
ATOM	941	SD	MET	131	-33.597	21.082	51.629	1.00	20.94
ATOM	942	CG	MET	131	-34.411	19.573	52.379	1.00	9.59
ATOM	943	CB	MET	131	-35.664	19.199	51.580	1.00	5.73
ATOM	944	CA	MET	131	-36.732	20.297	51.529	1.00	9.93
ATOM	945	C	MET	131	-38.007	19.797	50.840	1.00	9.00
ATOM	946	O	MET	131	-38.962	19.372	51.519	1.00	10.48
ATOM	947	N	THR	132	-37.995	19.869	49.527	1.00	8.82
ATOM	948	CA	THR	132	-39.129	19.393	48.710	1.00	5.72
ATOM	949	C	THR	132	-38.769	18.054	48.108	1.00	7.44
ATOM	950	O	THR	132	-37.719	17.850	47.428	1.00	9.83
ATOM	951	CB	THR	132	-39.497	20.516	47.675	1.00	6.44
ATOM	952	OG1	THR	132	-39.851	21.700	48.434	1.00	9.35
ATOM	953	CG2	THR	132	-40.681	20.100	46.737	1.00	7.59
ATOM	954	N	ARG	133	-39.640	17.061	48.306	1.00	4.85
ATOM	955	NH2	ARG	133	-42.116	12.875	51.526	1.00	39.69
ATOM	956	NH1	ARG	133	-43.846	11.985	50.304	1.00	32.03
ATOM	957	CZ	ARG	133	-42.539	12.272	50.397	1.00	36.90
ATOM	958	NE	ARG	133	-41.666	11.948	49.418	1.00	28.98
ATOM	959	CD	ARG	133	-40.253	12.204	49.398	1.00	20.06
ATOM	960	CG	ARG	133	-39.832	13.218	48.354	1.00	11.77
ATOM	961	CB	ARG	133	-40.079	14.660	48.801	1.00	6.59
ATOM	962	CA	ARG	133	-39.443	15.674	47.833	1.00	6.76
ATOM	963	C	ARG	133	-40.092	15.457	46.455	1.00	7.46
ATOM	964	O	ARG	133	-41.227	15.963	46.241	1.00	9.38
ATOM	965	N	THR	134	-39.360	14.793	45.552	1.00	9.68
ATOM	966	CG2	THR	134	-39.353	17.060	43.521	1.00	7.44
ATOM	967	OG1	THR	134	-38.110	15.030	42.788	1.00	8.17
ATOM	968	CB	THR	134	-39.392	15.603	43.141	1.00	8.74
ATOM	969	CA	THR	134	-39.921	14.565	44.202	1.00	8.24
ATOM	970	C	THR	134	-39.576	13.135	43.785	1.00	8.06
ATOM	971	O	THR	134	-38.694	12.518	44.396	1.00	9.92
ATOM	972	N	THR	135	-40.301	12.622	42.770	1.00	7.24
ATOM	973	CG2	THR	135	-42.463	10.541	42.733	1.00	12.10
ATOM	974	OG1	THR	135	-41.763	11.403	40.497	1.00	11.13
ATOM	975	CB	THR	135	-41.362	10.601	41.650	1.00	10.58
ATOM	976	CA	THR	135	-40.037	11.294	42.228	1.00	8.03
ATOM	977	C	THR	135	-38.974	11.340	41.147	1.00	7.98
ATOM	978	O	THR	135	-38.731	10.327	40.471	1.00	9.10
ATOM	979	N	VAL	136	-38.326	12.452	40.852	1.00	10.38
ATOM	980	CG2	VAL	136	-38.483	14.754	39.130	1.00	6.65
ATOM	981	CG1	VAL	136	-36.094	14.300	38.374	1.00	10.08
ATOM	982	CB	VAL	136	-37.136	14.096	39.495	1.00	9.89
ATOM	983	CA	VAL	136	-37.296	12.595	39.813	1.00	9.10
ATOM	984	C	VAL	136	-35.990	11.927	40.235	1.00	9.23
ATOM	985	O	VAL	136	-35.640	12.113	41.414	1.00	11.00
ATOM	986	N	CYS	137	-35.273	11.188	39.408	1.00	7.90
ATOM	987	CA	CYS	137	-33.997	10.564	39.780	1.00	8.61
ATOM	988	C	CYS	137	-32.841	11.600	39.681	1.00	9.07
ATOM	989	O	CYS	137	-33.024	12.659	39.015	1.00	9.87

Fig. 2

19/25

ATOM	990	CB	CYS	137	-33.702	9.452	38.761	1.00	8.35
ATOM	991	SG	CYS	137	-33.425	10.011	37.031	1.00	11.68
ATOM	992	N	ALA	138	-31.687	11.330	40.300	1.00	7.09
ATOM	993	CB	ALA	138	-30.467	13.454	41.104	1.00	8.40
ATOM	994	CA	ALA	138	-30.503	12.207	40.220	1.00	8.25
ATOM	995	C	ALA	138	-29.294	11.352	40.568	1.00	8.58
ATOM	996	O	ALA	138	-29.409	10.287	41.211	1.00	10.28
ATOM	997	N	GLU	139	-28.105	11.803	40.178	1.00	9.17
ATOM	998	OE2	GLU	139	-27.880	7.597	37.175	1.00	10.81
ATOM	999	OE1	GLU	139	-25.864	8.348	37.135	1.00	10.87
ATOM	1000	CD	GLU	139	-26.946	8.270	37.673	1.00	12.62
ATOM	1001	CG	GLU	139	-27.289	9.053	38.912	1.00	10.79
ATOM	1002	CB	GLU	139	-26.414	10.298	39.196	1.00	8.09
ATOM	1003	CA	GLU	139	-26.818	11.099	40.431	1.00	9.02
ATOM	1004	C	GLU	139	-25.776	12.156	40.775	1.00	9.85
ATOM	1005	O	GLU	139	-25.966	13.362	40.507	1.00	9.59
ATOM	1006	N	PRO	140	-24.677	11.769	41.394	1.00	11.00
ATOM	1007	CG	PRO	140	-23.255	10.606	42.890	1.00	10.81
ATOM	1008	CD	PRO	140	-24.305	10.376	41.788	1.00	10.23
ATOM	1009	CB	PRO	140	-22.595	11.921	42.569	1.00	13.07
ATOM	1010	CA	PRO	140	-23.611	12.741	41.794	1.00	10.28
ATOM	1011	C	PRO	140	-23.095	13.561	40.611	1.00	9.93
ATOM	1012	O	PRO	140	-22.846	13.081	39.498	1.00	11.30
ATOM	1013	N	GLY	141	-23.015	14.865	40.884	1.00	7.17
ATOM	1014	CA	GLY	141	-22.596	15.857	39.927	1.00	7.59
ATOM	1015	C	GLY	141	-23.845	16.611	39.448	1.00	6.72
ATOM	1016	O	GLY	141	-23.742	17.715	38.907	1.00	7.49
ATOM	1017	N	ASP	142	-25.050	16.077	39.671	1.00	7.35
ATOM	1018	CA	ASP	142	-26.325	16.710	39.296	1.00	6.21
ATOM	1019	C	ASP	142	-26.663	17.752	40.369	1.00	5.40
ATOM	1020	O	ASP	142	-27.522	18.627	40.062	1.00	3.95
ATOM	1021	CB	ASP	142	-27.497	15.784	39.058	1.00	7.83
ATOM	1022	CG	ASP	142	-27.531	14.867	37.860	1.00	7.53
ATOM	1023	OD1	ASP	142	-28.075	13.736	37.908	1.00	7.92
ATOM	1024	OD2	ASP	142	-27.048	15.355	36.863	1.00	6.85
ATOM	1025	N	SER	143	-26.112	17.668	41.546	1.00	5.60
ATOM	1026	CA	SER	143	-26.422	18.670	42.589	1.00	5.95
ATOM	1027	C	SER	143	-26.287	20.098	42.102	1.00	7.22
ATOM	1028	O	SER	143	-25.328	20.407	41.346	1.00	7.03
ATOM	1029	CB	SER	143	-25.451	18.527	43.777	1.00	7.47
ATOM	1030	OG	SER	143	-25.764	17.255	44.327	1.00	11.26
ATOM	1031	N	GLY	144	-27.206	20.956	42.571	1.00	5.35
ATOM	1032	CA	GLY	144	-27.301	22.370	42.249	1.00	5.48
ATOM	1033	C	GLY	144	-28.051	22.665	40.945	1.00	6.00
ATOM	1034	O	GLY	144	-28.334	23.858	40.698	1.00	7.24
ATOM	1035	N	GLY	145	-28.295	21.671	40.140	1.00	5.00
ATOM	1036	CA	GLY	145	-28.959	21.818	38.828	1.00	5.08
ATOM	1037	C	GLY	145	-30.400	22.272	38.981	1.00	6.80
ATOM	1038	O	GLY	145	-31.096	22.093	40.013	1.00	8.09
ATOM	1039	N	SER	146	-31.016	22.823	37.953	1.00	4.98
ATOM	1040	CA	SER	146	-32.375	23.344	37.961	1.00	4.54
ATOM	1041	C	SER	146	-33.561	22.389	38.160	1.00	5.95
ATOM	1042	O	SER	146	-33.513	21.305	37.566	1.00	6.69
ATOM	1043	CB	SER	146	-32.609	23.870	36.500	1.00	4.69

Fig. 2

20/25

ATOM	1044	OG	SER	146	-31.487	24.440	35.945	1.00	7.80
ATOM	1045	N	TYR	147	-34.584	22.813	38.888	1.00	4.96
ATOM	1046	OH	TYR	147	-34.586	16.409	41.718	1.00	15.17
ATOM	1047	CD2	TYR	147	-36.809	19.212	40.614	1.00	8.25
ATOM	1048	CE2	TYR	147	-36.419	17.910	40.955	1.00	10.83
ATOM	1049	CZ	TYR	147	-35.130	17.695	41.413	1.00	13.00
ATOM	1050	CE1	TYR	147	-34.196	18.722	41.524	1.00	8.41
ATOM	1051	CD1	TYR	147	-34.601	20.028	41.200	1.00	7.28
ATOM	1052	CG	TYR	147	-35.885	20.262	40.762	1.00	6.98
ATOM	1053	CB	TYR	147	-36.258	21.677	40.422	1.00	5.48
ATOM	1054	CA	TYR	147	-35.875	22.091	39.028	1.00	5.55
ATOM	1055	C	TYR	147	-36.829	23.167	38.409	1.00	6.41
ATOM	1056	O	TYR	147	-36.859	24.306	38.918	1.00	6.54
ATOM	1057	N	ILE	148	-37.559	22.845	37.365	1.00	5.67
ATOM	1058	CA	ILE	148	-38.454	23.821	36.710	1.00	6.64
ATOM	1059	C	ILE	148	-39.776	23.154	36.317	1.00	6.20
ATOM	1060	O	ILE	148	-39.743	21.993	35.834	1.00	6.60
ATOM	1061	CB	ILE	148	-37.661	24.408	35.475	1.00	8.25
ATOM	1062	CG1	ILE	148	-38.445	25.567	34.843	1.00	10.19
ATOM	1063	CG2	ILE	148	-37.269	23.309	34.443	1.00	11.02
ATOM	1064	CD1	ILE	148	-37.739	26.438	33.738	1.00	11.12
ATOM	1065	N	SER	149	-40.878	23.912	36.472	1.00	6.67
ATOM	1066	OG	SER	149	-42.874	22.350	38.136	1.00	15.36
ATOM	1067	CB	SER	149	-43.209	23.415	37.231	1.00	9.17
ATOM	1068	CA	SER	149	-42.219	23.396	36.098	1.00	7.08
ATOM	1069	C	SER	149	-42.712	24.364	35.000	1.00	7.85
ATOM	1070	O	SER	149	-43.087	25.496	35.341	1.00	8.98
ATOM	1071	N	GLY	150	-42.632	23.897	33.754	1.00	10.00
ATOM	1072	CA	GLY	150	-43.066	24.798	32.663	1.00	11.86
ATOM	1073	C	GLY	150	-41.990	25.883	32.482	1.00	8.97
ATOM	1074	O	GLY	150	-40.850	25.591	32.148	1.00	12.79
ATOM	1075	N	THR	151	-42.463	27.096	32.745	1.00	9.09
ATOM	1076	CG2	THR	151	-42.428	29.087	30.347	1.00	13.40
ATOM	1077	OG1	THR	151	-43.398	29.844	32.497	1.00	13.13
ATOM	1078	CB	THR	151	-42.170	29.426	31.816	1.00	11.88
ATOM	1079	CA	THR	151	-41.527	28.257	32.661	1.00	10.61
ATOM	1080	C	THR	151	-41.196	28.758	34.085	1.00	9.76
ATOM	1081	O	THR	151	-40.553	29.810	34.179	1.00	10.13
ATOM	1082	N	GLN	152	-41.628	28.099	35.157	1.00	6.87
ATOM	1083	CA	GLN	152	-41.440	28.600	36.494	1.00	7.20
ATOM	1084	C	GLN	152	-40.304	27.909	37.266	1.00	8.56
ATOM	1085	O	GLN	152	-40.488	26.681	37.461	1.00	12.38
ATOM	1086	CB	GLN	152	-42.770	28.493	37.286	1.00	6.03
ATOM	1087	CG	GLN	152	-43.935	29.238	36.607	1.00	9.11
ATOM	1088	CD	GLN	152	-43.668	30.705	36.459	1.00	7.44
ATOM	1089	OE1	GLN	152	-43.411	31.422	37.422	1.00	11.18
ATOM	1090	NE2	GLN	152	-43.686	31.229	35.247	1.00	15.32
ATOM	1091	N	ALA	153	-39.288	28.691	37.696	1.00	7.16
ATOM	1092	CA	ALA	153	-38.166	28.065	38.442	1.00	6.99
ATOM	1093	C	ALA	153	-38.696	27.572	39.786	1.00	6.78
ATOM	1094	O	ALA	153	-39.432	28.329	40.450	1.00	8.03
ATOM	1095	CB	ALA	153	-37.062	29.133	38.567	1.00	6.81
ATOM	1096	N	GLN	154	-38.383	26.349	40.198	1.00	4.41
ATOM	1097	CA	GLN	154	-38.827	25.782	41.460	1.00	6.90

Fig. 2

21/25

ATOM	1098	C	GLN	154	-37.692	25.687	42.494	1.00	7.22
ATOM	1099	O	GLN	154	-37.931	26.098	43.640	1.00	7.22
ATOM	1100	CB	GLN	154	-39.459	24.374	41.221	1.00	6.12
ATOM	1101	CG	GLN	154	-40.644	24.402	40.211	1.00	6.24
ATOM	1102	CD	GLN	154	-41.732	25.321	40.671	1.00	9.04
ATOM	1103	OE1	GLN	154	-42.271	25.234	41.795	1.00	9.56
ATOM	1104	NE2	GLN	154	-42.164	26.267	39.859	1.00	4.50
ATOM	1105	N	GLY	155	-36.547	25.153	42.078	1.00	7.56
ATOM	1106	CA	GLY	155	-35.475	24.954	43.098	1.00	7.31
ATOM	1107	C	GLY	155	-34.202	24.370	42.501	1.00	7.69
ATOM	1108	O	GLY	155	-34.029	24.335	41.280	1.00	7.17
ATOM	1109	N	VAL	156	-33.252	24.073	43.370	1.00	6.91
ATOM	1110	CA	VAL	156	-31.925	23.515	42.968	1.00	7.24
ATOM	1111	C	VAL	156	-31.760	22.136	43.631	1.00	5.91
ATOM	1112	O	VAL	156	-32.096	21.942	44.815	1.00	6.78
ATOM	1113	CB	VAL	156	-30.786	24.527	43.154	1.00	6.19
ATOM	1114	CG1	VAL	156	-31.048	25.862	42.407	1.00	5.61
ATOM	1115	CG2	VAL	156	-30.409	24.754	44.616	1.00	8.17
ATOM	1116	N	THR	157	-31.186	21.164	42.911	1.00	3.82
ATOM	1117	CG2	THR	157	-30.184	17.395	42.515	1.00	4.16
ATOM	1118	OG1	THR	157	-30.991	19.138	41.073	1.00	8.01
ATOM	1119	CB	THR	157	-30.243	18.893	42.293	1.00	3.37
ATOM	1120	CA	THR	157	-30.971	19.799	43.383	1.00	4.97
ATOM	1121	C	THR	157	-30.083	19.754	44.627	1.00	5.89
ATOM	1122	O	THR	157	-28.979	20.281	44.589	1.00	5.74
ATOM	1123	N	SER	158	-30.588	19.070	45.635	1.00	5.99
ATOM	1124	CA	SER	158	-29.830	18.914	46.876	1.00	7.64
ATOM	1125	C	SER	158	-29.316	17.473	46.969	1.00	10.26
ATOM	1126	O	SER	158	-28.087	17.229	47.132	1.00	10.04
ATOM	1127	CB	SER	158	-30.619	19.304	48.134	1.00	8.30
ATOM	1128	OG	SER	158	-29.853	18.975	49.296	1.00	9.39
ATOM	1129	N	GLY	159	-30.150	16.443	46.900	1.00	9.83
ATOM	1130	CA	GLY	159	-29.635	15.060	47.040	1.00	9.90
ATOM	1131	C	GLY	159	-30.756	14.048	47.006	1.00	12.82
ATOM	1132	O	GLY	159	-31.878	14.478	46.680	1.00	13.31
ATOM	1133	N	GLY	160	-30.510	12.792	47.352	1.00	12.00
ATOM	1134	CA	GLY	160	-31.646	11.846	47.257	1.00	12.56
ATOM	1135	C	GLY	160	-31.091	10.410	47.219	1.00	15.35
ATOM	1136	O	GLY	160	-29.988	10.197	47.741	1.00	15.70
ATOM	1137	N	SER	161	-31.869	9.497	46.679	1.00	13.10
ATOM	1138	OG	SER	161	-33.410	7.381	47.752	1.00	18.73
ATOM	1139	CB	SER	161	-31.996	7.324	47.833	1.00	16.84
ATOM	1140	CA	SER	161	-31.379	8.089	46.671	1.00	14.66
ATOM	1141	C	SER	161	-31.670	7.448	45.325	1.00	13.50
ATOM	1142	O	SER	161	-32.491	8.066	44.640	1.00	13.10
ATOM	1143	N	GLY	162	-31.078	6.310	45.040	1.00	11.84
ATOM	1144	CA	GLY	162	-31.318	5.641	43.734	1.00	12.53
ATOM	1145	C	GLY	162	-30.457	6.331	42.672	1.00	12.12
ATOM	1146	O	GLY	162	-29.545	7.088	42.957	1.00	11.79
ATOM	1147	N	ASN	163	-30.786	6.068	41.407	1.00	10.66
ATOM	1148	CA	ASN	163	-30.058	6.588	40.269	1.00	8.29
ATOM	1149	C	ASN	163	-31.033	6.671	39.088	1.00	11.02
ATOM	1150	O	ASN	163	-32.220	6.293	39.233	1.00	10.33
ATOM	1151	CB	ASN	163	-28.827	5.741	39.950	1.00	10.88

Fig. 2

22/25

ATOM	1152	CG	ASN	163	-29.238	4.312	39.578	1.00	14.23
ATOM	1153	OD1	ASN	163	-29.966	3.979	38.660	1.00	11.31
ATOM	1154	ND2	ASN	163	-28.649	3.362	40.334	1.00	18.48
ATOM	1155	N	CYS	164	-30.499	7.132	37.956	1.00	10.86
ATOM	1156	CA	CYS	164	-31.420	7.271	36.806	1.00	11.83
ATOM	1157	C	CYS	164	-31.687	6.006	35.998	1.00	13.69
ATOM	1158	O	CYS	164	-32.428	6.145	34.993	1.00	15.15
ATOM	1159	CB	CYS	164	-31.100	8.500	35.971	1.00	10.31
ATOM	1160	SG	CYS	164	-31.448	10.097	36.795	1.00	9.57
ATOM	1161	N	ARG	165	-31.110	4.919	36.364	1.00	11.68
ATOM	1162	NH2	ARG	165	-26.089	2.173	38.339	1.00	59.15
ATOM	1163	NH1	ARG	165	-25.617	4.096	37.196	1.00	58.35
ATOM	1164	CZ	ARG	165	-26.258	2.909	37.212	1.00	55.39
ATOM	1165	NE	ARG	165	-27.054	2.356	36.310	1.00	47.93
ATOM	1166	CD	ARG	165	-27.631	2.632	35.037	1.00	40.44
ATOM	1167	CG	ARG	165	-28.933	3.381	34.944	1.00	31.56
ATOM	1168	CB	ARG	165	-30.065	2.765	35.785	1.00	18.33
ATOM	1169	CA	ARG	165	-31.324	3.621	35.703	1.00	17.34
ATOM	1170	C	ARG	165	-32.498	2.928	36.433	1.00	14.57
ATOM	1171	O	ARG	165	-33.499	2.588	35.782	1.00	15.39
ATOM	1172	N	THR	166	-32.347	2.784	37.751	1.00	12.62
ATOM	1173	CG2	THR	166	-31.557	0.620	39.350	1.00	18.19
ATOM	1174	OG1	THR	166	-32.296	2.562	40.679	1.00	17.67
ATOM	1175	CB	THR	166	-32.716	1.474	39.795	1.00	16.75
ATOM	1176	CA	THR	166	-33.407	2.140	38.540	1.00	13.18
ATOM	1177	C	THR	166	-34.528	3.049	39.012	1.00	15.18
ATOM	1178	O	THR	166	-35.581	2.528	39.436	1.00	16.50
ATOM	1179	N	GLY	167	-34.296	4.347	39.040	1.00	13.17
ATOM	1180	CA	GLY	167	-35.255	5.345	39.536	1.00	13.42
ATOM	1181	C	GLY	167	-34.815	5.663	40.997	1.00	14.50
ATOM	1182	O	GLY	167	-33.957	4.993	41.596	1.00	13.35
ATOM	1183	N	GLY	168	-35.330	6.773	41.562	1.00	14.99
ATOM	1184	CA	GLY	168	-34.923	7.118	42.940	1.00	12.40
ATOM	1185	C	GLY	168	-35.852	8.241	43.371	1.00	15.29
ATOM	1186	O	GLY	168	-36.909	8.509	42.754	1.00	14.71
ATOM	1187	N	THR	169	-35.422	8.845	44.471	1.00	14.65
ATOM	1188	CG2	THR	169	-37.341	10.701	47.345	1.00	11.85
ATOM	1189	OG1	THR	169	-37.698	8.540	46.281	1.00	16.91
ATOM	1190	CB	THR	169	-36.711	9.582	46.529	1.00	14.83
ATOM	1191	CA	THR	169	-36.177	9.973	45.077	1.00	13.13
ATOM	1192	C	THR	169	-35.165	11.121	45.248	1.00	11.43
ATOM	1193	O	THR	169	-34.007	10.807	45.611	1.00	11.62
ATOM	1194	N	THR	170	-35.621	12.315	44.946	1.00	8.52
ATOM	1195	CG2	THR	170	-33.232	12.956	43.075	1.00	6.44
ATOM	1196	OG1	THR	170	-35.355	14.161	43.068	1.00	19.35
ATOM	1197	CB	THR	170	-34.090	13.942	43.798	1.00	12.63
ATOM	1198	CA	THR	170	-34.667	13.406	45.165	1.00	8.99
ATOM	1199	C	THR	170	-35.363	14.555	45.880	1.00	11.07
ATOM	1200	O	THR	170	-36.582	14.758	45.736	1.00	12.91
ATOM	1201	N	PHE	171	-34.531	15.291	46.609	1.00	9.07
ATOM	1202	CD2	PHE	171	-36.450	15.430	50.154	1.00	12.37
ATOM	1203	CE2	PHE	171	-37.017	14.281	50.750	1.00	12.72
ATOM	1204	CZ	PHE	171	-36.332	13.053	50.718	1.00	14.13
ATOM	1205	CE1	PHE	171	-35.064	12.901	50.136	1.00	11.85

Fig. 2

23/25

ATOM	1206	CD1	PHE	171	-34.501	14.041	49.547	1.00	12.01
ATOM	1207	CG	PHE	171	-35.187	15.262	49.538	1.00	14.42
ATOM	1208	CB	PHE	171	-34.500	16.430	48.855	1.00	8.65
ATOM	1209	CA	PHE	171	-34.946	16.484	47.353	1.00	10.31
ATOM	1210	C	PHE	171	-34.276	17.746	46.736	1.00	9.69
ATOM	1211	O	PHE	171	-33.096	17.749	46.336	1.00	10.28
ATOM	1212	N	TYR	172	-35.022	18.818	46.721	1.00	6.76
ATOM	1213	OH	TYR	172	-40.405	22.042	43.789	1.00	10.33
ATOM	1214	CD2	TYR	172	-37.368	19.978	44.053	1.00	7.13
ATOM	1215	CE2	TYR	172	-38.680	20.393	43.754	1.00	9.56
ATOM	1216	CZ	TYR	172	-39.128	21.645	44.088	1.00	11.06
ATOM	1217	CE1	TYR	172	-38.255	22.544	44.740	1.00	7.89
ATOM	1218	CD1	TYR	172	-36.943	22.125	44.984	1.00	5.66
ATOM	1219	CG	TYR	172	-36.496	20.849	44.693	1.00	5.21
ATOM	1220	CB	TYR	172	-35.049	20.462	44.892	1.00	6.84
ATOM	1221	CA	TYR	172	-34.465	20.077	46.256	1.00	7.19
ATOM	1222	C	TYR	172	-34.711	21.217	47.245	1.00	6.71
ATOM	1223	O	TYR	172	-35.673	21.172	48.064	1.00	8.96
ATOM	1224	N	GLN	173	-33.781	22.185	47.157	1.00	5.53
ATOM	1225	NE2	GLN	173	-33.746	26.714	50.033	1.00	6.96
ATOM	1226	OE1	GLN	173	-32.289	25.169	50.891	1.00	10.23
ATOM	1227	CD	GLN	173	-32.795	25.753	49.933	1.00	9.42
ATOM	1228	CG	GLN	173	-32.411	25.493	48.482	1.00	3.75
ATOM	1229	CB	GLN	173	-32.463	24.037	48.054	1.00	8.35
ATOM	1230	CA	GLN	173	-33.883	23.428	47.962	1.00	5.17
ATOM	1231	C	GLN	173	-34.741	24.402	47.187	1.00	6.61
ATOM	1232	O	GLN	173	-34.469	24.693	45.967	1.00	7.86
ATOM	1233	N	GLU	174	-35.814	24.921	47.782	1.00	6.75
ATOM	1234	OE2	GLU	174	-40.122	25.837	46.396	1.00	8.25
ATOM	1235	OE1	GLU	174	-40.521	23.919	47.243	1.00	10.88
ATOM	1236	CD	GLU	174	-39.899	24.969	47.265	1.00	10.25
ATOM	1237	CG	GLU	174	-38.863	25.164	48.362	1.00	8.85
ATOM	1238	CB	GLU	174	-37.861	26.313	48.083	1.00	9.36
ATOM	1239	CA	GLU	174	-36.686	25.892	47.108	1.00	7.86
ATOM	1240	C	GLU	174	-35.933	27.178	46.774	1.00	8.69
ATOM	1241	O	GLU	174	-35.082	27.712	47.515	1.00	9.98
ATOM	1242	N	VAL	175	-36.198	27.769	45.591	1.00	8.61
ATOM	1243	CG2	VAL	175	-34.568	29.950	43.032	1.00	11.90
ATOM	1244	CG1	VAL	175	-36.989	29.512	42.968	1.00	13.78
ATOM	1245	CB	VAL	175	-35.652	29.062	43.589	1.00	13.52
ATOM	1246	CA	VAL	175	-35.605	29.022	45.144	1.00	8.03
ATOM	1247	C	VAL	175	-36.396	30.221	45.869	1.00	8.45
ATOM	1248	O	VAL	175	-35.453	31.199	46.161	1.00	8.96
ATOM	1249	N	THR	176	-37.454	30.220	46.297	1.00	9.06
ATOM	1250	CG2	THR	176	-40.371	32.282	47.869	1.00	18.26
ATOM	1251	OG1	THR	176	-40.343	30.692	46.091	1.00	18.82
ATOM	1252	CB	THR	176	-39.648	31.030	47.350	1.00	15.35
ATOM	1253	CA	THR	176	-38.133	31.355	46.965	1.00	10.08
ATOM	1254	C	THR	176	-37.370	32.053	48.082	1.00	12.75
ATOM	1255	O	THR	176	-37.203	33.295	48.105	1.00	12.78
ATOM	1256	N	PRO	177	-36.827	31.275	49.019	1.00	13.60
ATOM	1257	CA	PRO	177	-36.059	31.831	50.137	1.00	14.56
ATOM	1258	C	PRO	177	-34.832	32.550	49.634	1.00	14.53
ATOM	1259	O	PRO	177	-34.405	33.537	50.205	1.00	14.33

Fig. 2



24/25

ATOM	1260	CB	PRO	177	-35.684	30.599	50.967	1.00	15.59
ATOM	1261	CG	PRO	177	-36.607	29.488	50.587	1.00	15.55
ATOM	1262	CD	PRO	177	-37.028	29.818	49.155	1.00	14.17
ATOM	1263	N	MET	178	-34.177	32.085	48.557	1.00	11.26
ATOM	1264	CE	MET	178	-31.755	28.533	46.007	1.00	19.72
ATOM	1265	SD	MET	178	-30.708	29.927	46.237	1.00	22.73
ATOM	1266	CG	MET	178	-31.639	30.737	47.651	1.00	17.28
ATOM	1267	CB	MET	178	-32.343	31.919	46.980	1.00	9.92
ATOM	1268	CA	MET	178	-32.991	32.789	48.077	1.00	11.19
ATOM	1269	C	MET	178	-33.372	34.163	47.572	1.00	14.99
ATOM	1270	O	MET	178	-32.631	35.161	47.724	1.00	16.24
ATOM	1271	N	VAL	179	-34.492	34.273	46.870	1.00	12.66
ATOM	1272	CG2	VAL	179	-35.871	34.516	44.214	1.00	11.56
ATOM	1273	CG1	VAL	179	-36.995	36.540	45.154	1.00	16.31
ATOM	1274	CB	VAL	179	-36.242	35.254	45.495	1.00	14.06
ATOM	1275	CA	VAL	179	-34.973	35.549	46.347	1.00	14.10
ATOM	1276	C	VAL	179	-35.411	36.462	47.516	1.00	17.87
ATOM	1277	O	VAL	179	-35.152	37.674	47.535	1.00	18.01
ATOM	1278	N	ASN	180	-36.139	35.872	48.451	1.00	17.87
ATOM	1279	ND2	ASN	180	-39.996	35.004	49.792	1.00	34.66
ATOM	1280	OD1	ASN	180	-39.173	36.590	48.442	1.00	26.20
ATOM	1281	CG	ASN	180	-39.030	35.860	49.435	1.00	27.22
ATOM	1282	CB	ASN	180	-37.798	35.850	50.334	1.00	22.46
ATOM	1283	CA	ASN	180	-36.683	36.628	49.576	1.00	21.81
ATOM	1284	C	ASN	180	-35.663	37.122	50.588	1.00	22.21
ATOM	1285	O	ASN	180	-35.786	38.276	51.007	1.00	25.30
ATOM	1286	N	SER	181	-34.775	36.258	50.952	1.00	20.13
ATOM	1287	OG	SER	181	-34.362	34.891	53.477	1.00	46.23
ATOM	1288	CB	SER	181	-33.268	35.230	52.620	1.00	29.26
ATOM	1289	CA	SER	181	-33.740	36.530	51.921	1.00	20.62
ATOM	1290	C	SER	181	-32.474	37.109	51.355	1.00	20.10
ATOM	1291	O	SER	181	-31.914	37.915	52.104	1.00	20.08
ATOM	1292	N	TRP	182	-32.042	36.665	50.186	1.00	17.06
ATOM	1293	CD2	TRP	182	-28.744	33.771	49.582	1.00	20.91
ATOM	1294	CE3	TRP	182	-28.470	33.240	48.331	1.00	15.11
ATOM	1295	CZ3	TRP	182	-27.853	31.999	48.269	1.00	15.36
ATOM	1296	CH2	TRP	182	-27.529	31.313	49.436	1.00	15.65
ATOM	1297	CZ2	TRP	182	-27.769	31.806	50.713	1.00	19.64
ATOM	1298	CE2	TRP	182	-28.381	33.057	50.742	1.00	24.59
ATOM	1299	NE1	TRP	182	-28.738	33.820	51.828	1.00	27.77
ATOM	1300	CD1	TRP	182	-29.323	34.986	51.373	1.00	29.42
ATOM	1301	CG	TRP	182	-29.377	35.009	50.004	1.00	22.91
ATOM	1302	CB	TRP	182	-29.884	36.098	49.127	1.00	20.07
ATOM	1303	CA	TRP	182	-30.771	37.210	49.681	1.00	14.46
ATOM	1304	C	TRP	182	-30.992	38.306	48.680	1.00	14.45
ATOM	1305	O	TRP	182	-30.007	38.974	48.321	1.00	16.23
ATOM	1306	N	GLY	183	-32.203	38.445	48.182	1.00	13.61
ATOM	1307	CA	GLY	183	-32.431	39.519	47.179	1.00	13.59
ATOM	1308	C	GLY	183	-31.864	39.105	45.800	1.00	12.98
ATOM	1309	O	GLY	183	-31.478	40.015	45.005	1.00	11.51
ATOM	1310	N	VAL	184	-31.805	37.788	45.559	1.00	12.12
ATOM	1311	CG2	VAL	184	-31.741	34.892	44.375	1.00	20.41
ATOM	1312	CG1	VAL	184	-29.458	35.739	44.931	1.00	20.83
ATOM	1313	CB	VAL	184	-30.729	35.966	44.088	1.00	14.52

Fig. 2

25/25

ATOM	1314	CA	VAL	184	-31.288	37.397	44.216	1.00	13.35
ATOM	1315	C	VAL	184	-32.431	37.647	43.201	1.00	13.39
ATOM	1316	O	VAL	184	-33.619	37.490	43.538	1.00	13.79
ATOM	1317	N	ARG	185	-32.041	37.991	41.974	1.00	11.85
ATOM	1318	NH2	ARG	185	-31.382	44.754	43.270	1.00	30.49
ATOM	1319	NH1	ARG	185	-30.633	44.370	41.110	1.00	29.76
ATOM	1320	CZ	ARG	185	-31.320	43.982	42.177	1.00	30.81
ATOM	1321	NE	ARG	185	-31.986	42.816	42.217	1.00	27.27
ATOM	1322	CD	ARG	185	-31.978	41.937	41.036	1.00	23.48
ATOM	1323	CG	ARG	185	-32.959	40.840	41.410	1.00	19.17
ATOM	1324	CB	ARG	185	-32.789	39.732	40.349	1.00	14.23
ATOM	1325	CA	ARG	185	-32.980	38.274	40.869	1.00	11.15
ATOM	1326	C	ARG	185	-32.746	37.319	39.703	1.00	8.87
ATOM	1327	O	ARG	185	-31.721	37.472	39.065	1.00	8.01
ATOM	1328	N	LEU	186	-33.644	36.370	39.444	1.00	9.17
ATOM	1329	CA	LEU	186	-33.463	35.447	38.328	1.00	9.78
ATOM	1330	C	LEU	186	-33.503	36.225	36.995	1.00	10.75
ATOM	1331	O	LEU	186	-34.316	37.132	36.787	1.00	10.04
ATOM	1332	CB	LEU	186	-34.648	34.435	38.305	1.00	8.11
ATOM	1333	CG	LEU	186	-34.760	33.549	39.546	1.00	16.49
ATOM	1334	CD1	LEU	186	-35.699	32.375	39.276	1.00	14.66
ATOM	1335	CD2	LEU	186	-33.400	32.928	39.887	1.00	16.56
ATOM	1336	N	ARG	187	-32.652	35.750	36.102	1.00	7.79
ATOM	1337	NH2	ARG	187	-30.740	39.908	29.630	1.00	46.94
ATOM	1338	NH1	ARG	187	-29.232	39.169	31.188	1.00	49.29
ATOM	1339	CZ	ARG	187	-30.477	39.174	30.718	1.00	44.29
ATOM	1340	NE	ARG	187	-31.443	38.474	31.338	1.00	36.97
ATOM	1341	CD	ARG	187	-31.199	37.750	32.536	1.00	28.81
ATOM	1342	CG	ARG	187	-31.219	36.300	32.604	1.00	27.43
ATOM	1343	CB	ARG	187	-31.340	35.889	34.068	1.00	12.14
ATOM	1344	CA	ARG	187	-32.653	36.298	34.718	1.00	9.41
ATOM	1345	C	ARG	187	-33.901	35.672	34.023	1.00	10.55
ATOM	1346	O	ARG	187	-34.139	34.427	33.990	1.00	10.23
ATOM	1347	N	THR	188	-34.769	36.530	33.478	1.00	9.32
ATOM	1348	CA	THR	188	-35.996	36.175	32.723	1.00	10.52
ATOM	1349	C	THR	188	-35.889	36.694	31.263	1.00	11.51
ATOM	1350	O	THR	188	-34.786	37.058	30.810	1.00	10.45
ATOM	1351	CB	THR	188	-37.361	36.593	33.422	1.00	7.88
ATOM	1352	OG1	THR	188	-37.427	38.057	33.443	1.00	7.10
ATOM	1353	CG2	THR	188	-37.581	36.118	34.850	1.00	8.10
ATOM	1354	OXT	THR	188	-36.851	36.451	30.513	1.00	13.52

Fig. 2

10508-010-DK.ST25  
SEQUENCE LISTINGPatent- og  
Varemærkestyrelsen

01 MRS. 2004

Modtaget

<110> Novozymes A/S  
<120> Protease Variants  
<130> 10508.010-DK  
<160> 12  
<170> PatentIn version 3.2  
<210> 1  
<211> 1596  
<212> DNA  
<213> Nocardiopsis sp. NRRL 18262 ("Protease 10")

<220>  
<221> CDS  
<222> (900)..(1466)

<400> 1  
acgttttgta cgggtaccgg tgtccgcatg tggccagaat gcccccttgc gacaggggaac 60  
ggattcggtc ggtagcgcac cgactccgac aaccgcgagg tggcgttcg cgtcgccacg 120  
ttctgcgacc gtcattgcgac ccatcatcgg gtgacccac cgagctctga atggtccacc 180  
gttctgacgg tctttccctc accaaaacgt gcacctatgg ttaggacggt gtttaccgaa 240  
tgtctcggtg aacgacaggg gccggacggt attcggcccc gatcccccggt tgatcccccc 300  
aggagagtag ggaccccatg cgaccctccc ccgttgcttc cgccatcgggt acgggagcgc 360  
tggccttcgg tctggcgctg tccgggtaccc cgggtgccct cgcgccacc ggagcgctcc 420  
cccagtcacc caccgccgag gccgacgcgg tctccatgca ggaggcgctc cagcgcgacc 480  
tcgacctgac ctccgccgag gccgaggagc tgctggccgc ccaggacacc gccttcgagg 540  
tcgacgaggc cgcgcccgag gccgcccggg acgcctacgg cggctccgct ttcgacaccg 600  
agagcctgga actgaccgtc ctggtcaccg atgccgccgc ggtcgaggcc gtggaggcca 660  
ccggcgccgg gaccgagctg gtctcctacg gcatcgacgg tctcgacgag atcgtccagg 720  
agctcaacgc cgccgacgcc gttcccgggt tggtcggctg gtaccgggac gtggcgggtg 780  
acaccgtcgt cctggagggt ctggagggtt ccggagccga cgtcagcggc ctgctcgagg 840  
acgccggcgt ggacgcctcg gccgtcgagg tgaccacgag cgaccagccc gagctctac 899  
gcc gac atc atc ggt ggt ctg gcc tac acc atg ggc ggc cgc tgt tctg 947  
Ala Asp Ile Ile Gly Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser  
1 5 10 15  
gtc ggc ttc gcg gcc acc aac gcc gcc ggt cag ccc ggg ttc gtc acc 995  
Val Gly Phe Ala Ala Thr Asn Ala Ala Gly Gln Pro Gly Phe Val Thr  
20 25 30  
gcc ggt cac tgc ggc cgc gtg gcc acc cag gtg acc atc ggc aac gcc 1043  
Ala Gly His Cys Gly Arg Val Gly Thr Gln Val Thr Ile Gly Asn Gly  
35 40 45  
agg ggc gtc ttc gag cag tcc gtc ttc ccc ggc aac gac gcg gcc ttc 1091  
Arg Gly Val Phe Glu Gln Ser Val Phe Pro Gly Asn Asp Ala Ala Phe  
50 55 60

10508-010-DK.ST25

gtc cgc ggt acg tcc aac ttc acg ctg acc aac ctg gtc agc cgc tac 1139  
Val Arg Gly Thr Ser Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr 80  
65 70 75

aac acc ggc ggg tac gcc acg gtc gcc ggt cac aac cag gcc ccc atc 1187  
Asn Thr Gly Gly Tyr Ala Thr Val Ala Gly His Asn Gln Ala Pro Ile 95  
85 90

ggc tcc tcc gtc tgc cgc tcc ggc tcc acc acc ggt tgg cac tgc ggc 1235  
Gly Ser Ser Val Cys Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly 110  
100 105

acc atc cag gcc cgc ggc cag tgc gtc agc tac ccc gag ggc acc gtc 1283  
Thr Ile Gln Ala Arg Gly Gln Ser Val Ser Tyr Pro Glu Gly Thr Val 125  
115 120

acc aac atg acc cgg acc acc gtc tgc gcc gag ccc ggc gac tcc ggc 1331  
Thr Asn Met Thr Arg Thr Thr Val Cys Ala Glu Pro Gly Asp Ser Gly 140  
130 135

ggc tcc tac atc tcc ggc acc cag gcc cag ggc gtc acc tcc ggc ggc 1379  
Gly Ser Tyr Ile Ser Gly Thr Gln Ala Gln Gly Val Thr Ser Gly Gly 160  
145 150 155

tcc ggc aac tgc cgc acc ggc ggc acc acc ttc tac cag gag gtc acc 1427  
Ser Gly Asn Cys Arg Thr Gly Gly Thr Thr Phe Tyr Gln Glu Val Thr 175  
165 170

ccc atg gtc aac tcc tgg ggc gtc cgt ctc cgg acc tga tccccgcggt 1476  
Pro Met Val Asn Ser Trp Gly Val Arg Leu Arg Thr 185  
180

tccaggcgga ccgacgggtcg tgacctgagt accaggcgtc cccgccgctt ccagcggcgt 1536  
ccgcaccggg gtgggaccgg gcgtggccac ggccccaccc gtgaccggac cgccccggcta 1596

<210> 2  
<211> 188  
<212> PRT  
<213> Nocardiosis sp. NRRL 18262 ("Protease 10")

<400> 2

Ala Asp Ile Ile Gly Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser  
1 5 10 15

Val Gly Phe Ala Ala Thr Asn Ala Ala Gly Gln Pro Gly Phe Val Thr  
20 25 30

Ala Gly His Cys Gly Arg Val Gly Thr Gln Val Thr Ile Gly Asn Gly  
35 40 45

Arg Gly Val Phe Glu Gln Ser Val Phe Pro Gly Asn Asp Ala Ala Phe  
50 55 60

Val Arg Gly Thr Ser Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr  
65 70 75 80

Asn Thr Gly Gly Tyr Ala Thr Val Ala Gly His Asn Gln Ala Pro Ile  
85 90 95

10508-010-DK.ST25

Gly Ser Ser Val Cys Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly  
100 105 110

Thr Ile Gln Ala Arg Gly Gln Ser Val Ser Tyr Pro Glu Gly Thr Val  
115 120 125

Thr Asn Met Thr Arg Thr Thr Val Cys Ala Glu Pro Gly Asp Ser Gly  
130 135 140

Gly Ser Tyr Ile Ser Gly Thr Gln Ala Gln Gly Val Thr Ser Gly Gly  
145 150 155 160

Ser Gly Asn Cys Arg Thr Gly Gly Thr Thr Phe Tyr Gln Glu Val Thr  
165 170 175

Pro Met Val Asn Ser Trp Gly Val Arg Leu Arg Thr  
180 185

<210> 3  
<211> 1065  
<212> DNA  
<213> Nocardiosis dassonvillei subspecies dassonvillei DSM 43235 ("Protease  
18")

<220>  
<221> CDS  
<222> (1)..(1062)

<220>  
<221> mat\_peptide  
<222> (499)..(1062)

<400> 3  
gct ccg gcc ccc gtc ccc cag acc ccc gtc gcc gac gac agc gcc 45  
Ala Pro Ala Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala  
-165 -160 -155  
gcc agc atg acc gag gcg ctc aag cgc gac ctc gac ctc acc tcg 90  
Ala Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asp Leu Thr Ser  
-150 -145 -140  
gcc gag gcc gag gag ctt ctc tcg gcg cag gaa gcc gcc atc gag 135  
Ala Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu  
-135 -130 -125  
acc gac gcc gag gcc acc gag gcc gcg ggc gag gcc tac ggc ggc 180  
Thr Asp Ala Glu Ala Thr Glu Ala Ala Gly Glu Ala Tyr Gly Gly  
-120 -115 -110  
tca ctg ttc gac acc gag acc ctc gaa ctc acc gtg ctg gtc acc gac 228  
Ser Leu Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
-105 -100 -95  
gcc tcc gcc gtc gag gcg gtc gag gcc acc gga gcc cag gcc acc gtc 276  
Ala Ser Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gln Ala Thr Val  
-90 -85 -80 -75  
gtc tcc cac ggc acc gag ggc ctg acc gag gtc gtg gag gac ctc aac 324  
Val Ser His Gly Thr Glu Gly Leu Thr Glu Val Val Glu Asp Leu Asn  
-70 -65 -60

## 10508-010-DK.ST25

ggc gcc gag gtt ccc gag agc gtc ctc ggc tgg tac ccg gac gtg gag Gly Ala Glu Val Pro Glu Ser Val Leu Gly Trp Tyr Pro Asp Val Glu	372
agc gac acc gtc gtg gtc gag gtg ctg gag ggc tcc gac gcc gac gtc Ser Asp Thr Val Val Val Glu Val Leu Glu Gly Ser Asp Ala Asp Val	420
gcc gcc ctg ctc gcc gac gcc ggt gtg gac tcc tcc tcg gtc cgg gtg Ala Ala Leu Leu Ala Asp Ala Gly Val Asp Ser Ser Ser Val Arg Val	468
gag gag gcc gag gag gcc ccg cag gtc tac gcc gac atc atc ggc ggc Glu Glu Ala Glu Glu Ala Pro Gln Val Tyr Ala Asp Ile Ile Gly Gly	516
ctg gcc tac tac atg ggc ggc cgc tgc tcc gtc ggc ttc gcc gcg acc Leu Ala Tyr Tyr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr	564
aac agc gcc ggt cag ccc ggt ttc gtc acc gcc ggc cac tgc ggc acc Asn Ser Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Thr	612
gtc ggc acc ggc gtg acc atc ggc aac ggc acc ggc acc ttc cag aac Val Gly Thr Gly Val Thr Ile Gly Asn Gly Thr Gly Thr Phe Gln Asn	660
tcg gtc ttc ccc ggc aac gac gcc gcc ttc gtc cgc ggc acc tcc aac Ser Val Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn	708
ttc acc ctg acc aac ctg gtc tcg cgc tac aac tcc ggc ggc tac cag Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Ser Gly Gly Tyr Gln	756
tcg gtg acc ggt acc agc cag gcc ccg gcc ggc tcg gcc gtg tgc cgc Ser Val Thr Gly Thr Ser Gln Ala Pro Ala Gly Ser Ala Val Cys Arg	804
tcc ggc tcc acc acc ggc tgg cac tgc ggc acc atc cag gcc cgc aac Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Asn	852
cag acc gtg cgc tac ccg cag ggc acc gtc tac tcg ctc acc cgc acc Gln Thr Val Arg Tyr Pro Gln Gly Thr Val Tyr Ser Leu Thr Arg Thr	900
aac gtg tgc gcc gag ccc ggc gac tcc ggc ggt tcg ttc atc tcc ggc Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser Gly	948
tcg cag gcc cag ggc gtc acc tcc ggc ggc tcc ggc aac tgc tcc gtc Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser Val	996
ggc ggc acg acc tac tac cag gag gtc acc ccg atg atc aac tcc tgg Gly Gly Thr Thr Tyr Tyr Gln Glu Val Thr Pro Met Ile Asn Ser Trp	1044
ggt gtc agg atc cgg acc taa Gly Val Arg Ile Arg Thr	1065

<210> 4  
<211> 354

10508-010-DK.ST25

<212> PRT

<213> Nocardiosis dassonvillei subspecies dassonvillei DSM 43235 ("Protease  
18")

<400> 4

Ala Pro Ala Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala  
-165 -160 -155

Ala Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asp Leu Thr Ser  
-150 -145 -140

Ala Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu  
-135 -130 -125

Thr Asp Ala Glu Ala Thr Glu Ala Ala Gly Glu Ala Tyr Gly Gly  
-120 -115 -110

Ser Leu Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
-105 -100 -95

Ala Ser Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gln Ala Thr Val  
-90 -85 -80 -75

Val Ser His Gly Thr Glu Gly Leu Thr Glu Val Val Glu Asp Leu Asn  
-70 -65 -60

Gly Ala Glu Val Pro Glu Ser Val Leu Gly Trp Tyr Pro Asp Val Glu  
-55 -50 -45

Ser Asp Thr Val Val Val Glu Val Leu Glu Gly Ser Asp Ala Asp Val  
-40 -35 -30

Ala Ala Leu Leu Ala Asp Ala Gly Val Asp Ser Ser Ser Val Arg Val  
-25 -20 -15

Glu Glu Ala Glu Glu Ala Pro Gln Val Tyr Ala Asp Ile Ile Gly Gly  
-10 -5 -1 1 5

Leu Ala Tyr Tyr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr  
10 15 20

Asn Ser Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Thr  
25 30 35

Val Gly Thr Gly Val Thr Ile Gly Asn Gly Thr Gly Thr Phe Gln Asn  
40 45 50

Ser Val Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn  
55 60 65 70

Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Ser Gly Gly Tyr Gln  
75 80 85

10508-010-DK.ST25

Ser Val Thr Gly Thr Ser Gln Ala Pro Ala Gly Ser Ala Val Cys Arg  
90 95 100

Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Asn  
105 110 115

Gln Thr Val Arg Tyr Pro Gln Gly Thr Val Tyr Ser Leu Thr Arg Thr  
120 125 130

Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser Gly  
135 140 145 150

Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser Val  
155 160 165

Gly Gly Thr Thr Tyr Tyr Gln Glu Val Thr Pro Met Ile Asn Ser Trp  
170 175 180

Gly Val Arg Ile Arg Thr  
185

```
<210> 5
<211> 1062
<212> DNA
<213> Nocardioopsis prasina DSM 15648 ("Protease 11")
```

<220>  
<221> CDS  
<222> (1) .. (1059)

```
<220>
<221> mat_peptide
<222> (496)..(1059)
```

[illegible]



## 10508-010-DK.ST25

gtc tcc tac ggc atc gag ggc ctc gac gag atc atc cag gat ctc aac Val Ser Tyr Gly Ile Glu Gly Leu Asp Glu Ile Ile Gln Asp Leu Asn -70 -65 -60	324
gcc gcc gac gcc gtc ccc ggc gtg gtc ggc tgg tac ccg gac gtg gcg Ala Ala Asp Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala -55 -50 -45	372
ggt gac acc gtc gtc ctg gag gtc ctg gag ggt tcc gga gcc gac gtg Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val -40 -35 -30	420
agc ggc ctg ctc gcc gac gcc ggc gtg gac gcc tcc gcc gtc gag gtg Ser Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val -25 -20 -15 -10	468
acc agc agt gcg cag ccc gag ctc tac gcc gac atc atc ggc ggt ctg Thr Ser Ser Ala Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu -5 -1 1 5	516
gcc tac acc atg ggc ggc cgc tgt tcc gtc gga ttc gcg gcc acc aac Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn 10 15 20	564
gcc gcc ggt cag ccc gga ttc gtc acc gcc ggt cac tgt ggc cgc gtg Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val 25 30 35	612
ggc acc cag gtg agc atc ggc aac ggc cag ggc gtc ttc gag cag tcc Gly Thr Gln Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu Gln Ser 40 45 50 55	660
atc ttc ccg ggc aac gac gcc gcc ttc gtc cgc ggc acg tcc aac ttc Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe 60 65 70	708
acg ctg acc aac ctg gtc agc cgc tac aac acc ggc ggt tac gcc acc Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr 75 80 85	756
gtc gcc ggc cac aac cag gcg ccc atc ggc tcc tcc gtc tgc cgc tcc Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser 90 95 100	804
ggc tcc acc acc ggc tgg cac tgc ggc acc atc cag gcc cgc ggc cag Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln 105 110 115	852
tcc gtg agc tac ccc gag ggc acc gtc acc aac atg acc cgg acc acc Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr 120 125 130 135	900
gtg tgc gcc gag ccc ggc gac tcc ggc ggc tcc tac atc tcc gcc aac Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn 140 145 150	948
cag gcc cag ggc gtc acc tcc ggc ggc tcc ggc aac tgc cgc acc ggc Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly 155 160 165	996
ggg acc acc ttc tac cag gag gtc acc ccc atg gtg aac tcc tgg ggc Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly 170 175 180	1044
gtc cgt ctc cgg acc taa Val Arg Leu Arg Thr 185	1062

<210> 6  
 <211> 353  
 <212> PRT  
 <213> Nocardiosis prasina DSM 15648 ("Protease 11")

<400> 6

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala  
 -165 -160 -155

Val Ser Met Gln Glu Ala Leu Gln Arg Asp Leu Gly Leu Thr Pro  
 -150 -145 -140

Leu Glu Ala Asp Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu  
 -135 -130 -125

Val Asp Glu Ala Ala Ala Ala Ala Ala Gly Asp Ala Tyr Gly Gly  
 -120 -115 -110

Ser Val Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
 -105 -100 -95 -90

Ala Ala Ser Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu  
 -85 -80 -75

Val Ser Tyr Gly Ile Glu Gly Leu Asp Glu Ile Ile Gln Asp Leu Asn  
 -70 -65 -60

Ala Ala Asp Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala  
 -55 -50 -45

Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val  
 -40 -35 -30

Ser Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val  
 -25 -20 -15 -10

Thr Ser Ser Ala Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu  
 -5 -1 1 5

Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn  
 10 15 20

Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val  
 25 30 35

Gly Thr Gln Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu Gln Ser  
 40 45 50 55

Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe  
 60 65 70

10508-010-DK.ST25

Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr  
75 80 85

Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser  
90 95 100

Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln  
105 110 115

Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr  
120 125 130 135

Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn  
140 145 150

Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly  
155 160 165

Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly  
170 175 180

Val Arg Leu Arg Thr  
185

<210> 7  
<211> 1062  
<212> DNA  
<213> Nocardiosis prasina DSM 15649 ("Protease 35")

<220>  
<221> CDS  
<222> (1)..(1059)

<220>  
<221> mat\_peptide  
<222> (496)..(1059)

<400> 7

gcc Ala -165	acc gga cca ctc ccc Thr Gly Pro Leu Pro -160	cag tca ccc acc ccg Gln Ser Pro Thr Pro -155	gag gcc gac gcc Glu Ala Asp Ala	45
gtc Val -150	tcc atg cag gag gcg Ser Met Gln Glu Ala -145	ctc cag cgc gac ctc Leu Gln Arg Asp Leu -140	ggc ctg acc ccg Gly Leu Thr Pro	90
ctt Leu -135	gag gcc gat gaa ctg Glu Ala Asp Glu Leu -130	ctg gcc gcc cag gac Leu Ala Ala Gln Asp -125	acc gcc ttc gag Thr Ala Phe Glu	135
gtc Val -120	gac gag gcc gcg gcc Asp Glu Ala Ala Ala -115	gag gcc gcc ggt gac Glu Ala Ala Gly Asp -110	gcc tac ggc ggc Ala Tyr Gly Gly	180
tcc Ser -105	gtc ttc gac acc gag Val Phe Asp Thr Glu -100	acc ctg gaa ctg acc Thr Leu Glu Leu Thr -95	gtc ctg gtc acc gac Val Leu Val Thr Asp -90	228

10508-010-DK.ST25

tcc gcc gcg gtc gag gcg gtg gag gcc acc ggc gcc ggg acc gaa ctg Ser Ala Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu -85 -80 -75	276
gtc tcc tac ggc atc acg ggc ctc gac gag atc gtc gag gag ctc aac Val Ser Tyr Gly Ile Thr Gly Leu Asp Glu Ile Val Glu Glu Leu Asn -70 -65 -60	324
gcc gcc gac gcc gtt ccc ggc gtg gtc ggc tgg tac ccg gac gtc gcg Ala Ala Asp Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala -55 -50 -45	372
ggt gac acc gtc gtg ctg gag gtc ctg gag ggt tcc ggc gcc gac gtg Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val -40 -35 -30	420
ggc ggc ctg ctc gcc gac gcc ggc gtg gac gcc tgg gcg gtc gag gtg Gly Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val -25 -20 -15 -10	468
acc acc acc gag cag ccc gag ctg tac gcc gac atc atc ggc ggt ctg Thr Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu -5 -1 1 5	516
gcc tac acc atg ggc ggc cgc tgt tgg gtc ggc ttc gcg gcc acc aac Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn 10 15 20	564
gcc gcc ggt cag ccc ggg ttc gtc acc gcc ggt cac tgt ggc cgc gtg Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val 25 30 35	612
ggc acc cag gtg acc atc ggc aac ggc cgg ggc gtc ttc gag cag tcc Gly Thr Gln Val Thr Ile Gly Asn Gly Arg Gly Val Phe Glu Gln Ser 40 45 50 55	660
atc ttc ccg ggc aac gac gcc gcc ttc gtc cgc gga acg tcc aac ttc Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe 60 65 70	708
acg ctg acc aac ctg gtc agc cgc tac aac acc ggc ggc tac gcc acc Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr 75 80 85	756
gtc gcc ggt cac aac cag gcg ccc atc ggc tcc tcc gtc tgc cgc tcc Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser 90 95 100	804
ggc tcc acc acc ggt tgg cac tgc ggc acc atc cag gcc cgc ggc cag Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln 105 110 115	852
tgg gtg agc tac ccc gag ggc acc gtc acc aac atg acg cgg acc acc Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr 120 125 130 135	900
gtg tgc gcc gag ccc ggc gac tcc ggc ggc tcc tac atc tcc ggc aac Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn 140 145 150	948
cag gcc cag ggc gtc acc tcc ggc ggc tcc ggc aac tgc cgc acc ggc Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly 155 160 165	996
ggg acc acc ttc tac cag gag gtc acc ccc atg gtg aac tcc tgg ggc Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly 170 175 180	1044

gtc cgt ctc cgg acc taa  
 val arg leu arg thr  
 185

<210> 8  
 <211> 353  
 <212> PRT  
 <213> Nocardiosis prasina DSM 15649 ("Protease 35")  
 <400> 8

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala  
 -165 -160 -155

Val Ser Met Gln Glu Ala Leu Gln Arg Asp Leu Gly Leu Thr Pro  
 -150 -145 -140

Leu Glu Ala Asp Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu  
 -135 -130 -125

Val Asp Glu Ala Ala Ala Glu Ala Ala Gly Asp Ala Tyr Gly Gly  
 -120 -115 -110

Ser Val Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
 -105 -100 -95 -90

Ser Ala Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu  
 -85 -80 -75

Val Ser Tyr Gly Ile Thr Gly Leu Asp Glu Ile Val Glu Glu Leu Asn  
 -70 -65 -60

Ala Ala Asp Ala Val Pro Gly val val Gly Trp Tyr Pro Asp Val Ala  
 -55 -50 -45

Gly Asp Thr Val Val Leu Glu val Leu Glu Gly Ser Gly Ala Asp Val  
 -40 -35 -30

Gly Gly Leu Leu Ala Asp Ala Gly val Asp Ala Ser Ala val Glu val  
 -25 -20 -15 -10

Thr Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu  
 -5 -1 1 5

Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn  
 10 15 20

Ala Ala Gly Gln Pro Gly Phe val Thr Ala Gly His Cys Gly Arg Val  
 25 30 35

Gly Thr Gln val Thr Ile Gly Asn Gly Arg Gly val Phe Glu Gln Ser  
 40 45 50 55

10508-010-DK.ST25

Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe  
60 65 70

Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr  
75 80 85

Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser  
90 95 100

Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln  
105 110 115

Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr  
120 125 130 135

Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn  
140 145 150

Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly  
155 160 165

Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly  
170 175 180

Val Arg Leu Arg Thr  
185

<210> 9  
<211> 1068  
<212> DNA  
<213> Nocardiosis alba DSM 15647 ("Protease 08")

<220>  
<221> CDS  
<222> (1)..(1065)

<220>  
<221> mat\_peptide  
<222> (502)..(1065)

<400> 9		
gcg acc ggc	ccc ctc ccc cag tcc	ccc acc ccg gat gaa gcc gag
Ala Thr Gly	Pro Leu Pro Gln Ser	Pro Thr Pro Asp Glu Ala Glu
-165	-160	-155
gcc acc acc	atg gtc gag gcc ctc	cag cgc gac ctc ggc ctg tcc
Ala Thr Thr	Met Val Glu Ala Leu	Gln Arg Asp Leu Gly Leu Ser
-150	-145	-140
ccc tct cag	gcc gac gag ctc ctc	gag gcg cag gcc gag tcc ttc
Pro Ser Gln	Ala Asp Glu Leu Leu	Glu Ala Gln Ala Glu Ser Phe
-135	-130	-125
gag atc gac	gag gcc gcc acc gcg	gcc gca gcc gac tcc tac gcc
Glu Ile Asp	Glu Ala Ala Thr Ala	Ala Ala Ala Asp Ser Tyr Gly
-120	-115	-110
ggc tcc atc	ttc gac acc gac agc	ctc acc ctg acc gtc ctg gtc acc
		228

## 10508-010-DK.ST25

Gly Ser Ile Phe Asp Thr Asp Ser Leu Thr Leu Thr Val Leu Val Thr  
 -105 -100 -95

gac gcc tcc gcc gtc gag gcg gtc gag gcc gcc gcc gcc gag gcc aag 276  
 Asp Ala Ser Ala Val Glu Ala Val Glu Ala Ala Gly Ala Glu Ala Lys  
 -90 -85 -80

gtg gtc tcg cac ggc atg gag ggc ctg gag gag atc gtc gcc gac ctg 324  
 Val Val Ser His Gly Met Glu Gly Leu Glu Ile Val Ala Asp Leu  
 -75 -70 -65 -60

aac gcg gcc gac gct cag ccc ggc gtc gtg ggc tgg tac ccc gac atc 372  
 Asn Ala Ala Asp Ala Gln Pro Gly Val Val Gly Trp Tyr Pro Asp Ile  
 -55 -50 -45

cac tcc gac acg gtc gtc ctc gag gtc ctc gag gcc tcc ggt gcc gac 420  
 His Ser Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp  
 -40 -35 -30

gtg gac tcc ctg ctc gcc gac gcc ggt gtg gac acc gcc gac gtc aag 468  
 Val Asp Ser Leu Leu Ala Asp Ala Gly Val Asp Thr Ala Asp Val Lys  
 -25 -20 -15

gtg gag agc acc acc gag cag ccc gag ctg tac gcc gac atc atc ggc 516  
 Val Glu Ser Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly  
 -10 -5 -1 1 5

ggt ctc gcc tac acc atg ggt ggc cgc tgc tgc gtc ggc ttc gcg gcc 564  
 Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala  
 10 15 20

acc aac gcc tcc ggc cag ccc ggc ttc gtc acc gcc ggc cac tgc ggc 612  
 Thr Asn Ala Ser Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly  
 25 30 35

acc gtc ggc acc ccg gtc agc atc ggc aac ggc cag ggc gtc ttc gag 660  
 Thr Val Gly Thr Pro Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu  
 40 45 50

cgt tcc gtc ttc ccc ggc aac gac tcc gcc ttc gtc cgc ggc acc tcg 708  
 Arg Ser Val Phe Pro Gly Asn Asp Ser Ala Phe Val Arg Gly Thr Ser  
 55 60 65

aac ttc acc ctg acc aac ctg gtc agc cgc tac aac acc ggt ggt tac 756  
 Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Tyr Asn Thr Gly Gly Tyr  
 70 75 80 85

gcg acc gtc tcc ggc tcc tcg cag gcg gcg atc gcc tcg cag atc tgc 804  
 Ala Thr Val Ser Gly Ser Ser Gln Ala Ala Ile Gly Ser Gln Ile Cys  
 90 95 100

cgt tcc ggc tcc acc acc ggc tgg cac tgc ggc acc gtc cag gcc cgc 852  
 Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Val Gln Ala Arg  
 105 110 115

ggc cag acg gtg agc tac ccc cag ggc acc gtg cag aac ctg acc cgc 900  
 Gly Gln Thr Val Ser Tyr Pro Gln Gly Thr Val Gln Asn Leu Thr Arg  
 120 125 130

acc aac gtc tgc gcc gag ccc ggt gac tcc ggc ggc tcc ttc atc tcc 948  
 Thr Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser  
 135 140 145

ggc agc cag gcc cag ggc gtc acc tcc ggt ggc tcc ggc aac tgc tcc 996  
 Gly Ser Gln Ala Gln Gly Val Thr Ser Gly Ser Gly Asn Cys Ser  
 150 155 160 165

ttc ggt ggc acc acc tac tac cag gag gtc aac ccg atg ctg agc agc 1044

Phe Gly Gly Thr Thr Tyr Tyr Gln Glu Val Asn Pro Met Leu Ser Ser  
170 175 180

1068

<400> 10

Thr Val Gly Thr Pro Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu  
Page 14



40

45

10508-010-DK.ST25  
50

Arg Ser Val Phe Pro Gly Asn Asp Ser Ala Phe Val Arg Gly Thr Ser  
55 60 65

Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr  
70 75 80 85

Ala Thr Val Ser Gly Ser Ser Gln Ala Ala Ile Gly Ser Gln Ile Cys  
90 95 100

Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Val Gln Ala Arg  
105 110 115

Gly Gln Thr Val Ser Tyr Pro Gln Gly Thr Val Gln Asn Leu Thr Arg  
120 125 130

Thr Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser  
135 140 145

Gly Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser  
150 155 160 165

Phe Gly Gly Thr Thr Tyr Tyr Gln Glu Val Asn Pro Met Leu Ser Ser  
170 175 180

Trp Gly Leu Thr Leu Arg Thr  
185

<210> 11  
<211> 1164  
<212> DNA  
<213> synthetic ("Protease 22")

<220>  
<221> CDS  
<222> (1)..(1164)

<220>  
<221> sig\_peptide  
<222> (1)..(81)

<220>  
<221> misc\_feature  
<222> (82)..(576)  
<223> Propeptide

<220>  
<221> mat\_peptide  
<222> (577)..(1164)

<400> 11  
atg aaa aaa ccg ctg gga aaa att gtc gca agc aca gca ctt ctt 45  
Met Lys Lys Pro Leu Gly Lys Ile Val Ala Ser Thr Ala Leu Leu  
-190 -185 -180

att tca gtg gca ttt agc tca tct att gca tca gca gct aca gga 90

## 10508-010-DK.ST25

Ile Ser Val	Ala Phe Ser Ser Ser	Ile Ala Ser Ala Ala	Thr Gly	
-175	-170	-165		
gca tta ccg	cag tct ccg aca ccg	gaa gca gat gca gtc	tca atg	135
Ala Leu Pro	Gln Ser Pro Thr Pro	Glu Ala Asp Ala Val	Ser Met	
-160	-155	-150		
caa gaa gca	ctg caa aga gat ctt	gat ctt aca tca gca	gaa gca	180
Gln Glu Ala	Leu Gln Arg Asp Leu	Asp Leu Thr Ser Ala	Glu Ala	
-145	-140	-135		
gaa gaa ctt	ctt gct gca caa gat	aca gca ttt gaa gtg	gat gaa	225
Glu Glu Leu	Leu Ala Ala Gln Asp	Thr Ala Phe Glu Val	Asp Glu	
-130	-125	-120		
gca gcg gca	gaa gca gca gga gat	gca tat ggc ggc tca	gtt ttt	270
Ala Ala Ala	Glu Ala Ala Gly Asp	Ala Tyr Gly Gly Ser	Val Phe	
-115	-110	-105		
gat aca gaa	tca ctt gaa ctt aca gtt	ctt gtt aca gat gca gca gca		318
Asp Thr Glu	Ser Leu Glu Leu Thr Val	Leu Val Thr Asp Ala Ala Ala		
-100	-95	-90		
gtt gaa gca	gtt gaa gca aca gga gca	gga aca gta ctt gtt tca tat		366
Val Glu Ala	Val Glu Ala Thr Gly Ala	Gly Thr Val Leu Val Ser Tyr		
-85	-80	-75		
gga att gat	ggc ctt gat gaa att gtt	caa gaa ctg aat gca gct gat		414
Gly Ile Asp	Gly Leu Asp Glu Ile Val	Gln Glu Leu Asn Ala Ala Asp		
-70	-65	-60		
gct gtt ccg	ggc gtt gtt ggc tgg tat	ccg gat gtt gct gga gat aca		462
Ala Val Pro	Gly Val Val Gly Trp Tyr	Pro Asp Val Ala Gly Asp Thr		
-50	-45	-40		
gtt gtc ctt	gaa gtt ctt gaa gga tca	ggc gca gat gtt tca ggc ctg		510
Val Val Leu	Glu Val Leu Glu Gly Ser	Gly Ala Asp Val Ser Gly Leu		
-35	-30	-25		
ctg gca gac	gca gga gtc gat gca tca	gca gtt gaa gtt aca aca tca		558
Leu Ala Asp	Ala Gly Val Asp Ala Ser	Ala Val Glu Val Thr Thr Ser		
-20	-15	-10		
gat caa ccg	gaa ctt tat gca gat att	att ggc ggc ctg gca tat tat		606
Asp Gln Pro	Glu Leu Tyr Ala Asp Ile	Ile Ile Gly Gly Leu Ala Tyr Tyr		
-5	-1	1		
atg ggc ggc	aga tgc agc gtt ggc ttt	gca gca aca aat gca tca ggc		654
Met Gly Gly	Arg Cys Ser Val Gly Phe	Ala Ala Thr Asn Ala Ser Gly		
	15	20		
caa ccg ggc	ttt gtt aca gca ggc cat	tgc ggc aca gtt ggc aca cca		702
Gln Pro Gly	Phe Val Thr Ala Gly His	Cys Gly Thr Val Gly Thr Pro		
	30	35		
gtt tca att	ggc aat ggc aaa ggc gtt	ttt gaa cga agc att ttt ccg		750
Val Ser Ile	Gly Asn Gly Lys Gly Val	Phe Glu Arg Ser Ile Phe Pro		
	45	50		
ggc aat gat	tca gca ttt gtt aga ggc	aca tca aat ttt aca ctt aca		798
Gly Asn Asp	Ser Ala Phe Val Arg Gly	Thr Ser Asn Phe Thr Leu Thr		
	60	65		
aat ctg gtt	tca aga tat aat tca ggc	ggc tat gca aca gtt gca ggc		846
Asn Leu Val	Ser Arg Tyr Asn Ser Gly	Gly Tyr Ala Thr Val Ala Gly		
	75	80		
cat aat caa	gca ccg att ggc tca gca	gtt tgc aga tca ggc tca aca		894

10508-010-OK.ST25

His Asn Gln Ala Pro Ile Gly Ser Ala Val Cys Arg Ser Gly Ser Thr  
95 100 105

aca ggc tgg cat tgc ggc aca att caa gca aga aat caa aca gtt agg 942  
Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Asn Gln Thr Val Arg  
110 115 120

tat ccg caa ggc aca gtt tat agt ctg aca aga aca aca gtt tgt gca 990  
Tyr Pro Gln Gly Thr Val Tyr Ser Leu Thr Arg Thr Thr Val Cys Ala  
125 130 135

gaa ccg ggc gat tca ggc ggc tca tat att agc ggc act caa gca caa 1038  
Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Thr Gln Ala Gln  
140 145 150

ggc gtt aca tca ggc ggc tca ggc aat tgc agt gct ggc ggc aca aca 1086  
Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser Ala Gly Gly Thr Thr  
155 160 165 170

tat tac caa gaa gtt aat ccg atg ctt agt tca tgg ggc ctt aca ctt 1134  
Tyr Tyr Gln Glu Val Asn Pro Met Leu Ser Ser Trp Gly Leu Thr Leu  
175 180 185

aga aca caa tcg cat gtt caa tcc gct cca 1164  
Arg Thr Gln Ser His Val Gln Ser Ala Pro  
190 195

<210> 12  
<211> 388  
<212> PRT  
<213> synthetic ("Protease 22")

<400> 12

Met Lys Lys Pro Leu Gly Lys Ile Val Ala Ser Thr Ala Leu Leu  
-190 -185 -180

Ile Ser Val Ala Phe Ser Ser Ser Ile Ala Ser Ala Ala Thr Gly  
-175 -170 -165

Ala Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala Val Ser Met  
-160 -155 -150

Gln Glu Ala Leu Gln Arg Asp Leu Asp Leu Thr Ser Ala Glu Ala  
-145 -140 -135

Glu Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu Val Asp Glu  
-130 -125 -120

Ala Ala Ala Glu Ala Ala Gly Asp Ala Tyr Gly Gly Ser Val Phe  
-115 -110 -105

Asp Thr Glu Ser Leu Glu Leu Thr Val Leu Val Thr Asp Ala Ala Ala  
-100 -95 -90

Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Val Leu Val Ser Tyr  
-85 -80 -75

Gly Ile Asp Gly Leu Asp Glu Ile Val Gln Glu Leu Asn Ala Ala Asp  
Page 17

-55

-40

-25

-10

10

25

City  
40

55

70

90

Set  
105

120

135

150

170

185

195



# Kongeriget Danmark


Patent application No.: PA 2003 01494  
Date of filing: 10 October 2003  
Applicant:  
(Name and address) Novozymes A/S  
Krogshøjvej 36  
DK-2880 Bagsværd  
Denmark

Title: Protese variants

IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)



**Patent- og Varemærkestyrelsen**  
Økonomi- og Erhvervsministeriet

12 October 2004

*Pia Høybye-Olsen*  
Pia Høybye-Olsen

Modtaget  
10 OKT. 2003  
PVS**PROTEASE VARIANTS****Field of the Invention**

5           The present invention relates to variants of a parent protease, in particular variants of amended properties, such as improved thermostability. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of  
10 amended properties. Preferred parent proteases are the *Nocardiopsis* proteases comprising SEQ ID NOs: 2, 4, 6, 8 and 10.

**Background of the Invention**

15           Proteases derived from strains of *Nocardiopsis* are disclosed in WO 88/03947, WO 01/58276, and DK 1996 00013 ("Protease 10," SEQ ID NOs: 1-2); DK 2003 00912 ("Protease 08," SEQ ID NOs: 9-10); DK 2003 00913 ("Protease 11," SEQ ID NOs: 5-6); DK 2003 00914 ("Protease 18," SEQ ID NOs: 3-4); DK 2003 00915 ("Protease 35," SEQ ID NO: 7-8), DD 2004328, and in JP 02255081.

20           It is an object of the present invention to provide novel and improved protease variants, in particular of amended properties, such as improved thermostability.

**Summary of the Invention**

25           The present invention relates to a variant of a parent protease, comprising a substitution in at least one position of at least one region selected from the group of regions consisting of: 6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188; wherein

- (a) the variant has protease activity; and
- (b) each position corresponds to a position of SEQ ID NO: 2; and
- (c) the variant has a percentage of identity to SEQ ID NO: 2 of at least 60%.

30           The present invention also relates to isolated nucleic acid sequences encoding the protease variant and to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the protease variants.

**Brief Description of the Figures**

35           Figure 1 is a multiple alignment of Protease 10, Protease 18, Protease 11, Protease 35 and Protease 08 (the mature peptide parts of SEQ ID NOs: 2, 4, 6, 8 and 10, respectively); and

10508.000-DK

Figure 2 provides the coordinates of the novel 3D structure of Protease 10 (SEQ ID NO: 2) derived from *Nocardioopsis* sp. NRRL 18262.

### Detailed Description of the Invention

#### 5 Three-dimensional Structure of Protease 10

The structure of Protease 10 was solved in accordance with the principles for X-ray crystallographic methods as given, for example, in X-Ray Structure Determination, Stout, G.K. and Jensen, L.H., John Wiley & Sons, Inc. NY, 1989. The structural coordinates for the crystal structure at 2.2 Å resolution using the isomorphous replacement method are given in Fig. 2 in standard PDB format (Protein Data Bank, Brookhaven National Laboratory, Brookhaven, CT).  
10 The PDB file of Fig. 2 relates to the mature peptide part of Protease 10 corresponding to residues 1-188 of SEQ ID NO: 2.

#### Molecular Dynamics (MD)

15 Molecular Dynamics (MD) simulations are indicative of the mobility of the amino acids in a protein structure (see McCammon, JA and Harvey, SC., (1987), "Dynamics of proteins and nucleic acids", Cambridge University Press). Such protein dynamics are often compared to the crystallographic B-factors (see Stout, GH and Jensen, LH, (1989), "X-ray structure determination", Wiley). By running the MD simulation at, e.g., different temperatures, the  
20 temperature related mobility of residues is simulated. Regions having the highest mobility or flexibility (here isotropic fluctuations) may be suggested for random mutagenesis. It is here understood that the high mobility found in certain areas of the protein, may be thermally improved by substituting these residues.

Using the programs CHARMM (Accelrys) and NAMD (University of Illinois at Urbana-  
25 Champaign) the Protease 10 structure described above was subjected to MD at 300 and 400K. Starting from the coordinates of Figure 2 hydrogen and missing heavy atoms were built using CHARMM procedures HBUILD and IC BUILD respectively. Then the structure was minimized using CHARMM Conjugate Gradients (CONJ) minimization procedure for a total of 200 steps. The protein was then put on a 70 X 70 X 70 Angstrom box and solvated with TIP3  
30 water molecules. A total of 11124 water molecules were added and then minimized, keeping the protein coordinates fixed, using CHARMM Adopted Basis Newton Raphson (ABNR) minimization procedure for 20000 steps. The system was then heated to the desired temperature at a rate of 1K every 100 steps using the NAMD software. After an equilibration of 50 picoseconds, an NVE ensemble MD was run for 1 nanosecond, both steps done with the  
35 software NAMD. A cut-off of 12 Angstrom was used for the non-bonded interactions. Periodic boundary conditions were used after the solvation step and for all the subsequent ones. The isotropic root mean square (RMS) fluctuations were calculated with the CHARMM procedure

10508.000-DK

**COOR DYNA.**

The following suggested regions for mutagenesis result from MD simulations: From residue 160 to 170, from residue 78 to 90, from residue 43 to 50, from residue 66 to 75, and from residue 22 to 28.

5

**Strategy for Preparing Variants**

Regions of amino acid residues, as well as individual amino acid substitutions, were suggested for mutagenesis based on the 3D-structure of Fig. 2 and the alignment of Fig. 1, mainly with a view to improving thermostability.

10 The following regions were suggested, cf. claim 1: 6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188.

At least one of the following positions of the above regions are preferably subjected to mutagenesis, cf. claim 3: 6; 7; 8; 9; 10; 12; 13; 16; 17; 18; 22; 23; 24; 25; 26; 27; 28; 32; 33; 37; 38; 39; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 58; 62; 63; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 103; 105; 106; 111; 113; 114; 118; 120; 122; 124; 125; 127; 129; 130; 131; 134; 135; 136; 139; 140; 141; 144; 145; 146; 147; 148; 149; 150; 151; 155; 156; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 179; 180; 181; 184; 185; 186; 187; and/or 188.

20 Contemplated specific variants are listed in the claims, viz. variants of Protease 10, Protease 18, Protease 11, Protease 35 as well as Protease 08 in claims 4 and 15; variants of Protease 10 in claim 16; variants of Protease 18 in claim 17; variants of Protease 11 in claim 18; variants of Protease 35 in claim 19; and variants of Protease 08 in claim 20. Subgroups of specific variants are listed in claims 21-23.

25 The various concepts underlying the invention are also reflected in the claims as follows: Stabilization by disulfide-bridges in claims 5 and 6; proline-stabilization in claims 7-8; substitution of exposed neutral residues with negatively charged residues in claims 9-10; substitution of exposed neutral residues with positively charged residues in claims 11-12; substitution of small residues with bulkier residues inside the protein in claim 13; and regions proposed for mutagenesis following MD simulations in claim 14.

30 The term "at least one" means "one or more," viz., e.g. in the context of regions: One, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen; or, in the context of positions or substitutions: One, two, three, four, five, and so on, up to e.g. ninety.

35

In a particular embodiment, the number of regions proposed for and/or subjected to mutagenesis is at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve,



10508.000-DK

thirteen, fourteen, fifteen, sixteen, or at least seventeen.

In another particular embodiment, the number of regions proposed for and/or subjected to mutagenesis is no more than one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or no more than seventeen.

5

### **Polypeptides Having Protease Activity**

Polypeptides having protease activity, or proteases, are sometimes also designated peptidases, proteinases, peptide hydrolases, or proteolytic enzymes. Proteases may be of the exo-type that hydrolyse peptides starting at either end thereof, or of the endo-type that act internally in polypeptide chains (endopeptidases). Endopeptidases show activity on N- and C-terminally blocked peptide substrates that are relevant for the specificity of the protease in question.

The term "protease" is defined herein as an enzyme that hydrolyses peptide bonds. This definition of protease also applies to the protease-part of the terms "parent protease" and "protease variant," as used herein. The term "protease" includes any enzyme belonging to the EC 3.4 enzyme group (including each of the thirteen subclasses thereof). The EC number refers to Enzyme Nomenclature 1992 from NC-IUBMB, Academic Press, San Diego, California, including supplements 1-5 published in Eur. J. Bio-chem. 1994, 223, 1-5; Eur. J. Biochem. 1995, 232, 1-6; Eur. J. Biochem. 1996, 237, 1-5; Eur. J. Biochem. 1997, 250, 1-6; and Eur. J. Biochem. 1999, 264, 610-650; respectively. The nomenclature is regularly supplemented and updated; see e.g. the World Wide Web (WWW) at <http://www.chem.qmw.ac.uk/iubmb/enzyme/index.html>.

Proteases are classified on the basis of their catalytic mechanism into the following groups: Serine proteases (S), Cysteine proteases (C), Aspartic proteases (A), Metallo proteases (M), and Unknown, or as yet unclassified, proteases (U), see Handbook of Proteolytic Enzymes, A.J.Barrett, N.D.Rawlings, J.F.Woessner (eds), Academic Press (1998), in particular the general introduction part.

In particular embodiments, the parent proteases and/or the protease variants of the invention and for use according to the invention are selected from the group consisting of:

- (a) Proteases belonging to the EC 3.4.-.- enzyme group;
- (b) Serine proteases belonging to the S group of the above Handbook;
- (c1) Serine proteases of peptidase family S2A; and
- (c2) Serine proteases of peptidase family S1E as described in Biochem.J. 290:205-218 (1993) and in MEROPS protease database, release 6.20, March 24, 2003, ([www.merops.ac.uk](http://www.merops.ac.uk)). The database is described in Rawlings, N.D., O'Brien, E. A. & Barrett, A.J. (2002) MEROPS: the protease database. Nucleic Acids Res. 30, 343-346.

For determining whether a given protease is a Serine protease, and a family S2A pro-

10508.000-DK

tease, reference is made to the above Handbook and the principles indicated therein. Such determination can be carried out for all types of proteases, be it naturally occurring or wild-type proteases; or genetically engineered or synthetic proteases.

Protease activity can be measured using any assay, in which a substrate is employed, that includes peptide bonds relevant for the specificity of the protease in question. Assay-pH and assay-temperature are likewise to be adapted to the protease in question. Examples of assay-pH-values are pH 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. Examples of assay-temperatures are 30, 35, 37, 40, 45, 50, 55, 60, 65, 70, 80, 90, or 95°C. Examples of protease substrates are casein, such as Azurine-Crosslinked Casein (AZCL-casein). Examples of suitable protease assays are described in Example 1.

### Parent Protease

The parent protease is a protease from which the protease variant is, or can be, derived. For the present purposes, any protease can be used as the parent protease, as long as the resulting protease variant is homologous to Protease 10, i.e. the protease derived from *Nocardiopsis* sp. NRRL 18262 and comprising amino acids 1-188 of SEQ ID NO: 2.

In a particular embodiment the parent protease is also homologous to Protease 10.

In the present context, homologous means having an identity of at least 60% to SEQ ID NO: 2, viz. amino acids 1-188 of the mature peptide part of Protease 10. Homology is determined as generally described below in the section entitled Amino Acid Homology.

The parent protease may be a wild-type or naturally occurring polypeptide, or an allelic variant thereof, or a fragment thereof that has protease activity, in particular a mature part thereof. It may also be a variant thereof and/or a genetically engineered or synthetic polypeptide.

In a particular embodiment the wild-type parent protease is i) a bacterial protease; ii) a protease of the phylum *Actinobacteria*; iii) of the class *Actinobacteria*; iv) of the order *Actinomycetales* v) of the family *Nocardiopsaceae*; vi) of the genus *Nocardiopsis*; and/or a protease derived from vii) *Nocardiopsis* species, such as *Nocardiopsis alba*, *Nocardiopsis antarctica*, *Nocardiopsis composta*, *Nocardiopsis dassonvillei*, *Nocardiopsis exhalans*, *Nocardiopsis halophila*, *Nocardiopsis halotolerans*, *Nocardiopsis kunsanensis*, *Nocardiopsis listeri*, *Nocardiopsis lucentensis*, *Nocardiopsis metallicus*, *Nocardiopsis prasina*, *Nocardiopsis* sp., *Nocardiopsis synnemataformans*, *Nocardiopsis trehalosi*, *Nocardiopsis tropica*, *Nocardiopsis umidischolae*, or *Nocardiopsis xinjiangensis*.

Examples of such strains are: *Nocardiopsis alba* DSM 15647 (wild-type producer of Protease 08), *Nocardiopsis dassonvillei* NRRL 18133 (wild-type producer of Protease M58-1 described in WO 88/03947), *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235 (wild-type producer of Protease 18), *Nocardiopsis prasina* DSM 15648 (wild-type producer of

10508.000-DK

Protease 11), *Nocardiopsis prasina* DSM 15649 (wild-type producer of Protease 35), *Nocardiopsis* sp. NRRL 18262 (wild-type producer of Protease 10), *Nocardiopsis* sp. strain FERM P-10508 (described in JP 02255081), or *Nocardiopsis dassonvillei* strain ZIMET 43647 (described in DD 2,004,328).

5 Strains of these species are accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL), e.g. *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235 is  
10 publicly available from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). The strain was also deposited at other depository institutions as follows: ATCC 23219, IMRU 1250, NCTC 10489.

The following biological materials were deposited in connection with the filing of other patent applications under the terms of the Budapest Treaty with the Agricultural Research  
15 Culture Collection (NRRL), Peoria, US, or the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, and given the following accession numbers:

Deposit	Accession Number	Date of Deposit
<i>Nocardiopsis</i> sp.	NRRL 18262	November 10, 1987
20 <i>Nocardiopsis dassonvillei</i>	NRRL 18133	November 13, 1986
<i>Nocardiopsis alba</i>	DSM 15647	May 30, 2003
<i>Nocardiopsis prasina</i>	DSM 15648	May 30, 2003
<i>Nocardiopsis prasina</i>	DSM 15649	May 30, 2003

These strains have been deposited under conditions that assure that access to the  
25 cultures will be available during the pendency of the other patent applications to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122. The deposits represent substantially pure cultures of the deposited strains. The deposits are available as required by foreign patent laws in countries wherein counterparts of these applications, or their progeny are filed. However, it should be  
30 understood that the availability of a deposit does not constitute a license to practice the invention in derogation of patent rights granted by governmental action.

Of the above strains, the three last-mentioned were isolated in 2001 from soil samples from Denmark.

Furthermore, such polypeptides may be identified and obtained from other sources  
35 including microorganisms or DNA isolated from nature (e.g., soil, composts, water, etc.) using suitable probes. Techniques for isolating microorganisms or DNA from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a

10508.000-DK

genomic or cDNA library of another microorganism. Once a nucleic acid sequence encoding a polypeptide has been detected with the probe(s), the sequence may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see, e.g., Sambrook *et al.*, 1989, *supra*).

5       The parent protease may be a mature part of any of the amino acid sequences referred to above. A mature part means a mature amino acid sequence and refers to that part of an amino acid sequence which remains after a potential signal peptide part and/or pro-peptide part has been cleaved off.

10       The parent protease may also be a fragment of a specified amino acid sequence, viz. a polypeptide having one or more amino acids deleted from the amino and/or carboxyl terminus of this amino acid sequence. In one embodiment, a fragment contains at least 80, or at least 90, or at least 100, or at least 110, or at least 120, or at least 130, or at least 140, or at least 150, or at least 160, or at least 170, or at least 180, or at least 185 amino acid residues.

15       The parent protease may also be an allelic variant, allelic referring to the existence of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

20       In another embodiment, the parent protease may be a genetically engineered protease, e.g. a variant of the wild-type or natural parent proteases referred to above comprising a substitution, deletion, and/or insertion of one or more amino acids. In other words: The parent protease may itself be a protease variant. The amino acid sequence of such parent protease may differ from the amino acid sequence specified by an insertion or  
25       deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. The amino acid changes may be of a minor, or of a major, nature. Amino acid changes of a major nature are e.g. those resulting in a variant protease of the present invention with amended properties. In another particular embodiment, the amino acid changes are of a minor nature, that is conservative amino acid substitutions  
30       that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

35       Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and

10508.000-DK

valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

Still further examples of genetically engineered parent proteases are synthetic proteases, designed by man, and expectedly not occurring in nature. EP 897985 discloses a process of preparing a consensus protein. Shuffled proteases are other examples of synthetic or genetically engineered parent proteases, which can be prepared as is generally known in the art, eg by Site-directed Mutagenesis, by PCR (using a PCR fragment containing the desired mutation as one of the primers in the PCR reactions), or by Random Mutagenesis. Included in the concept of a synthetic protease is also any hybrid or chimeric protease, i.e. a protease which comprises a combination of partial amino acid sequences derived from at least two proteases.

In further particular embodiments, the parent protease comprises, or consists of, respectively, the amino acid sequence specified, or an allelic variant thereof; or a fragment thereof that has protease activity.

In still further particular embodiments, the protease variant of the invention is not identical to:

- (i) amino acids 1-188 of SEQ ID NO: 2, amino acids 1-188 of SEQ ID NO: 4, amino acids 1-188 of SEQ ID NO: 6, amino acids 1-188 of SEQ ID NO: 8, and amino acids 1-188 of SEQ ID NO: 10;
- (ii) the protease derived from *Nocardioopsis dassonvillei* NRRL 18133;
- (iii) the protease derived from *Nocardioopsis* sp. FERM P-10508;
- (iv) the protease derived from *Nocardioopsis dassonvillei* strain ZIMET 43647; and/or
- (v) any prior art protease of a percentage of identity to SEQ ID NO: 2 of at least 60%.

### Microorganism Taxonomy

Questions relating to taxonomy may be solved by consulting a taxonomy data base, such as the NCBI Taxonomy Browser which is available at the following internet site: <http://www.ncbi.nlm.nih.gov/Taxonomy/taxonomyhome.html/>, and/or by consulting Taxonomy handbooks. For the present purposes, the taxonomy is preferably according to the chapter: The road map to the Manual by G.M. Garrity & J. G. Holt in Bergey's Manual of Systematic Bacteriology, 2001, second edition, volume 1, David R. Boone, Richard W. Castenholz.

10508.000-DK

### Amino Acid Homology

The present invention refers to proteases, viz. parent proteases, and/or protease variants, having a certain degree of identity to SEQ ID NO: 2, such parent and/or variant proteases being hereinafter designated "homologous proteases".

5 For purposes of the present invention the degree of identity between two amino acid sequences, as well as the degree of identity between two nucleotide sequences, is determined by the program "align" which is a Needleman-Wunsch alignment (i.e. a global alignment). The program is used for alignment of polypeptide, as well as nucleotide sequences. The default scoring matrix BLOSUM50 is used for polypeptide alignments, and the default identity matrix is used for nucleotide alignments. The penalty for the first residue of a gap is -12 for polypeptides and -16 for nucleotides. The penalties for further residues of a gap are -2 for polypeptides, and -4 for nucleotides.

"Align" is part of the FASTA package version v20u6 (see W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and 15 W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," Methods in Enzymology 183:63-98). FASTA protein alignments use the Smith-Waterman algorithm with no limitation on gap size (see "Smith-Waterman algorithm", T. F. Smith and M. S. Waterman (1981) J. Mol. Biol. 147:195-197).

Multiple alignments of protein sequences may be made using "ClustalW" (Thompson, 20 J.D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Research, 22:4673-4680). Multiple alignment of DNA sequences may be done using the protein alignment as a template, replacing the amino acids with the corresponding codon from the DNA sequence.

25 In particular embodiments, the homologous protease has an amino acid sequence which has a degree of identity to SEQ ID NO: 2 of at least 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or of at least about 99%.

In alternative embodiments, the homologous protease has an amino acid sequence 30 which has a degree of identity to SEQ ID NO: 2 of at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, or at least 59%.

In another particular embodiment, the parent protease, and/or the protease variant, comprises a mature amino acid sequence which differs by no more than seventyfive, seventyfour, seventythree, seventytwo, seventyone, seventy, sixty-nine, sixtyeight, sixtyseven, 35 sixtysix, sixtyfive, sixtyfour, sixtythree, sixtytwo, sixtyone, sixty, fifty-nine, fiftyeight, fiftyseven, fiftysix, fiftyfive, fiftyfour, fiftythree, fiftytwo, fiftyone, fifty, forty-nine, fortyeight, fortyseven, fourtysix, fortyfive, fourtyfour, fortythree, fourtytwo, fourtyone, forty, thirtynine, thirtyeight,

10508.000-DK

thirtyseven, thirtysix, thirtyfive, thirtyfour, thirtythree, thirtytwo, thirtyone, thirty, twentynine, twentyeight, twentyseven, twentysix, twentyfive, twentyfour, twentythree, twentytwo, twentyone, twenty, nineteen, eighteen, seventeen, sixteen, fifteen, fourteen, thirteen, twelve, eleven, ten, nine, eight, seven, six, five, four, three, by no more than two, or only by one amino acid(s) from the specified amino acid sequence, e.g. SEQ ID NO: 2.

In a still further particular embodiment, the parent protease, and/or the protease variant, comprises a mature amino acid sequence which differs by at least seventyfive, seventyfour, seventythree, seventytwo, seventyone, seventy, sixty-nine, sixtyeight, sixtyseven, sixtysix, sixtyfive, sixtyfour, sixtythree, sixtytwo, sixtyone, sixty, fifty-nine, fiftyeight, fiftyseven, fiftysix, fiftyfive, fiftyfour, fiftythree, fiftytwo, fiftyone, fifty, fourtynine, fourtyeight, fourtyseven, fourtysix, fourtyfive, fourtyfour, fourtythree, fourtytwo, fourtyone, fourty, thirtynine, thirtyeight, thirtyseven, thirtysix, thirtyfive, thirtyfour, thirtythree, thirtytwo, thirtyone, thirty, twentynine, twentyeight, twentyseven, twentysix, twentyfive, twentyfour, twentythree, twentytwo, twentyone, twenty, nineteen, eighteen, seventeen, sixteen, fifteen, fourteen, thirteen, twelve, eleven, ten, nine, eight, seven, six, five, four, three, by at least two, or by one amino acid(s) from the specified amino acid sequence, e.g. SEQ ID NO: 2.

#### Nucleic Acid Hybridization

In the alternative, homologous parent proteases, as well as variant proteases, may be defined as being encoded by a nucleic acid sequence which hybridizes under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with nucleotides 900-1466 of SEQ ID NO: 1, or a subsequence or a complementary strand thereof (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York). A subsequence may be at least 100 nucleotides, or at least 200, 300, 400, or at least 500 nucleotides. Moreover, the subsequence may encode a polypeptide fragment that has the relevant enzyme activity.

For long probes of at least 100 nucleotides in length, very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures.

For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 2 x SSC, 0.2% SDS preferably at least at 45°C (very low stringency), more preferably at least at 50°C (low stringency), more preferably at

10508.000-DK

least at 55°C (medium stringency), more preferably at least at 60°C (medium-high stringency), even more preferably at least at 65°C (high stringency), and most preferably at least at 70°C (very high stringency).

For short probes which are about 15 nucleotides to about 70 nucleotides in length, stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at 5°C to 10°C below the calculated  $T_m$  using the calculation according to Bolton and McCarthy (1962, *Proceedings of the National Academy of Sciences USA* 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

For short probes which are about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated  $T_m$ .

#### 15 Position numbering

In the present context, the basis for numbering positions is SEQ ID NO: 2, Protease 10, starting with A1 and ending with T188, see Fig. 1. A parent protease, as well as a variant protease, may comprise extensions as compared to SEQ ID NO: 2, i.e. in the N-terminal, and/or the C-terminal ends thereof. The amino acids of such extensions, if any, are to be numbered as is usual in the art, i.e. for a C-terminal extension: 189, 190, 191 and so forth, and for an N-terminal extension -1, -2, -3 and so forth.

#### Alterations, such as Substitutions, Deletions, Insertions

In the present context, the following are examples of various ways in which a protease variant can be designed or derived from a parent amino acid sequence: An amino acid can be substituted with another amino acid; an amino acid can be deleted; an amino acid can be inserted; as well as any combination of any number of such alterations.

For the present purposes, the term substitution is intended to include any number of any type of such alterations. This is a reasonable definition, because, for example, a deletion can be regarded as a substitution of an amino acid, AA, in a given position, nn, with nothing, (). Such substitution can be designated: AAnn(). Likewise, an insertion of only one amino acid, BB, downstream an amino acid, AA, in a given position, nn, can be designated: ()nnaBB. And if two amino acids, BB and CC, are inserted downstream of amino acid AA in position nn, this substitution (combination of two substitutions) can be designated: ()nnaBB+()nnbCC, the thus created gaps between amino acids nn and nn+1 in the parent sequence being assigned lower case or subscript letters a, b, c etc. to the former position number, here nn. A similar numbering procedure is followed when aligning a new sequence to the multiple alignment of



10508.000-DK

Fig. 1, in case of a gap being created by the alignment between amino acids nn and nn+1: Each position of the gap is assigned a number: nna, nnb etc.. A comma (,) between substituents, as e.g. in the substitution T129E,D,Y,Q means "either or", i.e. that T129 is substituted with E, or D, or Y, or Q. A plus-sign (+) between substitutions, e.g. 129D+135P means "and", i.e. that these two single substitutions are combined in one and the same protease variant.

In the present context, the term "a substitution" means at least one substitution. At least one means one or more, e.g. one, or two, or three, or four, or five, or six, or seven, or eight, or nine, or ten, or twelve, or fourteen, or fifteen, or sixteen, or eighteen, or twenty, or twentytwo or twentyfour, or twentyfive, or twenty eight, or thirty, and so on, to include in principle, any number of substitutions. The variants of the invention, however, still have to be, e.g., at least 60% identical to SEQ ID NO: 2, this percentage being determined by the above-mentioned program. The substitutions can be applied to any position encompassed by any region mentioned in claim 1, and variants comprising combinations of any number and type of such substitutions are also included. The term substitution as used herein also include deletions, as well as extensions, or insertions, that may add to the length of the sequence corresponding to SEQ ID NO: 2.

Furthermore, the term "a substitution" embraces a substitution into any one of the other nineteen natural amino acids, or into other amino acids, such as non-natural amino acids. For example, a substitution of amino acid T in position 22 includes each of the following substitutions: 22A, 22C, 22D, 22E, 22F, 22G, 22H, 22I, 22K, 22L, 22M, 22N, 22P, 22Q, 22R, 22S, 22V, 22W, and 22Y. This is, by the way, equivalent to the designation 22X, wherein X designates any amino acid. These substitutions can also be designated T22A, T22C, T22X, etc. The same applies by analogy to each and every position mentioned herein, to specifically include herein any one of such substitutions.

#### Identifying Corresponding Position Numbers

For each amino acid residue in each parent or variant protease, of the invention and/or for use according to the invention, it is possible to directly and unambiguously assign an amino acid residue in SEQ ID NO: 2 to which it corresponds. Corresponding residues are assigned the same number, by reference to the Protease 10 sequence.

As it appears from the numbering of Fig. 1, in conjunction with the numbering of the sequence listing, for each amino acid residue of each of the proteases Protease 10, Protease 18, Protease 11, Protease 35, and Protease 08, the corresponding amino acid residue in SEQ ID NO: 2 has the same number. This number is easily derivable from Fig. 1. At least in case of these five proteases, the number is the same as the number assigned to this amino acid residue in the sequence listing for the mature part of the respective protease.

10508.000-DK

For a given position in another protease - be it a parent or a variant protease - a corresponding position of SEQ ID NO: 2 can always be found, as follows:

5 The amino acid sequence of another parent protease, or, in turn, of a variant protease amino acid sequence, is designated SEQ-X. A position corresponding to position N of SEQ ID NO: 2 is found as follows: The parent or variant protease amino acid sequence SEQ-X is aligned with SEQ ID NO: 2 as specified above in the section entitled Amino Acid Homology. From the alignment, the position in sequence SEQ-X corresponding to position N of SEQ ID NO: 2 can be clearly and unambiguously derived, using the principles described below.

10 SEQ-X may be a mature part of the protease in question, or it may also include a signal peptide part, or it may be a fragment of the mature protease which has protease activity, e.g. a fragment of the same length as SEQ ID NO: 2, and/or it may be the fragment which extends from A1 to T188 when aligned with SEQ ID NO: 2 as described herein.

### Region and Position

15 In the present context, the term region means at least one position of a parent protease amino acid sequence, the term position designating an amino acid residue of such amino acid sequence. In one embodiment, region means one or more successive positions of the parent protease amino acid sequence, e.g. one, two, three, four, five, six, seven, eight, etc., up to any number of consecutive positions of the sequence. Accordingly, a region may  
20 consist of one position only, or it may consist of any number of consecutive positions, such as, e.g., position no. 62 and 63; or position no. 111, 112, 113 and 114. For the present purposes, these two regions are designated 62-63, and 111-114, respectively. The boundaries of these regions or ranges are included in the region.

25 A region encompasses specifically each and every position it embraces. For example, region 111-114 specifically encompasses each of the positions 111, 112, 113, and 114. The same applies by analogy for the other regions mentioned herein.

### Thermostability

30 For the present purposes, the term thermostable as applied in the context of a certain polypeptide, refers to the melting temperature,  $T_m$ , of such polypeptide, as determined using Differential Scanning Calorimetry (DSC) in 10mM sodium phosphate, 50 mM sodium chloride, pH 7.0, using a constant scan rate of 1.5°C/min.

The following  $T_m$ 's were determined under the above conditions: 76.5°C (Protease 10), 83.0°C (Protease 18), 78.3°C (Protease 08), 76.6°C (Protease 35), and 73.7°C (Protease 11).

35 For a thermostable polypeptide, the  $T_m$  is at least 83.1°C. In particular embodiments, the  $T_m$  is at least 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or at least 100°C.

In the alternative, the term thermostable refers to a melting temperature of at least 73.8, or at least 76.7°C, or at least 78.4°C, preferably at least 74, 75, 76, 77, 78, 79, 80, 81, 82, or at least 83°C, still as determined using DSC at a pH of 7.0.

For the determination of T<sub>m</sub>, a sample of the polypeptide with a purity of at least 90% (or 91, 92, 93, 94, 95, 96, 97, or 98%) as determined by SDS-PAGE may be used. Still further, the enzyme sample may have a concentration of between 0.5 and 2.5 mg/ml protein (or between 0.6 and 2.4, or between 0.7 and 2.2, or between 0.8 and 2.0 mg/ml protein), as determined from absorbance at 280 nm and based on an extinction coefficient calculated from the amino acid sequence of the enzyme in question.

The DSC takes place at the desired pH (e.g. pH 5.5, 7.0, 3.0, or 2.5) and with a constant heating rate, e.g. of 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10°C/min.

In a particular embodiment, the protease variant of the invention is more thermostable than the parent protease. A preferred parent protease for this purpose is Protease 18.

### **Low-allergenic Variants**

In a specific embodiment, the protease variants of the present invention are (also) low-allergenic variants, designed to invoke a reduced immunological response when exposed to animals, including man. The term immunological response is to be understood as any reaction by the immune system of an animal exposed to the protease variant. One type of immunological response is an allergic response leading to increased levels of IgE in the exposed animal. Low-allergenic variants may be prepared using techniques known in the art. For example the protease variant may be conjugated with polymer moieties shielding portions or epitopes of the protease variant involved in an immunological response. Conjugation with polymers may involve in vitro chemical coupling of polymer to the protease variant, e.g. as described in WO 96/17929, WO 98/30682, WO 98/35026, and/or WO 99/00489. Conjugation may in addition or alternatively thereto involve in vivo coupling of polymers to the protease variant. Such conjugation may be achieved by genetic engineering of the nucleotide sequence encoding the protease variant, inserting consensus sequences encoding additional glycosylation sites in the protease variant and expressing the protease variant in a host capable of glycosylating the protease variant, see e.g. WO 00/26354. Another way of providing low-allergenic variants is genetic engineering of the nucleotide sequence encoding the protease variant so as to cause the protease variants to self-oligomerize, effecting that protease variant monomers may shield the epitopes of other protease variant monomers and thereby lowering the antigenicity of the oligomers. Such products and their preparation is described e.g. in WO 96/16177. Epitopes involved in an immunological response may be identified by various methods such as the phage display method described in WO 00/26230 and WO 01/83559, or the random approach described in EP 561907. Once an epitope has

10508.000-DK

been identified, its amino acid sequence may be altered to produce altered immunological properties of the protease variant by known gene manipulation techniques such as site directed mutagenesis (see e.g. WO 00/26230, WO 00/26354 and/or WO 00/22103) and/or conjugation of a polymer may be done in sufficient proximity to the epitope for the polymer to shield the epitope.

### Nucleic Acid Sequences and Constructs

The present invention also relates to nucleic acid sequences comprising a nucleic acid sequence which encodes a protease variant of the invention.

The term "isolated nucleic acid sequence" refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

The nucleic acid sequences of the invention can be prepared by introducing at least one mutation into the parent protease coding sequence or a subsequence thereof, wherein the mutant nucleic acid sequence encodes a variant protease. The introduction of a mutation into the nucleic acid sequence to exchange one nucleotide for another nucleotide may be accomplished by site-directed mutagenesis using any of the methods known in the art, e.g. by site-directed mutagenesis, by random mutagenesis, or by doped, spiked, or localized random mutagenesis.

Random mutagenesis is suitably performed either as localized or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid sequence shown in question, or within the whole gene. When the mutagenesis is performed by the use of an oligonucleotide, the oligonucleotide may be doped or spiked with the three non-parent nucleotides during the synthesis of the oligonucleotide at the positions which are to be changed. The doping or spiking may be performed so that codons for unwanted amino acids are avoided. The doped or spiked oligonucleotide can be incorporated into the DNA encoding the protease enzyme by any technique, using, e.g., PCR, LCR or any DNA polymerase and ligase as deemed appropriate.

10508.000-DK

Preferably, the doping is carried out using "constant random doping", in which the percentage of wild-type and mutation in each position is predefined. Furthermore, the doping may be directed toward a preference for the introduction of certain nucleotides, and thereby a preference for the introduction of one or more specific amino acid residues. The doping may be made, e.g., so as to allow for the introduction of 90% wild type and 10% mutations in each position. An additional consideration in the choice of a doping scheme is based on genetic as well as protein-structural constraints.

The random mutagenesis may be advantageously localized to a part of the parent protease in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme.

Alternative methods for providing variants of the invention include gene shuffling e.g. as described in WO 95/22625 or in WO 96/00343, and the consensus derivation process as described in EP 897985.

The present invention does not relate to the following nucleic acid sequences:

(i) Nucleotides 900-1466 of SEQ ID NO: 1, nucleotides 499-1062 of SEQ ID NO: 3, nucleotides 496-1059 of SEQ ID NO: 5, nucleotides 496-1059 of SEQ ID NO: 7, and nucleotides 502-1065 of SEQ ID NO: 9;

(ii) the nucleic acid sequence encoding the mature peptide part of the protease derived from *Nocardiopsis dassonvillei* NRRL 18133, in the event that this protease has at least 60% identity to SEQ ID NO: 2;

(iii) the nucleic acid sequence encoding the mature peptide part of the protease derived from *Nocardiopsis* sp. FERM P-10508, in the event that this protease has at least 60% identity to SEQ ID NO: 2;

(iv ) the nucleic acid sequence encoding the mature peptide part of the protease derived from *Nocardiopsis dassonvillei* strain ZIMET 43647; and/or

(v) nucleic acid sequences encoding any prior art proteases of at least 60% identity to SEQ ID NO: 2.

### Nucleic Acid Constructs

A nucleic acid construct comprises a nucleic acid sequence of the present invention operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

### Expression vector

10508.000-DK

A nucleic acid sequence encoding a protease variant of the invention can be expressed using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

5 The recombinant expression vector carrying the DNA sequence encoding a protease variant of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. The vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into  
10 which it has been integrated.

The protease variant may also be co-expressed together with at least one other enzyme of animal feed interest, such as a phytase, a galactanase, a xylanase, an endoglucanase, an endo-1,3(4)-beta-glucanase, an alpha-galactosidase, and/or a protease. The enzymes may be co-expressed from different vectors, from one vector, or using a mixture  
15 of both techniques. When using different vectors, the vectors may have different selectable markers, and different origins of replication. When using only one vector, the genes can be expressed from one or more promoters. If cloned under the regulation of one promoter (di- or multi-cistronic), the order in which the genes are cloned may affect the expression levels of the proteins. The protease variant may also be expressed as a fusion protein, i.e. that the gene  
20 encoding the protease variant has been fused in frame to the gene encoding another protein. This protein may be another enzyme or a functional domain from another enzyme.

### Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid  
25 sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a nucleic acid sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.  
30 The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote cell, such as an animal, a mammalian, an insect, a plant, or a fungal cell. Preferred animal cells are non-human animal cells.

35 In a preferred embodiment, the host cell is a fungal cell, or a yeast cell, such as a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell. The fungal host cell may be a filamentous fungal cell, such as a cell of a species

10508.000-DK

of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Mycelophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma*. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*, or a *Streptomyces* cell, such as *Streptomyces lividans* or *Streptomyces murinus*, or a *Nocardiopsis* cell, or cells of lactic acid bacteria; or gram negative bacteria such as *E. coli* and *Pseudomonas* sp. Lactic acid bacteria include, but are not limited to, species of the genera *Lactococcus*, *Lactobacillus*, *Leuconostoc*, *Streptococcus*, *Pediococcus*, and *Enterococcus*.

### Methods of Production

The present invention also relates to methods for producing a protease variant of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the protease variant; and (b) recovering the protease variant.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the protease is secreted into the nutrient medium, it can be recovered directly from the medium. If it is not secreted, it can be recovered from cell lysates.

The resulting protease may be recovered by methods known in the art. For example, it can be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The proteases of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

### Plants

10508.000-DK

The present invention also relates to a transgenic plant, plant part, or plant cell which has been transformed with a nucleic acid sequence encoding a polypeptide having protease activity of the present invention so as to express and produce the polypeptide in recoverable quantities. The polypeptide may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the recombinant polypeptide may be used as such for improving the quality of a food or feed, e.g., improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.

In a particular embodiment, the polypeptide is targeted to the endosperm storage vacuoles in seeds. This can be obtained by synthesizing it as a precursor with a suitable signal peptide, see Horvath et al in PNAS, Feb. 15, 2000, vol. 97, no. 4, p. 1914-1919.

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot) or engineered variants thereof. Examples of monocot plants are grasses, such as meadow grass (blue grass, *Poa*), forage grass such as fescue, *lolium*, temperate grass, such as *Agrostis*, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, and maize (corn).

Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family *Brassicaceae*), such as cauliflower, rape seed, and the closely related model organism *Arabidopsis thaliana*. Low-phytate plants as described e.g. in US patent no. 5,689,054 and US patent no. 6,111,168 are examples of engineered plants. Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers. Also specific plant tissues, such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes, and cytoplasm are considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part.

Also included within the scope of the present invention are the progeny of such plants, plant parts and plant cells.

The transgenic plant or plant cell expressing a polypeptide of the present invention may be constructed in accordance with methods known in the art. Briefly, the plant or plant cell is constructed by incorporating one or more expression constructs encoding a polypeptide of the present invention into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

Conveniently, the expression construct is a nucleic acid construct which comprises a nucleic acid sequence encoding a polypeptide of the present invention operably linked with appropriate regulatory sequences required for expression of the nucleic acid sequence in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminator sequences and



10508.000-DK

optionally signal or transit sequences are determined, for example, on the basis of when, where, and how the polypeptide is desired to be expressed. For instance, the expression of the gene encoding a polypeptide of the present invention may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are, for example, described by Tague *et al.*, 1988, *Plant Physiology* 86: 506.

For constitutive expression, the 35S-CaMV promoter may be used (Franck *et al.*, 1980, *Cell* 21: 285-294). Organ-specific promoters may be, for example, a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990, *Ann. Rev. Genet.* 24: 275-303), or from metabolic sink tissues such as meristems (Ito *et al.*, 1994, *Plant Mol. Biol.* 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice (Wu *et al.*, 1998, *Plant and Cell Physiology* 39: 885-889), a *Vicia faba* promoter from the legumin B4 and the unknown seed protein gene from *Vicia faba* (Conrad *et al.*, 1998, *Journal of Plant Physiology* 152: 708-711), a promoter from a seed oil body protein (Chen *et al.*, 1998, *Plant and Cell Physiology* 39: 935-941), the storage protein napA promoter from *Brassica napus*, or any other seed specific promoter known in the art, e.g., as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the *rbcs* promoter from rice or tomato (Kyoizuka *et al.*, 1993, *Plant Physiology* 102: 991-1000), the chloroella virus adenine methyltransferase gene promoter (Mitra and Higgins, 1994, *Plant Molecular Biology* 26: 85-93), or the *aldP* gene promoter from rice (Kagaya *et al.*, 1995, *Molecular and General Genetics* 248: 668-674), or a wound inducible promoter such as the potato pin2 promoter (Xu *et al.*, 1993, *Plant Molecular Biology* 22: 573-588).

A promoter enhancer element may also be used to achieve higher expression of the enzyme in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding a polypeptide of the present invention. For instance, Xu *et al.*, 1993, *supra* disclose the use of the first intron of the rice actin 1 gene to enhance expression.

Still further, the codon usage may be optimized for the plant species in question to improve expression (see Horvath *et al* referred to above).

The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.

The nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including *Agrobacterium*-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation, and electroporation (Gasser *et al.*, 1990, *Science* 244: 1293; Potrykus, 1990, *Bio/Technology* 8: 535; Shimamoto *et al.*, 1989, *Nature* 338: 274).

10508.000-DK

Presently, *Agrobacterium tumefaciens*-mediated gene transfer is the method of choice for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, *Plant Molecular Biology* 19: 15-38). However it can also be used for transforming monocots, although other transformation methods are generally preferred for these plants. Presently, the method of choice for generating transgenic monocots is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, *Plant Journal* 2: 275-281; Shimamoto, 1994, *Current Opinion Biotechnology* 5: 158-162; Vasil *et al.*, 1992, *Bio/Technology* 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh *et al.*, 1993, *Plant Molecular Biology* 21: 415-428.

Following transformation, the transformants having incorporated therein the expression construct are selected and regenerated into whole plants according to methods well-known in the art.

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a transgenic plant or a plant cell comprising a nucleic acid sequence encoding a protease variant of the present invention under conditions conducive for production of the protease variant; and (b) recovering the protease variant.

#### **Animals as Expression Hosts**

The present invention also relates to a transgenic, non-human animal and products or elements thereof, examples of which are body fluids such as milk and blood, organs, flesh, and animal cells. Techniques for expressing proteins, e.g. in mammalian cells, are known in the art, see e.g. the handbook *Protein Expression: A Practical Approach*, Higgins and Hames (eds), Oxford University Press (1999), and the three other handbooks in this series relating to Gene Transcription, RNA processing, and Post-translational Processing. Generally speaking, to prepare a transgenic animal, selected cells of a selected animal are transformed with a nucleic acid sequence encoding a protease variant of the present invention so as to express and produce the protease variant. The protease variant may be recovered from the animal, e.g. from the milk of female animals, or it may be expressed to the benefit of the animal itself, e.g. to assist the animal's digestion. Examples of animals are mentioned below in the section headed *Animal Feed and Animal Feed Additives*.

To produce a transgenic animal with a view to recovering the protease variant from the milk of the animal, a gene encoding the protease variant may be inserted into the fertilized eggs of an animal in question, e.g. by use of a transgene expression vector which comprises a suitable milk protein promoter, and the gene encoding the protease variant. The transgene expression vector is microinjected into fertilized eggs, and preferably permanently integrated into the chromosome. Once the egg begins to grow and divide, the potential embryo is

10508.000-DK

implanted into a surrogate mother, and animals carrying the transgene are identified. The resulting animal can then be multiplied by conventional breeding. The protease variant may be purified from the animal's milk, see e.g. Meade, H.M. et al (1999): Expression of recombinant proteins in the milk of transgenic animals, Gene expression systems: Using nature for the art of expression. J. M. Fernandez and J. P. Hoeffler (eds.), Academic Press.

In the alternative, in order to produce a transgenic non-human animal that carries in the genome of its somatic and/or germ cells a nucleic acid sequence including a heterologous transgene construct including a transgene encoding the protease variant, the transgene may be operably linked to a first regulatory sequence for salivary gland specific expression of the protease variant, as disclosed in WO 2000064247.

### **Animal Feed and Animal Feed Additives**

For the present purposes, the term animal includes all animals, including human beings. In a particular embodiment, the protease variants and compositions of the invention can be used as a feed additive for non-human animals. Examples of animals are non-ruminants, and ruminants, such as cows, sheep and horses. In a particular embodiment, the animal is a non-ruminant animal. Non-ruminant animals include mono-gastric animals, e.g. pigs or swine (including, but not limited to, piglets, growing pigs, and sows); poultry such as turkeys, ducks and chicken (including but not limited to broiler chicks, layers); young calves; and fish (including but not limited to salmon, trout, tilapia, catfish and carps; and crustaceans (including but not limited to shrimps and prawns).

The term feed or feed composition means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal. The feed can be fed to the animal before, after, or simultaneously with the diet. The latter is preferred.

The composition of the invention, when intended for addition to animal feed, may be designated an animal feed additive. Such additive always comprises the protease variant in question, preferably in the form of stabilized liquid or dry compositions. The additive may comprise other components or ingredients of animal feed. The so-called pre-mixes for animal feed are particular examples of such animal feed additives. Pre-mixes may contain the enzyme(s) in question, and in addition at least one vitamin and/or at least one mineral.

Accordingly, in a particular embodiment, in addition to the component polypeptides, the composition of the invention may comprise or contain at least one fat-soluble vitamin, and/or at least one water-soluble vitamin, and/or at least one trace mineral. Also at least one macro mineral may be included.

Examples of fat-soluble vitamins are vitamin A, vitamin D3, vitamin E, and vitamin K, e.g. vitamin K3.

Examples of water-soluble vitamins are vitamin B12, biotin and choline, vitamin B1,

10508.000-DK

vitamin B2, vitamin B6, niacin, folic acid and panthothenate, e.g. Ca-D-panthothenate.

Examples of trace minerals are manganese, zinc, iron, copper, iodine, selenium, and cobalt.

Examples of macro minerals are calcium, phosphorus and sodium.

5 Further, optional, feed-additive ingredients are colouring agents, aroma compounds, stabilizers, additional enzymes, and antimicrobial peptides.

Additional enzyme components of the composition of the invention include at least one polypeptide having xylanase activity; and/or at least one polypeptide having endoglucanase activity; and/or at least one polypeptide having endo-1,3(4)-beta-glucanase activity; and/or at  
10 least one polypeptide having phytase activity; and/or at least one polypeptide having galactanase activity; and/or at least one polypeptide having alpha-galactosidase activity.

Xylanase activity can be measured using any assay, in which a substrate is employed, that includes 1,4-beta-D-xylosidic endo-linkages in xylans. Different types of substrates are available for the determination of xylanase activity e.g. Xylazyme cross-linked arabinoxylan  
15 tablets (from MegaZyme), or insoluble powder dispersions and solutions of azo-dyed arabinoxylan.

Endoglucanase activity can be determined using any endoglucanase assay known in the art. For example, various cellulose- or beta-glucan-containing substrates can be applied. An endoglucanase assay may use AZCL-Barley beta-Glucan, or preferably (1) AZCL-HE-  
20 Cellulose, or (2) Azo-CM-cellulose as a substrate. In both cases, the degradation of the substrate is followed spectrophotometrically at OD<sub>595</sub> (see the Megazyme method for AZCL-polysaccharides for the assay of endo-hydrolases at <http://www.megazyme.com/booklets/AZCLPOL.pdf>).

Endo-1,3(4)-beta-glucanase activity can be determined using any endo-1,3(4)-beta-glucanase assay known in the art. A preferred substrate for endo-1,3(4)-beta-glucanase activity measurements is a cross-linked azo-coloured beta-glucan Barley substrate, wherein the measurements are based on spectrophotometric determination principles.

Phytase activity can be measured using any suitable assay, e.g. the FYT assay described in Example 4 of WO 98/28408.

30 Galactanase can be assayed e.g. with AZCL galactan from Megazyme, and alpha-galactosidase can be assayed e.g. with pNP-alpha-galactoside.

For assaying these enzyme activities the assay-pH and the assay-temperature are to be adapted to the enzyme in question (preferably a pH close to the optimum pH, and a temperature close to the optimum temperature). A preferred assay pH is in the range of 2-10, preferably 3-9, more preferably pH 3 or 4 or 5 or 6 or 7 or 8, for example pH 3 or pH 7. A  
35 preferred assay temperature is in the range of 20-90°C, preferably 30-90°C, more preferably 40-80°C, even more preferably 40-70°C, preferably 40 or 45 or 50°C. The enzyme activity is

10508.000-DK

defined by reference to appropriate blinds, e.g. a buffer blind.

Examples of antimicrobial peptides (AMP's) are CAP18, Leucocin A, Tiritricin, Pro-  
tegrin-1, Thanatin, Defensin, Lactoferrin, Lactoferricin, and Ovispirin such as Novispirin  
(Robert Lehrer, 2000), Plectasins, and Statins, including the compounds and polypeptides  
disclosed in WO 03/044049 and PCT/DK02/00812, as well as variants or fragments of the  
above that retain antimicrobial activity.

Examples of antifungal polypeptides (AFP's) are the *Aspergillus giganteus*, and *As-  
pergillus niger* peptides, as well as variants and fragments thereof which retain antifungal ac-  
tivity, as disclosed in WO 94/01459 and WO 02/090384.

Usually fat and water soluble vitamins, as well as trace minerals form part of a so-called  
premix intended for addition to the feed, whereas macro minerals are usually separately added  
to the feed. A premix enriched with a protease of the invention, is an example of an animal  
feed additive of the invention.

In a particular embodiment, the animal feed additive of the invention is intended for  
being included (or prescribed as having to be included) in animal diets or feed at levels of 0.01  
to 10.0%; more particularly 0.05 to 5.0%; or 0.2 to 1.0% (% meaning g additive per 100 g  
feed). This is so in particular for premixes.

The nutritional requirements of these components (exemplified with poultry and  
piglets/pigs) are listed in Table A of WO 01/58275. Nutritional requirement means that these  
components should be provided in the diet in the concentrations indicated.

In the alternative, the animal feed additive of the invention comprises at least one of  
the individual components specified in Table A of WO 01/58275. At least one means either of,  
one or more of, one, or two, or three, or four and so forth up to all thirteen, or up to all fifteen  
individual components. More specifically, this at least one individual component is included in  
the additive of the invention in such an amount as to provide an in-feed-concentration within  
the range indicated in column four, or column five, or column six of Table A.

The present invention also relates to animal feed compositions. Animal feed  
compositions or diets have a relatively high content of protein. Poultry and pig diets can be  
characterised as indicated in Table B of WO 01/58275, columns 2-3. Fish diets can be  
characterised as indicated in column 4 of this Table B. Furthermore such fish diets usually  
have a crude fat content of 200-310 g/kg. WO 01/58275 corresponds to US 09/779334 which  
is hereby incorporated by reference.

An animal feed composition according to the invention has a crude protein content of  
50-800 g/kg, and furthermore comprises at least one protease variant as claimed herein.

Furthermore, or in the alternative (to the crude protein content indicated above), the  
animal feed composition of the invention has a content of metabolisable energy of 10-30  
MJ/kg; and/or a content of calcium of 0.1-200 g/kg; and/or a content of available phosphorus

10508.000-DK

of 0.1-200 g/kg; and/or a content of methionine of 0.1-100 g/kg; and/or a content of methionine plus cysteine of 0.1-150 g/kg; and/or a content of lysine of 0.5-50 g/kg.

In particular embodiments, the content of metabolisable energy, crude protein, calcium, phosphorus, methionine, methionine plus cysteine, and/or lysine is within any one of ranges 2, 3, 4 or 5 in Table B of WO 01/58275 (R. 2-5).

Crude protein is calculated as nitrogen (N) multiplied by a factor 6.25, i.e. Crude protein (g/kg) = N (g/kg) x 6.25. The nitrogen content is determined by the Kjeldahl method (A.O.A.C., 1984, Official Methods of Analysis 14th ed., Association of Official Analytical Chemists, Washington DC).

Metabolisable energy can be calculated on the basis of the NRC publication Nutrient requirements in swine, ninth revised edition 1988, subcommittee on swine nutrition, committee on animal nutrition, board of agriculture, national research council. National Academy Press, Washington, D.C., pp. 2-6, and the European Table of Energy Values for Poultry Feed-stuffs, Spelderholt centre for poultry research and extension, 7361 DA Beekbergen, The Netherlands. Grafisch bedrijf Ponsen & Iooijen bv, Wageningen. ISBN 90-71463-12-5.

The dietary content of calcium, available phosphorus and amino acids in complete animal diets is calculated on the basis of feed tables such as Veevoedertabel 1997, gegevens over chemische samenstelling, verteerbaarheid en voederwaarde van voedermiddelen, Central Veevoederbureau, Runderweg 6, 8219 pk Lelystad. ISBN 90-72839-13-7.

In a particular embodiment, the animal feed composition of the invention contains at least one vegetable protein or protein source as defined above.

In still further particular embodiments, the animal feed composition of the invention contains 0-80% maize; and/or 0-80% sorghum; and/or 0-70% wheat; and/or 0-70% Barley; and/or 0-30% oats; and/or 0-40% soybean meal; and/or 0-10% fish meal; and/or 0-20% whey.

Animal diets can e.g. be manufactured as mash feed (non pelleted) or pelleted feed. Typically, the milled feed-stuffs are mixed and sufficient amounts of essential vitamins and minerals are added according to the specifications for the species in question. Enzymes can be added as solid or liquid enzyme formulations. For example, a solid enzyme formulation is typically added before or during the mixing step; and a liquid enzyme preparation is typically added after the pelleting step. The enzyme may also be incorporated in a feed additive or premix.

The final enzyme concentration in the diet is within the range of 0.01-200 mg enzyme protein per kg diet, for example in the range of 0.5-25 mg enzyme protein per kg animal diet.

The protease variant should of course be applied in an effective amount, i.e. in an amount adequate for improving solubilisation and/or improving nutritional value of feed. It is at present contemplated that the enzyme is administered in one or more of the following amounts (dosage ranges): 0.01-200; 0.01-100; 0.5-100; 1-50; 5-100; 10-100; 0.05-50; or 0.10-10 – all these ranges being in mg protease enzyme protein per kg feed (ppm).

10508.000-DK

For determining mg enzyme protein per kg feed, the protease is purified from the feed composition, and the specific activity of the purified protease is determined using a relevant assay (see under protease activity, substrates, and assays). The protease activity of the feed composition as such is also determined using the same assay, and on the basis of these two determinations, the dosage in mg enzyme protein per kg feed is calculated.

The same principles apply for determining mg enzyme protein in feed additives. Of course, if a sample is available of the protease used for preparing the feed additive or the feed, the specific activity is determined from this sample (no need to purify the protease from the feed composition or the additive).

### Detergent Compositions

The protease variant of the invention may be added to and thus become a component of a detergent composition.

The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.

In a specific aspect, the invention provides a detergent additive comprising the protease variant of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as another protease, such as alkaline proteases from *Bacillus*, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.

In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from *Humicola* (synonym *Thermomyces*), e.g. from *H. lanuginosa* (*T. lanuginosus*) as described in EP 258068 and EP 305216 or from *H. insolens* as described in WO 96/13580, a *Pseudomonas* lipase, e.g. from *P. alcaligenes* or *P. pseudoalcaligenes* (EP 218272), *P. cepacia* (EP 331376), *P. stutzeri* (GB 1,372,034), *P. fluorescens*, *Pseudomonas* sp. strain SD 705 (WO 95/06720 and WO 96/27002), *P. wisconsinensis* (WO 96/12012), a *Bacillus* lipase, e.g. from *B. subtilis* (Dartois et al. (1993), *Biochemica et Biophysica Acta*, 1131, 253-360), *B. stearothermophilus* (JP 64/744992) or *B. pumilus* (WO 91/16422). Other examples are lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407225, EP 260105,

10508.000-DK

WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202. Preferred commercially available lipase enzymes include Lipolase<sup>TM</sup> and Lipolase Ultra<sup>TM</sup> (Novozymes A/S).

Suitable amylases (alpha- and/or beta-) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, alpha-amylases obtained from *Bacillus*, e.g. a special strain of *B. licheniformis*, described in more detail in GB 1,296,839. Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444. Commercially available amylases are Duramyl<sup>TM</sup>, Termamyl<sup>TM</sup>, Fungamyl<sup>TM</sup> and BANTM (Novozymes A/S), Rapidase<sup>TM</sup> and Purastar<sup>TM</sup> (from Genencor International Inc.).

Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g. the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259. Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495257, EP 531372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and WO 99/01544. Commercially available cellulases include Celluzyme<sup>TM</sup>, and Carezyme<sup>TM</sup> (Novozymes A/S), Clazinas<sup>TM</sup>, and Puradax HATM (Genencor International Inc.), and KAC-500(B)<sup>TM</sup> (Kao Corporation).

Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g. from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include Guardzyme<sup>TM</sup> (Novozymes).

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separate additive or a combined additive, can be formulated e.g. as a granulate, a liquid, a slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy



10508.000-DK

coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238216.

The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically containing up to 70 % water and 0-30 % organic solvent, or non-aqueous.

The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight.

When included therein the detergent will usually contain from about 1% to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.

When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyl dimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl, N-alkyl derivatives of glucosamine ("glucamides").

The detergent may contain 0-65 % of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose, poly(vinylpyrrolidone), poly(ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a H<sub>2</sub>O<sub>2</sub> source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetythylenediamine or nonanoyloxybenzenesulfonate. Alternatively, the bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.

The enzyme(s) of the detergent composition of the invention may be stabilized using

10508.000-DK

conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.

5        The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

10       It is at present contemplated that in the detergent compositions any enzyme, in particular the enzyme of the invention, may be added in an amount corresponding to 0.01-100 mg of enzyme protein per liter of wash liquor, preferably 0.05-5 mg of enzyme protein per liter of wash liquor, in particular 0.1-1 mg of enzyme protein per liter of wash liquor.

15       The enzyme of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202.

#### Method for Generating Protease Variants

The invention also relates to a method for generating a protease variant of an improved property, the method comprising the following steps:

- 20       (a) selecting a parent protease of at least 60% identity to SEQ ID NO: 2;
- (b) establishing a 3D structure of the parent protease by homology modelling using the Fig. 2 structure as a model; and/or aligning the parent protease according to the alignment of Fig. 1;
- (c) proposing at least one amino acid substitution, e.g. by:
  - 25        (i) subjecting the 3D structure of (b) to MD simulations at increased temperatures, and identifying regions in the amino acid sequence of the parent protease of high mobility (isotropic fluctuations);
  - (ii) introducing disulfid bridges by way of cysteine substitutions (C-C);
  - (iii) introducing proline substitutions (P);
  - (iv) replacing exposed neutral amino acid residues with negatively charged amino acid residues (E,D);
  - 30        (v) replacing exposed neutral amino acid residues with positively charged amino acid residues (R,K);
  - (vi) replacing small amino acid residues inside the protein with bulkier amino acid residues (W);
  - 35        (vii) comparing by homology alignment and/or homology modelling according to step (c)(i) at least two related parent proteases and transferring amino acid residue differences inbetween these protease backbones, preferably from a

10508.000-DK

backbone having the improved property to a backbone not having this improved property;

(d) preparing a DNA sequence encoding the parent protease but for inclusion of a DNA codon of the at least one amino acid substitution proposed in steps (c)(ii)-(c)(vii), or  
5     subjecting the parent DNA sequence to random mutagenesis, targeting at least one of the regions identified in step (c)(i);

(e)     expressing the DNA sequence obtained in step (d) in a host cell, and

(h)     selecting a host cell expressing a protease variant with an improved property.

The invention furthermore relates to a method for producing a protease variant  
10     obtainable or obtained by the method of generating protease variants described above, comprising (a) cultivating the host cell to produce a supernatant comprising the variant; and  
       (b) recovering the variant.

### Alternative Embodiment

15     In an alternative embodiment, the term "alteration" is used instead of "substitution" as the general term for amendments in the protease molecule. This alternative embodiment includes each of the claims formulated as exemplified below for claim 1, and also specifically includes everything what is stated herein, e.g. definitions (other than the definition of substitution), i.e. the various aspects, particular embodiments etc.

20     A variant of a parent protease, comprising an alteration in at least one position of at least one region selected from the group of regions consisting of:

6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188; wherein

(a) the alteration(s) are independently

- 25     (i)     an insertion of an amino acid immediately downstream of the position,  
       (ii)     a deletion of the amino acid which occupies the position, and/or  
       (iii)    a substitution of the amino acid which occupies the position;

(b)     the variant has protease activity; and

(c)     each position corresponds to a position of SEQ ID NO: 2; and

30     (d)     the variant has a percentage of identity to SEQ ID NO: 2 of at least 60%.

The term "polypeptide variant", "protein variant", "enzyme variant", "protease variant" or simply "variant" refers to a polypeptide of the invention comprising one or more alteration(s), such as substitution(s), insertion(s), deletion(s), and/or truncation(s) of one or more specific amino acid residue(s) in one or more specific position(s) in the polypeptide.

35     The term "parent polypeptide", "parent protein", "parent enzyme", "standard enzyme", "parent protease" or simply "parent" refers to the polypeptide on which the variant was based. This term also refers to the polypeptide with which a variant is compared and aligned.

10508.000-DK

The term "randomized library", "variant library", or simply "library" refers to a library of variant polypeptides. Diversity in the variant library can be generated via mutagenesis of the genes encoding the variants at the DNA triplet level, such that individual codons are variegated e.g. by using primers of partially randomized sequence in a PCR reaction. Several techniques have been described, by which one can create a diverse combinatorial library by variegating several nucleotide positions in a gene and recombining them, for instance where these positions are too far apart to be covered by a single (spiked or doped) oligonucleotide primer. These techniques include the use of in vivo recombination of the individually diversified gene segments as described in WO 97/07205 on page 3, lines 8 to 29 (Novozymes A/S). They also include the use of DNA shuffling techniques to create a library of full length genes, wherein several gene segments are combined, and wherein each segment may be diversified e.g. by spiked mutagenesis (Stemmer, Nature 370, pp. 389-391, 1994 and US 5,811,238; US 5,605,793; and US 5,830,721). One can use a gene encoding a protein "backbone" (wildtype parent polypeptide) as a template polynucleotide, and combine this with one or more single or double-stranded oligonucleotides as described in WO 98/41623 and in WO 98/41622 (Novozymes A/S). The single-stranded oligonucleotides could be partially randomized during synthesis. The double-stranded oligonucleotides could be PCR products incorporating diversity in a specific region. In both cases, one can dilute the diversity with corresponding segments encoding the sequence of the backbone protein in order to limit the average number of changes that are introduced.

Methods have also been established for designing the ratios of nucleotide mixtures (A; C; T; G) to be inserted in specific codon positions during oligo- or polynucleotide synthesis, so as to introduce a bias in order to approximate a desired frequency distribution towards a set of one or more desired amino acids that will be encoded by the particular codons. It may be of interest to produce a variant library, that comprises permutations of a number of known amino acid modifications in different locations in the primary sequence of the polypeptide. These could be introduced post-translationally or by chemical modification sites, or they could be introduced through mutations in the encoding genes. The modifications by themselves may previously have been proven beneficial for one reason or another (e.g. decreasing antigenicity, or improving specific activity, performance, stability, or other characteristics). In such instances, it may be desirable first to create a library of diverse combinations of known sequences. For example, if twelve individual mutations are known, one could combine (at least) twelve segments of the parent protein encoding gene, wherein each segment is present in two forms: one with, and one without the desired mutation. By varying the relative amounts of those segments, one could design a library (of size 212) for which the average number of mutations per gene can be predicted. This can be a useful way of combining mutations, that by themselves give some, but not sufficient effect, without resorting to very large libraries, as

10508.000-DK

is often the case when using 'spiked mutagenesis'. Another way to combine these 'known mutations' could be by using family shuffling of oligomeric DNA encoding the known mutations with fragments of the full length wild type sequence.

In describing the various variants produced or contemplated according to the invention, a number of nomenclatures and conventions are used which are described in detail below. A frame of reference is first defined by aligning the variant polypeptide with a parent enzyme. A preferred parent enzyme is Protease 10 (SEQ ID NO: 2). Thereby a number of alterations will be defined in relation to the amino acid sequence of SEQ ID NO: 2.

A substitution in a variant is indicated as:

Original amino acid - position - substituted amino acid;

The three or one letter codes are used, including the codes Xaa and X to indicate any amino acid residue. Accordingly, the notation "T82S" or "Thr82Ser" means, that the variant comprises a substitution of threonine with serine in the variant amino acid position corresponding to the amino acid in position 82 in the parent enzyme, when the two are aligned as indicated above.

Where the original amino acid residue may be any amino acid residue, a short hand notation may at times be used indicating only the position, and the substituted amino acid, for example:

Position - substituted amino acid; or "82S",

Such a notation is particular relevant in connection with modification(s) in a series of homologous polypeptides.

Similarly when the identity of the substituting amino acid residue(s) is immaterial:

Original amino acid - position; or "T82"

When both the original amino acid(s) and substituted amino acid(s) may be any amino acid, then only the position is indicated, e.g.: "82".

When the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s), then the amino acids are listed separated by commas:

Original amino acids - position no. - substituted amino acids; or "T10E,D,Y".

A number of examples of this nomenclature are listed below:

The substitution of threonine for histidine in position 91 is designated as: "His91Thr" or "H91T"; or the substitution of any amino acid residue acid for histidine in position 91 is designated as: "His91Xaa" or "H91X" or "His91" or "H91".

For a modification where the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s), the substitution of glutamic acid, aspartic acid, or tyrosine for threonine in position 10:

"Thr10Glu,Asp,Tyr" or "T10E,D,Y"; which indicates the specific variants: "T10E", "T10D", and "T10Y".

10508.000-DK

A deletion of glycine in position 26 will be indicated by: "Gly26\*" or "G26\*"

Correspondingly, the deletion of more than one amino acid residue, such as the deletion of glycine and glutamine in positions 26 and 27 will be designated "Gly26\*+Gln27\*" or "G26\*+Q27\*"

5 The insertion of an additional amino acid residue such as e.g. a lysine after G26 is indicated by: "Gly26GlyLys" or "G26GK"; or, when more than one amino acid residue is inserted, such as e.g. a Lys, and Ala after G26 this will be indicated as: "Gly26GlyLysAla" or "G26GKA".

10 In such cases the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s). In the above example the sequences would thus be:

Parent:	Variant:		
26	26	26a	26b
G	G	K	A

15 In cases where an amino acid residue identical to the existing amino acid residue is inserted, it is clear that degeneracy in the nomenclature arises. If for example a glycine is inserted after the glycine in the above example this would be indicated by "G26GG".

Given that an alanine were present in position 25, the same actual change could just as well be indicated as "A25AG":

	Parent:		Variant:			
20	Numbering I:	25	26	25	26	26a
	Sequence:	A	G	A	G	G
	Numbering II:			25	25a	26

25 Such instances will be apparent to the skilled person, and the indication "G26GG" and corresponding indications for this type of insertions is thus meant to comprise such equivalent degenerate indications.

30 By analogy, if amino acid sequence segments are repeated in the parent polypeptide and/or in the variant, it will be apparent to the skilled person that equivalent degenerate indications are comprised, also when other alterations than insertions are listed such as deletions and/or substitutions. For instance, the deletion of two consecutive amino acids "AG" in the sequence "AGAG" from position 194-197, may be written as "A194\*+G1956\*" or "A196\*+G197\*":

	Parent:				Variant:		
35	Numbering I:	194	195	196	197	194	195
	Sequence:	A	G	A	G	A	G
	Numbering II:					196	197

10508.000-DK

Variants comprising multiple modifications are separated by pluses, e.g.:

"Arg170Tyr+Gly195Glu" or "R170Y+G195E", representing modifications in positions 170 and 195 substituting tyrosine and glutamic acid for arginine and glycine, respectively. Thus,

"Tyr167Gly,Ala,Ser,Thr+Arg170Gly,Ala,Ser,Thr" designates the following variants:

- 5 "Tyr167Gly+Arg170Gly", "Tyr167Gly+Arg170Ala", "Tyr167Gly+Arg170Ser",  
 "Tyr167Gly+Arg170Thr", "Tyr167Ala+Arg170Gly", "Tyr167Ala+Arg170Ala",  
 "Tyr167Ala+Arg170Ser", "Tyr167Ala+Arg170Thr", "Tyr167Ser+Arg170Gly",  
 "Tyr167Ser+Arg170Ala", "Tyr167Ser+Arg170Ser", "Tyr167Ser+Arg170Thr",  
 10 "Tyr167Thr+Arg170Gly", "Tyr167Thr+Arg170Ala", "Tyr167Thr+Arg170Ser", and  
 "Tyr167Thr+Arg170Thr".

This nomenclature is particular relevant relating to modifications aimed at substituting, inserting or deleting amino acid residues having specific common properties, such modifications are referred to as conservative amino acid modification(s).

- 15 The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

## Examples

### Example 1: Protease assays

#### 20 pNA assay

pNA substrate : Suc-AAPF-pNA (Bachem L-1400).

Temperature : Room temperature (25°C)

- 25 Assay buffers : 100mM succinic acid, 100mM HEPES, 100mM CHES, 100mM CABS,  
 1mM CaCl<sub>2</sub>, 150mM KCl, 0.01% Triton X-100 adjusted to pH-values 2.0, 2.5, 3.0, 3.5, 4.0,  
 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, and 12.0 with HCl or NaOH.

20µl protease (diluted in 0.01% Triton X-100) is mixed with 100µl assay buffer. The assay is started by adding 100µl pNA substrate (50mg dissolved in 1.0ml DMSO and further diluted 45x with 0.01% Triton X-100). The increase in OD405 is monitored as a measure of the protease activity.

30

#### Protazyme AK assay

Substrate : Protazyme AK tablet (cross-linked and dyed casein; from Megazyme)

Temperature : controlled (assay temperature).

- 35 Assay buffers : 100mM succinic acid, 100mM HEPES, 100mM CHES, 100mM CABS,  
 1mM CaCl<sub>2</sub>, 150mM KCl, 0.01% Triton X-100 adjusted to pH-values 2.0, 2.5, 3.0, 3.5, 4.0,  
 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 and 11.0 with HCl or NaOH.

A Protazyme AK tablet is suspended in 2.0ml 0.01% Triton X-100 by gentle stirring.

10508.000-DK

500 $\mu$ l of this suspension and 500 $\mu$ l assay buffer are mixed in an Eppendorf tube and placed on ice. 20 $\mu$ l protease sample (diluted in 0.01% Triton X-100) is added. The assay is initiated by transferring the Eppendorf tube to an Eppendorf thermomixer, which is set to the assay temperature. The tube is incubated for 15 minutes on the Eppendorf thermomixer at its highest shaking rate (1400 rpm). The incubation is stopped by transferring the tube back to the ice bath. Then the tube is centrifuged in an icecold centrifuge for a few minutes and 200 $\mu$ l supernatant is transferred to a microtiter plate. OD650 is read as a measure of protease activity. A buffer blind is included in the assay (instead of enzyme).

10 The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. In the case of conflict, the present disclosure including definitions will control.

15 Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.



10508.000-DK

## Claims

1. A variant of a parent protease, comprising a substitution in at least one position of at least one region selected from the group of regions consisting of:  
6-18; 22-28; 32-39; 42-58; 62-63; 66-76; 78-100; 103-106; 111-114; 118-131; 134-136; 139-141; 144-151; 155-156; 160-176; 179-181; and 184-188; wherein
- (a) the variant has protease activity; and  
(b) each position corresponds to a position of SEQ ID NO: 2; and  
(c) the variant has a percentage of identity to SEQ ID NO: 2 of at least 60%.
2. The variant of claim 1 which comprises a substitution in at least one of the following positions: 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 22; 23; 24; 25; 26; 27; 28; 32; 33; 34; 35; 36; 37; 38; 39; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57; 58; 62; 63; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 103; 104; 105; 106; 111; 112; 113; 114; 118; 119; 120; 121; 122; 123; 124; 125; 126; 127; 128; 129; 130; 131; 134; 135; 136; 139; 140; 141; 144; 145; 146; 147; 148; 149; 150; 151; 155; 156; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 179; 180; 181; 184; 185; 186; 187; and/or 188.
3. The variant of claim 2 which comprises a substitution in at least one of the following positions: 6; 7; 8; 9; 10; 12; 13; 16; 17; 18; 22; 23; 24; 25; 26; 27; 28; 32; 33; 37; 38; 39; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 58; 62; 63; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 103; 105; 106; 111; 113; 114; 118; 120; 122; 124; 125; 127; 129; 130; 131; 134; 135; 136; 139; 140; 141; 144; 145; 146; 147; 148; 149; 150; 151; 155; 156; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 179; 180; 181; 184; 185; 186; 187; and/or 188.
4. The variant of claim 3, which comprises at least one of the following substitutions: 6C; 7P; 8C; 9C; 10E,D; 12E,D; 13E,D,P; 16C; 17C; 18C; 22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; 23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; 25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; 26A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y; 28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; 32C; 33C; 37C; 39R,K; 42E,D; 43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; 44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y; 45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; 46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 49A,C,D,E,F,G,H,I,K,L,M,N,P,S,V,W,Y; 50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 52C;

10508.000-DK

55C; 56R,K; 58E,D; 62C; 63C; 66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; 70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 5 73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; 74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 76C; 78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y;  
 79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y; 80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W;  
 81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; 82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y;  
 83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 10 85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; 86C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y; 88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y; 90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 92P,R,K;  
 93P; 94C,P; 95E,D; 96E,D,P; 97R,K; 98P; 99R,K; 103C; 105C,P; 106C; 111R,K; 113E,D;  
 118R,K; 120E,D; 122K; 124R,K; 125P; 127R,K; 129E,D; 130E,D; 134C; 135P; 136P; 139C;  
 15 140E,D; 141C; 144C; 145C; 146C; 147W; 148C; 149C; 150E,D; 151P,E,D; 155C; 156C;  
 160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y;  
 162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,T,V,W,Y;  
 166A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,W,Y; 167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 20 168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; 169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; 172C; 173C; 174P; 175P; 176P; 180R,K;  
 181R,K; 184P; 187P; and/or 188R,K.

5. The variant of any one of claims 1-4 which comprises at least one of the following pairs  
 25 of substitutions: 6C+103C; 8C+105C; 76C+85C; 94C+149C; 55C+63C; 16C+145C;  
 33C+144C; 62C+173C; 106C+141C; 9C+17C; 18C+156C; 32C+144C; 37C+52C; 67C+71C;  
 134C+170C; 139C+163C; 146C+148C; and/or 155C+172C.

6. The variant of claim 5, which comprises at least one of the following pairs of  
 30 substitutions: 6C+103C; 8C+105C; 76C+85C; 94C+149C; 55C+63C; 16C+145C; 33C+144C;  
 62C+173C; and/or 106C+141C.

7. The variant of any one of claims 1-4 which comprises at least one of the following  
 substitutions: 81P; 82P; 151P; 176P; 24P; 25P; 92P; 93P; 94P; 96P; 98P; 105P; 136P; 184P;  
 35 187P; 174P; 7P; 13P; 23P; 27P; 125P; 135P; and/or 175P.

8. The variant of claim 7, which comprises at least one of the following substitutions: 81P;

10508.000-DK

82P; 151P; 176P; 24P; 25P; 92P; 93P; 94P; 96P; 98P; 105P; 136P; 184P; and/or 187P.

9. The variant of any one of claims 1-4 which comprises at least one of the following substitutions: 95E,D; 42E,D; 84E,D; 96E,D; 47E,D; 46E,D; 150E,D; 70E,D; 13E,D; 140E,D;  
 5 10E,D; 151E,D; 129E,D; 130E,D; 166E,D; 161E,D; 120E,D; 82E,D; 58E,D; 12E,D; 81E,D;  
 69E,D; 113E,D; 89E,D; and/or 160E,D.

10. The variant of claim 9 which comprises at least one of the following substitutions:  
 95E,D; 42E,D; 84E,D; 96E,D; 47E,D; 46E,D; 150E,D; 70E,D; 13E,D; and/or 140E,D.

10

11. The variant of any one of claims 1-4 which comprises at least one of the following substitutions: 124R,K; 72R,K; 97R,K; 127R,K; 56R,K; 122R,K; 181R,K; 180R,K; 25R,K;  
 92R,K; 39R,K; 99R,K; 111R,K; 24R,K; 118R,K; 162R,K; and/or 188R,K.

15

12. The variant of claim 11 which comprises at least one of the following substitutions:  
 124R,K; 72R,K; 97R,K; 127R,K; 56R,K; 122R,K; 181R,K; 180R,K; 25R,K; and/or 92R,K.

20

13. The variant of any one of claims 1-4 which comprises at least one of the following substitutions: 147W; 43W.

14. The variant of any one of claims 1-4 which comprises a substitution in at least one position of at least one region selected from the group of regions consisting of:

(i) 160-170, 78-90, 43-50, 66-75, and 22-28;

(ii) 160-170, 78-90, 43-50, and 66-75;

25

(iii) 160-170, 78-90, and 43-50;

(iv) 160-170, and 78-90; and/or

(v) 160-170.

30

15. The variant of any one of claims 1-4 which comprises at least one of the following substitutions: 6C; 8C; 13E,D; 16C; 24P; 25K,P,R; 33C; 42E,D; 46D,E; 47D,E; 55C; 56R,K;  
 62C; 63C; 70D,E; 72K,R; 76C; 81P; 82P; 84D,E; 85C; 92P,R,K; 93P; 94C,P; 95E,D; 96E,D,P;  
 97R,K; 98P; 103C; 105C,P; 106C; 122R,K; 124R,K; 127R,K; 136P; 140E,D; 141C; 144C;  
 145C; 149C; 150E,D; 151P; 173C; 176P; 180R,K; 181R,K; 184P; and/or 187P.

35

16. The variant of any one of claims 1-3, which comprises at least one of the following substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C;  
 T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;

10508.000-DK

A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);  
 A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S);  
 G26A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; R38T; V39R,K;  
 5 Q42E,D,G,P; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 T44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T44S);  
 I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R49A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R49T,Q);  
 10 G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; Q54N,R; S55C; V56R,K;  
 P58E,D; A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 15 L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;  
 S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 20 G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);  
 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; A89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A89T,S); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; H91T,S; N92P,R,K,S;  
 25 Q93P; A94C,P; P95A,E,D; I96A,E,D,P; G97R,K; S98P; S99A,Q,R,K; V100I; S103C; S105C,P;  
 T106C; C111R,K; T113E,D; I114V; G118N,R,K; S120T,E,D; S122R,K; P124R,K; E125P,Q;  
 T127R,K; T129E,D,Y,Q; N130E,D,S; M131L; T134C; T135P,N; V136P; E139C; P140E,D;  
 G141C; G144C; G145C; S146C; Y147F,W; I148C; S149C; G150E,D; T151P,E,D,S; G155C;  
 V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 30 S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R165S);  
 T166A,C,D,F,E,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T166V,F);  
 G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 35 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 F171Y; Y172C; Q173C; E174P; V175P; T176N,P; V179I,L; N180R,K,S; S181R,K; V184L,P;  
 R185T; L186I; R187P; and/or T188R,K.

10508.000-DK

17. The variant of any one of claims 1-3, which comprises at least one of the following substitutions: G6C; L7P; A8C; Y9C; Y10E,D,T; G12E,D; G13E,D,P; S16C; V17C; G18C; T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;
- 5 S24A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S24A); A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S); G26A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y; P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; T38R; V39R,K; G42E,D,P,Q; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;
- 10 T44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T44S); I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T49A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T49R,Q); T51V; G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; F52C; Q53E; N54Q,R; S55C; V56R,K; P58E,D;
- 15 A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y; G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;
- 20 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C; S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y; Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; S82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S82T); G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;
- 25 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; Q86A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y (preferably Q86A); S87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S87T); V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; T89A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T89A,S); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T91H,S; S92P,R,K,N; Q93P; A94C,P; P95A,E,D; A96E,D,I,P; G97R,K; S98P; A99R,K,S; V100; S103C; S105C,P;
- 30 T106C; C111R,K; T113E,D; I114V; N118G,R,K; T120E,D,S; R122K,S; P124R,K; Q125E,P; T127R,K; Y129E,D,T; S130E,D,N; L131M; T134C; N135P,T; V136P; E139C; P140E,D; G141C; G144C; G145C; S146C; F147W,Y; I148C; S149C; G150E,D; S151P,E,D,T; G155C; V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;
- S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;
- 35 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; S165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S165R); V166A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y (preferably V166F,T);

10508.000-DK

G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 Y171F; Y172C; Q173C; E174P; V175P; T176P,N; I179L,V N180R,K,S; S181R,K; V184L,P;  
 R185T; I186L; R187P; and/or T188R,K;

5

18. The variant of any one of claims 1-3, which comprises at least one of the following  
 substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C;  
 T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);

10

A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S);  
 G26A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; R38T; V39R,K;  
 Q42E,D,G,P; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 S44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S44T);

15

I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Q49A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y (preferably Q49R,T);  
 G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; Q54N,R; S55C; I56R,K;  
 P58E,D; A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;

20

G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;

25

S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y

30

(preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);  
 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; A89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A89T,S); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; H91T,S; N92P,R,K,S;  
 Q93P; A94C,P; P95A,E,D; I96A,E,D,P; G97R,K; S98P; S99A,Q,R,K; V100I; S103C; S105C,P;  
 T106C; C111R,K; T113E,D; I114V; G118N,R,K; S120E,D,T; S122R,K; P124R,K; E125P,Q;  
 T127R,K; T129E,D,Q,Y; N130E,D,S; M131L; T134C; T135N,P; V136P; E139C; P140E,D;  
 G141C; G144C; G145C; S146C; Y147F,W; I148C; S149C; G150E,D; N151P,E,D,T; G155C;  
 V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;

35

10508.000-DK

- S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R165S);  
 T166A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T166F,V);
- 5 G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 F171Y; Y172C; Q173C; E174P; V175P; T176N,P; V179I,L; N180R,K,S; S181R,K; V184L,P;  
 R185T; L186I; R187P; and/or T188R,K.
- 10 19. The variant of any one of claims 1-3, which comprises at least one of the following  
 substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C;  
 T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);  
 A25C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A25S);
- 15 G26A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; R38T; V39R,K;  
 Q42E,D,G,P; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 T44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T44S);  
 I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;
- 20 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R49A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R49Q,T);  
 G50A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; Q54N,R; S55C; I56R,K;  
 P58E,D; A62C,S; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 G67A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;
- 25 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;  
 S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;
- 30 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 G83A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);
- 35 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; A89C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y  
 (preferably A89S,T); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; H91T,S; N92P,R,K,S;  
 Q93P; A94C,P; P95A,E,D; I96A,E,D,P; G97R,K; S98P; S99A,Q,R,K; V100I; S103C; S105C,P;

10508.000-DK

T106C; C111R,K; T113E,D; I114V; G118N,R,K; S120E,D,T; S122R,K; P124R,K; E125P,Q;  
 T127R,K; T129E,D,Q,Y; N130E,D,S; M131L; T134C; T135N,P; V136P; E139C; P140E,D;  
 G141C; G144C; G145C; S146C; Y147F,W; I148C; S149C; G150E,D; N151P,E,D,S; G155C;  
 V156C; G160A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 5 S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 R165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y (preferably R165S);  
 T166A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T166V);  
 G167A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 10 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 F171Y; Y172C; Q173C; E174P; V175P; T176N,P; V179I,L; N180R,K,S; S181R,K; V184L,P;  
 R185T; L186I; R187P; and/or T188R,K.

20. The variant of any one of claims 1-3, which comprises at least one of the following  
 15 substitutions: G6C; L7P; A8C; Y9C; T10E,D,Y; G12E,D; G13E,D,P; S16C; V17C; G18C;  
 T22A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; N23A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 A24C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably A24S);  
 S25A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S25A);  
 G26A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; Q27A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y;  
 20 P28A,C,D,E,F,G,H,I,K,L,M,N,Q,R,S,T,V,W,Y; T32C; A33C; G37C; T38R; V39R,K;  
 P42E,D,G,Q; V43A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y;  
 S44A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S44T);  
 I45A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S,T,V,W,Y; G46A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 N47A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; G48A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 25 Q49A,C,D,E,F,G,H,I,K,L,M,N,P,R,S,T,V,W,Y (preferably Q49R,T);  
 G50A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; V51T; F52C; E53Q; R54N,Q; S55C; V56R,K;  
 P58E,D; S62A,C; A63C; R66A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 G67A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T68A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 S69A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; N70A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 30 F71A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; T72A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 L73A,C,D,E,F,G,H,I,K,M,N,P,Q,R,S,T,V,W,Y; T74A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 N75A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; L76C;  
 S78A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; R79A,C,D,E,F,G,H,I,K,L,M,N,P,Q,S,T,V,W,Y;  
 Y80A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; N81A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y;  
 35 T82A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T82S);  
 G83A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G84A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 Y85A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W; A86C,D,E,F,G,H,I,K,L,M,N,P,R,Q,S,T,V,W,Y



10508.000-DK

(preferably A86Q); T87A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y (preferably T87S);  
 V88A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y; S89A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y  
 (preferably S89A,T); G90A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; S91H,T; S92P,R,K,N;  
 Q93P; A94C,P; P95A,E,D; I96A,E,D,P; G97R,K; S98P; Q99A,R,K,S; I100V; S103C; S105C,P;  
 5 T106C; C111R,K; T113E,D; V114I; G118N,R,K; T120E,D,S; S122R,K; P124R,K; Q125E,P;  
 T127R,K; Q129E,D,Y,T; N130E,D,S; L131M T134C; N135P,T; V136P; E139C; P140E,D;  
 G141C; G144C; G145C; S146C; F147W,Y; I148C; S149C; G150E,D; S151P,E,D,T; G155C;  
 V156C; G160A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 S161A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y; G162A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 10 N163A,C,D,E,F,G,H,I,K,L,M,P,Q,R,S,T,V,W,Y; C164A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 S165A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,T,V,W,Y (preferably S165R);  
 F166A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y (preferably F166,T,V);  
 G167A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y; G168A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y;  
 T169A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y; T170A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,V,W,Y;  
 15 Y171F; Y172C; Q173C; E174P; V175P; T176N,P; L179I,V; S180R,K,N; S181R,K; L184P,V;  
 T185R; L186I; R187P; and/or T188R,K.

21. The variant of any one of claims 1-16 and 18-20 which comprises at least one of the  
 following substitutions: T10Y, A24S, V51T, E53Q, T82S, A86Q, T87S, I96A, G118N, S122R,  
 20 N130S, L186I.

22. The variant of any one of claims 1-16 and 18-19 which comprises at least one of the  
 following substitutions: R38T; Q42G,P; R49T,Q; Q54N,R; A89S,T; H91S,T; N92S; S99A,Q;  
 A120T; E125Q; T129Y,Q; M131L; T135N; Y147F; N151S; R165S; T166V,F; F171Y; V179I,L;  
 25 preferably at least one of the following substitutions: R38T; N92S; A120T; E125Q; M131L;  
 T135N; Y147F; N151S; R165S; and/or F171Y.

23. The variant of any one of claims 1-19 which comprises at least one of the following  
 substitutions: A25S, T44S, A62S, P95A, V100I, I114V, T176N, N180S, V184L, R185T.

24. The variant of any one of claims 1-23 which is not identical to any one of the following  
 amino acid sequences: SEQ ID NO: 2, amino acids 1-188 of SEQ ID NO: 4, amino acids 1-  
 188 of SEQ ID NO: 6, amino acids 1-188 of SEQ ID NO: 8, and amino acids 1-188 of SEQ ID  
 NO: 10.

25. The variant of any one of claims 1-24 which is not identical to the protease derived  
 from *Nocardiopsis dassonvillei* NRRL 18133, provided the latter has at least 60% identity to

10508.000-DK

SEQ ID NO: 2.

26. The variant of any one of claims 1-25 which is not identical to the protease derived from *Nocardiopsis* sp. FERM P-10508, and/or *Nocardiopsis dassonvillei* strain ZIMET 43647 provided the respective protease has at least 60% identity to SEQ ID NO: 2.
27. The variant of any one of claims 1-26 which is not identical to any protease that may belong to the prior art and which has at least 60% identity to SEQ ID NO: 2.
28. The variant of any one of claims 1-27 which has amended properties, such as an improved thermostability.
29. The variant of claim 28 which has a  $T_m$  of at least 83.1°C as measured by DSC in 10mM sodium phosphate, 50 mM sodium chloride, pH 7.0.
30. The variant of any one of claims 1-29 which derives from a strain of the genus *Nocardiopsis*.
31. The variant of claim 30 which derives from a strain of *Nocardiopsis alba*, *Nocardiopsis antarctica*, *Nocardiopsis prasina*, *Nocardiopsis composta*, *Nocardiopsis dassonvillei*, *Nocardiopsis exhalans*, *Nocardiopsis halophila*, *Nocardiopsis halotolerans*, *Nocardiopsis kunsanensis*, *Nocardiopsis listeri*, *Nocardiopsis lucentensis*, *Nocardiopsis metallicus*, *Nocardiopsis* sp., *Nocardiopsis synnemataformans*, *Nocardiopsis trehalosi*, *Nocardiopsis tropica*, *Nocardiopsis umidischolae*, or *Nocardiopsis xinjiangensis*.
32. The variant of claim 31 which derives from *Nocardiopsis alba* DSM 15647, *Nocardiopsis dassonvillei* NRRL 18133, *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235, *Nocardiopsis prasina* DSM 15648, *Nocardiopsis prasina* DSM 15649, *Nocardiopsis* sp. NRRL 18262, *Nocardiopsis dassonvillei* strain ZIMET 43647, or *Nocardiopsis* sp. FERM P-10508.
33. A method for generating a protease variant of an improved property, the method comprising the following steps:
- selecting a parent protease of at least 60% identity to SEQ ID NO: 2;
  - establishing a 3D structure of the parent protease by homology modelling using the Fig. 2 structure as a model; and/or aligning the parent protease according to the alignment of Fig. 1;

10508.000-DK

(c) proposing at least one amino acid substitution, e.g. by:

(i) subjecting the 3D structure of (b) to MD simulations at increased temperatures, and identifying regions in the amino acid sequence of the parent protease of high mobility (isotropic fluctuations);

(ii) introducing disulfid bridges by way of cysteine substitutions (C-C);

(iii) introducing proline substitutions (P);

(iv) replacing exposed neutral amino acid residues with negatively charged amino acid residues (E,D);

(v) replacing exposed neutral amino acid residues with positively charged amino acid residues (R,K);

(vi) replacing small amino acid residues inside the protein with bulkier amino acid residues (W);

(vii) comparing by homology alignment and/or homology modelling according to step (c)(i) at least two related parent proteases and transferring amino acid residue differences inbetween these protease backbones, preferably from a backbone having the improved property to a backbone not having this improved property;

(d) preparing a DNA sequence encoding the parent protease but for inclusion of a DNA codon of the at least one amino acid substitution proposed in steps (c)(ii)-(c)(vii), or subjecting the parent DNA sequence to random mutagenesis, targetting at least one of the regions identified in step (c)(i);

(e) expressing the DNA sequence obtained in step (d) in a host cell, and

(h) selecting a host cell expressing a protease variant with an improved property.

34. A method of preparing a protease variant, the method comprising the steps of  
(a) cultivating the host cell of claim 33(h) to produce a supernatant comprising the variant; and  
(b) recovering the variant.

35. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the protease variant of any of claims 1-32, or the protease variant obtainable according to claim 34.

36. The nucleic acid sequence of claim 35 which is not identical to any one of the following nucleic acid sequences: Nucleotides 900-1466 of SEQ ID NO: 1, nucleotides 499-1062 of SEQ ID NO: 3, nucleotides 496-1059 of SEQ ID NO: 5, nucleotides 496-1059 of SEQ ID NO: 7, and nucleotides 502-1065 of SEQ ID NO: 9.

10508.000-DK

37. The nucleic acid sequence of claim 35 which is not identical to the nucleic acid sequence encoding the mature peptide part of the protease derived from *Nocardiopsis dassonvillei* NRRL 18133, provided this protease has at least 60% identity to SEQ ID NO: 2.
- 5 38. The nucleic acid sequence of claim 35 which is not identical to the nucleic acid sequence encoding the mature peptide part of the proteases derived from *Nocardiopsis sp.* FERM P-10508, and/or *Nocardiopsis dassonvillei* strain ZIMET 43647, provided the respective protease has at least 60% identity to SEQ ID NO: 2.
- 10 39. A nucleic acid construct comprising the nucleic acid sequence of any one of claims 35-38 operably linked to one or more control sequences that direct the production of the protease variant in a suitable expression host.
40. A recombinant expression vector comprising the nucleic acid construct of claim 39.
- 15 41. A recombinant host cell comprising the nucleic acid construct of claim 39 and/or the expression vector of claim 40.
42. A method for producing the protease variant of any one of claims 1-32, or the variant obtainable according to claim 34, the method comprising:
- 20 (a) cultivating the host cell of claim 41 to produce a supernatant comprising the variant; and  
(b) recovering the variant.
43. A transgenic plant, or plant part, capable of expressing a protease variant of any one of claims 1-32, and/or a protease variant obtainable according to claim 34.
- 25 44. A transgenic, non-human animal, or products, or elements thereof, being capable of expressing a protease variant of any one of claims 1-32, and/or a protease variant obtainable according to claim 34.
- 30 45. A composition comprising at least one protease variant of any one of claims 1-32, and/or a protease variant obtainable according to claim 34, and
- (a) at least one fat soluble vitamin;
- (b) at least one water soluble vitamin; and/or
- 35 (c) at least one trace mineral.
46. The composition of claim 45 further comprising at least one enzyme selected from the

10508.000-DK

following group of enzymes: galactanases, alpha-galactosidases, xylanases, endoglucanases, endo-1,3(4)-beta-glucanases, and phytases.

- 5 47. The composition of any one of claims 45-46 which is an animal feed additive.
48. An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-47.
- 10 49. A method for improving the nutritional value of an animal feed, wherein the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-48 is added to the feed.
- 15 50. A method for the treatment of vegetable proteins, comprising the step of adding the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-48 to at least one vegetable protein or protein source.
- 20 51. Use of the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34, and/or the composition of any one of claims 45-48 (i) in animal feed; (ii) in the preparation of animal feed; (iii) for improving the nutritional value of animal feed; and/or (iv) for the treatment of vegetable proteins.
- 25 52. Use of the protease variant of any one of claims 1-32, and/or the protease variant obtainable according to claim 34 in detergents.

**Abstract**

The invention relates to variants of a parent protease homologous to *Nocardiopsis* proteases, in particular variants of improved thermostability. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as  
5 methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.

10508DK.ST25  
SEQUENCE LISTING

<110> Novozymes A/S  
<120> Protease Variants  
<130> 10508  
<160> 10  
<170> PatentIn version 3.2  
<210> 1  
<211> 1596  
<212> DNA  
<213> Nocardiosis sp. NRRL 18262 ("Protease 10")

<220>  
<221> CDS  
<222> (900)..(1466)

```

<400> 1
acgttttgta cgggtaccgg tgtccgcatg tggccagaat gcccccttgc gacaggggaac      60
ggattcggtc ggtagcgcat cgactccgac aaccgcgagg tggccgttcg cgtcgccacg      120
ttctgcgacc gtcatgcgac ccatacatcg gtgacccacg cgagctctga atggtccacc      180
gttctgacgg tctttccctc accaaaacgt gcacctatgg ttaggacggt gtttaccgaa      240
tgtctcggtg aacgacaggg gccggacggt attcggcccc gatcccccggt tgatcccccc      300
aggagagtag ggaccccatg cgacctccc ccgttgctc cgccatcggt acgggagcgc      360
tggccttcgg tctggcgctg tccggtaccc cgggtgccct cgcggccacc ggagcgctcc      420
cccagtcacc caccgccgag gccgacgcgg tctccatgca ggaggcgctc cagcgcgacc      480
tcgacctgac ctccgccgag gccgaggagc tgctggccgc ccaggacacc gccttcgagg      540
tcgacgaggc cgcggccgag gccgccgggg acgcctacgg cggctccgct ttcgacaccg      600
agagcctgga actgaccgtc ctggtcaccg atgccgctgc ggtcgaggcc gtggaggcca      660
ccggcgccgg gaccgagctg gtctcctacg gcatcgacgg tctcgacgag atcgctccagg      720
agctcaacgc cgccgacgcc gttcccgggt tggtcggctg gtaccgggac gtggcgggtg      780
acaccgtcgt cctggagggt ctggagggtt ccggagccga cgtcagcggc ctgctcgcgg      840
acgccggcgt ggacgcctcg gccgtcgagg tgaccacgag cgaccagccc gagctctac      899
gcc gac atc atc ggt ggt ctg gcc tac acc atg ggc ggc cgc tgt tgc      947
Ala Asp Ile Ile Gly Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser
1 5 10 15
gtc ggc ttc gcg gcc acc aac gcc gcc ggt cag ccc ggg ttc gtc acc      995
Val Gly Phe Ala Ala Thr Asn Ala Ala Gly Gln Pro Gly Phe Val Thr
20 25 30
gcc ggt cac tgc gcc cgc gtg gcc acc cag gtg acc atc ggc aac gcc      1043
Ala Gly His Cys Gly Arg Val Gly Thr Gln Val Thr Ile Gly Asn Gly
35 40 45
agg ggc gtc ttc gag cag tcc gtc ttc ccc ggc aac gac gcg gcc ttc      1091
Arg Gly Val Phe Glu Gln Ser Val Phe Pro Gly Asn Asp Ala Ala Phe
50 55 60

```

## 10508DK.ST25

gtc cgc ggt acg tcc aac ttc acg ctg acc aac ctg gtc agc cgc tac 1139  
 Val Arg Gly Thr Ser Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr  
 65 70 75 80  
 aac acc ggc ggg tac gcc acg gtc gcc ggt cac aac cag gcc ccc atc 1187  
 Asn Thr Gly Gly Tyr Ala Thr Val Ala Gly His Asn Gln Ala Pro Ile  
 85 90 95  
 ggc tcc tcc gtc tgc cgc tcc ggc tcc acc acc ggt tgg cac tgc ggc 1235  
 Gly Ser Ser Val Cys Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly  
 100 105 110  
 acc atc cag gcc cgc ggc cag tcg gtg agc tac ccc gag ggc acc gtc 1283  
 Thr Ile Gln Ala Arg Gly Gln Ser Val Ser Tyr Pro Glu Gly Thr Val  
 115 120 125  
 acc aac atg acc cgg acc acc gtg tgc gcc gag ccc ggc gac tcc ggc 1331  
 Thr Asn Met Thr Arg Thr Thr Val Cys Ala Glu Pro Gly Asp Ser Gly  
 130 135 140  
 ggc tcc tac atc tcc ggc acc cag gcc cag ggc gtg acc tcc ggc ggc 1379  
 Gly Ser Tyr Ile Ser Gly Thr Gln Ala Gln Gly Val Thr Ser Gly Gly  
 145 150 155 160  
 tcc ggc aac tgc cgc acc ggc ggc acc acc ttc tac cag gag gtc acc 1427  
 Ser Gly Asn Cys Arg Thr Gly Gly Thr Thr Phe Tyr Gln Glu Val Thr  
 165 170 175  
 ccc atg gtg aac tcc tgg ggc gtc cgt ctc cgg acc tga tccccgcggt 1476  
 Pro Met Val Asn Ser Trp Gly Val Arg Leu Arg Thr  
 180 185  
 tccagggcga ccgacggtcg tgacctgagt accagggcgc cccgccgctt ccagcggcgt 1536  
 ccgcaccggg gtgggaccgg gcgtggccac ggccccaccc gtgaccggac cgcccggcta 1596

<210> 2  
 <211> 188  
 <212> PRT  
 <213> Nocardiosis sp. NRRL 18262 ("Protease 10")

<400> 2

Ala Asp Ile Ile Gly Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser  
 1 5 10 15  
 Val Gly Phe Ala Ala Thr Asn Ala Ala Gly Gln Pro Gly Phe Val Thr  
 20 25 30  
 Ala Gly His Cys Gly Arg Val Gly Thr Gln Val Thr Ile Gly Asn Gly  
 35 40 45  
 Arg Gly Val Phe Glu Gln Ser Val Phe Pro Gly Asn Asp Ala Ala Phe  
 50 55 60  
 Val Arg Gly Thr Ser Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr  
 65 70 75 80  
 Asn Thr Gly Gly Tyr Ala Thr Val Ala Gly His Asn Gln Ala Pro Ile  
 85 90 95



## 10508DK.ST25

Gly Ser Ser Val Cys Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly  
 100 105 110

Thr Ile Gln Ala Arg Gly Gln Ser Val Ser Tyr Pro Glu Gly Thr Val  
 115 120 125

Thr Asn Met Thr Arg Thr Thr Val Cys Ala Glu Pro Gly Asp Ser Gly  
 130 135 140

Gly Ser Tyr Ile Ser Gly Thr Gln Ala Gln Gly Val Thr Ser Gly Gly  
 145 150 155 160

Ser Gly Asn Cys Arg Thr Gly Gly Thr Thr Phe Tyr Gln Glu Val Thr  
 165 170 175

Pro Met Val Asn Ser Trp Gly Val Arg Leu Arg Thr  
 180 185

<210> 3  
 <211> 1065  
 <212> DNA  
 <213> Nocardiosis dassonvillei subspecies dassonvillei DSM 43235 ("Protease 18")

<220>  
 <221> CDS  
 <222> (1)..(1062)

<220>  
 <221> mat\_peptide  
 <222> (499)..(1062)

<400> 3  
 gct ccg gcc ccc gtc ccc cag acc ccc gtc gcc gac gac agc gcc 45  
 Ala Pro Ala Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala  
 -165 -160 -155  
 gcc agc atg acc gag gcg ctc aag cgc gac ctc gac ctc acc tcg 90  
 Ala Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asp Leu Thr Ser  
 -150 -145 -140  
 gcc gag gcc gag gag ctt ctc tcg gcg cag gaa gcc gcc atc gag 135  
 Ala Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu  
 -135 -130 -125  
 acc gac gcc gag gcc acc gag gcc gcg gcc gag gcc tac ggc gcc 180  
 Thr Asp Ala Glu Ala Thr Glu Ala Ala Gly Glu Ala Tyr Gly Gly  
 -120 -115 -110  
 tca ctg ttc gac acc gag acc ctc gaa ctc acc gtg ctg gtc acc gac 228  
 Ser Leu Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
 -105 -100 -95  
 gcc tcc gcc gtc gag gcg gtc gag gcc acc gga gcc cag gcc acc gtc 276  
 Ala Ser Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gln Ala Thr Val  
 -90 -85 -80 -75  
 gtc tcc cac ggc acc gag gcc ctg acc gag gtc gtg gag gac ctc aac 324  
 Val Ser His Gly Thr Glu Gly Leu Thr Glu Val Val Glu Asp Leu Asn  
 -70 -65 -60

## 10508DK.ST25

ggc gcc gag gtt ccc gag agc gtc ctc ggc tgg tac ccg gac gtg gag Gly Ala Glu Val <sub>-55</sub> Pro Glu Ser Val <sub>-50</sub> Leu Gly Trp Tyr Pro Asp Val <sub>-45</sub> Glu	372
agc gac acc gtc gtg gtc gag gtg ctg gag ggc tcc gac gcc gac gtc Ser Asp Thr Val Val Val Glu Val <sub>-35</sub> Leu Glu Gly Ser Asp Ala Asp Val	420
gcc gcc ctg ctc gcc gac gcc ggt gtg gac tcc tcc tcg gtc cgg gtg Ala Ala Leu Leu Ala Asp Ala Gly Val Asp Ser Ser Ser Val Arg Val	468
gag gag gcc gag gag gcc ccg cag gtc tac gcc gac atc atc ggc ggc Glu Glu Ala Glu Glu Ala Pro Gln Val Tyr <sub>-1</sub> Ala Asp Ile Ile Gly Gly <sub>5</sub>	516
ctg gcc tac tac atg ggc ggc cgc tgc tcc gtc ggc ttc gcc gcg acc Leu Ala Tyr Tyr <sub>10</sub> Met Gly Gly Arg Cys <sub>15</sub> Ser Val Gly Phe Ala Ala Thr	564
aac agc gcc ggt cag ccc ggt ttc gtc acc gcc ggc cac tgc ggc acc Asn Ser Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Thr	612
gtc ggc acc ggc gtg acc atc ggc aac ggc acc ggc acc ttc cag aac Val Gly Thr Gly Val Thr Ile Gly Asn Gly Thr Gly Thr Phe Gln Asn	660
tcg gtc ttc ccc ggc aac gac gcc gcc ttc gtc cgc ggc acc tcc aac Ser Val Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn	708
ttc acc ctg acc aac ctg gtc tcg cgc tac aac tcc ggc ggc tac cag Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr <sub>80</sub> Asn Ser Gly Gly Tyr <sub>85</sub> Gln	756
tcg gtg acc ggt acc agc cag gcc ccg gcc ggc tcg gcc gtg tgc cgc Ser Val Thr Gly Thr Ser Gln Ala Pro <sub>95</sub> Ala Gly Ser Ala Val <sub>100</sub> Cys Arg	804
tcc ggc tcc acc acc ggc tgg cac tgc ggc acc atc cag gcc cgc aac Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Asn	852
cag acc gtg cgc tac ccg cag ggc acc gtc tac tcg ctc acc cgc acc Gln Thr Val Arg Tyr Pro Gln Gly Thr Val Tyr <sub>130</sub> Leu Thr Arg Thr	900
aac gtg tgc gcc gag ccc ggc gac tcc ggc ggt tcg ttc atc tcc ggc Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly <sub>145</sub> Ser Phe Ile Ser Gly	948
tcg cag gcc cag ggc gtc acc tcc ggc ggc tcc ggc aac tgc tcc gtc Ser Gln Ala Gln Gly Val Thr Ser Gly <sub>160</sub> Ser Gly Asn Cys Ser Val	996
ggc ggc acg acc tac tac cag gag gtc acc ccg atg atc aac tcc tgg Gly Gly Thr Thr Tyr Tyr Gln Glu Val <sub>175</sub> Thr Pro Met Ile Asn Ser Trp	1044
ggt gtc agg atc cgg acc taa Gly Val Arg Ile Arg Thr	1065

<210> 4  
<211> 354

10508DK.ST25

<212> PRT  
<213> Nocardiosis dassonvillei subspecies dassonvillei DSM 43235 ("Protease 18")

<400> 4

Ala Pro Ala Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala  
-165 -160 -155

Ala Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asp Leu Thr Ser  
-150 -145 -140

Ala Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu  
-135 -130 -125

Thr Asp Ala Glu Ala Thr Glu Ala Ala Gly Glu Ala Tyr Gly Gly  
-120 -115 -110

Ser Leu Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
-105 -100 -95

Ala Ser Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gln Ala Thr Val  
-90 -85 -80 -75

Val Ser His Gly Thr Glu Gly Leu Thr Glu Val Val Glu Asp Leu Asn  
-70 -65 -60

Gly Ala Glu Val Pro Glu Ser Val Leu Gly Trp Tyr Pro Asp Val Glu  
-55 -50 -45

Ser Asp Thr Val Val Val Glu Val Leu Glu Gly Ser Asp Ala Asp Val  
-40 -35 -30

Ala Ala Leu Leu Ala Asp Ala Gly Val Asp Ser Ser Ser Val Arg Val  
-25 -20 -15

Glu Glu Ala Glu Glu Ala Pro Gln Val Tyr Ala Asp Ile Ile Gly Gly  
-10 -5 -1 1 5

Leu Ala Tyr Tyr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr  
10 15 20

Asn Ser Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Thr  
25 30 35

Val Gly Thr Gly Val Thr Ile Gly Asn Gly Thr Gly Thr Phe Gln Asn  
40 45 50

Ser Val Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn  
55 60 65 70

Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Ser Gly Gly Tyr Gln  
75 80 85



## 10508DK.ST25

gtc Val	tcc Ser	tac Tyr	ggc Gly -70	atc Ile	gag Glu	ggc Gly	ctc Leu	gac Asp -65	gag Glu	atc Ile	atc Ile	cag Gln -60	gat Asp	ctc Leu	aac Asn	324
gcc Ala	gcc Ala	gac Asp -55	ggc Ala	gtc Val	ccc Pro	ggc Gly	gtg Val -50	gtc Val	ggc Gly	tgg Trp	tac Tyr	ccg Pro -45	gac Asp	gtg Val	gcg Ala	372
ggc Gly	gac Asp -40	acc Thr	gtc Val	gtc Val	ctg Leu	gag Glu -35	gtc Val	ctg Leu	gag Glu	ggc Gly	tcc Ser -30	gga Gly	gcc Ala	gac Asp	gtg Val	420
agc Ser -25	ggc Gly	ctg Leu	ctc Leu	gcc Ala	gac Asp -20	ggc Ala	ggc Gly	gtg Val	gac Asp	gcc Ala -15	tcg Ser	gcc Ala	gtc Val	gag Glu	gtg Val -10	468
acc Thr	agc Ser	agt Ser	gcg Ala	cag Gln -5	ccc Pro	gag Glu	ctc Leu	tac Tyr -1	gcc Ala 1	gac Asp	atc Ile	atc Ile	ggc Gly 5	ggc Gly	ctg Leu	516
gcc Ala	tac Tyr	acc Thr 10	atg Met	ggc Gly	ggc Gly	cgc Arg	tgt Cys 15	tcg Ser	gtc Val	gga Gly	ttc Phe	gcg Ala 20	gcc Ala	acc Thr	aac Asn	564
gcc Ala	gcc Ala 25	ggc Gly	cag Gln	ccc Pro	gga Gly	ttc Phe 30	gtc Val	acc Thr	gcc Ala	ggc Gly	cac His 35	tgt Cys	ggc Gly	cgc Arg	gtg Val	612
ggc Gly 40	acc Thr	cag Gln	gtg Val	agc Ser	atc Ile 45	ggc Gly	aac Asn	ggc Gly	cag Gln	ggc Gly 50	gtc Val	ttc Phe	gag Glu	cag Gln	tcc Ser 55	660
atc Ile	ttc Phe	ccg Pro	ggc Gly	aac Asn 60	gac Asp	ggc Ala	ggc Ala	ttc Phe	gtc Val 65	cgc Arg	ggc Gly	acg Thr	tcc Ser	aac Asn 70	ttc Phe	708
acg Thr	ctg Leu	acc Thr	aac Asn 75	ctg Leu	gtc Val	agc Ser	cgc Arg	tac Tyr 80	aac Asn	acc Thr	ggc Gly	ggc Gly	tac Tyr 85	gcc Ala	acc Thr	756
gtc Val	gcc Ala	ggc Gly 90	cac His	aac Asn	cag Gln	ggc Ala	ccc Pro 95	atc Ile	ggc Gly	tcc Ser	tcc Ser	gtc Val 100	tgc Cys	cgc Arg	tcc Ser	804
ggc Gly	tcc Ser 105	acc Thr	acc Thr	ggc Gly	tgg Trp	cac His 110	tgc Cys	ggc Gly	acc Thr	atc Ile	cag Gln 115	gcc Ala	cgc Arg	ggc Gly	cag Gln	852
tcg Ser 120	gtg Val	agc Ser	tac Tyr	ccc Pro	gag Glu 125	ggc Gly	acc Thr	gtc Val	acc Thr	aac Asn 130	atg Met	acc Thr	cgg Arg	acc Thr	acc Thr 135	900
gtg Val	tgc Cys	gcc Ala	gag Glu	ccc Pro 140	ggc Gly	gac Asp	tcc Ser	ggc Gly	ggc Gly 145	tcc Ser	tac Tyr	atc Ile	tcc Ser	ggc Gly 150	aad Asn	948
cag Gln	gcc Ala	cag Gln	ggc Gly 155	gtc Val	acc Thr	tcc Ser	ggc Gly	ggc Gly 160	tcc Ser	ggc Gly	aac Asn	tgc Cys	cgc Arg 165	acc Thr	ggc Gly	996
ggg Gly	acc Thr	acc Thr 170	ttc Phe	tac Tyr	cag Gln	gag Glu	gtc Val 175	acc Thr	ccc Pro	atg Met	gtg Val	aac Asn 180	tcc Ser	tgg Trp	ggc Gly	1044
gtc Val	cgt Arg 185	ctc Leu	cgg Arg	acc Thr	taa											1062

10508DK.ST25

<210> 6  
<211> 353  
<212> PRT  
<213> Nocardiosis prasina DSM 15648 ("Protease 11")

<400> 6

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala  
-165 -160 -155

Val Ser Met Gln Glu Ala Leu Gln Arg Asp Leu Gly Leu Thr Pro  
-150 -145 -140

Leu Glu Ala Asp Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu  
-135 -130 -125

Val Asp Glu Ala Ala Ala Ala Ala Ala Gly Asp Ala Tyr Gly Gly  
-120 -115 -110

Ser Val Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
-105 -100 -95 -90

Ala Ala Ser Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu  
-85 -80 -75

Val Ser Tyr Gly Ile Glu Gly Leu Asp Glu Ile Ile Gln Asp Leu Asn  
-70 -65 -60

Ala Ala Asp Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala  
-55 -50 -45

Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val  
-40 -35 -30

Ser Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val  
-25 -20 -15 -10

Thr Ser Ser Ala Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu  
-5 -1 1 5

Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn  
10 15 20

Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val  
25 30 35

Gly Thr Gln Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu Gln Ser  
40 45 50 55

Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe  
60 65 70

10508DK.ST25

Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr  
75 80 85

Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser  
90 95 100

Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln  
105 110 115

Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr  
120 125 130 135

Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn  
140 145 150

Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly  
155 160 165

Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly  
170 175 180

Val Arg Leu Arg Thr  
185

```
<210> 7
<211> 1062
<212> DNA
<213> Nocardiosis prasina DSM 15649 ("Protease 35")
```

```
<220>
<221> CDS
<222> (1)..(1059)
```

```
<220>
<221> mat_peptide
<222> (496)..(1059)
```

<400> gcc Ala -165	7 acc Thr	gga Gly	cca Pro	ctc Leu	ccc Pro -160	cag Gln	tca Ser	ccc Pro	acc Thr	ccg Pro -155	gag Glu	gcc Ala	gac Asp	gcc Ala	45	
gtc Val -150	tcc Ser	atg Met	cag Gln	gag Glu	gcg Ala -145	ctc Leu	cag Gln	cgc Arg	gac Asp	ctc Leu -140	ggc Gly	ctg Leu	acc Thr	ccg Pro	90	
ctt Leu -135	gag Glu	gcc Ala	gat Asp	gaa Glu	ctg Leu -130	ctg Leu	gcc Ala	gcc Ala	cag Gln	gac Asp -125	acc Thr	gcc Ala	ttc Phe	gag Glu	135	
gtc Val -120	gac Asp	gag Glu	gcc Ala	gcg Ala	gcc Ala -115	gag Glu	gcc Ala	gcc Ala	ggt Gly	gac Asp -110	gcc Ala	tac Tyr	ggc Gly	ggc Gly	180	
tcc Ser -105	gtc Val	ttc Phe	gac Asp	acc Thr	gag Glu -100	acc Thr	ctg Leu	gaa Glu	ctg Leu	acc Thr -95	gtc Val	ctg Leu	gtc Val	acc Thr	gac Asp -90	228

10508DK.ST25

tcc gcc gcg gtc gag gcg gtg gag gcc acc ggc gcc ggg acc gaa ctg	276
Ser Ala Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu	
-85 -80 -75	
gtc tcc tac ggc atc acg ggc ctc gac gag atc gtc gag gag ctc aac	324
Val Ser Tyr Gly Ile Thr Gly Leu Asp Glu Ile Val Glu Glu Leu Asn	
-70 -65 -60	
gcc gcc gac gcc gtt ccc ggc gtg gtc ggc tgg tac ccg gac gtc gcg	372
Ala Ala Asp Ala Val Pro Gly Val Gly Trp Tyr Pro Asp Val Ala	
-55 -50 -45	
ggc gac acc gtc gtg ctg gag gtc ctg gag ggt tcc ggc gcc gac gtg	420
Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val	
-40 -35 -30	
ggc ggc ctg ctc gcc gac gcc ggc gtg gac gcc tcg gcg gtc gag gtg	468
Gly Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val	
-25 -20 -15 -10	
acc acc acc gag cag ccc gag ctg tac gcc gac atc atc ggc ggt ctg	516
Thr Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu	
-5 -1 1 5	
gcc tac acc atg ggc ggc cgc tgt tcg gtc ggc ttc gcg gcc acc aac	564
Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn	
10 15 20	
gcc gcc ggt cag ccc ggc ttc gtc acc gcc ggt cac tgt ggc cgc gtg	612
Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val	
25 30 35	
ggc acc cag gtg acc atc ggc aac ggc cgc ggc gtc ttc gag cag tcc	660
Gly Thr Gln Val Thr Ile Gly Asn Gly Arg Gly Val Phe Glu Gln Ser	
40 45 50 55	
atc ttc ccg ggc aac gac gcc gcc ttc gtc cgc gga acg tcc aac ttc	708
Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe	
60 65 70	
acg ctg acc aac ctg gtc agc cgc tac aac acc ggc ggc tac gcc acc	756
Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr	
75 80 85	
gtc gcc ggt cac aac cag gcg ccc atc ggc tcc tcc gtc tgc cgc tcc	804
Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser	
90 95 100	
ggc tcc acc acc ggt tgg cac tgc ggc acc atc cag gcc cgc ggc cag	852
Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln	
105 110 115	
tcg gtg agc tac ccc gag ggc acc gtc acc aac atg acg cgc acc acc	900
Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr	
120 125 130 135	
gtg tgc gcc gag ccc ggc gac tcc ggc ggc tcc tac atc tcc ggc aac	948
Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn	
140 145 150	
cag gcc cag ggc gtc acc tcc ggc ggc tcc ggc aac tgc cgc acc ggc	996
Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly	
155 160 165	
ggg acc acc ttc tac cag gag gtc acc ccc atg gtg aac tcc tgg ggc	1044
Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly	
170 175 180	



gtc cgt ctc cgg acc taa  
 Val Arg Leu Arg Thr  
 185

<210> 8  
 <211> 353  
 <212> PRT  
 <213> Nocardiosis prasina DSM 15649 ("Protease 35")

<400> 8

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala  
 -165 -160 -155

Val Ser Met Gln Glu Ala Leu Gln Arg Asp Leu Gly Leu Thr Pro  
 -150 -145 -140

Leu Glu Ala Asp Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu  
 -135 -130 -125

Val Asp Glu Ala Ala Ala Glu Ala Ala Gly Asp Ala Tyr Gly Gly  
 -120 -115 -110

Ser Val Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp  
 -105 -100 -95 -90

Ser Ala Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu  
 -85 -80 -75

Val Ser Tyr Gly Ile Thr Gly Leu Asp Glu Ile Val Glu Glu Leu Asn  
 -70 -65 -60

Ala Ala Asp Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala  
 -55 -50 -45

Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val  
 -40 -35 -30

Gly Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val  
 -25 -20 -15 -10

Thr Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu  
 -5 -1 1 5

Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn  
 10 15 20

Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val  
 25 30 35

Gly Thr Gln Val Thr Ile Gly Asn Gly Arg Gly Val Phe Glu Gln Ser  
 40 45 50 55

**10508DK.ST25**

75

90

105

120

140

155

170

185

**<210>**

**<211> 1068**

**<212> DNA**

<213> *Nocardioopsis alba* DSM 15647 ("Protease 08")

**<220>**

**<221> CDS**

**<222> (1) . . (1065)**

**<220>**

**<221> mat\_peptide**

<222> (502) .. (1065)

**<400>**

gcg acc ggc ccc ctc ccc cag tcc ccc acc ccg gat gaa gcc gag  
Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Asp Glu Ala Glu  
-165 -160 -155

45

acc a

Ala Thr Thr Met Val Glu Ala Leu Gln Arg Asp Leu Gly Leu Ser  
-150 -145 -140

90

ccc t

Pro Ser Gln Ala Asp Glu Leu Glu Ala Gln Ala Glu Ser Phe  
-135 -130 -125

135

030 3

Glu Ile Asp Glu Ala Ala Thr Ala Ala Ala Asp Ser Tyr Gly  
-120 -115 -110

180

ggc \*

Page 12

228

## 10508DK.ST25

Gly Ser Ile Phe Asp Thr Asp Ser Leu Thr Leu Thr Val Leu Val Thr  
 -105 -100 -95

gac ggc tcc gcc gtc gag gcg gtc gag gcc gcc ggc gcc gag gcc aag Asp Ala Ser Ala Val Glu Ala Val Glu Ala Ala Gly Ala Glu Ala Lys -90 -85 -80	276
gtg gtc tcg cac ggc atg gag ggc ctg gag gag atc gtc gcc gac ctg Val Val Ser His Gly Met Glu Gly Leu Glu Glu Ile Val Ala Asp Leu -75 -70 -65 -60	324
aac gcg gcc gac gct cag ccc ggc gtc gtg ggc tgg tac ccc gac atc Asn Ala Ala Asp Ala Gln Pro Gly Val Val Gly Trp Tyr Pro Asp Ile -55 -50 -45	372
cac tcc gac acg gtc gtc ctc gag gtc ctc gag ggc tcc ggt gcc gac His Ser Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp -40 -35 -30	420
gtg gac tcc ctg ctc gcc gac gcc ggt gtg gac acc gcc gac gtc aag Val Asp Ser Leu Leu Ala Asp Ala Gly Val Asp Thr Ala Asp Val Lys -25 -20 -15	468
gtg gag agc acc acc gag cag ccc gag ctg tac gcc gac atc atc ggc Val Glu Ser Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly -10 -5 -1 1 5	516
ggt ctc gcc tac acc atg ggt ggc cgc tgc tcg gtc ggc ttc gcg gcc Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys 15 Ser Val Gly Phe Ala Ala 10 20	564
acc aac gcc tcc ggc cag ccc ggc ttc gtc acc gcc ggc cac tgc ggc Thr Asn Ala Ser Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly 25 30 35	612
acc gtc ggc acc ccg gtc agc atc ggc aac ggc cag ggc gtc ttc gag Thr Val Gly Thr Pro Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu 40 45 50	660
cgt tcc gtc ttc ccc ggc aac gac tcc gcc ttc gtc cgc ggc acc tcg Arg Ser Val Phe Pro Gly Asn Asp Ser Ala Phe Val Arg Gly Thr Ser 55 60 65	708
aac ttc acc ctg acc aac ctg gtc agc cgc tac aac acc ggt ggt tac Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr 70 75 80 85	756
gcg acc gtc tcc ggc tcc tcg cag gcg gcg atc ggc tcg cag atc tgc Ala Thr Val Ser Gly Ser Ser Gln Ala Ala Ile Gly Ser Gln Ile Cys 90 95 100	804
cgt tcc ggc tcc acc acc ggc tgg cac tgc ggc acc gtc cag gcc cgc Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Val Gln Ala Arg 105 110 115	852
ggc cag acg gtg agc tac ccc cag ggc acc gtg cag aac ctg acc cgc Gly Gln Thr Val Ser Tyr Pro Gln Gly Thr Val Gln Asn Leu Thr Arg 120 125 130	900
acc aac gtc tgc gcc gag ccc ggt gac tcc ggc ggc tcc ttc atc tcc Thr Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser 135 140 145	948
ggc agc cag gcc cag ggc gtc acc tcc ggt ggc tcc ggc aac tgc tcc Gly Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser 150 155 160 165	996
ttc ggt ggc acc acc tac tac cag gag gtc aac ccg atg ctg agc agc	1044

1068

```
<210> 10
<211> 355
<212> PRT
<213> Nocardiosis alba DSM 15647 ("Protease 08")
<400> 10
```

Ala Thr Thr Met Val Glu Ala Leu Gln Arg Asp Leu Gly Leu Ser  
~150 ~145 ~140

Glu Ile Asp   Glu Ala Ala Thr   Ala   Ala Ala Ala Asp   Ser   Tyr Gly  
-120                      -115                      -110

Gly Ser Ile Phe Asp Thr Asp Ser Leu Thr Leu Thr Val Leu Val Thr  
-105 -100 -95

Asp Ala Ser Ala Val Glu Ala Val Glu Ala Ala Gly Ala Glu Ala Lys  
-90 -85 -80

Val Val Ser His Gly Met Glu Gly Leu Glu Glu Ile Val Ala Asp Leu  
-75 -70 -65 -60

Asn Ala Ala Asp Ala Gln Pro Gly Val Val Gly Trp Tyr Pro Asp Ile  
-55 -50 -45

His Ser Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp  
-40 -35 -30

Val Asp Ser Leu Leu Ala Asp Ala Gly Val Asp Thr Ala Asp Val Lys  
-25 -20 -15

Val Glu Ser Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly  
-10 -5 -1 1 5

Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala  
10 15 20

Thr Asn Ala Ser Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly  
25 30 35

Thr Val Gly Thr Pro Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu  
Page 14

40

45

50

Arg Ser Val Phe Pro Gly Asn Asp Ser Ala Phe Val Arg Gly Thr Ser  
 55 60 65

Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr  
 70 75 80 85

Ala Thr Val Ser Gly Ser Ser Gln Ala Ala Ile Gly Ser Gln Ile Cys  
 90 95 100

Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Val Gln Ala Arg  
 105 110 115

Gly Gln Thr Val Ser Tyr Pro Gln Gly Thr Val Gln Asn Leu Thr Arg  
 120 125 130

Thr Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser  
 135 140 145

Gly Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser  
 150 155 160 165

Phe Gly Gly Thr Thr Tyr Tyr Gln Glu Val Asn Pro Met Leu Ser Ser  
 170 175 180

Trp Gly Leu Thr Leu Arg Thr  
 185

Modtaget

10 OKT. 2003

PVS

1/26

10	20	30	40	50	
ADIIGGLAYT	MGGRCSVGFA	ATNAAGQPGF	VTAGHCGRVG	TQVTIGNGRG	Protease 10
ADIIGGLAYY	MGGRCSVGFA	ATNSAGQPGF	VTAGHCCTVG	TGVTIGNGTG	Protease 18
ADIIGGLAYT	MGGRCSVGFA	ATNAAGQPGF	VTAGHCGRVG	TQVSIENGQG	Protease 11
ADIIGGLAYT	MGGRCSVGFA	ATNAAGQPGF	VTAGHCGRVG	TQVTIGNGRG	Protease 35
ADIIGGLAYT	MGGRCSVGFA	ATNASGQPGF	VTAGHCCTVG	TPVSIENGQG	Protease 08
10	20	30	40	50	
60	70	80	90	100	
VFEQSVFPGN	DAAFVRGTSN	FTLTNLVSRV	NTGGYATVAG	HNQAPIGSSV	Protease 10
TFQNSVFPGN	DAAFVRGTSN	FTLTNLVSRV	NSGGYQSVTG	TSQAPAGSAV	Protease 18
VFEQSIFPGN	DAAFVRGTSN	FTLTNLVSRV	NTGGYATVAG	HNQAPIGSSV	Protease 11
VFEQSIFPGN	DAAFVRGTSN	FTLTNLVSRV	NTGGYATVAG	HNQAPIGSSV	Protease 35
VFERSVFPGN	DSAFVRGTSN	FTLTNLVSRV	NTGGYATVSG	SSQAAIGSQI	Protease 08
60	70	80	90	100	
110	120	130	140	150	
CRSGSTTGWH	CGTIQARGQS	VSYPEGTVTN	MTRTTVCAEP	GDSGGSYISG	Protease 10
CRSGSTTGWH	CGTIQARNQT	VRYPQGTVYS	LTRTNVCAEP	GDSGGSFISG	Protease 18
CRSGSTTGWH	CGTIQARGQS	VSYPEGTVTN	MTRTTVCAEP	GDSGGSYISG	Protease 11
CRSGSTTGWH	CGTIQARGQS	VSYPEGTVTN	MTRTTVCAEP	GDSGGSYISG	Protease 35
CRSGSTTGWH	CGTVQARGQT	VSYPQGTVQN	LTRTNVCAEP	GDSGGSFISG	Protease 08
110	120	130	140	150	
160	170	180	188		
TQAQGVTS GG	SGNCRTGGTT	FYQEVTPMVN	SWGVRRLRT		Protease 10
SQAQGVTS GG	SGNC SVGGTT	YYQEVTPMIN	SWGVRIRT		Protease 18
NQAQGVTS GG	SGNCRTGGTT	FYQEVTPMVN	SWGVRRLRT		Protease 11
NQAQGVTS GG	SGNCRTGGTT	FYQEVTPMVN	SWGVRRLRT		Protease 35
SQAQGVTS GG	SGNC SFGGTT	YYQEVNPMLS	SWGLTLRT		Protease 08
160	170	180	188		

Fig. 1

Modtaget  
10 OKT. 2003  
PVS

2/26

ATOM	1	N	ALA	1	-18.517	32.531	28.661	1.00	8.90
ATOM	2	CB	ALA	1	-18.802	30.741	30.290	1.00	12.24
ATOM	3	CA	ALA	1	-19.308	31.313	28.965	1.00	10.86
ATOM	4	C	ALA	1	-20.783	31.666	29.080	1.00	12.18
ATOM	5	O	ALA	1	-21.113	32.695	29.712	1.00	12.73
ATOM	6	N	ASP	2	-21.722	30.930	28.510	1.00	12.01
ATOM	7	CA	ASP	2	-23.176	31.225	28.612	1.00	12.07
ATOM	8	C	ASP	2	-23.667	30.604	29.929	1.00	10.24
ATOM	9	O	ASP	2	-23.359	29.410	30.109	1.00	11.30
ATOM	10	CB	ASP	2	-23.995	30.629	27.422	1.00	12.43
ATOM	11	CG	ASP	2	-23.545	31.314	26.129	1.00	16.23
ATOM	12	OD1	ASP	2	-23.300	30.668	25.134	1.00	21.68
ATOM	13	OD2	ASP	2	-23.346	32.527	26.168	1.00	17.64
ATOM	14	N	ILE	3	-24.387	31.321	30.757	1.00	9.80
ATOM	15	CA	ILE	3	-24.850	30.687	32.027	1.00	8.80
ATOM	16	C	ILE	3	-26.252	30.135	31.768	1.00	7.97
ATOM	17	O	ILE	3	-27.160	30.953	31.648	1.00	8.91
ATOM	18	CB	ILE	3	-24.789	31.723	33.207	1.00	7.85
ATOM	19	CG1	ILE	3	-23.378	32.342	33.312	1.00	5.63
ATOM	20	CG2	ILE	3	-25.284	31.096	34.549	1.00	4.75
ATOM	21	CD1	ILE	3	-22.221	31.320	33.579	1.00	5.82
ATOM	22	N	ILE	4	-26.319	28.814	31.563	1.00	7.21
ATOM	23	CD1	ILE	4	-26.578	27.854	27.424	1.00	8.61
ATOM	24	CG1	ILE	4	-27.102	28.463	28.794	1.00	8.70
ATOM	25	CB	ILE	4	-27.272	27.363	29.888	1.00	7.20
ATOM	26	CG2	ILE	4	-28.446	26.419	29.544	1.00	6.35
ATOM	27	CA	ILE	4	-27.569	28.083	31.259	1.00	7.04
ATOM	28	C	ILE	4	-27.799	27.046	32.350	1.00	7.12
ATOM	29	O	ILE	4	-26.841	26.414	32.764	1.00	5.80
ATOM	30	N	GLY	5	-29.017	26.894	32.834	1.00	8.40
ATOM	31	CA	GLY	5	-29.415	25.958	33.863	1.00	5.51
ATOM	32	C	GLY	5	-29.031	24.550	33.483	1.00	6.74
ATOM	33	O	GLY	5	-29.222	24.181	32.306	1.00	8.02
ATOM	34	N	GLY	6	-28.492	23.787	34.436	1.00	5.32
ATOM	35	CA	GLY	6	-28.113	22.385	34.125	1.00	6.51
ATOM	36	C	GLY	6	-26.697	22.143	33.678	1.00	7.67
ATOM	37	O	GLY	6	-26.264	20.957	33.687	1.00	8.08
ATOM	38	N	LEU	7	-25.941	23.127	33.235	1.00	7.02
ATOM	39	CD2	LEU	7	-25.075	23.250	29.859	1.00	15.01
ATOM	40	CD1	LEU	7	-24.009	25.544	29.892	1.00	12.10
ATOM	41	CG	LEU	7	-24.823	24.494	30.662	1.00	11.57
ATOM	42	CB	LEU	7	-24.100	24.149	31.987	1.00	7.81
ATOM	43	CA	LEU	7	-24.543	22.889	32.774	1.00	7.23
ATOM	44	C	LEU	7	-23.543	22.624	33.891	1.00	8.17
ATOM	45	O	LEU	7	-23.779	23.055	35.054	1.00	8.83
ATOM	46	N	ALA	8	-22.450	21.931	33.560	1.00	7.85
ATOM	47	CB	ALA	8	-20.568	20.517	33.998	1.00	7.20
ATOM	48	CA	ALA	8	-21.436	21.658	34.583	1.00	6.67
ATOM	49	C	ALA	8	-20.554	22.867	34.856	1.00	8.14
ATOM	50	O	ALA	8	-20.241	23.793	34.058	1.00	7.62
ATOM	51	N	TYR	9	-20.078	22.906	36.110	1.00	6.90
ATOM	52	CA	TYR	9	-19.074	23.854	36.602	1.00	7.03
ATOM	53	C	TYR	9	-18.138	22.960	37.480	1.00	8.21
ATOM	54	O	TYR	9	-18.560	21.945	38.048	1.00	7.61

Fig. 2

modtaget  
10 OKT. 2003  
PVS

3/26

ATOM	55	CB	TYR	9	-19.474	25.108	37.320	1.00	7.45
ATOM	56	CG	TYR	9	-20.138	24.925	38.664	1.00	9.14
ATOM	57	CD1	TYR	9	-19.401	24.898	39.853	1.00	8.86
ATOM	58	CD2	TYR	9	-21.559	24.818	38.673	1.00	8.66
ATOM	59	CE1	TYR	9	-20.044	24.756	41.062	1.00	7.11
ATOM	60	CE2	TYR	9	-22.214	24.696	39.930	1.00	8.78
ATOM	61	C2	TYR	9	-21.438	24.673	41.072	1.00	7.41
ATOM	62	OH	TYR	9	-22.115	24.537	42.248	1.00	8.28
ATOM	63	N	THR	10	-16.867	23.367	37.552	1.00	8.23
ATOM	64	CG2	THR	10	-15.380	21.144	36.171	1.00	21.51
ATOM	65	OG1	THR	10	-14.022	22.954	36.816	1.00	17.27
ATOM	66	CB	THR	10	-14.816	21.869	37.398	1.00	15.54
ATOM	67	CA	THR	10	-15.881	22.592	38.334	1.00	12.22
ATOM	68	C	THR	10	-15.190	23.495	39.381	1.00	12.59
ATOM	69	O	THR	10	-15.040	24.724	39.295	1.00	11.83
ATOM	70	N	MET	11	-14.719	22.854	40.422	1.00	13.86
ATOM	71	CE	MET	11	-18.117	21.521	42.992	0.70	10.20
ATOM	72	SD	MET	11	-16.364	21.817	43.260	0.70	13.92
ATOM	73	CG	MET	11	-16.351	23.607	42.742	0.70	8.87
ATOM	74	CB	MET	11	-14.945	24.074	42.557	0.70	13.60
ATOM	79	CA	MET	11	-14.003	23.423	41.576	1.00	14.74
ATOM	80	C	MET	11	-13.204	22.219	42.141	1.00	16.84
ATOM	81	O	MET	11	-13.132	22.126	43.360	1.00	18.29
ATOM	82	N	GLY	12	-12.650	21.380	41.252	1.00	17.41
ATOM	83	CA	GLY	12	-11.931	20.160	41.721	1.00	20.30
ATOM	84	C	GLY	12	-12.961	19.034	41.377	1.00	22.00
ATOM	85	O	GLY	12	-12.730	18.252	40.444	1.00	25.04
ATOM	86	N	GLY	13	-14.079	19.064	42.126	1.00	17.68
ATOM	87	CA	GLY	13	-15.219	18.171	41.900	1.00	15.21
ATOM	88	C	GLY	13	-16.127	18.873	40.846	1.00	15.26
ATOM	89	O	GLY	13	-15.681	19.862	40.228	1.00	14.61
ATOM	90	N	ARG	14	-17.370	18.410	40.657	1.00	12.77
ATOM	91	NH2	ARG	14	-20.479	14.276	37.036	1.00	17.15
ATOM	92	NH1	ARG	14	-21.587	16.075	36.340	1.00	13.21
ATOM	93	CZ	ARG	14	-20.415	15.529	36.584	1.00	16.51
ATOM	94	NE	ARG	14	-19.265	16.236	36.423	1.00	15.10
ATOM	95	CD	ARG	14	-19.240	17.643	36.031	1.00	15.25
ATOM	96	CG	ARG	14	-19.255	18.517	37.291	1.00	14.76
ATOM	97	CB	ARG	14	-18.333	18.056	38.435	1.00	11.53
ATOM	98	CA	ARG	14	-18.269	19.018	39.659	1.00	11.00
ATOM	99	C	ARG	14	-19.665	19.162	40.278	1.00	9.52
ATOM	100	O	ARG	14	-20.027	18.274	41.091	1.00	8.13
ATOM	101	N	CYS	15	-20.368	20.221	39.853	1.00	8.85
ATOM	102	CA	CYS	15	-21.782	20.417	40.285	1.00	6.14
ATOM	103	C	CYS	15	-22.455	21.027	39.084	1.00	6.53
ATOM	104	O	CYS	15	-21.754	21.176	38.036	1.00	8.10
ATOM	105	CB	CYS	15	-21.897	21.271	41.568	1.00	7.27
ATOM	106	SG	CYS	15	-21.795	20.241	43.088	1.00	8.70
ATOM	107	N	SER	16	-23.746	21.368	39.154	1.00	5.13
ATOM	108	CA	SER	16	-24.402	21.936	37.975	1.00	4.73
ATOM	109	C	SER	16	-24.969	23.294	38.269	1.00	6.73
ATOM	110	O	SER	16	-25.331	23.536	39.470	1.00	7.15
ATOM	111	CB	SER	16	-25.540	20.930	37.602	1.00	5.02
ATOM	112	OG	SER	16	-25.031	19.670	37.228	1.00	7.01

Fig. 3



Modtaget  
10 OKT. 2003  
PVS

4/26

ATOM	113	N	VAL	17	-25.177	24.129	37.276	1.00	5.71
ATOM	114	CA	VAL	17	-25.780	25.469	37.450	1.00	6.30
ATOM	115	C	VAL	17	-27.274	25.365	37.742	1.00	6.27
ATOM	116	O	VAL	17	-27.904	24.514	37.084	1.00	6.87
ATOM	117	CB	VAL	17	-25.589	26.211	36.113	1.00	4.80
ATOM	118	CG1	VAL	17	-26.252	27.572	36.079	1.00	2.00
ATOM	119	CG2	VAL	17	-24.108	26.435	35.892	1.00	5.56
ATOM	120	N	GLY	18	-27.836	26.136	38.622	1.00	5.84
ATOM	121	CA	GLY	18	-29.277	26.067	38.899	1.00	4.89
ATOM	122	C	GLY	18	-29.898	27.072	37.958	1.00	7.79
ATOM	123	O	GLY	18	-30.578	26.683	36.960	1.00	8.56
ATOM	124	N	PHE	19	-29.783	28.366	38.175	1.00	6.84
ATOM	125	CA	PHE	19	-30.368	29.391	37.291	1.00	8.35
ATOM	126	C	PHE	19	-29.457	30.625	37.254	1.00	8.67
ATOM	127	O	PHE	19	-28.889	30.984	38.285	1.00	7.20
ATOM	128	CB	PHE	19	-31.761	29.873	37.827	1.00	6.74
ATOM	129	CG	PHE	19	-32.786	28.779	38.033	1.00	8.40
ATOM	130	CD1	PHE	19	-33.490	28.300	36.918	1.00	9.81
ATOM	131	CD2	PHE	19	-32.921	28.194	39.301	1.00	8.27
ATOM	132	CE1	PHE	19	-34.414	27.241	37.060	1.00	7.45
ATOM	133	CE2	PHE	19	-33.804	27.129	39.460	1.00	7.36
ATOM	134	CZ	PHE	19	-34.541	26.662	38.347	1.00	8.66
ATOM	135	N	ALA	20	-29.375	31.284	36.114	1.00	8.32
ATOM	136	CB	ALA	20	-28.552	32.954	34.501	1.00	7.08
ATOM	137	CA	ALA	20	-28.577	32.514	35.976	1.00	6.99
ATOM	138	C	ALA	20	-29.347	33.558	36.793	1.00	8.39
ATOM	139	O	ALA	20	-30.614	33.548	36.744	1.00	6.62
ATOM	140	N	ALA	21	-28.653	34.461	37.453	1.00	6.45
ATOM	141	CB	ALA	21	-29.774	34.943	39.600	1.00	6.04
ATOM	142	CA	ALA	21	-29.305	35.514	38.244	1.00	9.09
ATOM	143	C	ALA	21	-28.267	36.598	38.599	1.00	10.25
ATOM	144	O	ALA	21	-27.048	36.412	38.434	1.00	10.39
ATOM	145	N	THR	22	-28.734	37.704	39.154	1.00	10.87
ATOM	146	CA	THR	22	-27.795	38.747	39.633	1.00	9.81
ATOM	147	C	THR	22	-28.044	38.773	41.139	1.00	12.70
ATOM	148	O	THR	22	-29.153	38.378	41.607	1.00	13.28
ATOM	149	CB	THR	22	-28.009	40.191	39.000	1.00	12.32
ATOM	150	OG1	THR	22	-29.443	40.520	39.201	1.00	17.96
ATOM	151	CG2	THR	22	-27.730	40.314	37.512	1.00	10.22
ATOM	152	N	ASN	23	-27.067	39.261	41.919	1.00	12.56
ATOM	153	ND2	ASN	23	-23.651	39.789	44.187	1.00	14.15
ATOM	154	OD1	ASN	23	-25.034	41.090	43.182	1.00	11.99
ATOM	155	CG	ASN	23	-24.917	40.044	43.825	1.00	13.60
ATOM	156	CB	ASN	23	-26.025	39.065	44.153	1.00	12.41
ATOM	157	CA	ASN	23	-27.308	39.367	43.381	1.00	14.31
ATOM	158	C	ASN	23	-27.947	40.754	43.600	1.00	15.71
ATOM	159	O	ASN	23	-28.252	41.558	42.664	1.00	13.68
ATOM	160	N	ALA	24	-28.043	41.088	44.883	1.00	16.68
ATOM	161	CB	ALA	24	-28.899	42.370	46.862	1.00	19.20
ATOM	162	CA	ALA	24	-28.626	42.344	45.371	1.00	20.06
ATOM	163	C	ALA	24	-27.831	43.543	44.936	1.00	22.43
ATOM	164	O	ALA	24	-28.408	44.658	44.795	1.00	24.93
ATOM	165	N	ALA	25	-26.556	43.412	44.648	1.00	23.59
ATOM	166	CA	ALA	25	-25.727	44.513	44.128	1.00	20.79

Fig. 4

modtaget  
10 OKT. 2003  
PVS

5/26

ATOM	167	C	ALA	25	-25.765	44.542	42.613	1.00	21.34
ATOM	168	O	ALA	25	-25.018	45.388	42.040	1.00	24.26
ATOM	169	CB	ALA	25	-24.278	44.379	44.584	1.00	24.28
ATOM	170	N	GLY	26	-26.508	43.687	41.910	1.00	16.97
ATOM	171	CA	GLY	26	-26.453	43.763	40.456	1.00	15.31
ATOM	172	C	GLY	26	-25.320	43.024	39.803	1.00	13.98
ATOM	173	O	GLY	26	-25.158	43.168	38.560	1.00	15.90
ATOM	174	N	GLN	27	-24.594	42.196	40.523	1.00	13.26
ATOM	175	NE2	GLN	27	-19.688	42.607	42.319	1.00	23.84
ATOM	176	OE1	GLN	27	-21.306	41.674	43.669	1.00	19.08
ATOM	177	CD	GLN	27	-20.952	42.234	42.626	1.00	20.42
ATOM	178	CG	GLN	27	-21.934	42.487	41.519	1.00	16.87
ATOM	179	CB	GLN	27	-22.364	41.130	40.909	1.00	13.66
ATOM	180	CA	GLN	27	-23.488	41.430	39.904	1.00	11.98
ATOM	181	C	GLN	27	-24.023	40.113	39.345	1.00	11.67
ATOM	182	O	GLN	27	-24.829	39.428	39.949	1.00	11.63
ATOM	183	N	PRO	28	-23.539	39.714	38.197	1.00	10.36
ATOM	184	CG	PRO	28	-22.111	39.444	36.367	1.00	11.95
ATOM	185	CD	PRO	28	-22.544	40.519	37.403	1.00	10.61
ATOM	186	CB	PRO	28	-23.429	38.692	36.116	1.00	11.06
ATOM	187	CA	PRO	28	-23.977	38.497	37.537	1.00	9.08
ATOM	188	C	PRO	28	-23.418	37.248	38.194	1.00	9.80
ATOM	189	O	PRO	28	-22.278	37.282	38.749	1.00	9.50
ATOM	190	N	GLY	29	-24.245	36.179	38.101	1.00	6.29
ATOM	191	CA	GLY	29	-23.721	34.885	38.671	1.00	4.48
ATOM	192	C	GLY	29	-24.827	33.875	38.440	1.00	6.36
ATOM	193	O	GLY	29	-25.604	34.036	37.454	1.00	7.58
ATOM	194	N	PHE	30	-24.889	32.917	39.339	1.00	7.28
ATOM	195	CA	PHE	30	-25.971	31.891	39.292	1.00	7.77
ATOM	196	C	PHE	30	-26.232	31.306	40.703	1.00	6.83
ATOM	197	O	PHE	30	-25.281	31.334	41.532	1.00	8.49
ATOM	198	CB	PHE	30	-25.653	30.741	38.312	1.00	3.78
ATOM	199	CG	PHE	30	-24.384	29.955	38.483	1.00	5.51
ATOM	200	CD1	PHE	30	-24.299	28.836	39.311	1.00	5.54
ATOM	201	CD2	PHE	30	-23.251	30.336	37.752	1.00	8.26
ATOM	202	CE1	PHE	30	-23.126	28.108	39.451	1.00	8.21
ATOM	203	CE2	PHE	30	-21.996	29.661	37.898	1.00	6.20
ATOM	204	CZ	PHE	30	-21.971	28.509	38.739	1.00	7.61
ATOM	205	N	VAL	31	-27.413	30.739	40.862	1.00	4.85
ATOM	206	CA	VAL	31	-27.751	30.017	42.118	1.00	6.26
ATOM	207	C	VAL	31	-27.445	28.530	41.828	1.00	6.68
ATOM	208	O	VAL	31	-27.515	28.036	40.680	1.00	4.79
ATOM	209	CB	VAL	31	-29.141	30.296	42.666	1.00	7.03
ATOM	210	CG1	VAL	31	-29.230	31.765	43.136	1.00	11.46
ATOM	211	CG2	VAL	31	-30.190	29.902	41.646	1.00	8.54
ATOM	212	N	THR	32	-27.150	27.786	42.910	1.00	5.51
ATOM	213	CA	THR	32	-26.762	26.373	42.892	1.00	7.30
ATOM	214	C	THR	32	-26.833	25.866	44.356	1.00	8.85
ATOM	215	O	THR	32	-27.382	26.568	45.240	1.00	6.58
ATOM	216	CB	THR	32	-25.318	26.271	42.249	1.00	6.85
ATOM	217	OG1	THR	32	-24.927	24.904	42.030	1.00	6.22
ATOM	218	CG2	THR	32	-24.141	26.895	43.109	1.00	4.90
ATOM	219	N	ALA	33	-26.318	24.676	44.619	1.00	8.92
ATOM	220	CA	ALA	33	-26.313	24.007	45.928	1.00	9.53

Fig. 5

Modtaget  
10 OKT. 2003  
PVS

6/26

ATOM	221	C	ALA	33	-25.158	24.465	46.827	1.00	9.16
ATOM	222	O	ALA	33	-24.007	24.503	46.369	1.00	8.53
ATOM	223	CB	ALA	33	-26.294	22.473	45.773	1.00	7.77
ATOM	224	N	GLY	34	-25.408	24.724	48.076	1.00	7.16
ATOM	225	CA	GLY	34	-24.348	25.143	49.024	1.00	8.05
ATOM	226	C	GLY	34	-23.390	24.043	49.347	1.00	7.39
ATOM	227	O	GLY	34	-22.194	24.315	49.698	1.00	8.30
ATOM	228	N	HIS	35	-23.788	22.780	49.271	1.00	7.52
ATOM	229	CA	HIS	35	-22.821	21.714	49.636	1.00	6.58
ATOM	230	C	HIS	35	-21.744	21.601	48.560	1.00	8.95
ATOM	231	O	HIS	35	-20.702	20.945	48.747	1.00	8.96
ATOM	232	CB	HIS	35	-23.497	20.364	49.883	1.00	8.85
ATOM	233	CG	HIS	35	-23.991	19.599	48.686	1.00	6.87
ATOM	234	ND1	HIS	35	-25.305	19.481	48.321	1.00	8.56
ATOM	235	CD2	HIS	35	-23.326	18.872	47.769	1.00	5.55
ATOM	236	CE1	HIS	35	-25.414	18.744	47.228	1.00	7.54
ATOM	237	NE2	HIS	35	-24.217	18.313	46.906	1.00	8.64
ATOM	238	N	CYS	36	-21.930	22.183	47.376	1.00	8.15
ATOM	239	CA	CYS	36	-20.940	22.145	46.312	1.00	8.05
ATOM	240	C	CYS	36	-19.746	23.062	46.679	1.00	11.13
ATOM	241	O	CYS	36	-18.715	22.841	45.999	1.00	10.34
ATOM	242	CB	CYS	36	-21.518	22.598	44.977	1.00	5.97
ATOM	243	SG	CYS	36	-22.774	21.389	44.403	1.00	9.16
ATOM	244	N	GLY	37	-19.855	24.012	47.601	1.00	9.60
ATOM	245	CA	GLY	37	-18.632	24.821	47.862	1.00	8.52
ATOM	246	C	GLY	37	-18.853	25.793	48.998	1.00	11.72
ATOM	247	O	GLY	37	-19.923	26.350	49.153	1.00	12.57
ATOM	248	N	ARG	38	-17.807	26.044	49.767	1.00	9.44
ATOM	249	NH2	ARG	38	-13.066	27.478	54.730	0.00	41.69
ATOM	250	NH1	ARG	38	-14.258	25.862	55.765	0.00	42.03
ATOM	251	CZ	ARG	38	-13.968	26.494	54.619	0.00	41.38
ATOM	252	NE	ARG	38	-14.559	26.142	53.467	0.00	39.87
ATOM	253	CD	ARG	38	-15.763	25.165	53.320	0.00	37.50
ATOM	254	CG	ARG	38	-17.064	25.666	52.814	1.00	23.13
ATOM	255	CB	ARG	38	-16.602	26.727	51.799	1.00	14.90
ATOM	256	CA	ARG	38	-17.812	27.040	50.845	1.00	12.65
ATOM	257	C	ARG	38	-17.566	28.415	50.239	1.00	11.84
ATOM	258	O	ARG	38	-16.987	28.562	49.137	1.00	10.80
ATOM	259	N	VAL	39	-17.953	29.488	50.953	1.00	12.22
ATOM	260	CA	VAL	39	-17.723	30.881	50.483	1.00	11.55
ATOM	261	C	VAL	39	-16.224	31.002	50.149	1.00	11.46
ATOM	262	O	VAL	39	-15.406	30.540	50.944	1.00	12.65
ATOM	263	CB	VAL	39	-18.195	31.902	51.513	1.00	14.37
ATOM	264	CG1	VAL	39	-17.541	33.262	51.282	1.00	18.26
ATOM	265	CG2	VAL	39	-19.720	32.035	51.617	1.00	19.01
ATOM	266	N	GLY	40	-15.853	31.595	49.017	1.00	10.59
ATOM	267	CA	GLY	40	-14.467	31.715	48.658	1.00	9.21
ATOM	268	C	GLY	40	-13.962	30.690	47.689	1.00	11.61
ATOM	269	O	GLY	40	-12.904	30.954	47.066	1.00	13.99
ATOM	270	N	THR	41	-14.603	29.592	47.441	1.00	10.26
ATOM	271	CG2	THR	41	-14.886	26.180	45.550	1.00	8.90
ATOM	272	OG1	THR	41	-15.058	26.792	47.930	1.00	14.49
ATOM	273	CB	THR	41	-15.123	27.285	46.571	1.00	12.41
ATOM	274	CA	THR	41	-14.199	28.566	46.525	1.00	9.98

Fig. 6

Modtaget  
10 OKT. 2003  
PVS

7/26

ATOM	275	C	THR	41	-14.360	29.148	45.121	1.00	11.13
ATOM	276	O	THR	41	-15.404	29.657	44.713	1.00	10.17
ATOM	277	N	GLN	42	-13.297	28.983	44.365	1.00	12.36
ATOM	278	NE2	GLN	42	-11.317	32.840	43.178	0.70	32.68
ATOM	279	OE1	GLN	42	-9.407	31.714	42.552	0.70	35.48
ATOM	280	CD	GLN	42	-10.512	31.791	43.080	0.70	30.29
ATOM	281	CG	GLN	42	-11.132	30.558	43.680	0.70	24.69
ATOM	282	CB	GLN	42	-11.801	29.729	42.592	0.70	18.80
ATOM	288	CA	GLN	42	-13.263	29.456	42.977	1.00	11.77
ATOM	289	C	GLN	42	-13.852	28.392	42.063	1.00	13.86
ATOM	290	O	GLN	42	-13.615	27.187	42.330	1.00	12.07
ATOM	291	N	VAL	43	-14.544	28.817	41.002	1.00	13.96
ATOM	292	CG2	VAL	43	-17.397	28.751	39.309	1.00	15.91
ATOM	293	CG1	VAL	43	-17.192	27.656	41.542	1.00	10.29
ATOM	294	CB	VAL	43	-16.657	27.731	40.117	1.00	14.08
ATOM	295	CA	VAL	43	-15.132	27.886	40.018	1.00	11.05
ATOM	296	C	VAL	43	-14.717	28.297	38.584	1.00	10.70
ATOM	297	O	VAL	43	-14.393	29.467	38.214	1.00	8.75
ATOM	298	N	THR	44	-14.726	27.266	37.757	1.00	8.19
ATOM	299	CG2	THR	44	-13.085	26.655	34.277	1.00	16.80
ATOM	300	OG1	THR	44	-12.054	27.080	36.423	1.00	14.72
ATOM	301	CB	THR	44	-13.232	26.536	35.773	1.00	7.96
ATOM	302	CA	THR	44	-14.459	27.387	36.328	1.00	8.95
ATOM	303	C	THR	44	-15.708	26.877	35.588	1.00	10.78
ATOM	304	O	THR	44	-16.155	25.743	35.947	1.00	9.00
ATOM	305	N	ILE	45	-16.219	27.660	34.626	1.00	10.77
ATOM	306	CA	ILE	45	-17.352	27.175	33.850	1.00	11.78
ATOM	307	C	ILE	45	-16.950	27.476	32.396	1.00	10.56
ATOM	308	O	ILE	45	-16.976	28.673	32.030	1.00	10.62
ATOM	309	CB	ILE	45	-18.743	27.767	34.312	1.00	8.73
ATOM	310	CG1	ILE	45	-19.767	27.359	33.217	1.00	14.25
ATOM	311	CG2	ILE	45	-18.635	29.300	34.483	1.00	14.91
ATOM	312	CD1	ILE	45	-21.239	27.351	33.717	1.00	17.74
ATOM	313	N	GLY	46	-16.588	26.493	31.623	1.00	11.49
ATOM	314	CA	GLY	46	-16.162	26.796	30.214	1.00	13.72
ATOM	315	C	GLY	46	-15.009	27.812	30.282	1.00	12.34
ATOM	316	O	GLY	46	-14.011	27.661	31.002	1.00	14.15
ATOM	317	N	ASN	47	-15.134	28.895	29.512	1.00	13.14
ATOM	318	ND2	ASN	47	-15.075	31.342	26.221	1.00	26.89
ATOM	319	OD1	ASN	47	-16.257	31.266	28.086	1.00	18.12
ATOM	320	CG	ASN	47	-15.180	31.045	27.520	1.00	19.67
ATOM	321	CB	ASN	47	-13.914	30.476	28.081	1.00	17.20
ATOM	322	CA	ASN	47	-14.106	29.967	29.522	1.00	14.86
ATOM	323	C	ASN	47	-14.409	31.129	30.484	1.00	14.20
ATOM	324	O	ASN	47	-13.929	32.264	30.367	1.00	16.69
ATOM	325	N	GLY	48	-15.234	30.900	31.476	1.00	11.79
ATOM	326	CA	GLY	48	-15.629	31.860	32.487	1.00	10.60
ATOM	327	C	GLY	48	-15.114	31.350	33.840	1.00	8.68
ATOM	328	O	GLY	48	-14.741	30.180	34.021	1.00	8.85
ATOM	329	N	ARG	49	-15.067	32.286	34.782	1.00	8.71
ATOM	330	NH2	ARG	49	-10.753	29.684	38.714	0.00	43.61
ATOM	331	NH1	ARG	49	-9.430	30.717	37.086	0.00	39.51
ATOM	332	CZ	ARG	49	-10.647	30.223	37.466	0.00	42.12
ATOM	333	NE	ARG	49	-11.803	30.174	36.714	0.00	38.98

Fig. 7

Modtaget  
10 OKT. 2003  
PVS

8/26

ATOM	334	CD	ARG	49	-11.625	30.774	35.625	1.00	24.44
ATOM	335	CG	ARG	49	-12.079	32.161	35.395	1.00	20.17
ATOM	336	CB	ARG	49	-13.190	32.537	36.355	1.00	13.15
ATOM	337	CA	ARG	49	-14.600	31.985	36.143	1.00	8.87
ATOM	338	C	ARG	49	-15.485	32.746	37.136	1.00	9.56
ATOM	339	O	ARG	49	-16.026	33.814	36.747	1.00	10.73
ATOM	340	N	GLY	50	-15.644	32.236	38.337	1.00	10.04
ATOM	341	CA	GLY	50	-16.416	32.933	39.372	1.00	6.68
ATOM	342	C	GLY	50	-15.985	32.438	40.758	1.00	7.46
ATOM	343	O	GLY	50	-15.035	31.654	40.838	1.00	8.57
ATOM	344	N	VAL	51	-16.755	32.885	41.756	1.00	9.13
ATOM	345	CG2	VAL	51	-15.047	33.181	45.219	1.00	9.31
ATOM	346	CG1	VAL	51	-16.041	34.936	43.760	1.00	9.54
ATOM	347	CB	VAL	51	-15.469	33.510	43.768	1.00	10.40
ATOM	348	CA	VAL	51	-16.439	32.474	43.145	1.00	8.97
ATOM	349	C	VAL	51	-17.739	32.363	43.951	1.00	8.46
ATOM	350	O	VAL	51	-18.657	33.166	43.726	1.00	8.01
ATOM	351	N	PHE	52	-17.778	31.394	44.846	1.00	7.71
ATOM	352	CD2	PHE	52	-20.510	28.198	46.287	1.00	7.34
ATOM	353	CE2	PHE	52	-20.952	27.038	45.614	1.00	12.48
ATOM	354	CZ	PHE	52	-20.103	26.415	44.672	1.00	11.92
ATOM	355	CE1	PHE	52	-18.857	26.983	44.355	1.00	8.56
ATOM	356	CD1	PHE	52	-18.454	28.151	45.012	1.00	7.30
ATOM	357	CG	PHE	52	-19.269	28.765	45.964	1.00	10.46
ATOM	358	CB	PHE	52	-18.820	30.015	46.703	1.00	9.22
ATOM	359	CA	PHE	52	-18.916	31.237	45.766	1.00	9.28
ATOM	360	C	PHE	52	-18.928	32.498	46.637	1.00	10.41
ATOM	361	O	PHE	52	-17.979	32.752	47.403	1.00	10.33
ATOM	362	N	GLU	53	-20.038	33.239	46.481	1.00	8.81
ATOM	363	OE2	GLU	53	-22.012	37.756	45.426	1.00	27.06
ATOM	364	OE1	GLU	53	-21.229	39.265	46.722	1.00	33.78
ATOM	365	CD	GLU	53	-21.338	38.087	46.413	1.00	28.63
ATOM	366	CG	GLU	53	-20.701	36.961	47.162	1.00	15.08
ATOM	367	CB	GLU	53	-20.818	35.612	46.441	1.00	10.91
ATOM	368	CA	GLU	53	-20.172	34.475	47.239	1.00	10.55
ATOM	369	C	GLU	53	-21.035	34.208	48.485	1.00	13.01
ATOM	370	O	GLU	53	-20.664	34.743	49.558	1.00	14.89
ATOM	371	N	GLN	54	-22.095	33.444	48.352	1.00	9.12
ATOM	372	NE2	GLN	54	-26.256	36.329	49.251	1.00	43.84
ATOM	373	OE1	GLN	54	-25.933	35.594	51.419	1.00	46.53
ATOM	374	CD	GLN	54	-25.586	35.741	50.241	1.00	40.72
ATOM	375	CG	GLN	54	-24.256	35.205	49.756	1.00	29.81
ATOM	376	CB	GLN	54	-24.346	33.707	49.555	1.00	17.82
ATOM	377	CA	GLN	54	-22.955	33.105	49.508	1.00	10.81
ATOM	378	C	GLN	54	-23.164	31.600	49.527	1.00	12.82
ATOM	379	O	GLN	54	-23.418	31.101	48.410	1.00	13.75
ATOM	380	N	SER	55	-23.074	30.926	50.665	1.00	10.56
ATOM	381	OG	SER	55	-22.169	27.372	50.204	1.00	14.02
ATOM	382	CB	SER	55	-21.995	28.781	50.228	1.00	9.88
ATOM	383	CA	SER	55	-23.280	29.470	50.637	1.00	11.20
ATOM	384	C	SER	55	-23.730	28.998	52.014	1.00	12.70
ATOM	385	O	SER	55	-23.084	29.298	53.011	1.00	11.84
ATOM	386	N	VAL	56	-24.824	28.274	52.086	1.00	11.38
ATOM	387	CA	VAL	56	-25.345	27.735	53.342	1.00	9.56

Fig. 8

Modtaget  
10 OKT. 2003  
PVS

9/26

ATOM	388	C	VAL	56	-25.516	26.223	53.218	1.00	11.47
ATOM	389	O	VAL	56	-26.250	25.756	52.302	1.00	10.80
ATOM	390	CB	VAL	56	-26.691	28.365	53.715	1.00	12.57
ATOM	391	CG1	VAL	56	-27.250	27.561	54.895	1.00	13.65
ATOM	392	CG2	VAL	56	-26.542	29.809	54.111	1.00	14.61
ATOM	393	N	PHE	57	-24.903	25.475	54.116	1.00	9.44
ATOM	394	CA	PHE	57	-25.035	24.030	54.173	1.00	10.86
ATOM	395	C	PHE	57	-24.351	23.597	55.503	1.00	12.68
ATOM	396	O	PHE	57	-23.200	24.057	55.632	1.00	14.31
ATOM	397	CB	PHE	57	-24.383	23.289	52.962	1.00	9.20
ATOM	398	CG	PHE	57	-24.530	21.797	53.071	1.00	7.41
ATOM	399	CD1	PHE	57	-23.489	20.999	53.547	1.00	10.87
ATOM	400	CD2	PHE	57	-25.748	21.211	52.762	1.00	10.76
ATOM	401	CE1	PHE	57	-23.654	19.621	53.690	1.00	16.75
ATOM	402	CE2	PHE	57	-25.948	19.851	52.869	1.00	9.80
ATOM	403	CZ	PHE	57	-24.897	19.033	53.326	1.00	17.07
ATOM	404	N	PRO	58	-24.888	22.759	56.355	1.00	11.76
ATOM	405	CA	PRO	58	-26.182	22.082	56.294	1.00	11.15
ATOM	406	C	PRO	58	-27.302	22.967	56.755	1.00	9.63
ATOM	407	O	PRO	58	-27.072	24.207	56.657	1.00	10.82
ATOM	408	CB	PRO	58	-25.955	20.768	57.043	1.00	11.03
ATOM	409	CG	PRO	58	-24.947	21.178	58.078	1.00	12.71
ATOM	410	CD	PRO	58	-24.125	22.322	57.531	1.00	12.73
ATOM	411	N	GLY	59	-28.466	22.432	57.103	1.00	10.97
ATOM	412	CA	GLY	59	-29.594	23.338	57.495	1.00	11.26
ATOM	413	C	GLY	59	-30.330	23.680	56.200	1.00	10.98
ATOM	414	O	GLY	59	-31.477	23.240	56.091	1.00	11.30
ATOM	415	N	ASN	60	-29.767	24.482	55.291	1.00	10.66
ATOM	416	CA	ASN	60	-30.400	24.729	53.962	1.00	8.17
ATOM	417	C	ASN	60	-29.377	24.099	52.981	1.00	9.56
ATOM	418	O	ASN	60	-28.346	23.532	53.474	1.00	8.76
ATOM	419	CB	ASN	60	-30.598	26.175	53.595	1.00	9.50
ATOM	420	CG	ASN	60	-31.369	26.934	54.664	1.00	12.19
ATOM	421	OD1	ASN	60	-30.872	27.984	55.082	1.00	16.81
ATOM	422	ND2	ASN	60	-32.478	26.340	55.060	1.00	15.11
ATOM	423	N	ASP	61	-29.582	24.193	51.661	1.00	7.15
ATOM	424	CA	ASP	61	-28.544	23.661	50.701	1.00	7.83
ATOM	425	C	ASP	61	-28.598	24.692	49.547	1.00	8.69
ATOM	426	O	ASP	61	-29.213	24.393	48.519	1.00	7.71
ATOM	427	CB	ASP	61	-28.818	22.216	50.313	1.00	4.48
ATOM	428	CG	ASP	61	-27.637	21.575	49.640	1.00	6.18
ATOM	429	OD1	ASP	61	-27.591	20.419	49.245	1.00	6.86
ATOM	430	OD2	ASP	61	-26.622	22.316	49.431	1.00	8.20
ATOM	431	N	ALA	62	-28.041	25.868	49.751	1.00	7.72
ATOM	432	CB	ALA	62	-29.258	27.857	49.385	1.00	8.64
ATOM	433	CA	ALA	62	-28.134	26.967	48.775	1.00	8.98
ATOM	434	C	ALA	62	-26.880	27.802	48.618	1.00	9.19
ATOM	435	O	ALA	62	-26.114	27.939	49.618	1.00	10.25
ATOM	436	N	ALA	63	-26.667	28.360	47.434	1.00	7.69
ATOM	437	CA	ALA	63	-25.476	29.189	47.173	1.00	7.50
ATOM	438	C	ALA	63	-25.668	30.110	45.987	1.00	7.33
ATOM	439	O	ALA	63	-26.526	29.843	45.116	1.00	6.36
ATOM	440	CB	ALA	63	-24.247	28.263	46.886	1.00	4.57
ATOM	441	N	PHE	64	-24.889	31.172	45.985	1.00	8.23

Fig. 9

Modtaget  
10 OKT. 2003  
PVS

10/26

ATOM	442	CD2	PHE	64	-24.221	35.364	43.942	1.00	6.73
ATOM	443	CE2	PHE	64	-24.051	36.237	42.841	1.00	7.23
ATOM	444	CZ	PHE	64	-25.063	36.205	41.842	1.00	6.08
ATOM	445	CE1	PHE	64	-26.166	35.352	41.959	1.00	10.30
ATOM	446	CD1	PHE	64	-26.263	34.453	43.038	1.00	10.04
ATOM	447	CG	PHE	64	-25.287	34.477	44.027	1.00	6.69
ATOM	448	CB	PHE	64	-25.415	33.537	45.240	1.00	6.42
ATOM	449	CA	PHE	64	-24.840	32.152	44.922	1.00	7.87
ATOM	450	C	PHE	64	-23.351	32.196	44.518	1.00	10.06
ATOM	451	O	PHE	64	-22.454	32.478	45.362	1.00	10.39
ATOM	452	N	VAL	65	-23.080	31.952	43.234	1.00	8.61
ATOM	453	CA	VAL	65	-21.722	32.028	42.662	1.00	8.62
ATOM	454	C	VAL	65	-21.686	33.327	41.831	1.00	8.89
ATOM	455	O	VAL	65	-22.514	33.548	40.948	1.00	7.44
ATOM	456	CB	VAL	65	-21.338	30.840	41.722	1.00	11.34
ATOM	457	CG1	VAL	65	-20.018	31.055	40.967	1.00	10.37
ATOM	458	CG2	VAL	65	-21.333	29.530	42.493	1.00	9.94
ATOM	459	N	ARG	66	-20.744	34.213	42.094	1.00	6.55
ATOM	460	NH2	ARG	66	-16.111	39.098	43.470	1.00	18.29
ATOM	461	NH1	ARG	66	-17.309	39.979	41.747	1.00	18.67
ATOM	462	CZ	ARG	66	-17.271	39.260	42.832	1.00	18.74
ATOM	463	NE	ARG	66	-18.308	38.673	43.409	1.00	22.97
ATOM	464	CD	ARG	66	-19.672	38.751	42.950	1.00	23.13
ATOM	465	CG	ARG	66	-19.916	37.827	41.797	1.00	18.33
ATOM	466	CB	ARG	66	-19.949	36.464	42.422	1.00	12.11
ATOM	467	CA	ARG	66	-20.545	35.475	41.416	1.00	8.00
ATOM	468	C	ARG	66	-19.501	35.310	40.305	1.00	7.85
ATOM	469	O	ARG	66	-18.447	34.738	40.557	1.00	8.51
ATOM	470	N	GLY	67	-19.828	35.857	39.132	1.00	8.23
ATOM	471	CA	GLY	67	-18.921	35.779	37.962	1.00	3.28
ATOM	472	C	GLY	67	-17.838	36.834	38.114	1.00	7.11
ATOM	473	O	GLY	67	-18.123	38.019	38.332	1.00	9.23
ATOM	474	N	THR	68	-16.585	36.418	37.933	1.00	6.19
ATOM	475	CA	THR	68	-15.407	37.292	37.994	1.00	6.13
ATOM	476	C	THR	68	-14.784	37.468	36.611	1.00	10.55
ATOM	477	O	THR	68	-13.939	38.358	36.375	1.00	9.20
ATOM	478	CB	THR	68	-14.366	36.832	39.071	1.00	13.02
ATOM	479	OG1	THR	68	-13.865	35.569	38.579	1.00	9.29
ATOM	480	CG2	THR	68	-14.870	36.773	40.522	1.00	11.87
ATOM	481	N	SER	69	-15.205	36.672	35.618	1.00	12.02
ATOM	482	CA	SER	69	-14.736	36.796	34.233	1.00	11.62
ATOM	483	C	SER	69	-15.660	36.069	33.264	1.00	12.37
ATOM	484	O	SER	69	-15.911	34.865	33.480	1.00	11.23
ATOM	485	CB	SER	69	-13.337	36.184	34.027	1.00	12.32
ATOM	486	OG	SER	69	-12.823	36.389	32.763	1.00	15.07
ATOM	487	N	ASN	70	-16.100	36.767	32.236	1.00	12.58
ATOM	488	ND2	ASN	70	-16.685	36.201	28.330	1.00	20.03
ATOM	489	OD1	ASN	70	-15.425	34.370	28.194	1.00	19.07
ATOM	490	CG	ASN	70	-15.954	35.243	28.878	1.00	14.54
ATOM	491	CB	ASN	70	-15.848	35.335	30.379	1.00	8.27
ATOM	492	CA	ASN	70	-16.894	36.195	31.131	1.00	11.17
ATOM	493	C	ASN	70	-18.166	35.424	31.400	1.00	10.53
ATOM	494	O	ASN	70	-18.343	34.319	30.817	1.00	14.17
ATOM	495	N	PHE	71	-19.048	35.946	32.209	1.00	8.98

Fig. 10

Modtaget  
10 OKT. 2003  
PVS

11/26

ATOM	496	CD2	PHE	71	-21.139	34.054	36.002	1.00	5.72
ATOM	497	CE2	PHE	71	-20.735	33.063	36.900	1.00	7.44
ATOM	498	CZ	PHE	71	-19.483	32.395	36.669	1.00	10.35
ATOM	499	CE1	PHE	71	-18.713	32.681	35.550	1.00	10.41
ATOM	500	CD1	PHE	71	-19.159	33.681	34.652	1.00	9.67
ATOM	501	CG	PHE	71	-20.350	34.372	34.873	1.00	5.76
ATOM	502	CB	PHE	71	-20.839	35.417	33.897	1.00	7.11
ATOM	503	CA	PHE	71	-20.346	35.257	32.435	1.00	10.26
ATOM	504	C	PHE	71	-21.337	35.958	31.503	1.00	11.61
ATOM	505	O	PHE	71	-21.429	37.207	31.537	1.00	14.68
ATOM	506	N	THR	72	-22.071	35.275	30.691	1.00	11.03
ATOM	507	CA	THR	72	-23.133	35.902	29.860	1.00	9.26
ATOM	508	C	THR	72	-24.405	35.261	30.425	1.00	9.51
ATOM	509	O	THR	72	-24.562	34.027	30.269	1.00	11.35
ATOM	510	CB	THR	72	-23.036	35.596	28.328	1.00	15.61
ATOM	511	OG1	THR	72	-21.768	36.189	27.928	1.00	15.86
ATOM	512	CG2	THR	72	-24.177	36.178	27.494	1.00	14.54
ATOM	513	N	LEU	73	-25.282	36.028	31.020	1.00	11.12
ATOM	514	CA	LEU	73	-26.502	35.479	31.608	1.00	9.31
ATOM	515	C	LEU	73	-27.504	35.184	30.484	1.00	9.04
ATOM	516	O	LEU	73	-27.563	35.896	29.460	1.00	8.44
ATOM	517	CB	LEU	73	-27.046	36.412	32.687	1.00	8.84
ATOM	518	CG	LEU	73	-26.215	36.869	33.883	1.00	13.85
ATOM	519	CD1	LEU	73	-27.074	37.521	34.968	1.00	12.85
ATOM	520	CD2	LEU	73	-25.471	35.702	34.530	1.00	9.85
ATOM	521	N	THR	74	-28.295	34.161	30.737	1.00	7.42
ATOM	522	CG2	THR	74	-27.696	32.554	28.200	1.00	13.40
ATOM	523	OG1	THR	74	-29.174	31.283	29.642	1.00	9.42
ATOM	524	CB	THR	74	-29.063	32.532	28.922	1.00	7.73
ATOM	525	CA	THR	74	-29.389	33.735	29.859	1.00	7.40
ATOM	526	C	THR	74	-30.600	33.347	30.732	1.00	10.05
ATOM	527	O	THR	74	-30.473	33.184	31.959	1.00	7.44
ATOM	528	N	ASN	75	-31.775	33.201	30.069	1.00	8.53
ATOM	529	ND2	ASN	75	-36.021	33.747	28.974	1.00	14.07
ATOM	530	OD1	ASN	75	-33.929	33.279	28.252	1.00	14.16
ATOM	531	CG	ASN	75	-34.723	33.526	29.157	1.00	15.69
ATOM	532	CB	ASN	75	-34.178	33.518	30.570	1.00	11.17
ATOM	533	CA	ASN	75	-32.924	32.729	30.849	1.00	9.39
ATOM	534	C	ASN	75	-33.156	31.252	30.465	1.00	10.95
ATOM	535	O	ASN	75	-34.322	30.835	30.620	1.00	13.03
ATOM	536	N	LEU	76	-32.177	30.516	29.993	1.00	7.99
ATOM	537	CD2	LEU	76	-32.993	29.592	26.412	1.00	11.04
ATOM	538	CD1	LEU	76	-30.530	29.917	26.112	1.00	13.41
ATOM	539	CG	LEU	76	-31.687	29.987	27.082	1.00	11.12
ATOM	540	CB	LEU	76	-31.416	29.013	28.250	1.00	10.63
ATOM	541	CA	LEU	76	-32.315	29.158	29.530	1.00	8.79
ATOM	542	C	LEU	76	-31.876	28.059	30.512	1.00	8.97
ATOM	543	O	LEU	76	-31.038	28.290	31.385	1.00	6.01
ATOM	544	N	VAL	77	-32.529	26.936	30.323	1.00	8.54
ATOM	545	CA	VAL	77	-32.285	25.689	31.062	1.00	8.05
ATOM	546	C	VAL	77	-32.125	24.578	29.973	1.00	9.00
ATOM	547	O	VAL	77	-33.126	24.380	29.178	1.00	6.78
ATOM	548	CB	VAL	77	-33.397	25.290	32.052	1.00	8.09
ATOM	549	CG1	VAL	77	-33.049	23.911	32.715	1.00	5.84

Fig. 11



Modtaget  
10 OKT. 2003  
PVS

12/26

ATOM	550	CG2	VAL	77	-33.575	26.350	33.142	1.00	10.07
ATOM	551	N	SER	78	-31.017	23.871	29.974	1.00	8.67
ATOM	552	OG	SER	78	-29.161	21.344	27.899	1.00	9.85
ATOM	553	CB	SER	78	-29.355	22.409	28.857	1.00	12.29
ATOM	554	CA	SER	78	-30.831	22.814	28.929	1.00	8.23
ATOM	555	C	SER	78	-31.710	21.583	29.189	1.00	9.82
ATOM	556	O	SER	78	-31.759	21.055	30.305	1.00	7.69
ATOM	557	N	ARG	79	-32.337	21.082	28.116	1.00	9.80
ATOM	558	NH2	ARG	79	-37.443	22.028	24.212	1.00	31.34
ATOM	559	NH1	ARG	79	-38.500	22.780	26.184	1.00	27.56
ATOM	560	CZ	ARG	79	-37.601	21.991	25.554	1.00	28.07
ATOM	561	NE	ARG	79	-36.785	21.131	26.161	1.00	21.89
ATOM	562	CD	ARG	79	-36.718	20.936	27.589	1.00	18.78
ATOM	563	CG	ARG	79	-35.265	21.118	27.992	1.00	9.14
ATOM	564	CB	ARG	79	-34.499	19.957	27.396	1.00	7.07
ATOM	565	CA	ARG	79	-33.163	19.879	28.166	1.00	10.01
ATOM	566	C	ARG	79	-32.272	18.740	27.659	1.00	11.09
ATOM	567	O	ARG	79	-32.799	17.622	27.476	1.00	11.76
ATOM	568	N	TYR	80	-30.980	18.901	27.456	1.00	10.89
ATOM	569	OH	TYR	80	-25.669	19.608	31.411	1.00	13.70
ATOM	570	CD2	TYR	80	-28.969	18.626	30.175	1.00	8.55
ATOM	571	CE2	TYR	80	-28.018	19.277	30.962	1.00	9.07
ATOM	572	CZ	TYR	80	-26.667	19.006	30.683	1.00	13.15
ATOM	573	CE1	TYR	80	-26.290	18.103	29.673	1.00	13.12
ATOM	574	CD1	TYR	80	-27.305	17.481	28.921	1.00	12.00
ATOM	575	CG	TYR	80	-28.646	17.742	29.153	1.00	10.87
ATOM	576	CB	TYR	80	-29.686	17.010	28.331	1.00	11.71
ATOM	577	CA	TYR	80	-30.100	17.809	27.036	1.00	13.19
ATOM	578	C	TYR	80	-30.669	16.889	25.939	1.00	15.57
ATOM	579	O	TYR	80	-31.074	17.414	24.848	1.00	16.53
ATOM	580	N	ASN	81	-30.732	15.583	26.157	1.00	15.67
ATOM	581	ND2	ASN	81	-30.251	12.075	23.672	0.50	23.42
ATOM	582	OD1	ASN	81	-31.653	10.851	24.930	0.50	22.68
ATOM	583	CG	ASN	81	-31.012	11.924	24.769	0.50	24.69
ATOM	584	CB	ASN	81	-30.915	13.117	25.699	0.50	20.33
ATOM	589	CA	ASN	81	-31.169	14.536	25.163	1.00	17.67
ATOM	590	C	ASN	81	-32.611	14.689	24.807	1.00	18.70
ATOM	591	O	ASN	81	-33.067	14.207	23.731	1.00	20.41
ATOM	592	N	THR	82	-33.405	15.385	25.621	1.00	15.25
ATOM	593	CG2	THR	82	-36.933	16.845	26.136	1.00	15.50
ATOM	594	OG1	THR	82	-35.944	14.838	27.235	1.00	15.80
ATOM	595	CB	THR	82	-35.663	16.070	26.495	1.00	13.76
ATOM	596	CA	THR	82	-34.787	15.661	25.275	1.00	16.61
ATOM	597	C	THR	82	-34.775	16.712	24.128	1.00	19.57
ATOM	598	O	THR	82	-35.725	16.765	23.314	1.00	20.18
ATOM	599	N	GLY	83	-33.765	17.555	23.973	1.00	17.44
ATOM	600	CA	GLY	83	-33.611	18.551	22.941	1.00	16.21
ATOM	601	C	GLY	83	-34.082	19.964	23.286	1.00	12.64
ATOM	602	O	GLY	83	-35.127	20.225	23.908	1.00	12.83
ATOM	603	N	GLY	84	-33.281	20.926	22.859	1.00	11.84
ATOM	604	CA	GLY	84	-33.604	22.331	23.082	1.00	11.09
ATOM	605	C	GLY	84	-33.492	22.741	24.541	1.00	9.78
ATOM	606	O	GLY	84	-32.796	22.177	25.384	1.00	10.83
ATOM	607	N	TYR	85	-34.104	23.875	24.825	1.00	10.88

Fig. 12

Modtaget  
10 OKT. 2003  
PVS

13/26

ATOM	608	OH	TYR	85	-28.004	24.555	24.203	1.00	18.98
ATOM	609	CD2	TYR	85	-31.561	25.395	24.068	1.00	12.07
ATOM	610	CE2	TYR	85	-30.266	25.023	23.693	1.00	13.73
ATOM	611	CZ	TYR	85	-29.263	24.890	24.644	1.00	15.05
ATOM	612	CE1	TYR	85	-29.519	25.081	26.012	1.00	12.94
ATOM	613	CD1	TYR	85	-30.826	25.421	26.395	1.00	12.96
ATOM	614	CG	TYR	85	-31.850	25.570	25.445	1.00	11.64
ATOM	615	CB	TYR	85	-33.264	25.866	25.882	1.00	10.50
ATOM	616	CA	TYR	85	-34.079	24.539	26.116	1.00	10.86
ATOM	617	C	TYR	85	-35.418	25.002	26.674	1.00	13.82
ATOM	618	O	TYR	85	-36.268	25.491	25.854	1.00	14.41
ATOM	619	N	ALA	86	-35.569	24.891	27.969	1.00	19.86
ATOM	620	CB	ALA	86	-37.046	24.630	29.971	1.00	19.75
ATOM	621	CA	ALA	86	-36.735	25.425	28.695	1.00	11.67
ATOM	622	C	ALA	86	-36.361	26.918	28.958	1.00	11.87
ATOM	623	O	ALA	86	-35.188	27.341	28.972	1.00	19.92
ATOM	624	N	THR	87	-37.345	27.829	29.131	1.00	10.43
ATOM	625	CG2	THR	87	-36.841	29.875	26.861	1.00	17.11
ATOM	626	OG1	THR	87	-38.959	29.934	28.083	1.00	17.19
ATOM	627	CB	THR	87	-37.539	30.174	28.200	1.00	17.24
ATOM	628	CA	THR	87	-37.057	29.241	29.379	1.00	10.64
ATOM	629	C	THR	87	-37.640	29.593	30.724	1.00	11.34
ATOM	630	O	THR	87	-38.696	29.055	31.041	1.00	13.09
ATOM	631	N	VAL	88	-37.001	30.448	31.521	1.00	10.66
ATOM	632	CA	VAL	88	-37.441	30.863	32.856	1.00	9.45
ATOM	633	C	VAL	88	-38.255	32.155	32.696	1.00	11.88
ATOM	634	O	VAL	88	-37.698	33.094	32.136	1.00	10.63
ATOM	635	CB	VAL	88	-36.246	31.053	33.821	1.00	7.00
ATOM	636	CG1	VAL	88	-36.652	31.636	35.192	1.00	5.32
ATOM	637	CG2	VAL	88	-35.478	29.746	33.985	1.00	9.05
ATOM	638	N	ALA	89	-39.467	32.233	33.201	1.00	10.89
ATOM	639	CB	ALA	89	-41.539	33.201	32.260	1.00	9.11
ATOM	640	CA	ALA	89	-40.325	33.440	33.132	1.00	11.01
ATOM	641	C	ALA	89	-40.690	33.918	34.548	1.00	11.13
ATOM	642	O	ALA	89	-41.242	35.028	34.655	1.00	11.90
ATOM	643	N	GLY	90	-40.351	33.181	35.617	1.00	9.54
ATOM	644	CA	GLY	90	-40.632	33.592	36.976	1.00	8.75
ATOM	645	C	GLY	90	-40.322	32.409	37.921	1.00	10.19
ATOM	646	O	GLY	90	-39.660	31.477	37.500	1.00	9.62
ATOM	647	N	HIS	91	-40.857	32.540	39.135	1.00	11.81
ATOM	648	CD2	HIS	91	-40.073	33.404	43.018	1.00	18.32
ATOM	649	NE2	HIS	91	-40.052	34.763	43.177	1.00	17.97
ATOM	650	CE1	HIS	91	-39.622	35.366	42.127	1.00	17.17
ATOM	651	ND1	HIS	91	-39.350	34.411	41.259	1.00	16.07
ATOM	652	CG	HIS	91	-39.605	33.184	41.765	1.00	16.04
ATOM	653	CB	HIS	91	-39.411	31.883	41.060	1.00	11.82
ATOM	654	CA	HIS	91	-40.637	31.530	40.180	1.00	10.58
ATOM	655	C	HIS	91	-41.854	31.229	41.025	1.00	12.38
ATOM	656	O	HIS	91	-41.723	31.032	42.248	1.00	13.11
ATOM	657	N	ASN	92	-43.013	31.126	40.369	1.00	12.16
ATOM	658	ND2	ASN	92	-46.608	32.760	41.360	1.00	44.37
ATOM	659	OD1	ASN	92	-45.564	33.225	39.385	1.00	40.52
ATOM	660	CG	ASN	92	-45.903	32.418	40.259	1.00	35.33
ATOM	661	CB	ASN	92	-45.524	30.938	40.252	1.00	23.82

Fig. 13

Modtaget  
10 OKT. 2003  
PVS

14/26

ATOM	662	CA	ASN	92	-44.261	30.746	41.119	1.00	13.35
ATOM	663	C	ASN	92	-44.164	29.268	41.493	1.00	12.66
ATOM	664	O	ASN	92	-43.930	28.437	40.582	1.00	11.76
ATOM	665	N	GLN	93	-44.364	28.935	42.749	1.00	11.08
ATOM	666	NE2	GLN	93	-42.340	27.432	47.693	1.00	21.50
ATOM	667	OE1	GLN	93	-44.559	27.501	47.458	1.00	31.26
ATOM	668	CD	GLN	93	-43.422	27.632	46.972	1.00	27.63
ATOM	669	CG	GLN	93	-43.291	28.002	45.511	1.00	20.72
ATOM	670	CB	GLN	93	-44.409	27.379	44.700	1.00	15.24
ATOM	671	CA	GLN	93	-44.262	27.516	43.171	1.00	12.74
ATOM	672	C	GLN	93	-45.394	26.705	42.566	1.00	13.82
ATOM	673	O	GLN	93	-46.572	27.162	42.672	1.00	15.94
ATOM	674	N	ALA	94	-45.166	25.549	42.048	1.00	11.74
ATOM	675	CA	ALA	94	-46.178	24.676	41.481	1.00	11.41
ATOM	676	C	ALA	94	-46.815	23.934	42.649	1.00	14.20
ATOM	677	O	ALA	94	-46.120	23.587	43.637	1.00	14.08
ATOM	678	CB	ALA	94	-45.495	23.704	40.529	1.00	6.58
ATOM	679	N	PRO	95	-48.112	23.645	42.551	1.00	14.96
ATOM	680	CG	PRO	95	-50.259	23.275	41.661	1.00	15.96
ATOM	681	CD	PRO	95	-48.954	24.020	41.412	1.00	15.38
ATOM	682	CB	PRO	95	-50.261	22.810	43.087	1.00	13.99
ATOM	683	CA	PRO	95	-48.815	22.843	43.571	1.00	13.77
ATOM	684	C	PRO	95	-48.308	21.414	43.670	1.00	12.85
ATOM	685	O	PRO	95	-47.789	20.722	42.764	1.00	13.21
ATOM	686	N	ILE	96	-48.439	20.860	44.892	1.00	9.64
ATOM	687	CD1	ILE	96	-46.305	19.698	47.937	1.00	20.39
ATOM	688	CG1	ILE	96	-47.785	19.940	47.690	1.00	17.20
ATOM	689	CB	ILE	96	-48.425	19.023	46.634	1.00	13.72
ATOM	690	CG2	ILE	96	-48.131	17.530	46.952	1.00	17.91
ATOM	691	CA	ILE	96	-48.058	19.444	45.141	1.00	11.51
ATOM	692	C	ILE	96	-48.841	18.627	44.138	1.00	13.14
ATOM	693	O	ILE	96	-50.052	18.979	43.880	1.00	15.21
ATOM	694	N	GLY	97	-48.332	17.575	43.528	1.00	10.18
ATOM	695	CA	GLY	97	-49.020	16.783	42.537	1.00	9.00
ATOM	696	C	GLY	97	-48.645	17.200	41.126	1.00	11.33
ATOM	697	O	GLY	97	-48.867	16.374	40.221	1.00	12.32
ATOM	698	N	SER	98	-48.108	18.393	40.935	1.00	10.97
ATOM	699	OG	SER	98	-48.122	21.262	40.073	0.70	15.96
ATOM	700	CB	SER	98	-47.149	20.355	39.724	0.70	13.01
ATOM	703	CA	SER	98	-47.643	18.918	39.637	1.00	11.70
ATOM	704	C	SER	98	-46.376	18.198	39.140	1.00	11.01
ATOM	705	O	SER	98	-45.567	17.708	39.906	1.00	12.53
ATOM	706	N	SER	99	-46.203	18.149	37.825	1.00	8.54
ATOM	707	OG	SER	99	-45.372	18.423	34.957	1.00	12.93
ATOM	708	CB	SER	99	-45.157	17.258	35.747	1.00	7.78
ATOM	709	CA	SER	99	-45.010	17.562	37.226	1.00	8.54
ATOM	710	C	SER	99	-43.921	18.659	37.391	1.00	7.90
ATOM	711	O	SER	99	-44.195	19.884	37.534	1.00	10.31
ATOM	712	N	VAL	100	-42.675	18.231	37.384	1.00	9.21
ATOM	713	CA	VAL	100	-41.468	19.082	37.505	1.00	5.59
ATOM	714	C	VAL	100	-40.375	18.343	36.773	1.00	5.35
ATOM	715	O	VAL	100	-40.380	17.108	36.785	1.00	9.03
ATOM	716	CB	VAL	100	-41.112	19.395	38.979	1.00	5.88
ATOM	717	CG1	VAL	100	-40.630	18.114	39.670	1.00	8.61

Fig. 14

Modtaget  
10 OKT. 2003  
PVS

15/26

ATOM	718	CG2	VAL	100	-40.142	20.579	39.127	1.00	5.24
ATOM	719	N	CYS	101	-39.423	19.055	36.168	1.00	5.24
ATOM	720	CA	CYS	101	-38.304	18.494	35.437	1.00	4.35
ATOM	721	C	CYS	101	-36.989	18.996	36.086	1.00	5.37
ATOM	722	O	CYS	101	-36.984	20.152	36.529	1.00	8.17
ATOM	723	CB	CYS	101	-38.312	18.824	33.935	1.00	5.99
ATOM	724	SG	CYS	101	-39.723	18.001	33.063	1.00	8.35
ATOM	725	N	ARG	102	-35.982	18.175	36.084	1.00	6.08
ATOM	726	CA	ARG	102	-34.649	18.527	36.587	1.00	7.57
ATOM	727	C	ARG	102	-33.605	18.534	35.462	1.00	8.71
ATOM	728	O	ARG	102	-33.604	17.647	34.598	1.00	8.00
ATOM	729	CB	ARG	102	-34.261	17.489	37.655	1.00	4.69
ATOM	730	CG	ARG	102	-32.859	17.784	38.286	1.00	3.27
ATOM	731	CD	ARG	102	-32.303	16.653	39.077	1.00	6.25
ATOM	732	NE	ARG	102	-32.250	15.402	38.343	1.00	7.04
ATOM	733	CZ	ARG	102	-31.471	15.083	37.294	1.00	9.62
ATOM	734	NH1	ARG	102	-31.692	13.864	36.773	1.00	9.55
ATOM	735	NH2	ARG	102	-30.608	15.953	36.805	1.00	5.91
ATOM	736	N	SER	103	-32.662	19.454	35.404	1.00	7.27
ATOM	737	CA	SER	103	-31.567	19.475	34.435	1.00	4.96
ATOM	738	C	SER	103	-30.259	19.365	35.228	1.00	6.42
ATOM	739	O	SER	103	-30.059	20.177	36.162	1.00	6.49
ATOM	740	CB	SER	103	-31.571	20.781	33.624	1.00	5.59
ATOM	741	OG	SER	103	-30.581	20.673	32.575	1.00	7.71
ATOM	742	N	GLY	104	-29.359	18.411	34.965	1.00	7.52
ATOM	743	CA	GLY	104	-28.071	18.282	35.661	1.00	5.92
ATOM	744	C	GLY	104	-27.031	17.745	34.686	1.00	6.41
ATOM	745	O	GLY	104	-27.354	17.083	33.665	1.00	7.09
ATOM	746	N	SER	105	-25.757	18.002	34.912	1.00	7.88
ATOM	747	OG	SER	105	-22.953	18.433	35.504	1.00	11.75
ATOM	748	CB	SER	105	-23.430	18.504	34.179	1.00	7.00
ATOM	749	CA	SER	105	-24.638	17.559	34.049	1.00	10.37
ATOM	750	C	SER	105	-24.255	16.085	34.102	1.00	10.06
ATOM	751	O	SER	105	-23.505	15.679	33.176	1.00	10.75
ATOM	752	N	THR	106	-24.719	15.248	35.018	1.00	9.74
ATOM	753	CA	THR	106	-24.403	13.811	35.029	1.00	9.92
ATOM	754	C	THR	106	-25.458	13.046	34.238	1.00	8.56
ATOM	755	O	THR	106	-25.079	12.174	33.464	1.00	10.42
ATOM	756	CB	THR	106	-24.322	13.103	36.435	1.00	10.71
ATOM	757	OG1	THR	106	-23.436	13.978	37.167	1.00	10.45
ATOM	758	CG2	THR	106	-23.782	11.671	36.508	1.00	6.76
ATOM	759	N	THR	107	-26.723	13.319	34.467	1.00	7.87
ATOM	760	CA	THR	107	-27.804	12.599	33.831	1.00	5.96
ATOM	761	C	THR	107	-28.634	13.349	32.838	1.00	7.88
ATOM	762	O	THR	107	-29.531	12.664	32.266	1.00	8.47
ATOM	763	CB	THR	107	-28.695	11.935	34.969	1.00	8.85
ATOM	764	OG1	THR	107	-29.241	13.086	35.695	1.00	7.24
ATOM	765	CG2	THR	107	-27.869	11.012	35.858	1.00	8.14
ATOM	766	N	GLY	108	-28.523	14.609	32.643	1.00	7.16
ATOM	767	CA	GLY	108	-29.341	15.323	31.611	1.00	8.94
ATOM	768	C	GLY	108	-30.668	15.756	32.223	1.00	10.50
ATOM	769	O	GLY	108	-30.722	16.175	33.436	1.00	8.98
ATOM	770	N	TRP	109	-31.691	15.642	31.408	1.00	6.52
ATOM	771	CD2	TRP	109	-35.413	18.684	30.968	1.00	5.39

Fig. 15

16/26

ATOM	772	CE3	TRP	109	-34.790	19.728	31.656	1.00	5.67
ATOM	773	CZ3	TRP	109	-35.588	20.864	31.900	1.00	10.11
ATOM	774	CH2	TRP	109	-36.931	20.950	31.533	1.00	7.46
ATOM	775	CZ2	TRP	109	-37.555	19.912	30.864	1.00	5.36
ATOM	776	CE2	TRP	109	-36.762	18.789	30.603	1.00	8.40
ATOM	777	NE1	TRP	109	-37.097	17.619	29.964	1.00	11.33
ATOM	778	CD1	TRP	109	-35.996	16.771	29.909	1.00	8.89
ATOM	779	CG	TRP	109	-34.928	17.409	30.506	1.00	7.87
ATOM	780	CB	TRP	109	-33.558	16.856	30.594	1.00	4.08
ATOM	781	CA	TRP	109	-33.070	16.106	31.803	1.00	6.13
ATOM	782	C	TRP	109	-34.031	15.013	32.176	1.00	7.55
ATOM	783	O	TRP	109	-34.244	14.017	31.372	1.00	8.28
ATOM	784	N	HIS	110	-34.566	15.040	33.380	1.00	6.29
ATOM	785	CD2	HIS	110	-32.409	12.573	33.819	1.00	8.99
ATOM	786	NE2	HIS	110	-31.845	11.558	33.121	1.00	10.03
ATOM	787	CE1	HIS	110	-32.751	10.595	32.981	1.00	12.94
ATOM	788	ND1	HIS	110	-33.856	11.027	33.562	1.00	12.68
ATOM	789	CG	HIS	110	-33.678	12.246	34.128	1.00	9.92
ATOM	790	CB	HIS	110	-34.761	13.004	34.840	1.00	8.94
ATOM	791	CA	HIS	110	-35.487	13.971	33.861	1.00	7.82
ATOM	792	C	HIS	110	-36.648	14.637	34.584	1.00	7.74
ATOM	793	O	HIS	110	-36.444	15.708	35.190	1.00	8.03
ATOM	794	N	CYS	111	-37.832	13.990	34.506	1.00	7.77
ATOM	795	CA	CYS	111	-39.052	14.589	35.065	1.00	7.64
ATOM	796	C	CYS	111	-39.864	13.660	35.952	1.00	9.31
ATOM	797	O	CYS	111	-39.559	12.451	35.928	1.00	11.03
ATOM	798	CB	CYS	111	-39.988	15.100	33.925	1.00	9.61
ATOM	799	SG	CYS	111	-39.150	16.153	32.711	1.00	9.12
ATOM	800	N	GLY	112	-40.828	14.245	36.638	1.00	8.81
ATOM	801	CA	GLY	112	-41.625	13.408	37.597	1.00	8.51
ATOM	802	C	GLY	112	-42.521	14.315	38.399	1.00	10.25
ATOM	803	O	GLY	112	-42.794	15.437	37.941	1.00	12.04
ATOM	804	N	THR	113	-42.979	13.969	39.595	1.00	10.08
ATOM	805	CA	THR	113	-43.870	14.809	40.372	1.00	8.62
ATOM	806	C	THR	113	-43.359	15.387	41.685	1.00	9.71
ATOM	807	O	THR	113	-42.441	14.786	42.268	1.00	10.48
ATOM	808	CB	THR	113	-45.240	13.996	40.648	1.00	17.08
ATOM	809	OG1	THR	113	-44.930	12.755	41.340	1.00	19.10
ATOM	810	CG2	THR	113	-46.004	13.705	39.362	1.00	15.24
ATOM	811	N	ILE	114	-43.963	16.488	42.073	1.00	8.35
ATOM	812	CA	ILE	114	-43.662	17.108	43.365	1.00	9.73
ATOM	813	C	ILE	114	-44.554	16.338	44.383	1.00	13.59
ATOM	814	O	ILE	114	-45.816	16.336	44.198	1.00	12.54
ATOM	815	CB	ILE	114	-44.008	18.621	43.384	1.00	10.58
ATOM	816	CG1	ILE	114	-43.089	19.319	42.341	1.00	12.00
ATOM	817	CG2	ILE	114	-43.864	19.215	44.814	1.00	12.84
ATOM	818	CD1	ILE	114	-43.555	20.750	42.065	1.00	10.62
ATOM	819	N	GLN	115	-43.977	15.668	45.379	1.00	12.39
ATOM	820	NE2	GLN	115	-43.951	10.378	45.759	1.00	33.00
ATOM	821	OE1	GLN	115	-42.098	11.415	46.407	1.00	34.76
ATOM	822	CD	GLN	115	-43.243	11.496	45.943	1.00	30.30
ATOM	823	CG	GLN	115	-43.993	12.758	45.524	1.00	18.83
ATOM	824	CB	GLN	115	-44.077	13.606	46.811	1.00	11.43
ATOM	825	CA	GLN	115	-44.732	14.936	46.396	1.00	11.59

Fig. 16

Modtaget  
10 OKT. 2003  
PVS

17/26

ATOM	826	C	GLN	115	-44.956	15.640	47.693	1.00	11.61
ATOM	827	O	GLN	115	-46.105	15.494	48.196	1.00	14.96
ATOM	828	N	ALA	116	-44.037	16.355	48.292	1.00	12.17
ATOM	829	CA	ALA	116	-44.291	16.976	49.618	1.00	10.65
ATOM	830	C	ALA	116	-43.263	18.055	49.863	1.00	9.88
ATOM	831	O	ALA	116	-42.162	17.978	49.326	1.00	13.41
ATOM	832	CB	ALA	116	-44.101	15.894	50.689	1.00	10.10
ATOM	833	N	ARG	117	-43.586	19.020	50.636	1.00	9.81
ATOM	834	NH2	ARG	117	-43.870	23.560	45.115	1.00	13.10
ATOM	835	NH1	ARG	117	-45.496	23.020	46.568	1.00	17.40
ATOM	836	CZ	ARG	117	-44.191	23.340	46.386	1.00	16.37
ATOM	837	NE	ARG	117	-43.268	23.465	47.330	1.00	14.91
ATOM	838	CD	ARG	117	-43.450	23.251	48.783	1.00	13.89
ATOM	839	CG	ARG	117	-43.323	21.801	49.092	1.00	10.78
ATOM	840	CB	ARG	117	-43.392	21.470	50.596	1.00	10.30
ATOM	841	CA	ARG	117	-42.725	20.137	50.983	1.00	10.62
ATOM	842	C	ARG	117	-42.465	20.023	52.496	1.00	12.42
ATOM	843	O	ARG	117	-43.122	19.229	53.201	1.00	14.36
ATOM	844	N	GLY	118	-41.566	20.803	52.999	1.00	10.94
ATOM	845	CA	GLY	118	-41.246	20.891	54.430	1.00	14.46
ATOM	846	C	GLY	118	-40.590	19.675	55.005	1.00	13.77
ATOM	847	O	GLY	118	-40.761	19.531	56.229	1.00	14.95
ATOM	848	N	GLN	119	-39.874	18.886	54.215	1.00	11.83
ATOM	849	NE2	GLN	119	-42.518	16.522	54.159	1.00	27.14
ATOM	850	OE1	GLN	119	-41.331	14.597	53.939	1.00	29.04
ATOM	851	CD	GLN	119	-41.505	15.779	53.683	1.00	26.05
ATOM	852	CG	GLN	119	-40.511	16.511	52.791	1.00	23.83
ATOM	853	CB	GLN	119	-39.161	16.633	53.499	1.00	15.28
ATOM	854	CA	GLN	119	-39.228	17.649	54.654	1.00	12.25
ATOM	855	C	GLN	119	-37.819	17.866	55.191	1.00	13.13
ATOM	856	O	GLN	119	-37.023	18.655	54.674	1.00	11.96
ATOM	857	N	SER	120	-37.520	17.136	56.272	1.00	12.77
ATOM	858	OG	SER	120	-36.874	16.674	59.024	0.50	13.43
ATOM	859	CB	SER	120	-36.074	17.591	58.330	0.50	15.06
ATOM	862	CA	SER	120	-36.147	17.234	56.873	1.00	11.79
ATOM	863	C	SER	120	-35.513	15.938	56.438	1.00	14.19
ATOM	864	O	SER	120	-36.167	14.855	56.352	1.00	14.17
ATOM	865	N	VAL	121	-34.228	16.035	56.037	1.00	14.53
ATOM	866	CG2	VAL	121	-34.392	15.445	53.235	1.00	20.02
ATOM	867	CG1	VAL	121	-32.537	13.814	53.494	1.00	22.53
ATOM	868	CB	VAL	121	-33.176	15.085	54.041	1.00	19.23
ATOM	869	CA	VAL	121	-33.466	14.920	55.565	1.00	14.60
ATOM	870	C	VAL	121	-32.106	14.892	56.248	1.00	17.85
ATOM	871	O	VAL	121	-31.399	15.890	56.335	1.00	16.78
ATOM	872	N	SER	122	-31.749	13.694	56.677	1.00	18.77
ATOM	873	OG	SER	122	-31.320	13.436	59.447	1.00	35.50
ATOM	874	CB	SER	122	-30.306	12.902	58.611	1.00	26.24
ATOM	875	CA	SER	122	-30.397	13.594	57.262	1.00	20.95
ATOM	876	C	SER	122	-29.504	12.911	56.238	1.00	20.78
ATOM	877	O	SER	122	-29.704	11.746	55.840	1.00	25.20
ATOM	878	N	TYR	123	-28.548	13.651	55.794	1.00	19.04
ATOM	879	CA	TYR	123	-27.479	13.164	54.927	1.00	21.72
ATOM	880	C	TYR	123	-26.478	12.615	55.995	1.00	25.29
ATOM	881	O	TYR	123	-26.521	13.015	57.187	1.00	26.53

Fig. 17

Modtaget  
10 OKT. 2003  
PVS

18/26

ATOM	882	CB	TYR	123	-26.981	14.342	54.135	1.00	18.93
ATOM	883	CG	TYR	123	-27.915	14.920	53.100	1.00	18.61
ATOM	884	CD1	TYR	123	-27.849	16.273	52.784	1.00	15.70
ATOM	885	CD2	TYR	123	-28.840	14.144	52.381	1.00	21.00
ATOM	886	CE1	TYR	123	-28.658	16.844	51.808	1.00	15.37
ATOM	887	CE2	TYR	123	-29.712	14.700	51.423	1.00	18.34
ATOM	888	CZ	TYR	123	-29.581	16.067	51.133	1.00	16.62
ATOM	889	OH	TYR	123	-30.390	16.593	50.172	1.00	15.25
ATOM	890	N	PRO	124	-25.578	11.721	55.647	1.00	28.48
ATOM	891	CG	PRO	124	-24.105	10.334	54.354	1.00	32.40
ATOM	892	CD	PRO	124	-25.391	11.155	54.297	1.00	30.53
ATOM	893	CB	PRO	124	-23.748	10.168	55.828	1.00	32.32
ATOM	894	CA	PRO	124	-24.583	11.183	56.598	1.00	31.44
ATOM	895	C	PRO	124	-23.732	12.285	57.226	1.00	32.68
ATOM	896	O	PRO	124	-23.355	12.124	58.408	1.00	33.64
ATOM	897	N	GLU	125	-23.417	13.329	56.485	1.00	32.09
ATOM	898	CA	GLU	125	-22.646	14.515	56.843	1.00	32.45
ATOM	899	C	GLU	125	-23.410	15.484	57.766	1.00	33.22
ATOM	900	O	GLU	125	-22.932	15.954	58.861	1.00	33.87
ATOM	901	CB	GLU	125	-22.144	15.220	55.588	1.00	28.10
ATOM	902	CG	GLU	125	-22.899	15.278	54.299	1.00	34.56
ATOM	903	CD	GLU	125	-23.341	14.605	53.384	0.00	53.35
ATOM	904	OE1	GLU	125	-23.517	15.100	52.231	0.00	59.96
ATOM	905	OE2	GLU	125	-23.156	13.352	53.591	0.00	58.46
ATOM	906	N	GLY	126	-24.666	15.793	57.397	1.00	31.75
ATOM	907	CA	GLY	126	-25.549	16.682	58.182	1.00	28.35
ATOM	908	C	GLY	126	-27.017	16.695	57.720	1.00	25.07
ATOM	909	O	GLY	126	-27.393	16.107	56.682	1.00	25.93
ATOM	910	N	THR	127	-27.811	17.417	58.486	1.00	19.30
ATOM	911	CG2	THR	127	-31.485	17.638	59.616	1.00	15.49
ATOM	912	OG1	THR	127	-29.548	16.190	60.199	1.00	22.50
ATOM	913	CB	THR	127	-29.964	17.487	59.664	1.00	14.93
ATOM	914	CA	THR	127	-29.242	17.558	58.256	1.00	13.91
ATOM	915	C	THR	127	-29.689	18.791	57.491	1.00	11.25
ATOM	916	O	THR	127	-29.203	19.885	57.803	1.00	10.59
ATOM	917	N	VAL	128	-30.649	18.626	56.584	1.00	11.18
ATOM	918	CA	VAL	128	-31.201	19.747	55.791	1.00	9.77
ATOM	919	C	VAL	128	-32.688	19.787	56.164	1.00	8.45
ATOM	920	O	VAL	128	-33.182	18.697	56.393	1.00	11.45
ATOM	921	CB	VAL	128	-30.956	19.633	54.298	1.00	7.25
ATOM	922	CG1	VAL	128	-29.466	19.790	54.013	1.00	11.55
ATOM	923	CG2	VAL	128	-31.377	18.285	53.735	1.00	9.36
ATOM	924	N	THR	129	-33.266	20.960	56.248	1.00	9.49
ATOM	925	CG2	THR	129	-34.182	21.202	59.125	1.00	18.71
ATOM	926	OG1	THR	129	-34.282	23.173	57.758	1.00	14.40
ATOM	927	CB	THR	129	-34.884	21.913	57.959	1.00	8.96
ATOM	928	CA	THR	129	-34.680	21.088	56.613	1.00	9.66
ATOM	929	C	THR	129	-35.407	21.804	55.487	1.00	10.11
ATOM	930	O	THR	129	-34.796	22.467	54.615	1.00	10.92
ATOM	931	N	ASN	130	-36.709	21.619	55.563	1.00	10.84
ATOM	932	ND2	ASN	130	-38.570	25.717	53.765	1.00	35.10
ATOM	933	OD1	ASN	130	-39.854	23.969	54.369	1.00	28.19
ATOM	934	CG	ASN	130	-38.739	24.527	54.362	1.00	30.11
ATOM	935	CB	ASN	130	-37.496	23.827	54.952	1.00	17.09

Fig. 18

Mndtaget  
10 OKT. 2003  
PVS

19/26

ATOM	936	CA	ASN	130	-37.620	22.299	54.616	1.00	12.34
ATOM	937	C	ASN	130	-37.388	21.988	53.136	1.00	11.59
ATOM	938	O	ASN	130	-37.557	22.883	52.268	1.00	11.46
ATOM	939	N	MET	131	-37.056	20.742	52.880	1.00	9.76
ATOM	940	CE	MET	131	-33.020	20.248	50.187	1.00	16.57
ATOM	941	SD	MET	131	-33.597	21.082	51.629	1.00	20.94
ATOM	942	CG	MET	131	-34.411	19.573	52.379	1.00	9.59
ATOM	943	CB	MET	131	-35.664	19.199	51.580	1.00	5.73
ATOM	944	CA	MET	131	-36.732	20.297	51.529	1.00	9.93
ATOM	945	C	MET	131	-38.007	19.797	50.840	1.00	9.00
ATOM	946	O	MET	131	-38.962	19.372	51.519	1.00	10.48
ATOM	947	N	THR	132	-37.995	19.869	49.527	1.00	8.82
ATOM	948	CA	THR	132	-39.129	19.393	48.710	1.00	5.72
ATOM	949	C	THR	132	-38.769	18.054	48.108	1.00	7.44
ATOM	950	O	THR	132	-37.719	17.850	47.428	1.00	9.83
ATOM	951	CB	THR	132	-39.497	20.516	47.675	1.00	6.44
ATOM	952	OG1	THR	132	-39.851	21.700	48.434	1.00	9.35
ATOM	953	CG2	THR	132	-40.681	20.100	46.737	1.00	7.59
ATOM	954	N	ARG	133	-39.640	17.061	48.306	1.00	4.85
ATOM	955	NH2	ARG	133	-42.116	12.875	51.526	1.00	39.69
ATOM	956	NH1	ARG	133	-43.846	11.985	50.304	1.00	32.03
ATOM	957	CZ	ARG	133	-42.539	12.272	50.397	1.00	36.90
ATOM	958	NE	ARG	133	-41.666	11.948	49.418	1.00	28.98
ATOM	959	CD	ARG	133	-40.253	12.204	49.398	1.00	20.06
ATOM	960	CG	ARG	133	-39.832	13.218	48.354	1.00	11.77
ATOM	961	CB	ARG	133	-40.079	14.660	48.801	1.00	6.59
ATOM	962	CA	ARG	133	-39.443	15.674	47.833	1.00	6.76
ATOM	963	C	ARG	133	-40.092	15.457	46.455	1.00	7.46
ATOM	964	O	ARG	133	-41.227	15.963	46.241	1.00	9.38
ATOM	965	N	THR	134	-39.360	14.793	45.552	1.00	9.68
ATOM	966	CG2	THR	134	-39.353	17.060	43.521	1.00	7.44
ATOM	967	OG1	THR	134	-38.110	15.030	42.788	1.00	8.17
ATOM	968	CB	THR	134	-39.392	15.603	43.141	1.00	8.74
ATOM	969	CA	THR	134	-39.921	14.565	44.202	1.00	8.24
ATOM	970	C	THR	134	-39.576	13.135	43.785	1.00	8.06
ATOM	971	O	THR	134	-38.694	12.518	44.396	1.00	9.92
ATOM	972	N	THR	135	-40.301	12.622	42.770	1.00	7.24
ATOM	973	CG2	THR	135	-42.463	10.541	42.733	1.00	12.10
ATOM	974	OG1	THR	135	-41.763	11.403	40.497	1.00	11.13
ATOM	975	CB	THR	135	-41.362	10.601	41.650	1.00	10.58
ATOM	976	CA	THR	135	-40.037	11.294	42.228	1.00	8.03
ATOM	977	C	THR	135	-38.974	11.340	41.147	1.00	7.98
ATOM	978	O	THR	135	-38.731	10.327	40.471	1.00	9.10
ATOM	979	N	VAL	136	-38.326	12.452	40.852	1.00	10.38
ATOM	980	CG2	VAL	136	-38.483	14.754	39.130	1.00	6.65
ATOM	981	CG1	VAL	136	-36.094	14.300	38.374	1.00	10.08
ATOM	982	CB	VAL	136	-37.136	14.096	39.495	1.00	9.89
ATOM	983	CA	VAL	136	-37.296	12.595	39.813	1.00	9.10
ATOM	984	C	VAL	136	-35.990	11.927	40.235	1.00	9.23
ATOM	985	O	VAL	136	-35.640	12.113	41.414	1.00	11.00
ATOM	986	N	CYS	137	-35.273	11.188	39.408	1.00	7.90
ATOM	987	CA	CYS	137	-33.997	10.564	39.780	1.00	8.61
ATOM	988	C	CYS	137	-32.841	11.600	39.681	1.00	9.07
ATOM	989	O	CYS	137	-33.024	12.659	39.015	1.00	9.87

Fig. 19



Modtaget  
10 OKT. 2003  
PVS

20/26

ATOM	990	CB	CYS	137	-33.702	9.452	38.761	1.00	8.35
ATOM	991	SG	CYS	137	-33.425	10.011	37.031	1.00	11.68
ATOM	992	N	ALA	138	-31.687	11.330	40.300	1.00	7.09
ATOM	993	CB	ALA	138	-30.467	13.454	41.104	1.00	8.40
ATOM	994	CA	ALA	138	-30.503	12.207	40.220	1.00	8.25
ATOM	995	C	ALA	138	-29.294	11.352	40.568	1.00	8.58
ATOM	996	O	ALA	138	-29.409	10.287	41.211	1.00	10.28
ATOM	997	N	GLU	139	-28.105	11.803	40.178	1.00	9.17
ATOM	998	OE2	GLU	139	-27.880	7.597	37.175	1.00	10.81
ATOM	999	OE1	GLU	139	-25.864	8.348	37.135	1.00	10.87
ATOM	1000	CD	GLU	139	-26.946	8.270	37.673	1.00	12.62
ATOM	1001	CG	GLU	139	-27.289	9.053	38.912	1.00	10.79
ATOM	1002	CB	GLU	139	-26.414	10.298	39.196	1.00	8.09
ATOM	1003	CA	GLU	139	-26.818	11.099	40.431	1.00	9.02
ATOM	1004	C	GLU	139	-25.776	12.156	40.775	1.00	9.85
ATOM	1005	O	GLU	139	-25.966	13.362	40.507	1.00	9.59
ATOM	1006	N	PRO	140	-24.677	11.769	41.394	1.00	12.00
ATOM	1007	CG	PRO	140	-23.255	10.606	42.890	1.00	10.81
ATOM	1008	CD	PRO	140	-24.305	10.376	41.788	1.00	10.23
ATOM	1009	CB	PRO	140	-22.595	11.921	42.569	1.00	13.07
ATOM	1010	CA	PRO	140	-23.611	12.741	41.794	1.00	10.28
ATOM	1011	C	PRO	140	-23.095	13.561	40.611	1.00	9.93
ATOM	1012	O	PRO	140	-22.846	13.081	39.498	1.00	11.30
ATOM	1013	N	GLY	141	-23.015	14.865	40.884	1.00	7.17
ATOM	1014	CA	GLY	141	-22.596	15.857	39.927	1.00	7.59
ATOM	1015	C	GLY	141	-23.845	16.611	39.448	1.00	6.72
ATOM	1016	O	GLY	141	-23.742	17.715	38.907	1.00	7.49
ATOM	1017	N	ASP	142	-25.050	16.077	39.671	1.00	7.35
ATOM	1018	CA	ASP	142	-26.325	16.710	39.296	1.00	6.21
ATOM	1019	C	ASP	142	-26.663	17.752	40.369	1.00	5.40
ATOM	1020	O	ASP	142	-27.522	18.627	40.062	1.00	3.95
ATOM	1021	CB	ASP	142	-27.497	15.784	39.058	1.00	7.83
ATOM	1022	CG	ASP	142	-27.531	14.867	37.860	1.00	7.53
ATOM	1023	OD1	ASP	142	-28.075	13.736	37.908	1.00	7.92
ATOM	1024	OD2	ASP	142	-27.048	15.355	36.863	1.00	6.85
ATOM	1025	N	SER	143	-26.112	17.668	41.546	1.00	5.60
ATOM	1026	CA	SER	143	-26.422	18.670	42.589	1.00	5.95
ATOM	1027	C	SER	143	-26.287	20.098	42.102	1.00	7.22
ATOM	1028	O	SER	143	-25.328	20.407	41.346	1.00	7.03
ATOM	1029	CB	SER	143	-25.451	18.527	43.777	1.00	7.47
ATOM	1030	OG	SER	143	-25.764	17.255	44.327	1.00	11.26
ATOM	1031	N	GLY	144	-27.206	20.956	42.571	1.00	5.35
ATOM	1032	CA	GLY	144	-27.301	22.370	42.249	1.00	5.48
ATOM	1033	C	GLY	144	-28.051	22.665	40.945	1.00	6.00
ATOM	1034	O	GLY	144	-28.334	23.858	40.698	1.00	7.24
ATOM	1035	N	GLY	145	-28.295	21.671	40.140	1.00	5.00
ATOM	1036	CA	GLY	145	-28.959	21.818	38.828	1.00	5.08
ATOM	1037	C	GLY	145	-30.400	22.272	38.981	1.00	6.80
ATOM	1038	O	GLY	145	-31.096	22.093	40.013	1.00	8.09
ATOM	1039	N	SER	146	-31.016	22.823	37.953	1.00	4.98
ATOM	1040	CA	SER	146	-32.375	23.344	37.961	1.00	4.54
ATOM	1041	C	SER	146	-33.561	22.389	38.160	1.00	5.95
ATOM	1042	O	SER	146	-33.513	21.305	37.566	1.00	6.69
ATOM	1043	CB	SER	146	-32.609	23.870	36.500	1.00	4.69

Fig. 20

Mordtaget  
10 OKT. 2003  
PVS

21/26

ATOM	1044	OG	SER	146	-31.487	24.440	35.945	1.00	7.80
ATOM	1045	N	TYR	147	-34.584	22.813	38.888	1.00	4.96
ATOM	1046	OH	TYR	147	-34.686	16.409	41.718	1.00	15.17
ATOM	1047	CD2	TYR	147	-36.809	19.212	40.614	1.00	8.25
ATOM	1048	CE2	TYR	147	-36.419	17.910	40.955	1.00	10.83
ATOM	1049	CZ	TYR	147	-35.130	17.695	41.413	1.00	13.00
ATOM	1050	CE1	TYR	147	-34.196	18.722	41.524	1.00	8.41
ATOM	1051	CD1	TYR	147	-34.601	20.028	41.200	1.00	7.28
ATOM	1052	CG	TYR	147	-35.885	20.262	40.762	1.00	6.98
ATOM	1053	CB	TYR	147	-36.258	21.677	40.422	1.00	5.48
ATOM	1054	CA	TYR	147	-35.875	22.091	39.028	1.00	5.55
ATOM	1055	C	TYR	147	-36.829	23.167	38.409	1.00	6.41
ATOM	1056	O	TYR	147	-36.859	24.306	38.918	1.00	6.54
ATOM	1057	N	ILE	148	-37.559	22.845	37.365	1.00	5.67
ATOM	1058	CA	ILE	148	-38.454	23.821	36.710	1.00	6.64
ATOM	1059	C	ILE	148	-39.776	23.154	36.317	1.00	6.20
ATOM	1060	O	ILE	148	-39.743	21.993	35.834	1.00	6.60
ATOM	1061	CB	ILE	148	-37.661	24.408	35.475	1.00	8.25
ATOM	1062	CG1	ILE	148	-38.445	25.567	34.843	1.00	10.19
ATOM	1063	CG2	ILE	148	-37.269	23.309	34.443	1.00	11.02
ATOM	1064	CD1	ILE	148	-37.739	26.438	33.738	1.00	11.12
ATOM	1065	N	SER	149	-40.878	23.912	36.472	1.00	6.67
ATOM	1066	OG	SER	149	-42.874	22.350	38.136	1.00	15.36
ATOM	1067	CB	SER	149	-43.209	23.415	37.231	1.00	9.17
ATOM	1068	CA	SER	149	-42.219	23.396	36.098	1.00	7.08
ATOM	1069	C	SER	149	-42.712	24.364	35.000	1.00	7.85
ATOM	1070	O	SER	149	-43.087	25.496	35.341	1.00	8.98
ATOM	1071	N	GLY	150	-42.632	23.897	33.754	1.00	10.00
ATOM	1072	CA	GLY	150	-43.066	24.798	32.663	1.00	11.86
ATOM	1073	C	GLY	150	-41.990	25.883	32.482	1.00	8.97
ATOM	1074	O	GLY	150	-40.850	25.591	32.148	1.00	12.79
ATOM	1075	N	THR	151	-42.463	27.096	32.745	1.00	9.09
ATOM	1076	CG2	THR	151	-42.428	29.087	30.347	1.00	13.40
ATOM	1077	OG1	THR	151	-43.398	29.844	32.497	1.00	13.13
ATOM	1078	CB	THR	151	-42.170	29.426	31.816	1.00	11.88
ATOM	1079	CA	THR	151	-41.527	28.257	32.661	1.00	10.61
ATOM	1080	C	THR	151	-41.196	28.758	34.085	1.00	9.76
ATOM	1081	O	THR	151	-40.553	29.810	34.179	1.00	10.13
ATOM	1082	N	GLN	152	-41.628	28.099	35.157	1.00	6.87
ATOM	1083	CA	GLN	152	-41.440	28.600	36.494	1.00	7.20
ATOM	1084	C	GLN	152	-40.304	27.909	37.266	1.00	8.56
ATOM	1085	O	GLN	152	-40.488	26.681	37.461	1.00	12.38
ATOM	1086	CB	GLN	152	-42.770	28.493	37.286	1.00	6.03
ATOM	1087	CG	GLN	152	-43.935	29.238	36.607	1.00	9.11
ATOM	1088	CD	GLN	152	-43.668	30.705	36.459	1.00	7.44
ATOM	1089	OE1	GLN	152	-43.411	31.422	37.422	1.00	11.18
ATOM	1090	NE2	GLN	152	-43.686	31.229	35.247	1.00	15.32
ATOM	1091	N	ALA	153	-39.288	28.691	37.696	1.00	7.16
ATOM	1092	CA	ALA	153	-38.166	28.065	38.442	1.00	6.99
ATOM	1093	C	ALA	153	-38.696	27.572	39.786	1.00	6.78
ATOM	1094	O	ALA	153	-39.432	28.329	40.450	1.00	8.03
ATOM	1095	CB	ALA	153	-37.062	29.133	38.567	1.00	6.81
ATOM	1096	N	GLN	154	-38.383	26.349	40.198	1.00	4.41
ATOM	1097	CA	GLN	154	-38.827	25.782	41.460	1.00	6.90

Fig. 21

Modtaget  
10 OKT. 2003  
PVS

22/26

ATOM	1098	C	GLN	154	-37.692	25.687	42.494	1.00	7.22
ATOM	1099	O	GLN	154	-37.931	26.098	43.640	1.00	7.22
ATOM	1100	CB	GLN	154	-39.459	24.374	41.221	1.00	6.12
ATOM	1101	CG	GLN	154	-40.644	24.402	40.211	1.00	6.24
ATOM	1102	CD	GLN	154	-41.732	25.321	40.671	1.00	9.04
ATOM	1103	OE1	GLN	154	-42.271	25.234	41.795	1.00	9.56
ATOM	1104	NE2	GLN	154	-42.164	26.267	39.859	1.00	4.50
ATOM	1105	N	GLY	155	-36.547	25.153	42.078	1.00	7.56
ATOM	1106	CA	GLY	155	-35.475	24.954	43.098	1.00	7.31
ATOM	1107	C	GLY	155	-34.202	24.370	42.501	1.00	7.69
ATOM	1108	O	GLY	155	-34.029	24.335	41.280	1.00	7.17
ATOM	1109	N	VAL	156	-33.252	24.073	43.370	1.00	6.91
ATOM	1110	CA	VAL	156	-31.925	23.515	42.968	1.00	7.24
ATOM	1111	C	VAL	156	-31.760	22.136	43.631	1.00	5.91
ATOM	1112	O	VAL	156	-32.096	21.942	44.815	1.00	6.78
ATOM	1113	CB	VAL	156	-30.786	24.527	43.154	1.00	6.19
ATOM	1114	CG1	VAL	156	-31.048	25.862	42.407	1.00	5.61
ATOM	1115	CG2	VAL	156	-30.409	24.754	44.616	1.00	8.17
ATOM	1116	N	THR	157	-31.186	21.164	42.911	1.00	3.82
ATOM	1117	CG2	THR	157	-30.184	17.395	42.515	1.00	4.16
ATOM	1118	OG1	THR	157	-30.991	19.138	41.073	1.00	8.01
ATOM	1119	CB	THR	157	-30.243	18.893	42.293	1.00	3.37
ATOM	1120	CA	THR	157	-30.971	19.799	43.383	1.00	4.97
ATOM	1121	C	THR	157	-30.083	19.754	44.627	1.00	5.89
ATOM	1122	O	THR	157	-28.979	20.281	44.589	1.00	5.74
ATOM	1123	N	SER	158	-30.588	19.070	45.635	1.00	5.99
ATOM	1124	CA	SER	158	-29.830	18.914	46.876	1.00	7.64
ATOM	1125	C	SER	158	-29.316	17.473	46.969	1.00	10.26
ATOM	1126	O	SER	158	-28.087	17.229	47.132	1.00	10.04
ATOM	1127	CB	SER	158	-30.619	19.304	48.134	1.00	8.30
ATOM	1128	OG	SER	158	-29.853	18.975	49.296	1.00	9.39
ATOM	1129	N	GLY	159	-30.150	16.443	46.900	1.00	9.83
ATOM	1130	CA	GLY	159	-29.635	15.060	47.040	1.00	9.90
ATOM	1131	C	GLY	159	-30.756	14.048	47.006	1.00	12.82
ATOM	1132	O	GLY	159	-31.878	14.478	46.680	1.00	13.31
ATOM	1133	N	GLY	160	-30.510	12.792	47.352	1.00	12.00
ATOM	1134	CA	GLY	160	-31.646	11.846	47.257	1.00	12.56
ATOM	1135	C	GLY	160	-31.091	10.410	47.219	1.00	15.35
ATOM	1136	O	GLY	160	-29.988	10.197	47.741	1.00	15.70
ATOM	1137	N	SER	161	-31.869	9.497	46.679	1.00	13.10
ATOM	1138	OG	SER	161	-33.410	7.381	47.752	1.00	18.73
ATOM	1139	CB	SER	161	-31.996	7.324	47.833	1.00	16.84
ATOM	1140	CA	SER	161	-31.379	8.089	46.671	1.00	14.66
ATOM	1141	C	SER	161	-31.670	7.448	45.325	1.00	13.50
ATOM	1142	O	SER	161	-32.491	8.066	44.640	1.00	13.10
ATOM	1143	N	GLY	162	-31.078	6.310	45.040	1.00	11.84
ATOM	1144	CA	GLY	162	-31.318	5.641	43.734	1.00	12.53
ATOM	1145	C	GLY	162	-30.457	6.331	42.672	1.00	12.12
ATOM	1146	O	GLY	162	-29.545	7.088	42.957	1.00	11.79
ATOM	1147	N	ASN	163	-30.786	6.068	41.407	1.00	10.66
ATOM	1148	CA	ASN	163	-30.058	6.588	40.269	1.00	8.29
ATOM	1149	C	ASN	163	-31.033	6.671	39.088	1.00	11.02
ATOM	1150	O	ASN	163	-32.220	6.293	39.233	1.00	10.33
ATOM	1151	CB	ASN	163	-28.827	5.741	39.950	1.00	10.88

Fig. 22

Modtaget  
10 OKT. 2003  
PVS

23/26

ATOM	1152	CG	ASN	163	-29.238	4.312	39.578	1.00	14.23
ATOM	1153	OD1	ASN	163	-29.966	3.979	38.660	1.00	11.31
ATOM	1154	ND2	ASN	163	-28.649	3.362	40.334	1.00	18.48
ATOM	1155	N	CYS	164	-30.499	7.132	37.956	1.00	10.86
ATOM	1156	CA	CYS	164	-31.420	7.271	36.806	1.00	11.83
ATOM	1157	C	CYS	164	-31.687	6.006	35.998	1.00	13.69
ATOM	1158	O	CYS	164	-32.428	6.145	34.993	1.00	15.15
ATOM	1159	CB	CYS	164	-31.100	8.500	35.971	1.00	10.31
ATOM	1160	SG	CYS	164	-31.448	10.097	36.795	1.00	9.57
ATOM	1161	N	ARG	165	-31.110	4.919	36.364	1.00	11.68
ATOM	1162	NH2	ARG	165	-26.089	2.173	38.339	1.00	59.15
ATOM	1163	NH1	ARG	165	-25.617	4.096	37.196	1.00	58.35
ATOM	1164	CZ	ARG	165	-26.258	2.909	37.212	1.00	55.39
ATOM	1165	NE	ARG	165	-27.054	2.356	36.310	1.00	47.93
ATOM	1166	CD	ARG	165	-27.631	2.632	35.037	1.00	40.44
ATOM	1167	CG	ARG	165	-28.933	3.381	34.944	1.00	31.56
ATOM	1168	CB	ARG	165	-30.065	2.765	35.785	1.00	18.33
ATOM	1169	CA	ARG	165	-31.324	3.621	35.703	1.00	17.34
ATOM	1170	C	ARG	165	-32.498	2.928	36.433	1.00	14.57
ATOM	1171	O	ARG	165	-33.499	2.588	35.782	1.00	15.39
ATOM	1172	N	THR	166	-32.347	2.784	37.751	1.00	12.62
ATOM	1173	CG2	THR	166	-31.557	0.620	39.350	1.00	18.19
ATOM	1174	OG1	THR	166	-32.296	2.562	40.679	1.00	17.67
ATOM	1175	CB	THR	166	-32.716	1.474	39.795	1.00	16.75
ATOM	1176	CA	THR	166	-33.407	2.140	38.540	1.00	13.18
ATOM	1177	C	THR	166	-34.528	3.049	39.012	1.00	15.18
ATOM	1178	O	THR	166	-35.581	2.528	39.436	1.00	16.50
ATOM	1179	N	GLY	167	-34.296	4.347	39.040	1.00	13.17
ATOM	1180	CA	GLY	167	-35.255	5.345	39.536	1.00	13.42
ATOM	1181	C	GLY	167	-34.815	5.663	40.997	1.00	14.50
ATOM	1182	O	GLY	167	-33.957	4.993	41.596	1.00	13.35
ATOM	1183	N	GLY	168	-35.330	6.773	41.562	1.00	14.99
ATOM	1184	CA	GLY	168	-34.923	7.118	42.940	1.00	12.40
ATOM	1185	C	GLY	168	-35.852	8.241	43.371	1.00	15.29
ATOM	1186	O	GLY	168	-36.909	8.509	42.754	1.00	14.71
ATOM	1187	N	THR	169	-35.422	8.845	44.471	1.00	14.65
ATOM	1188	CG2	THR	169	-37.341	10.701	47.345	1.00	11.85
ATOM	1189	OG1	THR	169	-37.698	8.540	46.281	1.00	16.91
ATOM	1190	CB	THR	169	-36.711	9.582	46.529	1.00	14.83
ATOM	1191	CA	THR	169	-36.177	9.973	45.077	1.00	13.13
ATOM	1192	C	THR	169	-35.165	11.121	45.248	1.00	11.43
ATOM	1193	O	THR	169	-34.007	10.807	45.611	1.00	11.62
ATOM	1194	N	THR	170	-35.621	12.315	44.946	1.00	8.52
ATOM	1195	CG2	THR	170	-33.232	12.956	43.075	1.00	6.44
ATOM	1196	OG1	THR	170	-35.355	14.161	43.068	1.00	19.35
ATOM	1197	CB	THR	170	-34.090	13.942	43.798	1.00	12.63
ATOM	1198	CA	THR	170	-34.667	13.406	45.165	1.00	8.99
ATOM	1199	C	THR	170	-35.363	14.555	45.880	1.00	11.07
ATOM	1200	O	THR	170	-36.582	14.758	45.736	1.00	12.91
ATOM	1201	N	PHE	171	-34.531	15.291	46.609	1.00	9.07
ATOM	1202	CD2	PHE	171	-36.450	15.430	50.154	1.00	12.37
ATOM	1203	CE2	PHE	171	-37.017	14.281	50.750	1.00	12.72
ATOM	1204	CZ	PHE	171	-36.332	13.053	50.718	1.00	14.13
ATOM	1205	CE1	PHE	171	-35.064	12.901	50.136	1.00	14.85

Fig. 23

Modtaget  
10 OKT. 2003  
PVS

24/26

ATOM	1206	CD1	PHE	171	-34.501	14.041	49.547	1.00	12.01
ATOM	1207	CG	PHE	171	-35.187	15.262	49.538	1.00	14.42
ATOM	1208	CB	PHE	171	-34.500	16.430	48.855	1.00	8.65
ATOM	1209	CA	PHE	171	-34.946	16.484	47.353	1.00	10.31
ATOM	1210	C	PHE	171	-34.276	17.746	46.736	1.00	9.69
ATOM	1211	O	PHE	171	-33.096	17.749	46.336	1.00	10.28
ATOM	1212	N	TYR	172	-35.022	18.818	46.721	1.00	6.76
ATOM	1213	OH	TYR	172	-40.405	22.042	43.789	1.00	10.33
ATOM	1214	CD2	TYR	172	-37.368	19.978	44.053	1.00	7.13
ATOM	1215	CE2	TYR	172	-38.680	20.393	43.754	1.00	9.56
ATOM	1216	CZ	TYR	172	-39.128	21.645	44.088	1.00	11.06
ATOM	1217	CE1	TYR	172	-38.255	22.544	44.740	1.00	7.89
ATOM	1218	CD1	TYR	172	-36.943	22.125	44.984	1.00	5.66
ATOM	1219	CG	TYR	172	-36.496	20.849	44.693	1.00	5.21
ATOM	1220	CB	TYR	172	-35.049	20.462	44.892	1.00	6.84
ATOM	1221	CA	TYR	172	-34.465	20.077	46.256	1.00	7.19
ATOM	1222	C	TYR	172	-34.711	21.217	47.245	1.00	6.71
ATOM	1223	O	TYR	172	-35.673	21.172	48.064	1.00	8.96
ATOM	1224	N	GLN	173	-33.781	22.185	47.157	1.00	5.53
ATOM	1225	NE2	GLN	173	-33.746	26.714	50.033	1.00	6.96
ATOM	1226	OE1	GLN	173	-32.289	25.169	50.891	1.00	10.23
ATOM	1227	CD	GLN	173	-32.795	25.753	49.933	1.00	9.42
ATOM	1228	CG	GLN	173	-32.411	25.493	48.482	1.00	3.75
ATOM	1229	CB	GLN	173	-32.463	24.037	48.054	1.00	8.35
ATOM	1230	CA	GLN	173	-33.883	23.428	47.962	1.00	5.17
ATOM	1231	C	GLN	173	-34.741	24.402	47.187	1.00	6.61
ATOM	1232	O	GLN	173	-34.469	24.693	45.967	1.00	7.86
ATOM	1233	N	GLU	174	-35.814	24.921	47.782	1.00	6.75
ATOM	1234	OE2	GLU	174	-40.122	25.837	46.396	1.00	8.25
ATOM	1235	OE1	GLU	174	-40.521	23.919	47.243	1.00	10.88
ATOM	1236	CD	GLU	174	-39.899	24.969	47.265	1.00	10.25
ATOM	1237	CG	GLU	174	-38.863	25.164	48.362	1.00	8.85
ATOM	1238	CB	GLU	174	-37.861	26.313	48.083	1.00	9.36
ATOM	1239	CA	GLU	174	-36.686	25.892	47.108	1.00	7.86
ATOM	1240	C	GLU	174	-35.933	27.178	46.774	1.00	8.69
ATOM	1241	O	GLU	174	-35.082	27.712	47.515	1.00	9.98
ATOM	1242	N	VAL	175	-36.198	27.769	45.591	1.00	8.61
ATOM	1243	CG2	VAL	175	-34.568	29.950	43.032	1.00	11.90
ATOM	1244	CG1	VAL	175	-36.989	29.512	42.968	1.00	13.78
ATOM	1245	CB	VAL	175	-35.652	29.062	43.589	1.00	13.52
ATOM	1246	CA	VAL	175	-35.605	29.022	45.144	1.00	8.03
ATOM	1247	C	VAL	175	-36.196	30.221	45.869	1.00	8.45
ATOM	1248	O	VAL	175	-35.453	31.199	46.161	1.00	8.96
ATOM	1249	N	THR	176	-37.454	30.220	46.297	1.00	9.06
ATOM	1250	CG2	THR	176	-40.371	32.282	47.869	1.00	18.26
ATOM	1251	OG1	THR	176	-40.343	30.692	46.091	1.00	18.82
ATOM	1252	CB	THR	176	-39.648	31.030	47.350	1.00	15.35
ATOM	1253	CA	THR	176	-38.133	31.355	46.965	1.00	10.08
ATOM	1254	C	THR	176	-37.370	32.053	48.082	1.00	12.75
ATOM	1255	O	THR	176	-37.203	33.295	48.105	1.00	12.78
ATOM	1256	N	PRO	177	-36.827	31.275	49.019	1.00	13.60
ATOM	1257	CA	PRO	177	-36.059	31.831	50.137	1.00	14.56
ATOM	1258	C	PRO	177	-34.832	32.550	49.634	1.00	14.53
ATOM	1259	O	PRO	177	-34.405	33.537	50.205	1.00	14.33

Fig. 24

Mortagat  
10 OCT 2003  
PVS

25/26

ATOM	1260	CB	PRO	177	-35.684	30.599	50.967	1.00	15.59
ATOM	1261	CG	PRO	177	-36.607	29.488	50.587	1.00	15.55
ATOM	1262	CD	PRO	177	-37.028	29.818	49.155	1.00	14.17
ATOM	1263	N	MET	178	-34.177	32.085	48.557	1.00	11.26
ATOM	1264	CE	MET	178	-31.755	28.533	46.007	1.00	19.72
ATOM	1265	SD	MET	178	-30.708	29.927	46.237	1.00	22.73
ATOM	1266	CG	MET	178	-31.639	30.737	47.651	1.00	17.28
ATOM	1267	CB	MET	178	-32.343	31.919	46.980	1.00	9.92
ATOM	1268	CA	MET	178	-32.991	32.789	48.077	1.00	11.19
ATOM	1269	C	MET	178	-33.372	34.163	47.572	1.00	14.99
ATOM	1270	O	MET	178	-32.631	35.161	47.724	1.00	16.24
ATOM	1271	N	VAL	179	-34.492	34.273	46.870	1.00	12.66
ATOM	1272	CG2	VAL	179	-35.871	34.516	44.214	1.00	11.56
ATOM	1273	CG1	VAL	179	-36.995	36.540	45.154	1.00	16.31
ATOM	1274	CB	VAL	179	-36.242	35.254	45.495	1.00	14.06
ATOM	1275	CA	VAL	179	-34.973	35.549	46.347	1.00	14.10
ATOM	1276	C	VAL	179	-35.411	36.462	47.516	1.00	17.87
ATOM	1277	O	VAL	179	-35.152	37.674	47.535	1.00	18.01
ATOM	1278	N	ASN	180	-36.139	35.872	48.451	1.00	17.87
ATOM	1279	ND2	ASN	180	-39.996	35.004	49.792	1.00	34.66
ATOM	1280	OD1	ASN	180	-39.173	36.590	48.442	1.00	26.20
ATOM	1281	CG	ASN	180	-39.030	35.860	49.435	1.00	27.22
ATOM	1282	CB	ASN	180	-37.798	35.850	50.334	1.00	22.46
ATOM	1283	CA	ASN	180	-36.683	36.628	49.576	1.00	21.81
ATOM	1284	C	ASN	180	-35.663	37.122	50.588	1.00	22.21
ATOM	1285	O	ASN	180	-35.786	38.276	51.007	1.00	25.30
ATOM	1286	N	SER	181	-34.775	36.258	50.952	1.00	20.13
ATOM	1287	OG	SER	181	-34.362	34.891	53.477	1.00	46.23
ATOM	1288	CB	SER	181	-33.268	35.230	52.620	1.00	29.26
ATOM	1289	CA	SER	181	-33.740	36.530	51.921	1.00	20.62
ATOM	1290	C	SER	181	-32.474	37.109	51.355	1.00	20.10
ATOM	1291	O	SER	181	-31.914	37.915	52.104	1.00	20.08
ATOM	1292	N	TRP	182	-32.042	36.665	50.186	1.00	17.06
ATOM	1293	CD2	TRP	182	-28.744	33.771	49.582	1.00	20.91
ATOM	1294	CE3	TRP	182	-28.470	33.240	48.331	1.00	15.11
ATOM	1295	CZ3	TRP	182	-27.853	31.999	48.269	1.00	15.36
ATOM	1296	CH2	TRP	182	-27.529	31.313	49.436	1.00	15.65
ATOM	1297	CZ2	TRP	182	-27.769	31.806	50.713	1.00	15.64
ATOM	1298	CE2	TRP	182	-28.381	33.057	50.742	1.00	24.59
ATOM	1299	NE1	TRP	182	-28.738	33.820	51.828	1.00	27.77
ATOM	1300	CD1	TRP	182	-29.323	34.986	51.373	1.00	29.42
ATOM	1301	CG	TRP	182	-29.377	35.009	50.004	1.00	22.91
ATOM	1302	CB	TRP	182	-29.884	36.098	49.127	1.00	20.07
ATOM	1303	CA	TRP	182	-30.771	37.210	49.681	1.00	14.46
ATOM	1304	C	TRP	182	-30.992	38.306	48.680	1.00	14.45
ATOM	1305	O	TRP	182	-30.007	38.974	48.321	1.00	16.23
ATOM	1306	N	GLY	183	-32.203	38.445	48.182	1.00	13.61
ATOM	1307	CA	GLY	183	-32.431	39.519	47.179	1.00	13.59
ATOM	1308	C	GLY	183	-31.864	39.105	45.800	1.00	12.98
ATOM	1309	O	GLY	183	-31.478	40.015	45.005	1.00	11.51
ATOM	1310	N	VAL	184	-31.805	37.788	45.559	1.00	12.12
ATOM	1311	CG2	VAL	184	-31.741	34.892	44.375	1.00	20.41
ATOM	1312	CG1	VAL	184	-29.458	35.739	44.931	1.00	20.83
ATOM	1313	CB	VAL	184	-30.729	35.966	44.088	1.00	14.52

Fig. 25

26/26

Modtaget  
10 Okt. 2003  
PVS

ATOM	1314	CA	VAL	184	-31.288	37.397	44.216	1.00	13.35
ATOM	1315	C	VAL	184	-32.431	37.647	43.201	1.00	13.39
ATOM	1316	O	VAL	184	-33.619	37.490	43.538	1.00	13.79
ATOM	1317	N	ARG	185	-32.041	37.991	41.974	1.00	11.85
ATOM	1318	NH2	ARG	185	-31.382	44.754	43.270	1.00	30.49
ATOM	1319	NH1	ARG	185	-30.633	44.370	41.110	1.00	29.76
ATOM	1320	CZ	ARG	185	-31.320	43.982	42.177	1.00	30.81
ATOM	1321	NE	ARG	185	-31.986	42.816	42.217	1.00	27.27
ATOM	1322	CD	ARG	185	-31.978	41.937	41.036	1.00	23.48
ATOM	1323	CG	ARG	185	-32.959	40.840	41.410	1.00	19.17
ATOM	1324	CB	ARG	185	-32.789	39.732	40.349	1.00	14.23
ATOM	1325	CA	ARG	185	-32.980	38.274	40.869	1.00	11.15
ATOM	1326	C	ARG	185	-32.746	37.319	39.703	1.00	8.87
ATOM	1327	O	ARG	185	-31.721	37.472	39.065	1.00	8.01
ATOM	1328	N	LEU	186	-33.644	36.370	39.444	1.00	9.17
ATOM	1329	CA	LEU	186	-33.463	35.447	38.328	1.00	9.78
ATOM	1330	C	LEU	186	-33.503	36.225	36.995	1.00	10.75
ATOM	1331	O	LEU	186	-34.316	37.132	36.787	1.00	10.04
ATOM	1332	CB	LEU	186	-34.648	34.435	38.305	1.00	8.11
ATOM	1333	CG	LEU	186	-34.760	33.549	39.546	1.00	16.49
ATOM	1334	CD1	LEU	186	-35.699	32.375	39.276	1.00	14.66
ATOM	1335	CD2	LEU	186	-33.400	32.928	39.887	1.00	16.56
ATOM	1336	N	ARG	187	-32.652	35.750	36.102	1.00	7.79
ATOM	1337	NH2	ARG	187	-30.740	39.908	29.630	1.00	46.94
ATOM	1338	NH1	ARG	187	-29.232	39.169	31.188	1.00	49.29
ATOM	1339	CZ	ARG	187	-30.477	39.174	30.718	1.00	44.29
ATOM	1340	NE	ARG	187	-31.443	38.474	31.338	1.00	36.97
ATOM	1341	CD	ARG	187	-31.199	37.750	32.536	1.00	28.81
ATOM	1342	CG	ARG	187	-31.219	36.300	32.604	1.00	27.43
ATOM	1343	CB	ARG	187	-31.340	35.889	34.068	1.00	12.14
ATOM	1344	CA	ARG	187	-32.653	36.298	34.718	1.00	9.41
ATOM	1345	C	ARG	187	-33.901	35.672	34.023	1.00	10.55
ATOM	1346	O	ARG	187	-34.139	34.427	33.990	1.00	10.23
ATOM	1347	N	THR	188	-34.769	36.530	33.478	1.00	9.32
ATOM	1348	CA	THR	188	-35.996	36.175	32.723	1.00	10.52
ATOM	1349	C	THR	188	-35.889	36.694	31.263	1.00	11.51
ATOM	1350	O	THR	188	-34.786	37.058	30.810	1.00	10.45
ATOM	1351	CB	THR	188	-37.361	36.593	33.422	1.00	7.88
ATOM	1352	OG1	THR	188	-37.427	38.057	33.443	1.00	7.10
ATOM	1353	CG2	THR	188	-37.581	36.118	34.850	1.00	8.10
ATOM	1354	OXT	THR	188	-36.851	36.451	30.513	1.00	13.52

Fig. 26

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**